SUPPLEMENT

FY2022 — Annual financial statements

FY2022PDF · 219 pages7.3 MB
for the year ended 30 June 2022
ANNUAL
FINANCIAL
STATEMENTS

-- 1 of 219 --

CONTENTS
CONSOLIDATED FINANCIAL STATEMENTS
Directors’ responsibility statement 	2
Chief executive and chief financial officer internal
financial control responsibility statement 	3
Certificate by the Company Secretary 	3
Report of the Discovery Limited Audit Committee 	4
Independent auditors’ report 	14
Directors’ report 	20
Statement of financial position 	25
Income statement 	26
Statement of other comprehensive income 	27
Statement of cash flows 	28
Statement of changes in equity 	29
Notes to the Group annual financial statements 	30
DISCOVERY LIMITED COMPANY
Statement of financial position 	139
Income statement 	140
Statement of other comprehensive income 	140
Statement of cash flows 	141
Statement of changes in equity 	142
Notes to the Company annual financial statements 	143
ANNEXURE A – GROUP STRUCTURE 	161
ANNEXURE B – GROUP ACCOUNTING POLICIES 	163
ANNEXURE C – DIRECTORATE 	198
ANNEXURE D – ANALYSIS OF SHAREHOLDERS 	203
ANNEXURE E – EMBEDDED VALUE 	204
Assurance report of the independent auditors 	204
Embedded value statement 	205
ANNEXURE F – FIVE-YEAR REVIEW 	216
GLOSSARY OF TERMS 	217
BASIS OF PREPARATION
The consolidated and separate Annual Financial Statements have
been prepared in accordance with International Financial Reporting
Standards (IFRS) as issued by the International Accounting
Standards Board (IASB), its interpretations adopted by the IASB, the
South African Institute of Chartered Accountants (SAICA) Financial
Reporting Guides as issued by the Accounting Practices Committee,
Financial pronouncements as issued by Financial Reporting
Standards Council, the JSE Listings Requirements, JSE Debt Listings
Requirements as well as the South African Companies Act. They
have been prepared in accordance with the going concern principle
using the historical cost basis except where otherwise stated in the
accounting policies (refer Annexure B).
The Annual Financial Statements have been prepared under the
supervision of Mr DM Viljoen CA(SA) the Group Chief Financial
Officer. The Annual Financial Statements are reviewed by
management, the Discovery Limited Audit Committee and Board
and are audited by the external auditors of the Group.
Embedded value statement prepared by P Bolink (FASSA) and
supervised by A Rayner (FASSA, FIA).
HOW WE REPORT TO OUR
STAKEHOLDERS
Our INTEGRATED ANNUAL REPORT – our primary report to
our shareholders, providers of financial capital and other
stakeholders – details our financial, economic and social
performance (2023 Ambition and beyond).
Our FULL ANNUAL FINANCIAL STATEMENTS include the
consolidated financial results of Discovery and its
subsidiaries, the embedded value statement and five-year
review.
Our 2022 Annual Financial Statements can be accessed
at www.discovery.co.za/corporate/investor-relations
W
Our SUSTAINABLE REPORT, provides information on how the
Group delivered on its commitment to be a powerful force
for good for our clients.
Our GOVERNANCE REPORT includes information on our
governance philosophy, leadership and our compliance
with King IV™
Our TCFD REPORT is our climate report against the
recommendations of the Task Force on Climate-related
Financial Disclosure.
Our REMUNERATION REPORT provides the material
disclosures of the Group’s Remuneration Policy and
implementation thereof.
DISCOVERY LIMITED
Registration number 1999/007789/06
Our ANNUAL FINANCIAL RESULTS Presentation provides an
overview of Discovery’s financial performance.
Our 2022 Annual Financial Results Presentation can be
accessed at www.discovery.co.za/corporate/investor-relations
W
1	Discovery Annual Financial Statements 2022

-- 2 of 219 --

DIRECTORS’ RESPONSIBILITY STATEMENT
for the year ended 30 June 2022
DIRECTORS’ RESPONSIBILITY
TO THE SHAREHOLDERS OF
DISCOVERY LIMITED AND ITS
SUBSIDIARIES (DISCOVERY
OR THE GROUP)
The directors of Discovery are required by the
Companies Act, Act 71 of 2008 (Companies Act), to
maintain adequate accounting records and to
prepare financial statements for each financial year
which fairly present the state of affairs of Discovery
at the end of the financial year, and of the results
and cash flows for the period. In preparing the
accompanying Annual Financial Statements,
International Financial Reporting Standards have
been used and reasonable estimates have been
made. The Annual Financial Statements incorporate
full and responsible disclosure, in line with
Discovery’s philosophy on corporate governance.
The directors have reviewed Discovery’s budget and
cash flow forecast for the year to 30 June 2023. On
the basis of this review, and in light of the current
financial position and available cash resources, the
directors have no reason to believe that Discovery
will not be a going concern for the foreseeable
future. The going concern basis has therefore been
adopted in preparing the Annual
Financial Statements.
The directors are responsible for Discovery’s
systems of internal control, which include internal
financial controls in the various subsidiaries that are
designed to provide reasonable, but not absolute,
assurance against material misstatement and loss.
Discovery maintains internal financial controls to
provide assurance regarding:
❚ 	Safeguarding of assets against unauthorised use
or disposition, and
❚ 	The maintenance of proper accounting records,
written or electronic and the reliability of financial
information used within the business, or for the
publication thereof, including submissions to the
companies and Intellectual Property Commission
(CIPC).
The controls contain self-monitoring mechanisms,
and actions are taken to correct deficiencies as they
are identified. Even an effective system of internal
control, no matter how well designed, has inherent
limitations, including the possibility of circumvention
and the overriding of controls. An effective system
of control therefore aims to provide reasonable
assurance with respect to the reliability of financial
information and, in particular, the presentation of
Annual Financial Statements.
To the best of their knowledge and belief, based on
the above, the directors are satisfied that no
material breakdown in the operation of the systems
of internal control and procedures has occurred
during the year under review.
Discovery’s external auditors, PricewaterhouseCoopers
Inc. and KPMG Inc., have audited the Annual
Financial Statements and their unqualified report
appears on pages 14 to 19.
The Annual Financial Statements of Discovery for the
year ended 30 June 2022, which appear on pages 25
to 202 have been approved by the Board of
Directors on 6 September 2022 and are signed on its
behalf by:
M Tucker
Chairperson
A Gore
Chief Executive Officer
2	Discovery Annual Financial Statements 2022

-- 3 of 219 --

CHIEF EXECUTIVE AND CHIEF FINANCIAL OFFICER INTERNAL
FINANCIAL CONTROL RESPONSIBILITY STATEMENT
for the year ended 30 June 2022
CERTIFICATE BY THE COMPANY SECRETARY
for the year ended 30 June 2022
After due, careful, and proper consideration, in accordance with the JSE Listings Requirements 3.84(k), each of the directors, whose names
are stated below, hereby confirm that:
a) the Annual Financial Statements set out on pages 25 to 202 fairly present, in all material respects, the financial position, financial
performance and cashflows of the issuer in terms of IFRS;
b) to best of our knowledge and belief, no facts have been omitted or untrue statements made that would make the Annual Financial
Statements false or misleading;
c) internal financial controls have been put in place to ensure that material information relating to the issuer and its consolidated
subsidiaries have been provided to prepare the financial statements of the issuer;
d) the internal financial controls are adequate and effective and can be relied upon in compiling the Annual Financial Statements, having
fulfilled our role and function as executive directors with primary responsibility for implementation and execution of controls;
e) where we are not satisfied, we have disclosed to the Discovery Limited Audit Committee and the auditors any deficiencies in design
and operational effectiveness of the internal financial controls, and have remediated or taken steps to remedy the deficiencies; and
f) We are not aware of any fraud involving directors.
A Gore 	DM Viljoen
Chief Executive Officer 	Chief Financial Officer
7 September 2022 	7 September 2022
It is hereby certified in terms of section 88(2)(e) of the Companies Act, that Discovery Limited has for the year ended 30 June 2022 lodged
with the Registrar of Companies all such returns as are required by a public company in terms of this Act and that all such returns are
true, correct and up to date.
NN Mbongo
Company Secretary
7 September 2022
3	Discovery Annual Financial Statements 2022

-- 4 of 219 --

REPORT OF THE DISCOVERY LIMITED AUDIT COMMITTEE
for the year ended 30 June 2022
We are pleased to present the Discovery Limited Audit Committee’s (DLAC) report for the financial year ended 30 June 2022. Our report
provides details on how we accomplished our various statutory obligations, as well as the various key and significant audit matters, we
considered during the period. Our committee carried out its responsibilities, including those relating to the audit and financial reporting
obligations of the Group, as set out in its Terms of Reference.
This report has been prepared based on the requirements of the Companies Act, Act 71 of 2008 (Companies Act), as amended, the King
Code of Governance for South Africa (King IV), the JSE Listings Requirements, JSE Debt Listings Requirements and other applicable
regulatory requirements.
TERMS OF REFERENCE, ROLES AND RESPONSIBILITIES
The DLAC is an independent statutory committee constituted under section 94 (7) of the Companies Act. DLAC recognises the important
oversight role it performs to meet the requirements of the Companies Act, the King Code of Governance for South Africa (King IV), the. JSE
Listing Requirments and other applicable regulatory requirements.
The DLAC provides independent oversight and challenge across the Group’s financial reporting and internal control procedures.
The Board has delegated the following key functions to the DLAC through a formal Terms of Reference which is reviewed annually. These
include, but are not limited to.
❚ 	Overseeing the Group’s financial reporting process. The review considers the integrity and fairness of the information and the review
of significant estimates and judgements made by management in producing the financial information. Furthermore, the DLAC deals
with concerns, if any, from outside Discovery regarding the application of accounting principles and external reporting. The review
includes the review of the financial statements and the annual integrated report, which requires information to be fair, balanced and
consistent with other information produced.
❚ 	Nominating for appointment, managing and overseeing the relationship with the Group’s joint external auditors, including scope, fees,
quality control, effectiveness and independence of the External Audit function. The DLAC also manages the policy, fees and the nature
of non-audit services provided by the external auditors. In its evaluation, the DLAC also must satisfy itself regarding the experience,
capacity, skill and respective accreditation of the audit team.
❚ 	Managing and overseeing the performance, conduct, quality and effectiveness of the Group’s internal audit functions. The DLAC also
reviews the annual work plan, capacity, scope and staffing of internal audit.
❚ 	Considering the appropriateness, capacity and expertise of senior members of the finance team.
❚ 	Reviewing the Group’s internal controls and assurance processes, including dealing with any complaints on the internal financial
control environment.
❚ 	Overseeing the effectiveness of Group governance with particular reference to the various subsidiary audit committee.
❚ 	Reviewing the appropriateness of the combined assurance model and plan for the Group, ensuring the inclusion of all material risk
areas, and that acceptable coordinated coverage of the various assurance activities result in an effective control environment to
support the integrity of information used for decision making as well as reporting to external stakeholders
❚ 	Undertaking formal assessments of finance and internal audit functions.
Structure of the audit committees in Discovery Group
The scope of the DLAC extends to all activities of the Discovery Limited Group and its subsidiaries, both locally and internationally. The
DLAC also acts as the statutory Audit Committee of Discovery Life Limited and Discovery Insure Limited.
The Discovery Group Europe Limited grouping, which includes Vitality Life and Vitality Health, the Discovery Bank Holdings Limited
grouping, and the Vitality Group International Inc grouping each have their own individual audit committees.
There is regular liaison and communication between the Chairperson of the DLAC and the Chairpersons of the various main subsidiary
audit committees on all key matters that are relevant to the Group. The DLAC receives regular reports from the various subsidiary audit
committees which includes in person feedback at reporting periods. In addition, the Chair of the DLAC has the opportunity to attend any
of the subsidiary audit committee meetings as an invitee.
4	Discovery Annual Financial Statements 2022

-- 5 of 219 --

REPORT OF THE DISCOVERY LIMITED AUDIT COMMITTEE continued
for the year ended 30 June 2022
COMPOSITION AND GOVERNANCE
The DLAC consists of a minimum of three independent non-executive directors of the Discovery Limited Board of Directors. During the
financial year ended 30 June 2022, the committee held six meetings as per the standard meeting cycle described below, two ad hoc
meetings and an annual trilateral meeting with the Prudential Authority.
The DLAC has the appropriate balance, diversity of knowledge, financial skills, and experience to execute its duties effectively. The
membership, qualifications, and attendance of the members of the DLAC for the year ended 30 June 2022 are as follows:
Committee member 	Qualifications
Number of meetings
eligible to attend
Number of meetings
attended
D Macready (Chairperson) 	BCom (Hons), CTA, CA (SA) 	6 	6
SE De Bruyn1 	LLB (Hons), MA 	3 	2
M Hlahla2 	BA (Hons) (Economics), MA 	6 	6
M Schreuder 	BCom (Hons), FIA, FASSA 	6 	6
SV Zilwa3 	BCompt (Hons), CTA, CA (SA) 	3 	3
1 M Hlahla appointed with effect from 15 August 2021.
2 SE de Bruyn retired with effect from 24 November 2021.
3 SV Zilwa did not stand for re-election as a member of the Audit Committee at the Annual General Meeting with effect from 24 November 2021
In addition to their membership on the DLAC, the committee members also serve across all key board committees to ensure a collective
and integrated oversight of key matters across the Discovery Group.
Committee member 	Actuarial committee
Risk and compliance
committee
Remuneration
committee
Social and Ethics
committee
D Macready 	x 	x
M Hlahla 	x 	x
M Schreuder 	x 	x (Chairperson)
The Chairperson of Discovery’s Board and other non-executive directors are entitled to attend any meetings on request. The Chief
Executive Officer, Chief Financial Officer, Chairperson of the Actuarial Committee, and executive directors attend meetings or parts of
meetings by invitation only. Other members of management are invited to attend meetings to provide the DLAC with greater insights into
specific issues or areas of the Group. The Chairperson has regular contact with the management team to discuss relevant matters
directly.
The DLAC Chairperson meets regularly with the Chief Financial Officer, the Heads of Actuarial, Risk and Compliance, and executive
management where necessary.
The internal and external auditors have direct access to the Chairperson, including closed sessions without management during the year,
on any matter that they regard as relevant to fulfilling the DLAC’s responsibilities. In addition, the Chairperson meets with the internal
audit and the external auditors before each meeting and at other times as necessary by either party before Committee meetings.
5	Discovery Annual Financial Statements 2022

-- 6 of 219 --

REPORT OF THE DISCOVERY LIMITED AUDIT COMMITTEE continued
for the year ended 30 June 2022
MEETINGS CYCLE FOR THE YEAR
The regular cycle of DLAC meetings during the financial year and the main focus areas were:
Review of year-end process for the year ended June 2021
and investor feedback following release of results.
Review of external auditor accreditation, independence
and recommendation of joint auditor appointment of
PwC and KPMG for the financial year end audit June
2022 at the annual general meeting.
COVID-19 monitoring.
IFRS 17 project progress.
October
COVID-19 monitoring.
Internal audit POPIA audit review.
Review of the external audit plan, with focus on the
allocation of audit work for purposes of joint audit.
IFRS 17 project progress with focus on the project plan.
Review of annual JSE proactive monitoring report.
November
Feedback from subsidiary audit committees as well as other
relevant committees such as Risk and Compliance and Actuarial.
Review of interim results for the six months to 31 December 2021
and SENS announcement
Feedback on the evaluation of the effectiveness of the DLAC by an
independent external consultancy firm.
February
Review of external audit plan and budgeted fees for the year
ended 30 June 2022.
Reviewed the accounting policies and IFRS developments,
including 	consideration 	for 	the 	recently 	concluded
AmplifyHealth transaction.
IFRS 17 project progress, with focus on feedback on the key
policies and decisions made by the respective governance
structures in the project, benchmarks Also reviewed the updated
timelines.
April
Review of unaudited year-to-date results and key financial and
accounting judgements as well as any relevant tax matters.
Review of annual impairment assessment in accordance with IFRS.
Actions finalised arising from the effectiveness review performed
December 2021 – February 2022.
Review and approve the annual internal audit plan, significant
areas of focus, as well as resources and budgeted fees
June
Discussion and review of year-end reports from the external
auditors and Group Internal audit (GIA), feedback from
subsidiary audit committees and other relevant committees
such as Risk and Compliance, and Actuarial
Consideration for going concern, solvency and liquidity.
Review and approval of the annual financial statements, related
SENS announcements and summary financial statements.
August
2022	2021
6	Discovery Annual Financial Statements 2022

-- 7 of 219 --

REPORT OF THE DISCOVERY LIMITED AUDIT COMMITTEE continued
for the year ended 30 June 2022
KEY FOCUS AREAS DURING THE FINANCIAL YEAR ENDED 30 JUNE 2022
Key audit matters
The DLAC annually assesses the Key Audit Matters (KAMs) reported by the external auditors and considers the key judgements and
estimates pertaining to the annual financial statements. Accordingly, the KAMs of the joint auditors for the current period were addressed
as follows.
Key Audit Matter 	How the DLAC addressed the matter
Valuation of assets and liabilities
arising from insurance contracts
The DLAC reviewed reports from the Group Chief Actuary and the external auditors on actuarial
assumptions and basis changes. Evaluated the appropriateness of actuarial assumptions used in
the setting of reserves, including negative rand reserves, taking into account recommendations
made by the Actuarial Committee.
Key judgements and estimates
made specifically associated with
COVID-19 pandemic in the
valuation of assets and liabilities
arising from insurance contracts.
The DLAC, together with the external auditors, have spent the past two years reviewing the
movements in estimates, assumptions, provisions and discretionary margins through the various
waves of COVID both in SA and UK. Special consideration was given during the current period to
the provisioning, both at the interim as well at the end of the year.
As COVID-19 moves from a pandemic to becoming more endemic, the Group wide COVID-19
specific provisions at the beginning of the period of R3.1 billion have either been utilized or
reversed within the period. No new specific provisions have been raised at year-end. Further
consideration has been given to the longer term effects in the long term mortality and morbidity
changes as well as short term strengthening in the individual Life businesses within their respective
Actuarial Committees.
The annual assessment for
impairment of goodwill and
intangible assets
The DLAC reviewed the impairment assessments that were based on the latest business planning
inputs.
It considered the sensitivity of these estimates to various scenarios. The most material of these is
the valuation of Discovery Bank which is sensitive to the discount rate, business plan performance
and most notably the terminal growth rate. Management re-engaged an external valuator to
perform an independent valuation and this valuation together with that performed by the auditors
provided acceptable headroom both at a Bank and Group carrying levels.
Note 4 ‘Significant accounting estimates and judgement in applying accounting policies’ of the
financial statements sets out the respective significant accounting estimates and judgements.
Significant matters
Significant matters are those matters which, in the view of the DLAC, were considered significant or material in nature, requiring either
the exercise of judgement or matters which were otherwise considered to be subjective from an accounting or auditing perspective. The
following areas received a key focus from DLAC during the year:
COVID 19 TREATMENT AND DISCLOSURES
DLAC has spent the past two years reviewing the movements in estimates, assumptions, provisions and discretionary margins through
the various waves of COVID in Discovery’s operations both in South Africa and United Kingdom. Whilst the impact of COVID-19 has been
experienced differently across the various Discovery Group of entities and geographies, the DLAC adopted a coordinated approach
across the various audit, actuarial and risk committees as well as the various control functions and assurance providers.
To fulfil its mandate of financial reporting DLAC has focused on transparent and understandable reporting particularly pertaining to the
specific COVID-19 claims provisioning and utilisation. Careful consideration was given during the current period to the provisioning both
at the interim and at the year-end.
As COVID-19 moves from a pandemic to becoming more endemic, the Group wide COVID specific provisions at the beginning of the
period of R3.1bn have either been utilised or reversed within the period under review. No new specific provisions have been raised at
year-end. Future consideration however has been given to the longer term effects of COVID 19 in the long term mortality and morbidity
changes as well as short term strengthening where required within the actuarial dynamics of each of the individual businesses.
7	Discovery Annual Financial Statements 2022

-- 8 of 219 --

REPORT OF THE DISCOVERY LIMITED AUDIT COMMITTEE continued
for the year ended 30 June 2022
IFRS 17 INSURANCE CONTRACTS
The successful implementation of IFRS 17 is a key focus of the DLAC. The Chairperson of the DLAC is also the chairperson of the IFRS 17
Governance Committee, which is a subset of the various Discovery and Vitality audit and actuarial committees. The IFRS 17 Governance
Committee receives detailed feedback from the respective IFRS 17 project groups and also allows for appropriate debates on key policy
and modelling elections. Note 29 of Annexure B sets out in more detail the governance structures of the IFRS 17 project.
The past year has seen significant progress being made in the preparation for transition of IFRS 17:
❚ 	With current working assumptions, Discovery has modelled the retrospective application of IFRS 17 up to June 2021 for the majority
of its insurance portfolios. The benefit of such a significant exercise has enabled a rigourous and informed debate on accounting
policy elections and modelling. The fully retrospective approach has allowed Discovery to evaluate how its products behave during
various scenarios such as the financial crises of 2008,volatile periods of market movements in foreign exchange and interest rates as
well as during the COVID-19 pandemic.
❚ 	The insights of these outputs have assisted both DLAC and the Board to consider how information will best be reported in the financial
statements, including directional steering of transitional balances. This enables a good understanding of the new reporting, which in
itself is a significant shift from existing reporting of insurance contracts and confirmed the value in richer presentation and disclosures
to enable more comparability within the industry.
❚ 	Discovery subject matter experts on IFRS, Tax and Actuarial actively partake in various insurance industry forums to keep close to
recent market practice and developments. This ensures that debates on the various accounting policy elections and modelling are well
thought through and benchmarked to best industry practice. In particular, Discovery has remained closely attuned to the developments
in draft tax legislation in both South Africa and United Kingdom so as to clearly understand any impacts the legislation could have on
the recognised assets and liabilities of Discovery.
❚ 	The members of Discovery Board, the various Board sub-committees, as well as executives of the various insurance business lines,
have had extensive training sessions on IFRS 17, including the practical interpretation and application within the context of the
Discovery Group businesses.
❚ 	The project focus for the next financial year is the implementation of the parallel run, completion of the audit of transition balances
and ensuring business as usual financial reporting. For a more detailed breakdown of the project focus for the next financial year,
refer to Note 29 of Annexure B.
OTHER SIGNIFICANT ITEMS ALSO CONSIDERED
❚ 	Evaluated management’s assessment of impairment of specified assets under IAS 36 Impairment of Assets. In addition to the focus on
Goodwill of Discovery Bank as noted in the KAMs above, the DLAC also considered specifically the goodwill of VitalityHealth and
VitalityLife as well as the carrying value of material associates. The DLAC is satisfied that there was no risk of impairment of these
assets.
❚ 	Reviewed the supportability of deferred tax assets raised on assessed losses.
❚ 	In February 2022 Discovery announced its partnership with AIA in establishing Amplify Health. The DLAC has considered and reviewed,
together with the external auditors, the appropriate accounting treatments to reflect the various elements arising from the Amplify
Health arrangement.
❚ 	As noted in last year’s DLAC report was the key focus to review progress and resolution of the Part VII transfer of the Prudential
Assurance Company (‘PAC‘) book in Vitality Life UK. DLAC notes the agreement reached by Discovery and the PAC earlier in the year to
defer the initially intended transfer of PAC book from the PAC balance sheet to the Vitality Life balance sheet. Given the deferral
options, this can be practically viewed as an indefinite deferral.
8	Discovery Annual Financial Statements 2022

-- 9 of 219 --

REPORT OF THE DISCOVERY LIMITED AUDIT COMMITTEE continued
for the year ended 30 June 2022
Financial statement and accounting practices
The DLAC has reviewed the accounting policies and the consolidated and separate financial statements of Discovery and is satisfied that
Discovery has established financial reporting procedures and that those procedures are operating as intended, are appropriate, and comply
with International Financial Reporting Standards (IFRS). This includes consideration of all entities included in the consolidated Annual
Financial Statements, to ensure access to all financial information to the issuer to effectively prepare and report on the financial statements
of Discovery. The DLAC confirmed the going concern basis for the preparation of the both interim and Annual Financial Statements.
During the year, the DLAC reviewed the following financial reporting matters to ensure the integrity and fairness of financial information:
❚ 	The IFRS interpretation committee issued a decision on ‘Configuration or Customisation Costs in a Cloud Computing Arrangement’.
The interpretation specifies how to account for customisation costs within a cloud computing arrangement. More specifically, whether
the customisations costs may be capitalised or deferred, or whether the costs should be expensed. The DLAC requested management
to perform a detail review of all customisation costs capitalised as part of software across Discovery Group. It was identified that
certain previously capitalised costs should be reclassified out of intangible assets, either as a prepayment or immediately expensed.
❚ 	Clarification on the policy for utilisation of discretionary margins when insurance contracts are backed by financial assets.
❚ 	A DLAC process is established to receive and deal appropriately with any concerns and complaints relating to Discovery’s accounting
and reporting practices. The DLAC immediately deals with any issues raised. No specific issues have been raised during the course of
the financial year.
❚ 	As part of its annual work plan, the DLAC evaluates management’s assessment of the findings in the most recent JSE’s Pro-active monitoring
report. Management performs a detailed assessment of the JSE findings against Discovery’s Annual Financial Statements to identify any
potential areas of non-compliance or future improvements or enhancement in Discovery’s disclosures. The review was completed in
November 2021 with the release of the JSE Pro-active monitoring report 2021. No significant deficiencies were identified, but smaller
changes were incorporated into the interim results and annual financial statements in light of recommendation from the report.
Finally, DLAC has considered the accounting treatments, significant unusual transactions, and accounting judgements. DLAC has
evaluated management’s judgements and reporting decisions in relation to the annual integrated report and ensured all material
disclosures had been included. In addition, it has reviewed both financial and non-financial information, forward-looking statements, and
sustainability information.
9	Discovery Annual Financial Statements 2022

-- 10 of 219 --

EXTERNAL AUDIT
Auditor appointment, accreditation and quality and fees
DLAC is responsible for the appointment, compensation and oversight of the independent joint external auditors namely KPMG Inc
(KPMG) and PricewaterhouseCoopers Inc. (PwC), who were appointed as joint auditors effective 1 July 2021.
❚ 	The DLAC has assessed both the independence and objectivity and satisfied itself that the external auditors are independent of
Discovery. The requisite assurance was sought and provided by the auditors that internal governance processes within each audit firm
support and demonstrate its claim to independence.
❚ 	The DLAC has also reviewed the appropriate JSE accreditation of the individual audit partners responsible for the audit sign-off, and
has reviewed the most recent IRBA inspection reports of the respective auditors.
❚ 	A formal policy exists in respect of the provision of non-audit services by the external auditors of Discovery and its subsidiaries, and a
formal procedure governs the process whereby the auditors are appointed to provide any non-audit services, including a limitation
on fees for non-audit services which shall not exceed 25% of each joint auditor audit fee. During the year, the policy was amended to
specifically address joint auditor appointments. Non-audit services was less than 5% of total audit fees of each respective joint auditor.
❚ 	The Chairperson of the DLAC pre-approves the nature and extent of any non-audit services that the external auditors provide in terms
of the agreed pre-approval policy, and the schedule of approved non-audit services is reviewed annually by the DLAC.
❚ 	The DLAC, following consultation with executive management, approved the engagement letter, terms, audit plan and main areas of
focus as well as budgeted audit fees for the year ending 30 June 2022. This approval of the audit plan included specific consideration
as to the allocation of work between the joint auditors.
❚ 	The DLAC Chairman met with both KPMG and PWC lead partners prior to every DLAC meeting to discuss the 2021/22 audit plan, key
areas of focus, scope, findings and conclusions as well as confirming the suitability of any reliance on GIA. The DLAC met with the
external auditors independently twice for the year under review during reporting periods.
❚ 	In terms of the conditions laid out in section 94(8) of the Companies Act and based on its assessment taking consideration of the
criteria of King IV, the JSE and general guidance to Audit Committees, the DLAC is satisfied with the performance and quality of the
external audit, the external auditors and lead partners for the year ended 30 June 2022.
❚ 	DLAC received feedback from the external auditors on the audit of the Annual Financial Statements of the Group, the critical accounting
estimates and judgements as well as cross reviews and including the Summary of Audit Differences for the year ended 30 June 2022.
DLAC notes the unqualified independent auditors report in relation to Discovery Limited and the Group.
❚ 	DLAC recommends to the Board the re- appointment of KPMG and PwC as external auditors of Discovery Limited and the Group for
the year ending 30 June 2023.
The DLAC has further considered the MAFR requirement, which mandates the rotation of PwC from 1 July 2023 and the announced
intention to nominate Deloitte & Touche to replace PwC from 1 July 2023 as joint external auditors with KPMG from that date. Accordingly,
the DLAC has considered the commencement of the shadow process starting during the forthcoming financial year.
10	Discovery Annual Financial Statements 2022

-- 11 of 219 --

GROUP INTERNAL AUDIT (GIA)
GIA provides independent objective assurance that the governance processes, including professional ethics, the management of risk and
systems of internal controls, are both adequate and effective. The Chief Audit Executive (CAE) has a functional reporting line to the DLAC
Chairperson and an administrative reporting line to the Group Chief Financial Officer (CFO).
DLAC is satisfied that GIA displays a high level of professional objectivity as well as professional ethics in performing its work.
An external independent quality assessment of internal audit was conducted by SizweNtsalubaGobodo Grant Thornton (“SNG GT”) in
2021 and GIA received a rating of “Generally Conforms” to the Institute of IIA Standards and Code of Ethics, as well as to each of the
individual Standards. “Generally conforms” is the best possible rating that can be achieved.
In assessing the quality, performance and delivery of the internal audit plan, including the scope of the work performed, the level of
resources and coverage of the audit plan, the DLAC took cognisance of the following:
❚ 	Reviewed and approved the internal audit charter and audit plan and evaluated the independence, effectiveness, and performance in
line with its charter.
❚ 	Challenged the audit plan’s focus, relevance, and risk-based emphasis in response to the extraordinary circumstances presented by
the COVID-19 pandemic and the potential impact on the control environments.
❚ 	Considered reports on the Group’s internal control systems, with a specific focus on the effectiveness of internal financial controls,
including financial reporting controls.
❚ 	Reviewed significant issues raised by the internal audit processes and the adequacy of corrective action and accountability taken in
response to such findings.
❚ 	Assessed the independence and effectiveness of the CAE, the internal audit function and the quality and extent of audit resources and
found them to be satisfactory.
❚ 	Received the annual assessment provided by internal audit confirming the effectiveness of Discovery’s governance, risk management
and control processes.
❚ 	Reviewed the external auditors’ annual assessment of internal audit in terms of the requirements of ISA 610, which reaffirmed the
extent of reliance that could be placed on the internal audit work.
REPORT OF THE DISCOVERY LIMITED AUDIT COMMITTEE continued
for the year ended 30 June 2022
11	Discovery Annual Financial Statements 2022

-- 12 of 219 --

FINANCIAL CONTROLS
The DLAC is responsible for assessing Discovery’s system of internal financial and accounting controls. In this regard, the DLAC has,
among other things, evaluated the adequacy and effectiveness of Discovery’s system of internal controls and made appropriate
recommendations to the Board. This has included a formal documented review by the internal audit function of the design, implementation,
and effectiveness of Discovery’s internal financial controls systems.
For the year ended 30 June 2022, DLAC reviewed the combined assurance reassessment of the design, documentation, and testing
coverage of financial controls inclusive of financial reporting controls as well as the executive attestation process to support the
responsibility statement attested by the Chief Executive and Chief Financial Officer. The attestation in terms of the JSE Equity Listings
Requirement 3.84(k) is set out on page 3 of the Discovery Limited’s Annual Financial Statements.
Based on the results of these reviews, it is the view of the DLAC that Discovery’s internal financial controls effectively produce accurate
financial information and a fair presentation of the financial performance of Discovery in the Annual Financial Statements
OTHER MATTERS CONSIDERED BY THE DLAC
In further fulfilling its duties and discharging its obligations for the year ended 30 June 2022, the DLAC also considered:
Matter considered 	Outcome
Assessment of the
effectiveness of DLAC
During the year an Independent externally managed assessment was performed by a renowned
international consultancy on the effectiveness of the DLAC. A satisfactory conclusion was achieved.
Regulator meetings 	The DLAC had participated in the annual bilateral and trilateral meetings as set up with the respective
regulator bodies.
Evaluation of the expertise
and experience of the finance
function and financial director
The DLAC reviewed and satisfied itself with the appropriateness of Discovery's finance function's
expertise, resources, and experience, including the Chief Financial Officer, Mr DM Viljoen.
Independent quality
assurance reviews on
Discovery internal and
external assurance providers
During the year, Discovery undertook independent quality assurance reviews on the various internal
and external assurance providers, i.e., excluding first-line management. Group Risk Management,
Group Compliance, and the Actuarial Function have been completed, obtaining high assurance.
Combined assurance 	The combined assurance model provides an integrated plan of the various activities and sources of
assurance, including risk and compliance, external and internal audit, corporate finance functions
and the Actuarial Committees. The DLAC has reviewed the combined assurance model, which has
been implemented throughout the Group and has concluded that the model is both appropriate and
effective in addressing the risks facing Discovery.
Whistleblowing 	The DLAC receives and deals with any complaints or whistleblowing, whether from within or outside
Discovery, relating to the accounting practices and internal audit of Discovery, the content or auditing
of Discovery’s financial statements, the internal financial controls of Discovery and related matters.
No such whistleblowing was received during the financial year.
Ethics and compliance 	The DLAC is responsible for reviewing any major breach of Discovery’s code of conduct and ethics
and relevant legal, regulatory, and other obligations reported to the DLAC by the Social and Ethics
Committee. The DLAC is satisfied that there has been no material breach of these standards or
material non-compliance with laws and regulations. The DLAC is satisfied that it has complied with all
its legal, regulatory, and other obligations during the period under review.
REPORT OF THE DISCOVERY LIMITED AUDIT COMMITTEE continued
for the year ended 30 June 2022
12	Discovery Annual Financial Statements 2022

-- 13 of 219 --

KEY FOCUS AREAS FOR THE FINANCIAL YEAR 2023
The DLAC will remain focused on:
❚ 	Monitoring and evaluation of the Group’s preparation for the implementation of IFRS 17 Insurance Contracts, which becomes effective
1 July 2023 for Discovery Group. DLAC will continue to play a pivotal role, together with the Group Actuarial Committee, in the IFRS 17
Governance Committee’s oversight in assessing, monitoring and reviewing the progress, challenges, major decision points and
impacts of its implementation across the Discovery Group.
❚ 	Ensuring the effective functioning of the Group’s financial systems and processes, financial control environment, monitored by an
effective combined assurance model. This includes the monitoring the implementation of the amended JSE Listings Requirements,
including the effectiveness of internal financial controls.
❚ 	Oversee the group’s second phase of its audit firm rotation plan in response to the IRBA’s Mandatory Audit Firm Rotation (MAFR) rule
with the proposed final audit of PwC for the year ended 30 June 2023. As was communicated previously, Deloitte will be proposed at
the next annual general meeting to be appointed as the incoming joint auditor with effect from 1 July 2023, i.e. for the year ended 30
June 2024.
❚ 	The implications of ESG risk in measuring the sustainability and societal impact of the Group, together with ESG accounting disclosures
and assurance processes.
❚ 	Supporting the Board of Discovery Limited in the implementation of a revised subsidiary governance framework which will further
enhance the governance and oversight of subsidiaries within a rapidly expanding and complex multi-national group whilst maintaining
its common purpose, values and Shared-Value business model.
CONCLUSION
The DLAC is satisfied that it has complied with all statutory duties and duties given to it by the Board under the Terms of Reference.
The DLAC has reviewed the consolidated and separate financial statements of Discovery Limited for the year ended 30 June 2022 and,
based on the information provided to the DLAC, considers that Discovery complies, in all material respects, with the requirements of the
Companies Act and International Financial Reporting Standards (IFRS).
The DLAC has recommended the Annual Financial Statements to the Board for approval. The Board has subsequently approved the
Annual Financial Statements, which will be open for discussion at the forthcoming Annual General Meeting.
D Macready
Chairperson: Discovery Limited Audit Committee
7 September 2022
REPORT OF THE DISCOVERY LIMITED AUDIT COMMITTEE continued
for the year ended 30 June 2022
13	Discovery Annual Financial Statements 2022

-- 14 of 219 --

INDEPENDENT AUDITORS’ REPORT
for the year ended 30 June 2022
TO THE SHAREHOLDERS OF DISCOVERY LIMITED
REPORT ON THE AUDIT OF THE CONSOLIDATED AND SEPARATE
FINANCIAL STATEMENTS
Our opinion
We have audited the consolidated and separate financial statements of Discovery Limited (the Group and Company), set out on pages
25 to 202 which comprise:
❚ 	the Group and Company statements of financial position at 30 June 2022;
❚ 	the Group and Company income statements for the year then ended;
❚ 	the Group and Company statements of other comprehensive income for the year then ended;
❚ 	the Group and Company statements of changes in equity for the year then ended;
❚ 	the Group and Company statements of cash flows for the year then ended;
❚ 	the notes to the Group and Company annual financial statements (which include Annexures A, B and C), including a summary of
significant accounting policies..
In our opinion, the consolidated and separate financial statements present fairly, in all material respects, the consolidated and separate
financial position of Discovery Limited at 30 June 2022, and its consolidated and separate financial performance and consolidated and
separate cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRS) and the requirements
of the Companies Act of South Africa.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are
further described in the Auditors’ responsibilities for the audit of the consolidated and separate financial statements section of our report.
We are independent of the Group and Company in accordance with the Independent Regulatory Board for Auditors’ Code of Professional
Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of financial statements in
South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical
requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the corresponding sections of the International
Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (including International Independence
Standards). We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
14	Discovery Annual Financial Statements 2022

-- 15 of 219 --

INDEPENDENT AUDITORS’ REPORT continued
for the year ended 30 June 2022
Key audit matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated and
separate financial statements of the current period. These matters were addressed in the context of our audit of the consolidated and
separate financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these
matters. We have determined that there are no key audit matters to communicate in respect of the separate financial statements.
Key audit matter 	How our audit addressed the key audit matter
Valuation of assets and liabilities arising from insurance contracts
Refer to Section 13 of Annexure B – Group accounting policies, and
notes 2, 4.1, 5 and 18 to the consolidated financial statements
At 30 June 2022, the Group held assets arising from insurance
contracts to the value of R56 645m and liabilities arising from
insurance contracts of R109 200m.
The assets and liabilities arising from insurance contracts related to
individual life and group life policies, with the key audit matter
focussing on individual life policies underwritten by Discovery Life.
The actuarial value of those individual life assets and liabilities
arising from insurance contracts that are long-term in nature is
determined based on a prospective discounted cash flow valuation
basis, calculated as the difference between the present value of
future benefit payments plus expenses and the present value of
future premiums.
In valuing these assets and liabilities arising from insurance
contracts relating to individual life policies underwritten by
Discovery Life, management applies significant judgement and
various assumptions are made, including best estimate assumptions
regarding the future expected claims experience, premium income,
expenses and commission. Changes to these assumptions may
result in a material change to the valuation.
The most significant assumptions made in determining the value of
these assets and liabilities arising from insurance contracts relate to:
Impact of the Vitality programme on the valuation of assets and
liabilities arising from insurance contracts relating to individual life
policies underwritten by Discovery Life –
As for most life insurers, assumptions relating to mortality,
morbidity and the level of surrender and lapses are significant in the
determination of the valuation of policyholder liabilities and assets
arising from insurance contracts. The Group is unique due to its
Vitality programme. In terms of this programme, policyholders are
provided access to a number of services and benefits to encourage
them to become healthier and are awarded Vitality points, which
ultimately determine their Vitality status. The mortality, morbidity
and lapse assumptions within the valuation of policyholder liabilities
and assets arising from insurance contracts in the Group are
specifically impacted by the Discovery Vitality policyholder statuses.
The Discovery Vitality policyholder statuses inform the policyholder
behaviour experience expected in future and adjustments are
therefore made to the mortality, morbidity, and lapse assumptions
to reflect the expected impact of engagement in the Vitality
programme. The Discovery Vitality status distribution is updated
every year based on the actual Vitality status of the policyholders.
The primary procedures we performed to address this key
audit matter included the following:
We involved our actuarial specialist, with specialised skills
and knowledge, to assist in:
❚ 	Gaining an understanding of the Group’s actuarial
internal control environment and governance, including
the functioning of the Group’s Actuarial Committee (and
where applicable, the subsidiaries’ Actuarial Committees)
and testing the design and implementation of certain key
controls related to this assessment.
❚ 	We tested the design and implementation of the liability
build-up control performed by management to support
the sources of profit and we corroborated the
movements in the liability to relevant underlying
information, from both internal and external sources.
❚ 	Evaluating the appropriateness of the valuation
methodology applied by the Group to determine the
value of assets and liabilities arising from insurance
contracts. In doing so, we considered the principles and
integrity of the Group’s models against acceptable
industry standards.
❚ 	Challenging management with respect to the
appropriateness of all significant assumptions adopted in
the determination of the valuation of assets and liabilities
arising from insurance contracts by comparing these
assumptions to the results of historical actuarial
experience investigations conducted by management,
including benchmarking these assumptions against
South African life insurance industry trends to determine
whether they are reasonable and supportable.
❚ 	Evaluating the compliance of the valuation of the assets
and liabilities arising from insurance contracts against the
requirements of the Financial Soundness Valuation (FSV)
basis as described in the Standard of Actuarial Practice
(SAP) 104 and the Group’s accounting policies as set out
in Section 13 of Annexure B – Group Accounting policies.
Our further procedures included:
❚ 	Evaluating, on a sample basis, the integrity of the
underlying data, which informs the assumptions used in
the determination of the value of assets and liabilities
arising from insurance contracts
❚ 	Assessing the appropriateness of disclosures included in
the consolidated financial statements in accordance with
the requirements of IFRS 4 – Insurance Contracts (IFRS 4)
and the directors’ approved valuation methodologies
and assumptions.
15	Discovery Annual Financial Statements 2022

-- 16 of 219 --

INDEPENDENT AUDITORS’ REPORT continued
for the year ended 30 June 2022
Key audit matter 	How our audit addressed the key audit matter
Use of discretionary margins with respect to profit recognition –
The individual life insurance operations sell profitable insurance
products. Applying the reserving basis using only compulsory
margins as prescribed by regulations would result in a premature
recognition of future profits being recognised at the inception of
new business contracts; and therefore, certain discretionary
margins are added to the best estimate assumptions Profits
recognised at initial recognition of the insurance contracts are,
however, limited to the extent of actual acquisition costs incurred
through the addition of discretionary margins. These discretionary
margins are reset at every valuation date to reflect the underlying
profitability of the portfolio and are released over the term of a
policy in line with the risk borne. Changes to these discretionary
margins have a direct impact on the profit recognition in a period
and the Group has therefore established a framework as disclosed
in Section 13 of Annexure B – Group accounting policies, to utilise
the available discretionary margin in a specified order.
We considered the valuation of assets and liabilities arising from
insurance contracts to be a key audit matter in our audit of the
consolidated financial statements, as it involves complex and
subjective judgement about future events, policyholder behaviour
and economic conditions.
Impact of the Vitality programme on the valuation of assets
and liabilities arising from insurance contracts relating to
individual life policies underwritten by Discovery Life –
In particular, our procedures included:
❚ 	Evaluating, on a sample basis, the reasonability of the
Group’s assumptions in setting the Discovery Vitality
status distribution, and the progression between
statuses, by comparing these against historical trends;
and
❚ 	Evaluating, on a sample basis, the integrity of the data
inputs captured in the models by assessing whether the
inputs used are consistent with historic actual
experience.
Use of discretionary margins with respect to profit recognition –
In particular, our procedures included:
❚ 	Assessing whether all acquisition costs were
appropriately captured in the determination of the
discretionary margins at 30 June 2022 by comparing
these input amounts to the audited acquisition cost
amounts included in the Group’s income statement; and
❚ 	Evaluating the appropriateness of the calculation of the
discretionary margin transfer against the requirements of
the methodology set out in the Group’s accounting
policies in Section 13 of Annexure B – Group Accounting
policies.
16	Discovery Annual Financial Statements 2022

-- 17 of 219 --

INDEPENDENT AUDITORS’ REPORT continued
for the year ended 30 June 2022
Key audit matter 	How our audit addressed the key audit matter
Impairment assessment of goodwill for the Discovery Bank cash-
generating unit (CGU)
Refer to Section 7 of Annexure B – Group accounting policies, and notes
4.2 and 10 to the consolidated financial statements
At 30 June 2022, the Group held goodwill in relation to the Discovery
Bank cash-generating unit (CGU) at a carrying value of R2 417
million. This goodwill arose from the acquisition of the
DiscoveryCard business.
In accordance with the terms of IAS 36 – Impairment of Assets (IAS
36), the Group annually assesses goodwill allocated to the Discovery
Bank CGU for impairment. The recoverable amount of the Discovery
Bank CGU is estimated based on the fair value less costs to sell.
Inherent in the determination of fair value less costs to sell is
estimation uncertainty, as the fair value measurement is categorised
as level 3 on the fair value hierarchy given that it makes use of
unobservable inputs using the income approach.
Management has applied judgement in determining the inputs in
deriving its fair value measurement with regards to the assets that
are attributable to the Discovery Bank CGU including the forecast
cash flows and customer growth rates, the expensing of system-
build costs and intangible assets acquired in the business
combination and in the determination of the terminal growth rate
and the discount rate applied. Furthermore, management has
applied judgement in determining the risk-free rate and the beta
factor to be applied in deriving the discount rate.
We considered the impairment assessment of goodwill for the
Discovery Bank CGU to be a key audit matter in our audit of the
consolidated financial statements, as it involves complex and
subjective judgement and is subject to estimation uncertainty.
The primary procedures we performed to address this key
audit matter included the following:
❚ 	Gaining an understanding of the process followed by
management to assess goodwill for the Discovery Bank
CGU for impairment, including management’s key
assumptions and testing the design and implementation
of certain key controls related to this assessment.
We involved our valuation and economic specialists, with
specialised skills and knowledge, to assist in:
❚ 	Evaluating the appropriateness of the valuation
methodology applied by management to calculate the
recoverable amount of the Discovery Bank CGU. In doing
so, we considered the principles and integrity of the
discounted cash flow model against the requirements of
IAS 36 and acceptable industry standards.
❚ 	Evaluating the appropriateness of management’s
assumptions against external market data or industry
standards, including the discount rate applied, customer
growth rates, and spend assumptions that drive income
as well as the reasonableness of the expensing of
system-build costs and intangible assets acquired and
other cash flow items, including working capital
requirements and the credit loss ratios applied in the
business valuation.
❚ 	Performing various sensitivity analyses over
management’s forecast cash flows, customer growth
rates, the terminal growth rate and discount rate applied
to assess the impact of changes in these key assumptions
on the recoverable amount of the Discovery Bank CGU.
Our further procedures included:
❚ 	Assessing the appropriateness of disclosures included in
the consolidated financial statements in accordance with
the requirements of IAS 36.
17	Discovery Annual Financial Statements 2022

-- 18 of 219 --

INDEPENDENT AUDITORS’ REPORT continued
for the year ended 30 June 2022
Other information
The directors are responsible for the other information. The other information comprises the information included in the document titled
“Discovery Limited Annual Financial Statements for the year ended 30 June 2022”, which includes the Directors’ report, the Report of the
Discovery Limited Audit Committee and the Certificate by the Company Secretary as required by the Companies Act of South Africa, which
we obtained prior to the date of this auditors’ report, and the document titled “Discovery Limited Integrated Annual Report for the year
ended 30 June 2022”, which is expected to be made available to us after that date. The other information does not include the consolidated
or the separate financial statements and our auditors’ report thereon
Our opinion on the consolidated and separate financial statements does not cover the other information and we do not and will not
express an audit opinion or any form of assurance conclusion thereon.
In connection with our audit of the consolidated and separate financial statements, our responsibility is to read the other information
and, in doing so, consider whether the other information is materially inconsistent with the consolidated and separate financial
statements, or our knowledge obtained in the audit, or otherwise appears to be materially misstated.
If, based on the work we have performed on the other information obtained prior to the date of this auditors’ report, we conclude that
there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.
Responsibilities of the directors for the consolidated and separate financial statements
The directors are responsible for the preparation and fair presentation of the consolidated and separate financial statements in
accordance with IFRS and the requirements of the Companies Act of South Africa, and for such internal control as the directors determine
is necessary to enable the preparation of consolidated and separate financial statements that are free from material misstatement,
whether due to fraud or error.
In preparing the consolidated and separate financial statements, the directors are responsible for assessing the Group and Company’s
ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of
accounting unless the directors either intend to liquidate the Group and/or the Company or to cease operations, or have no realistic
alternative but to do so.
Auditors’ responsibilities for the audit of the consolidated and separate financial statements
Our objectives are to obtain reasonable assurance about whether the consolidated and separate financial statements as a whole are free
from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable
assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material
misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate,
they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated and separate
financial statements.
As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the
audit. We also:
❚ 	Identify and assess the risks of material misstatement of the consolidated and separate financial statements, whether due to fraud or
error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to
provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting
from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
❚ 	Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group’s and the Company’s internal control.
❚ 	Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures
made by the directors.
❚ 	Conclude on the appropriateness of the directors’ use of the going concern basis of accounting and, based on the audit evidence
obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group’s and the
Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention
in our auditors’ report to the related disclosures in the consolidated and separate financial statements or, if such disclosures are
inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors’ report.
However, future events or conditions may cause the Group and/or the Company to cease to continue as a going concern.
❚ 	Evaluate the overall presentation, structure and content of the consolidated and separate financial statements, including the
disclosures, and whether the consolidated and separate financial statements represent the underlying transactions and events in a
manner that achieves fair presentation.
❚ 	Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group
to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of
the group audit. We remain solely responsible for our audit opinion.
18	Discovery Annual Financial Statements 2022

-- 19 of 219 --

INDEPENDENT AUDITORS’ REPORT continued
for the year ended 30 June 2022
We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit
findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and
to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where
applicable, actions taken to eliminate threats or safeguards applied.
From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the
consolidated and separate financial statements of the current period and are therefore the key audit matters. We describe these matters
in our auditors’ report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances,
we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably
be expected to outweigh the public interest benefits of such communication.
Report on other legal and regulatory requirements
In terms of the IRBA Rule published in Government Gazette Number 39475 dated 4 December 2015, we report that KPMG Inc. and
PricewaterhouseCoopers Inc. have been the joint auditors of Discovery Limited for one year.
Prior to the commencement of the joint audit relationship, PricewaterhouseCoopers Inc. was the sole auditor of Discovery Limited for
twenty-one years.
Pricewaterhouse Coopers Inc. 	KPMG Inc.
Director: Andrew Graham Taylor 	Director: Mark Danckwerts
Registered Auditor 	Registered Auditor
Jukskei View 	KPMG Crescent
4 Lisbon Lane 	85 Empire Road
Waterfall City 	Parktown
2090 	2193
South Africa 	South Africa
Date 7 September 2022 	Date 7 September 2022
19	Discovery Annual Financial Statements 2022

-- 20 of 219 --

The directors present their 23rd annual report, which forms part of the consolidated and separate annual financial statements of
Discovery Limited for the year ended 30 June 2022.
NATURE OF BUSINESS
Discovery Limited (the Company) is listed on the JSE Limited and is an integrated financial services organisation specialising in health
insurance, life assurance, wellness, investments and savings, short-term insurance and banking.
Discovery is a shared value insurance company whose purpose and ambition are achieved through a pioneering business model
that incentivises people to be healthier, and enhances and protects their lives. Our unique and sophisticated Shared-value insurance
model delivers better health and value for clients, superior actuarial dynamics for the insurer and a healthier society. It is a powerful
platform of integrated assets and capabilities, which has positioned us well to respond to the following key trends that were
accelerated by COVID-19 and remain relevant:
❚ 	a focus on health, wellness and resilience (nature of risk)
❚ 	accelerated use of technology and increased digitisation
❚ 	increased importance of purpose and trust
Discovery continues to drive the execution of existing market-specific strategies through its composite model, with the following strategic
objectives established for each:
❚ 	South Africa: To be the perfect composite model, number 1 in our chosen segments in every industry, and the Bank pivoting to growth
as the composite-maker within SA
❚ 	United Kingdom: To have best in breed products across businesses and operating as a fully integrated composite business with a
seamless One Vitality client journey and to have a successful entry into motor insurance
❚ 	Vitality Global (incorporating Vitality Group and Ping An Health Insurance): To be the foremost provider of health and wellness
intellectual property, powered by the right combination of technology and analytics - accelerating the growth of global insurers by
attracting, engaging and delighting their clients
Group Structure
The Company is directly and indirectly the holding company of subsidiaries and investments as set out in Annexure A. In addition,
Discovery is required to consolidate certain unit trusts which are deemed to be under the Group’s control in terms of IFRS 10
Consolidated Financial Statements. These are also set out in Annexure A.
YEAR UNDER REVIEW
The operating environment in the year under review was characterised by two significant factors: Firstly, the evolution of COVID-19, as
the pandemic has eased and appears to be approaching endemic stage, with conditions in most markets normalising, except for Asia,
which was affected by severe lockdowns and restrictions. Secondly, considerable geo-political polarisation and macro-economic volatility,
caused by a combination of the COVID-19 pandemic, Ukraine conflict, and supply side constraints. This resulted in higher inflation,
increased interest rates as well as currency and market volatility.
Discovery’s results for the full year ended 30 June 2022 reflected a strong operational performance.
❚ 	Normalised profit from operations increased by 45% to R9 384 million for the year under review. The SA and UK Composites delivered
strong growth in normalised operating profit and new business. The SA results were driven by a strong recovery from Discovery Life
partially offset by Discovery Insure’s results being severely impacted by adverse weather and supply-side inflation related to motor
vehicle repairs. The operating performance of Vitality Global reflected the specific dynamics of the impact of COVID-19 on the Asian
markets with PAH further impacted by the decline in the Chinese investment markets.
❚ 	The Group is emerging through a cycle of intense organic investment into new initiatives, dominated by the investment into Discovery
Bank, which has seen excellent high-quality growth over the period. The period saw increased investment into Vitality Health
International, particularly for the establishment of Amplify Health in partnership with AIA, as announced on 15 February 2022.
Additionally, the Group streamlined certain initiatives with a focus on those businesses expected to generate significant value. In
addition to reviewing its stake in AIA Health in Australia, the Group decided to exit the UK investment market given the structural
change in market conditions, mainly driven by significant margin compression.
❚ 	New Business API (Annual Premium Income) increased by 6% despite a reduction in PAH new business primarily due to a restructuring
of the cooperation with Ping An Life for business written in certain regions in China as part of the overall re-alignment of PAH to focus
on growing high quality own license business. Persistency continued to exceed expectations in all businesses
❚ 	Normalised Headline Earnings increased 71% to R5 816 million and headline earnings increased 74% to R5 204 million, both positively
impacted by mark-to-market foreign currency gains. Within headline earnings, the negative effect of higher long-term interest rates in
SA was partly offset by the benefit of higher long-term interest rates in the UK. A portion of the full benefit in the UK, after hedge
effects, was recognised as an increase in discretionary margins.
DIRECTORS’ REPORT
for the year ended 30 June 2022
20	Discovery Annual Financial Statements 2022

-- 21 of 219 --

DIRECTORS’ REPORT continued
for the year ended 30 June 2022
The reporting period included the end of the Delta third wave of the COVID-19 pandemic in South Africa (SA) and the highly infectious
but less virulent Omicron variant. While R3.7 billion COVID-19 claims, gross of reinsurance, were paid in the year in SA, the earnings
impact was limited as previously raised COVID-19 provisions have been adequate. As the pandemic appears to be approaching
endemic stage, focus has shifted to incorporating the longer-term implications of COVID-19, resulting in significant strengthening of
the mortality and morbidity bases in Discovery Life and Vitality Life in the June 2022 actuarial review.
Normalised profit from operations over prior year
The following table demonstrates the contribution of key businesses to the growth in normalised profit from operations of 45%
compared to the prior year.
Business
Normalised profit
from operations
12 months ended
30 June 2022
R million
% change
12 months ended
30 June 2022
Discovery Health 	3 600 	+5%
Discovery Life 	4 028 	+200%
Discovery Invest 	1 204 	+11%
Discovery Insure 	(162) 	-165%
SA Composite (excluding new initiatives)* 	8 679 	41%
VitalityHealth 	1 328 	+39%
VitalityLife 	671 	+4%
UK Composite (excluding new initiatives) 	1 999 	+25%
Vitality Group 	473 	+13%
Ping An Health 	338 	-18%
Vitality Global (excluding new initiatives) 	811 	-2%
New initiatives (excluding Bank) 	(1 115) 	Increase in spend 14%
Discovery Bank 	(990) 	Reduction in spend 10%
Normalised Profit from operations* 	9 384 	+45%
* Includes includes R9 million for SA Vitality (2021: R43 million)
21	Discovery Annual Financial Statements 2022

-- 22 of 219 --

SHARE CAPITAL
Details of the authorised and issued share capital, together with details of shares issued during the year, appear in note 17 to the
Annual Financial Statements.
DIVIDENDS
Details of dividends paid and declared are set out in note 43 and note 44 to the Annual Financial Statements. While the Group’s capital
position remains robust, in light of the uncertain future impact of COVID-19 and the volatile global macroeconomic environment, the
Discovery Board has decided to retain its prior stated position and has decided not to declare an ordinary final dividend for the year
ended 30 June 2022. The reintroduction of an ordinary dividend will be considered on an ongoing basis.
CAPITAL
Solvency and liquidity test
The directors have performed the requisite solvency and liquidity tests where required by the Companies Act, 71 of 2008, as
amended.
Statutory capital requirements
With effect from 1 July 2018, the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential Standards were implemented
in South Africa. Discovery Life and Discovery Insure are regulated under the Insurance Act, while Vitality Health and VitalityLife are
regulated under the European Solvency II regulatory regime, which was implemented from 1 January 2016. The values below are
estimated based on information extracted from the audited financial statements.
2022 	2021
Statutory Capital Requirements 	Cover 	Statutory Capital Requirements 	Cover
Discovery Life 	R20 322 million 	1.7 times 	R17 647 million 	1.8 times
Discovery Insure 	R1 138 million 	1.2 times 	R1 079 million 	1.6 times
Vitality Health 	GBP 117.2 million (R2 344 million) 	1.5 times 	GBP 105.6 million (R2 084 million) 	1.6 times
VitalityLife Limited 	GBP 297.1 million (R5 943 million) 	2.1 times 	GBP 225.5 million (R4 451million) 	2.4 times
EMBEDDED VALUE
Discovery generated a strong return on opening embedded value (RoEV) of 14.8%, benefitting from particularly favourable lapse
experience and after the impact of a significant strengthening of the future mortality and morbidity basis. Liquidity and solvency as
well as the Group’s capital position remained strong and is robust under various stress scenarios across the Group. The financial
leverage ratio improved to 23.8%, well below the internally set guidance threshold of 28%.
Ping An Health Insurance (PAH)
During the period under review, Discovery made a capital contribution to PAH of R1.5 billion. While this has been funded in the
interim by way of a bridge facility and internal resources, it had been indicated that in terms of the capital management principles
applied, such capital requirements by associates and subsidiaries are typically funded by way of capital issuance at Discovery
Limited level. Given that the final regulatory approval by the Chinese Banking and Insurance Regulatory Commission was prolonged,
the capital continues to be funded as set out above. However, it remains the intention to replace the funding with a capital issuance
of only this amount if and when markets are conducive.
Part VII Transfer Deferral
Discovery and the Prudential Assurance Company (PAC) have finalised the agreement to a long-term deferral of the transfer of the
initial Vitality Life back-book of business originally written on the PAC license that was to be transferred to the Vitality Life Limited
license (the Part VII transfer). The agreement is such that the Part VII transfer is now deferred for the long-term with options to
extend further and for all intents and purposes should be viewed as an indefinite deferral.
DIRECTORS’ REPORT continued
for the year ended 30 June 2022
22	Discovery Annual Financial Statements 2022

-- 23 of 219 --

DIRECTORS’ REPORT continued
for the year ended 30 June 2022
DIRECTORS AND PRESCRIBED OFFICERS
The following were directors and prescribed officers of the Company during the current financial year unless otherwise indicated:
Executive directors 	Non-executive directors
A Gore 	HL Bosman
HD Kallner 	R Farber
NS Koopowitz 	Independent non-executive directors
Dr A Ntsaluba 	ME Tucker (Chairperson)
A Pollard 	Dr BA Brink (retired 24 November 2021)
B Swartzberg 	SE De Bruyn (retired 24 November 2021)
DM Viljoen 	M Hlahla (appointed 15 August 2021)
F Khanyile
D Macready
Dr TV Maphai
T Mboweni (appointed 5 May 2022)
M Schreuder
B van Kralingen (appointed 7 April 2022)
SV Zilwa
Ms M Hlahla has been appointed as an independent non-executive director with effect from 15 August 2021. Ms Hlahla will be a
member of the Audit Committee as well as the Social and Ethics Committee and Remuneration Committee. Ms. Hlahla’s appointment
strengthens the independence and business skills on the board and its committees.
Ms SE De Bruyn, an independent non-executive director, retired, effective 24 November 2021. This is in line with the Company’s
board’s rotation and succession planning. Ms De Bruyn has served as an independent non-executive director of the Company since
2005 and has served as the chairperson of the Remuneration Committee and as a member of the Audit Committee. Ms De Bruyn
has also retired as a non-executive director of Discovery Life Limited, Discovery Health (Pty) Ltd and Discovery Vitality (Pty) Ltd.
Dr BA Brink, an independent non-executive director, retired, effective 24 November 2021. This is in line with the Company’s board’s
rotation and succession planning. Dr Brink has served as an independent non-executive director of the Company since 2004 and has
served as a member of the Treating Customers Fairly Subcommittee, Social and Ethics Committee as well as the Risk and Compliance
Committee. Dr Brink has also retired as a non-executive director of Discovery Health (Pty) Ltd and Discovery Vitality (Pty) Ltd.
Ms B van Kralingen has been appointed as an independent non-executive director with effect from 7 April 2022. Ms van Kralingen’s
appointment strengthens the Board’s global business experience, together with technology and artificial intelligence expertise.
Mr T Mboweni has been appointed as an independent non-executive director with effect from 5 May 2022. Mr Mboweni will be a
member of the Risk and Compliance Committee and the Remuneration Committee as well as a non-executive director of Discovery Life
Limited. Mr Mboweni’s appointment will bring a wealth of experience in finance, economics, and business advisory within emerging
markets.
Ms F Khanyile, an independent non-executive director, has been appointed as Chairperson of the Remuneration Committee
following the retirement of Ms SE De Bruyn.
The notice for the forthcoming Annual General Meeting of shareholders will include those names of individuals that retire by
rotation and are eligible and available for re-election.
Details of the directors’ emoluments, participation in share incentive schemes and interests in the Company are reflected in
Annexure C and in the Group’s Remuneration report.
23	Discovery Annual Financial Statements 2022

-- 24 of 219 --

DIRECTORS’ REPORT continued
for the year ended 30 June 2022
COMPANY SECRETARY
Ms NN Mbongo continues in office as Company Secretary.
Registered office 	Postal address
1 Discovery Place 	PO Box 786722
Sandton 	Sandton
2196 	2146
DIRECTORS’ INTERESTS IN CONTRACTS
No material contracts involving directors’ interests were entered into in the current year. The directors had no interest in any third
party or company responsible for managing any of the business activities of Discovery.
BORROWING POWERS
The directors may exercise all the powers of the Company to borrow money. In terms of the Memorandum of Incorporation, the
borrowing powers of the Company are unlimited. In terms of the Insurance Act, both Discovery Life and Discovery Insure may not
encumber its assets or directly or indirectly borrow.
INDEMNIFICATION AND INSURANCE OF DIRECTORS AND OFFICERS
The Company entered into agreements to indemnify its directors to the extent permitted by law against all liabilities including legal
costs incurred by the director in connection with or as a consequence of the director acting in any capacity, including as an
authorised representative of a Group company.
During the financial year, the Company paid insurance premiums in respect of a Directors and Officers Liability insurance contract,
which insures directors and officers of the Company against certain liabilities arising in the course of their duties to the Company
or Group companies. Details of the nature of the liabilities covered and the amount of premium paid are not disclosed as such
disclosure is prohibited under the terms of the contract.
EVENTS AFTER THE REPORTING DATE
Refer to Group note 44 for a list of the events after reporting date.
AUDITORS
It will be proposed at the Annual General Meeting of shareholders, that PricewaterhouseCoopers Inc. (PWC) and KPMG Inc. be
reappointed as joint external auditors in accordance with section 90(1) of the Companies Act.
In accordance with the IRBA requirements on mandatory audit firm rotation, this appointment will be the last re-appointment of
PWC. Thereafter, PWC may not be reappointed for a period of five financial years. Discovery has communicated in its SENS
announcement dated 9 June 2021 its intention to appoint Deloitte & Touche as joint auditor after 30 June 2023.
24	Discovery Annual Financial Statements 2022

-- 25 of 219 --

GROUP STATEMENT OF FINANCIAL POSITION
at 30 June 2022
R million 	Notes
Group
2022
Group
2021
Assets
Goodwill 	10 	4 912 	4 879
Intangible assets 	7 	6 539 	6 371
Property and equipment 	6 	3 811 	4 188
Assets arising from insurance contracts 	5 	56 645 	50 483
Deferred acquisition costs 	8 	640 	585
Assets arising from contracts with customers 	9A 	1 549 	1 248
Investment in equity-accounted investees 	11 	6 008 	3 459
Deferred tax asset 	24 	4 455 	3 948
Financial assets
– Loans and advances to customers at amortised cost 	12 	3 944 	3 361
– Investments at amortised cost 	12 	7 161 	5 604
– Investments at fair value through profit or loss 	12 	141 494 	130 937
– Derivative financial instruments at fair value through profit or loss 	13 	276 	249
Insurance receivables, contract receivables and other receivables 	14 	13 113 	10 533
Non-current assets held of sale 	11.2.1 	171 	–
Current tax asset 	220 	391
Reinsurance contracts 	15 	511 	445
Cash and cash equivalents 	16 	19 775 	20 013
TOTAL ASSETS 	271 224 	246 694
Equity
Capital and reserves
Ordinary share capital and share premium 	17.1 	10 178 	10 151
Perpetual preference share capital 	17.2 	779 	779
Other reserves 	3 621 	1 935
Retained earnings 	38 972 	33 550
Equity 	53 550 	46 415
Non-controlling interest 	5 	4
TOTAL EQUITY 	53 555 	46 419
Liabilities
Liabilities arising from insurance contracts 	18 	109 200 	100 977
Liabilities arising from reinsurance contracts 	19 	13 192 	12 525
Deferred tax liability 	24 	9 335 	8 814
Contract liabilities to customers 	9A 	944 	776
Financial liabilities
– Borrowings at amortised cost 	20 	20 584 	19 493
– Other payables 	22 	15 123 	14 904
– Deposits from customers 	23 	10 881 	8 985
– Investment contracts at fair value through profit or loss 	21 	37 361 	32 291
– Derivative financial instruments at fair value through profit or loss 	13 	202 	826
Employee benefits 	25 	320 	315
Current tax liability 	527 	369
TOTAL LIABILITIES 	217 669 	200 275
TOTAL EQUITY AND LIABILITIES 	271 224 	246 694
25	Discovery Annual Financial Statements 2022

-- 26 of 219 --

GROUP INCOME STATEMENT
for the year ended 30 June 2022
R million 	Notes
Group
2022
Group
2021
Insurance premium revenue 	58 782 	55 935
Reinsurance premiums 	(8 262) 	(7 729)
Accelerated reinsurance premiums 	42 	– 	(823)
Net insurance premium revenue 	26 	50 520 	47 383
Fee income from administration businesses 	9B 	12 752 	11 700
Vitality income 	9B 	3 495 	3 340
Net banking fee and commission income 	645 	480
Banking fee and commission income 	9B 	853 	633
Banking fee and commission expense 	(208) 	(153)
Net bank interest and similar income 	318 	241
Bank interest and similar income using the effective interest rate 	811 	627
Bank interest and similar expense using the effective interest rate 	(493) 	(386)
Investment income using the effective interest rate method 	27 	296 	280
Net fair value (losses)/gains on financial assets at fair value through profit or loss 	28 	(1 825) 	11 891
Other income 	1 341 	1 372
Receipts arising from reinsurance contracts 	– 	500
Net income 	67 542 	77 187
Net claims and policyholders’ benefits 	29 	(30 900) 	(28 178)
Claims and policyholders' benefits 	(38 207) 	(33 972)
Insurance claims recovered from reinsurers 	7 218 	5 794
Recapture of reinsurance 	89 	–
Acquisition costs 	30 	(4 774) 	(5 033)
Marketing and administration expenses 	31 	(25 209) 	(22 679)
Amortisation of intangibles from business combinations 	(59) 	(66)
Expected credit losses 	(67) 	(271)
Recovery of expenses from reinsurers 	2 859 	2 773
Net transfer to/from assets and liabilities under insurance contracts 	(1 494) 	(14 795)
– change in assets arising from insurance contracts 	5 786 	545
– change in assets arising from reinsurance contracts 	63 	56
– change in liabilities arising from insurance contracts 	(6 935) 	(17 941)
– change in liabilities arising from reinsurance contracts 	(577) 	1 755
– economic assumption adjustments net of discretionary margins 	169 	790
Fair value adjustment to liabilities under investment contracts 	(40) 	(3 634)
Profit from operations 	7 858 	5 304
Finance costs 	33 	(1 658) 	(1 648)
Foreign exchange gains/(losses) 	34 	155 	(389)
Gain on dilution and disposal of equity-accounted investments 	33 	554
Reversal of impairment/(Impairment) of equity-accounted investments 	134 	(149)
Share of net profits from equity-accounted investments 	422 	523
Profit before tax 	6 944 	4 195
Income tax expense 	35 	(1 465) 	(975)
Profit for the period 	5 479 	3 220
Profit attributable to:
– ordinary shareholders 	5 422 	3 157
– preference shareholders 	56 	63
– non-controlling interest 	1 	*
5 479 	3 220
Earnings per share for profit attributable to ordinary shareholders of the
company during the period (cents): 	36
– basic 	825.5 	480.7
– diluted 	817.8 	475.4
* Amount is less than R500 000.
26	Discovery Annual Financial Statements 2022

-- 27 of 219 --

GROUP STATEMENT OF OTHER COMPREHENSIVE INCOME
for the year ended 30 June 2022
R million
Group
2022
Group
2021
Profit for the period 	5 479 	3 220
Items that are or may be reclassified subsequently to profit or loss:
Currency translation differences 	467 	(1 576)
Cash flow hedges 	309 	260
– unrealised gains 	322 	360
– tax on unrealised gains 	(2) 	(25)
– losses recycled to profit or loss 	(10) 	(90)
– tax on recycled losses 	(1) 	15
Share of other comprehensive income from equity-accounted investments 	601 	(312)
– change in fair value of debt instruments at fair value through other comprehensive income 	17 	15
– currency translation differences 	584 	(327)
Other comprehensive income/(losses) for the period, net of tax 	1 377 	(1 628)
Total comprehensive income for the period 	6 856 	1 592
Attributable to:
– ordinary shareholders 	6 799 	1 529
– preference shareholders 	56 	63
– non-controlling interest 	1 	*
Total comprehensive income for the period 	6 856 	1 592
* Amount is less than R500 000.
27	Discovery Annual Financial Statements 2022

-- 28 of 219 --

GROUP STATEMENT OF CASH FLOWS
for the year ended 30 June 2022
R million 	Notes
Group
2022
Group
2021
Cash flow from operating activities 	3 597 	10 407
Cash generated/(utilised) by operations 	37.1 	20 943 	26 457
Purchase of investments held to back policyholder liabilities 	(56 588) 	(54 661)
Proceeds from disposal of investments held to back policyholder liabilities 	38 411 	38 709
Cash generated from operating activities 	2 766 	10 505
Dividends received 	600 	303
Interest received 	2 824 	2 513
Interest paid 	(1 412) 	(1 197)
Taxation paid 	37.2 	(1 181) 	(1 717)
Cash flow from investing activities 	(4 704) 	(6 740)
Purchase of financial assets 	(32 878) 	(32 569)
Proceeds from disposal of financial assets 	31 482 	27 828
Purchase of property and equipment 	(275) 	(277)
Proceeds from disposal of property and equipment 	25 	21
Purchase of software and other intangible assets 	(1 567) 	(1 587)
Proceeds from disposal of software and other intangible assets 	2 	–
Acquistion of business net of cash 	– 	(25)
Additional investment in equity-accounted investments 	(1 593) 	(240)
Dividends from equity-accounted investments 	100 	109
Cash flow from financing activities 	518 	(590)
Dividends paid to preference shareholders 	(56) 	(63)
Proceeds from borrowings 	37.3 	3 261 	1 839
Repayment of borrowings 	37.3 	(2 687) 	(2 366)
Net (decrease)/ increase in cash and cash equivalents 	(589) 	3 077
Cash and cash equivalents at beginning of the year 	20 013 	17 909
Exchange gains/(losses) on cash and cash equivalents 	195 	(973)
Cash and cash equivalents including bank overdraft at end of the year 	16 	19 619 	20 013
Reconciliation to Statement of Financial Position
Cash and cash equivalents 	19 775 	20 013
Bank overdraft included in borrowings at amortised cost 	(156) 	–
Cash and cash equivalents including bank overdraft at end of the year 	16 	19 619 	20 013
28	Discovery Annual Financial Statements 2022

-- 29 of 219 --

29	Discovery Annual Financial Statements 2022
GROUP STATEMENT OF CHANGES IN EQUITY
for the year ended 30 June 2022
Attributable to equity holders of the Company 	Attributable to equity holders of the Company
R million
Share
capital
and share
premium
Preference
share
capital
Share-based
payment
reserve
Investment
reserve1
Foreign
currency
translation
reserve
Hedging
reserve
Retained
earnings 	Total
Non-
controlling
interest 	Total
Year ended 30 June 2022
At beginning of the period 	10 151 	779 	489 	18 	1 772 	(344) 	33 550 	46 415 	4 	46 419
Total comprehensive income for the period 	– 	56 	– 	17 	1 051 	309 	5 422 	6 855 	1 	6 856
Profit for the period 	– 	56 	– 	– 	– 	– 	5 422 	5 478 	1 	5 479
Other comprehensive income 	– 	– 	– 	17 	1 051 	309 	– 	1 377 	– 	1 377
Transactions with owners 	27 	(56) 	309 	– 	– 	– 	– 	280 	– 	280
Share issue 	443 	– 	– 	– 	– 	– 	– 	443 	– 	443
Increase in treasury shares 	(443) 	– 	– 	– 	– 	– 	– 	(443) 	– 	(443)
Delivery of treasury shares 	27 	– 	(17) 	– 	– 	– 	– 	10 	– 	10
Employee share option schemes:
– Value of employee services 	– 	– 	326 	– 	– 	– 	– 	326 	– 	326
Dividends paid to preference shareholders 	– 	(56) 	– 	– 	– 	– 	– 	(56) 	– 	(56)
At end of the year 	10 178 	779 	798 	35 	2 823 	(35) 	38 972 	53 550 	5 	53 555
Year ended 30 June 2021
At beginning of the period 	10 148 	779 	195 	3 	3 675 	(604) 	30 353 	44 549 	4 	44 553
Total comprehensive income for the period 	– 	63 	– 	15 	(1 903) 	260 	3 157 	1 592 	* 	1 592
Profit for the period 	– 	63 	– 	– 	– 	– 	3 157 	3 220 	* 	3 220
Other comprehensive income 	– 	– 	– 	15 	(1 903) 	260 	– 	(1 628) 	– 	(1 628)
Transactions with owners 	3 	(63) 	294 	– 	– 	– 	40 	274 	– 	274
Share issue 	907 	– 	– 	– 	– 	– 	– 	907 	– 	907
Increase in treasury shares 	(907) 	– 	– 	– 	– 	– 	– 	(907) 	– 	(907)
Delivery of treasury shares 	3 	– 	(36) 	– 	– 	– 	40 	7 	– 	7
Employee share option schemes:
– Value of employee services 	– 	– 	330 	– 	– 	– 	– 	330 	– 	330
Dividends paid to preference shareholders 	– 	(63) 	– 	– 	– 	– 	– 	(63) 	– 	(63)
At end of the year 	10 151 	779 	489 	18 	1 772 	(344) 	33 550 	46 415 	4 	46 419
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments measured at FVOCI, in terms of IFRS 9 Financial Instruments.
* Amount is less than R500 000.

-- 30 of 219 --

1. 	SEGMENT INFORMATION
Discovery’s operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision-maker (CODM). The CODM have been identified as the Chief Executive Officers of Discovery’s businesses, as identified
in the segment information, who make strategic decisions regarding these businesses.
An operating segment is a component of an entity:
(a) 	That engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses
relating to transactions with other components of the same entity);
(b) Whose operating results are regularly reviewed by the entity’s CODM to make decisions about resources to be allocated to
the segment and assess its performance; and
(c) 	For which discrete financial information is available.
An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations
may be operating segments before earning revenues.
Discovery will report separately information about an operating segment that meets any of the following quantitative thresholds:
(a) 	Its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 per cent or more
of the combined revenue, internal and external, of all operating segments;
(b) The absolute amount of its reported profit or loss is 10 per cent or more of the greater, in absolute amount, of (i) the
combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all
operating segments that reported a loss; and
(c) 	Its assets are 10 per cent or more of the combined assets of all operating segments.
Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed,
if management believes that information about the segment would be useful to users of the financial statements.
Discovery may combine information about operating segments that do not meet the quantitative thresholds with information
about other operating segments that do not meet the quantitative thresholds to produce a reportable segment only if the
operating segments have similar economic characteristics.
The Group has identified its reportable segments based on a combination of products and services offered to customers and the
location of the markets served.
The following summary describes the operations of each of the Group’s reportable segments:
(i) 	Health South Africa: administers and provides managed care services to medical schemes and renders administration
services to other business segments within the Group.
(ii) 	Life South Africa: offers a range of insurance and financial solutions to the Group’s clients against the financial impact of
lifestyle-changing events in South Africa.
(iii) Invest South Africa: offers, through a range of investment fund choices, including Discovery managed unit trusts, a
comprehensive and flexible range of investment choices. These products are sold through a number of investment wrappers
including Discovery Life policies and are offered to individuals in South Africa.
(iv) Vitality South Africa: offers health and lifestyle benefits with selected partners to the Group’s clients.
(v) 	Insure South Africa: offers a range of personal line insurance (motor, building, household content and portable possessions)
to the Group’s clients against the financial impact of loss or damage. The segment also includes Discovery’s interest in
Cambridge Mobile Telematics (CMT).
(vi) Bank South Africa: offers retail banking solutions, including deposits and loans and advances, to clients in the South African
market. The Bank is still in start-up phase. It also includes DiscoveryCard.
(vii) Health United Kingdom: offers consumer-engaged private medical insurance products to employer groups and individuals
in the United Kingdom. All contracts in this segment are short-term insurance contracts.
(viii) Life United Kingdom: offers a risk-only life assurance product. All contracts in this segment are long-term assurance
contracts offered to both employer groups and individuals in the United Kingdom.
(ix) All other segments: includes those segments that do not meet the quantitative thresholds set out in IFRS 8 and cannot be
aggregated with another reportable segment. It includes the following operating segments:
– Insure South Africa commercial: provides commercial short-term risk insurance products to the South African market.
– SA Distribution: provides sales and distribution services in respect of all SA products.
– Vitality Group: provides a Vitality platform to international insurance businesses.
– Other new business development costs: expenses incurred to investigate new products and markets.
– UK, US, SA and Singapore head office costs, where not allocated to another segment.
– Invest United Kingdom: offers a comprehensive range of investment products to individuals in the United Kingdom.
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS
for the year ended 30 June 2022
30	Discovery Annual Financial Statements 2022

-- 31 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
1. 	SEGMENT INFORMATION continued
The Chief Executive Officers assess the performance of the reportable segments based on normalised profit/loss from operations.
Items which are excluded from the normalised profit/loss from operations are separately disclosed in the segmental information
to reconcile back to the segmental results.
The segment information is presented on the same basis as reported to the Chief Executive Officer. The segment total is then
adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the
following:
(i) The VitalityLife results are reclassified to account for the contractual arrangement in respect of the business written on the
Prudential Assurance Company license, as an insurance contract which Discovery issues under IFRS 4 Insurance Contracts;
(ii) Unit trusts which the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s
results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery’s
results, effectively being the income and expenses relating to units held by third parties;
(iii) The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments; and
(iv) The effects of reclassifying items to align to IFRS results.
31	Discovery Annual Financial Statements 2022

-- 32 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
1. 	SEGMENT INFORMATION continued
R million
SA
Health
SA
Life
SA
Invest
SA
Insure 2
SA
Vitality
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments
IFRS
total
30 June 2022
Income statement
Insurance premium revenue 	189 	15 041 	14 499 	4 657 	– 	– 	11 299 	6 750 	7 035 	59 470 	(688) 	58 782
Reinsurance premiums 	– 	(3 523) 	– 	(103) 	– 	– 	(1 556) 	(3 600) 	(168) 	(8 950) 	688 	(8 262)
Net insurance premium revenue 	189 	11 518 	14 499 	4 554 	– 	– 	9 743 	3 150 	6 867 	50 520 	– 	50 520
Fee income from administration businesses 	7 910 	– 	2 834 	15 	– 	– 	30 	– 	1 975 	12 764 	(12) 	12 752
Vitality income 	– 	– 	– 	– 	2 338 	– 	392 	227 	538 	3 495 	– 	3 495
Net banking fee and commission income 	– 	– 	– 	– 	– 	633 	– 	– 	12 	645 	– 	645
Banking fee and commission income 	– 	– 	– 	– 	– 	853 	– 	– 	– 	853 	– 	853
Banking fee and commission expense 	– 	– 	– 	– 	– 	(220) 	– 	– 	12 	(208) 	– 	(208)
Net bank interest and similar income 	– 	– 	– 	– 	– 	318 	– 	– 	– 	318 	– 	318
Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	– 	811 	– 	– 	– 	811 	– 	811
Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	– 	(493) 	– 	– 	– 	(493) 	– 	(493)
Investment income earned on assets backing policyholder liabilities 	– 	3 	– 	118 	– 	– 	9 	27 	7 	164 	(164) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	10 	485 	913 	1 	1 	– 	(52) 	(1 390) 	(1 195) 	(1 227) 	(598) 	(1 825)
Other income 	1 241 	12 	– 	– 	– 	– 	32 	– 	56 	1 341 	– 	1 341
Finance charge on negative reserve funding 	– 	– 	– 	– 	– 	– 	– 	1 368 	– 	1 368 	(1 368) 	–
Inter-segment funding1 	– 	(628) 	628 	– 	– 	– 	– 	– 	– 	– 	– 	–
Net income 	9 350 	11 390 	18 874 	4 688 	2 339 	951 	10 154 	3 362 	8 260 	69 368 	(2 142) 	67 226
Net claims and policyholders' benefits 	(49) 	(9 222) 	(12 260) 	(3 029) 	– 	– 	(4 331) 	(877) 	(1 132) 	(30 900) 	– 	(30 900)
Claims and policyholders' benefits 	(49) 	(14 013) 	(12 260) 	(3 151) 	– 	– 	(5 652) 	(2 231) 	(1 346) 	(38 702) 	495 	(38 207)
Insurance claims recovered from reinsurers 	– 	4 791 	– 	122 	– 	– 	1 321 	1 265 	214 	7 713 	(495) 	7 218
Recapture of reinsurance 	– 	– 	– 	– 	– 	– 	– 	89 	– 	89 	– 	89
Acquisition costs 	(27) 	(1 605) 	(1 144) 	(702) 	(111) 	– 	(963) 	(1 884) 	294 	(6 142) 	1 368 	(4 774)
Expected credit losses 	– 	– 	– 	– 	– 	(67) 	– 	– 	– 	(67) 	– 	(67)
Marketing and administration expenses
– depreciation and amortisation 	(106) 	(7) 	(11) 	(60) 	(12) 	(277) 	(458) 	(63) 	(739) 	(1 733) 	(169) 	(1 902)
– derecognition of intangible assets and property and equipment 	– 	– 	– 	(18) 	– 	– 	(1) 	(14) 	(17) 	(50) 	– 	(50)
– other expenses 	(5 568) 	(2 147) 	(1 156) 	(988) 	(2 207) 	(1 597) 	(4 091) 	(2 047) 	(3 032) 	(22 833) 	(424) 	(23 257)
Recovery of expenses from reinsurers 	– 	– 	– 	– 	– 	– 	1 041 	1 818 	– 	2 859 	– 	2 859
Transfer from assets/liabilities under insurance contracts
– 	change in assets arising from insurance contracts 	– 	5 299 	– 	– 	– 	– 	– 	3 606 	(101) 	8 804 	(3 018) 	5 786
– 	change in assets arising from reinsurance contracts 	– 	11 	– 	1 	– 	– 	40 	11 	1 	64 	(1) 	63
– 	change in liabilities arising from insurance contracts 	– 	662 	(3 247) 	(41) 	– 	– 	(65) 	(17) 	(4 488) 	(7 196) 	261 	(6 935)
– 	change in liabilities arising from reinsurance contracts 	– 	(351) 	– 	– 	– 	– 	– 	(3 244) 	– 	(3 595) 	3 018 	(577)
Fair value adjustment to liabilities under investment contracts 	– 	(2) 	148 	– 	– 	– 	– 	– 	42 	188 	(228) 	(40)
Share of net profits from equity-accounted investments 	– 	– 	– 	(13) 	– 	– 	2 	– 	474 	463 	(41) 	422
Reversal of impairment of equity accounted investment 	– 	– 	– 	– 	– 	– 	– 	– 	134 	134 	– 	134
Normalised profit/(loss) from operations 	3 600 	4 028 	1 204 	(162) 	9 	(990) 	1 328 	671 	(304) 	9 384 	(1 376) 	8 008
Economic assumptions adjustments net of discretionary margins and interest rate derivative 	– 	(651) 	– 	– 	– 	– 	– 	567 	– 	84 	253 	169
Economic assumptions adjustments net of discretionary margins 	– 	(651) 	– 	– 	– 	– 	– 	820 	– 	169 	– 	169
Fair value losses on VitalityLife interest rate derivative 	– 	– 	– 	– 	– 	– 	– 	(253) 	– 	(253) 	253 	–
Investment income earned on shareholder investments and cash 	37 	11 	38 	– 	28 	– 	– 	8 	18 	140 	156 	296
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	5 	913 	918 	(918) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	51 	27 	– 	– 	– 	– 	(454) 	(1) 	(377) 	377 	–
Gains from dilution of equity accounted investments 	– 	– 	– 	19 	– 	– 	– 	– 	14 	33 	– 	33
Expenses related to Prudential Book transfer 	– 	– 	– 	– 	– 	– 	– 	(182) 	– 	(182) 	182 	–
Covid-19 vaccination programme 	– 	– 	– 	– 	– 	– 	– 	– 	(157) 	(157) 	157 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	(41) 	– 	– 	– 	– 	(59) 	(100) 	41 	(59)
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	– 	(158) 	(158) 	158 	–
Finance costs 3 	(1) 	25 	– 	– 	– 	– 	(6) 	(104) 	(1 290) 	(1 376) 	(282) 	(1 658)
Intercompany finance costs 	(297) 	– 	– 	– 	– 	– 	(4) 	(230) 	(396) 	(927) 	927 	–
Foreign exchange gains 	4 	25 	37 	– 	– 	– 	– 	– 	89 	155 	– 	155
Profit before tax 	3 343 	3 489 	1 306 	(184) 	37 	(990) 	1 318 	281 	(1 331) 	7 269 	(325) 	6 944
Income tax expense 	(951) 	(718) 	(438) 	43 	(30) 	218 	(285) 	224 	147 	(1 709) 	325 	(1 465)
Profit for the year 	2 392 	2 771 	868 	(141) 	7 	(772) 	1 033 	505 	(1 184) 	5 479 	– 	5 479
* Amount is less than R500 000.
1 The inter-segment funding of R628 million reflects a notional allocation of interest earned on the negative reserve backing policyholders’ funds of guaranteed investment
products and hence is transferred to Discovery Invest.
2 This segment relates to SA Insure – Personal lines.
3 Finance costs in Discovery Life includes a reversal of interest payable to the South African Revenue Services provided for in the prior year.
32	Discovery Annual Financial Statements 2022

-- 33 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
1. 	SEGMENT INFORMATION continued
R million
SA
Health
SA
Life
SA
Invest
SA
Insure2
SA
Vitality
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments
IFRS
total
30 June 2021
Income statement
Insurance premium revenue 	294 	13 711 	14 824 	4 091 	– 	– 	11 075 	6 466 	6 351 	56 812 	(877) 	55 935
Reinsurance premiums 	1 	(3 262) 	– 	(66) 	– 	– 	(1 839) 	(3 354) 	(86) 	(8 606) 	877 	(7 729)
Accelerated reinsurance repayment 	– 	– 	– 	– 	– 	– 	(823) 	– 	– 	(823) 	– 	(823)
Net insurance premium revenue 	295 	10 449 	14 824 	4 025 	– 	– 	8 413 	3 112 	6 351 	47 383 	– 	47 383
Fee income from administration businesses 	7 540 	– 	2 401 	16 	– 	2 	28 	– 	1 724 	11 711 	(11) 	11 700
Vitality income 	– 	– 	– 	– 	2 295 	21 	240 	230 	554 	3 340 	– 	3 340
Net banking fee and commission income 	– 	– 	– 	– 	– 	464 	– 	– 	16 	480 	– 	480
Banking fee and commission income 	– 	– 	– 	– 	– 	633 	– 	– 	– 	633 	– 	633
Banking fee and commission expense 	– 	– 	– 	– 	– 	(169) 	– 	– 	16 	(153) 	– 	(153)
Net bank interest and similar income 	– 	– 	– 	– 	– 	214 	– 	– 	– 	214 	27 	241
Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	– 	627 	– 	– 	– 	627 	– 	627
Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	– 	(413) 	– 	– 	– 	(413) 	27 	(386)
Investment income earned on assets backing policyholder liabilities 	– 	10 	– 	111 	– 	– 	– 	9 	9 	139 	(139) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	6 	637 	9 172 	14 	– 	83 	29 	(792) 	1 358 	10 507 	1 384 	11 891
Other income 	968 	3 	– 	– 	– 	312 	60 	– 	10 	1 353 	19 	1 372
Finance charge on negative reserve funding 	– 	– 	– 	– 	– 	– 	– 	769 	– 	769 	(769) 	–
Inter-segment funding1 	– 	(714) 	714 	– 	– 	– 	– 	– 	– 	– 	– 	–
Receipts arising from reinsurance contracts 	– 	500 	– 	– 	– 	– 	– 	– 	– 	500 	– 	500
Net income 	8 809 	10 885 	27 111 	4 166 	2 295 	1 096 	8 770 	3 328 	10 022 	76 396 	511 	76 907
Net claims and policyholders' benefits 	(129) 	(8 113) 	(12 252) 	(2 270) 	– 	– 	(3 894) 	(837) 	(683) 	(28 178) 	– 	(28 178)
Claims and policyholders' benefits 	(129) 	(11 949) 	(12 252) 	(2 269) 	– 	– 	(5 219) 	(1 962) 	(761) 	(34 541) 	569 	(33 972)
Insurance claims recovered from reinsurers 	– 	3 836 	– 	(1) 	– 	– 	1 325 	1 125 	78 	6 363 	(569) 	5 794
Acquisition costs 	(40) 	(1 540) 	(1 056) 	(599) 	(61) 	– 	(942) 	(1 719) 	174 	(5 783) 	750 	(5 033)
Expected credit losses 	– 	– 	– 	– 	– 	(271) 	– 	– 	– 	(271) 	– 	(271)
Marketing and administration expenses
– depreciation and amortisation 	(118) 	(7) 	(11) 	(70) 	(13) 	(246) 	(447) 	(57) 	(669) 	(1 638) 	(210) 	(1 848)
– derecognition of intangible assets and property and equipment 	(26) 	– 	– 	(6) 	– 	– 	– 	(18) 	(50) 	– 	(50)
– impairment of intangible assets 	(15) 	– 	– 	– 	(1) 	– 	(5) 	– 	(40) 	(61) 	– 	(61)
– other expenses 	(5 058) 	(2 027) 	(1 031) 	(937) 	(2 177) 	(1 673) 	(3 297) 	(1 831) 	(2 598) 	(20 629) 	(91) 	(20 720)
Recovery of expenses from reinsurers 	– 	– 	– 	– 	– 	– 	912 	1 861 	– 	2 773 	– 	2 773
Transfer from assets/liabilities under insurance contracts
– 	change in assets arising from insurance contracts 	– 	3 433 	– 	– 	– 	– 	– 	(6 143) 	76 	(2 634) 	3 179 	545
– 	change in assets arising from reinsurance contracts 	– 	33 	– 	– 	– 	13 	10 	– 	56 	– 	56
– 	change in liabilities arising from insurance contracts 	– 	(206) 	(11 054) 	(47) 	– 	– 	(155) 	(17) 	(6 436) 	(17 915) 	(26) 	(17 941)
– 	change in liabilities arising from reinsurance contracts 	– 	(1 115) 	– 	– 	– 	– 	– 	6 049 	– 	4 934 	(3 179) 	1 755
Fair value adjustment to liabilities under investment contracts 	– 	(2) 	(623) 	– 	– 	– 	– 	– 	(255) 	(880) 	(2 754) 	(3 634)
Share of net profits from equity-accounted investments 	– 	– 	– 	13 	– 	– 	(2) 	– 	512 	523 	– 	523
Impairment of equity accounted investment 	– 	– 	– 	– 	– 	– 	– 	– 	(149) 	(149) 	– 	(149)
Normalised profit/(loss) from operations 	3 423 	1 341 	1 084 	250 	43 	(1 094) 	953 	644 	(150) 	6 494 	(1 820) 	4 674
Economic assumptions adjustments net of discretionary margins and interest rate derivative 	– 	(411) 	– 	– 	– 	– 	– 	(108) 	– 	(519) 	1 309 	790
Economic assumptions adjustments net of discretionary margins 	– 	(411) 	– 	– 	– 	– 	– 	1 201 	– 	790 	– 	790
Fair value losses on VitalityLife interest rate derivative 	– 	– 	– 	– 	– 	– 	– 	(1 309) 	– 	(1 309) 	1 309 	–
Investment income earned on shareholder investments and cash 	39 	14 	40 	– 	39 	– 	– 	3 	14 	149 	131 	280
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	7 	809 	816 	(816) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	138 	(28) 	– 	– 	– 	– 	139 	(471) 	(222) 	222 	–
Restructuring costs 	– 	– 	– 	– 	– 	– 	– 	(33) 	– 	(33) 	33 	–
Gains from dilution of equity accounted investments 	– 	– 	– 	537 	– 	– 	– 	– 	17 	554 	– 	554
Expenses related to Prudential Book transfer 	– 	– 	– 	– 	– 	– 	- 	(187) 	– 	(187) 	187 	–
Transaction costs related to VitalityLife interest rate derivatives 	– 	– 	– 	– 	– 	– 	– 	(4) 	– 	(4) 	4 	–
Covid-19 vaccination programme 	– 	– 	– 	– 	– 	– 	– 	– 	(42) 	(42) 	42 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	– 	– 	– 	– 	– 	(66) 	(66) 	– 	(66)
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	– 	(228) 	(228) 	228 	–
Finance costs 	(1) 	(26) 	– 	– 	– 	– 	(7) 	(65) 	(1 192) 	(1 291) 	(357) 	(1 648)
Intercompany finance costs 	(268) 	– 	– 	– 	– 	– 	(6) 	(236) 	(315) 	(825) 	825 	–
Foreign exchange (losses)/gains 	(6) 	3 	(25) 	– 	– 	– 	– 	– 	(361) 	(389) 	– 	(389)
Profit before tax 	3 187 	1 059 	1 071 	787 	82 	(1 094) 	940 	160 	(1 985) 	4 207 	(12) 	4 195
Income tax expense 	(894) 	(364) 	(331) 	(207) 	(24) 	334 	(149) 	363 	285 	(987) 	12 	(975)
Profit for the year 	2 293 	695 	740 	580 	58 	(760) 	791 	523 	(1 700) 	3 220 	– 	3 220
1 The inter-segment funding of R714 million reflects a notional allocation of interest earned on the negative reserve backing policyholders’ funds of guaranteed investment
products and hence is transferred to Discovery Invest.
2 This segment relates to SA Insure – Personal lines.
33	Discovery Annual Financial Statements 2022

-- 34 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK
Discovery’s accounting policy to recognise and measure insurance contracts can be viewed in Annexure B, accounting policy 13.
Discovery issues both short-term and long-term contracts that transfer significant insurance risk. Such contracts may also
transfer financial risk. An insurance contract is a contract in which Discovery as issuer and/or insurer accepts significant insurance
risk from the policyholder by agreeing to compensate the policyholder if a specified uncertain future event (the insured event)
adversely affects the policyholder. A significant insurance risk is the possibility of having to pay benefits, on the occurrence of an
insured event, that are significantly more than the benefits payable if the insured event did not occur. There is uncertainty around
the timing and/or the value of the resulting claim.
A large portfolio of independent but similar insurance contracts, allow for the use of probability theory to predict the number and
value of claims over a defined period. Insurance risk, when considering a large portfolio of insurance contracts, is thus the
probability that the actual number of claims over a defined period is different to those expected. This could in turn result in the
value of insurance liabilities being over or underestimated.
Experience shows that the larger the portfolio of similar insurance contracts, the smaller the relative variability of the expected
outcome will be. Discovery reduces claims variability by underwriting policies and by using reinsurance to protect against single
large claims or catastrophe reinsurance to mitigate concentration risks.
Discovery classifies its insurance contracts into five main categories, depending on the duration of the risk and the type of risk
insured. These are:
Contracts which are long term in nature
– Individual life insurance: These contracts insure against a comprehensive spectrum of risks, including life cover, severe illness,
disability and income continuation cover.
– Investment products with insurance risk: These contracts attract insurance risk arising from additional benefits offered which
mostly insure against life risks.
Contracts which are short term in nature
– Health insurance: These contracts insure policyholders against healthcare-related claims.
– Short-term insurance: These monthly contracts insure policyholders against a comprehensive spectrum of short-term risks
including, but not limited to, motor vehicle, household, business, property and liability cover.
– Group life insurance: These contracts insure against a comprehensive spectrum of protection benefits on a group basis. Life
cover, severe illness, disability and income continuation benefits are offered.
Refer to note 1 Segmental information for premium revenue per segment.
Discovery manages its insurance risk in terms of its risk management framework and holds regulatory and economic capital for
protection against adverse experience. The following summarises the insurance risk associated with the various contracts offered
by Discovery, and how Discovery manages these risks.
Insurance risk 	Description 	How Discovery manages the risk
Risks significant to all insurance business lines
Lapse and
surrender risk
Policyholders have the option to discontinue or
reduce contributions at any time.
Accordingly, there is a risk of financial loss due
to the withdrawal rate, lapses or premium
reductions (with associated reduced cover)
being higher than expected. The risk is highest
during the early duration of the policy since the
acquisition costs and commission incurred at
the inception of the policy would not yet have
been recouped.
Lapse risk is managed as follows:
Product design
Products are designed to be sustainable in the long
term. New product offerings are made available to
existing policyholders as far as possible to prevent
lapse and re-entry risk.
Integration between different product offerings
across Discovery enhances the value proposition of
the overall package of products from Discovery.
34	Discovery Annual Financial Statements 2022

-- 35 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
Insurance risk 	Description 	How Discovery manages the risk
Lapse and
surrender risk
continued
Contracts that are long term in nature
For individual life insurance products there is a
risk:
– of reduced profits arising from lower than
expected withdrawals at later durations of
certain policies in cases where the reserves
have turned positive. This is since withdrawals
on such policies allow the reserves to
bereleased as profits in the absence of
surrender values being offered; and
– that withdrawals are selective from a claims
experience point of view. For example, healthy
lives may find it easier to obtain cover
elsewhere compared to less healthy lives.
Future earnings on individual life plans are
dependent on the number of policies remaining
in future years and thus future earnings are
dependent on the lapse rate. The future
expected earnings vary by the premium funding
method chosen by the policyholder. In general,
the higher the increases, the higher the
withdrawal risk to future earnings.
For investment products with insurance risk,
there is a risk:
– that the surrender value may exceed the policy
value, net of expenses, at early durations; and
– that withdrawals are higher than expected.
Future earnings arising from Invest plans are
dependent on the value of assets under
management and thus future earnings are
dependent on the withdrawal and surrender
rate.
Contracts that are short term in nature
For Discovery Insure there is a risk of reduced
profits arising from higher than expected
withdrawals at early durations of policies,
resulting in acquisition costs not being recovered.
For example, Discovery provides unique rewards
and benefits as well as integration to members
which has proven to be a credible risk differentiator.
Premium discounts or cover increases are
available to policyholders who actively engage
in a healthier lifestyle and utilise the Vitality
benefits. Better terms are thus offered to healthy
lives compared to less healthy lives.
No surrender benefit is offered on risk benefits
and thus the loss on withdrawal is reduced.
Commission claw back
Discovery 	predominantly 	distributes 	via
independent brokers, intermediaries and tied
agents.
Commissions are clawed back from intermediaries
where a policy lapses within a specified timeframe
since inception. The amount of commission
clawback depends on the duration of the policy in
months and gradually reduces from 100% to 0%
and is over a specified period depending on
product sold.
Experience monitoring
Lapse experience is monitored on a monthly
basis and data is analysed to establish possible
trends for which management action can be
taken.
Where there is insufficient historic data to
provide credible results, for example within
VitalityLife Whole of Life, reliance is placed on
reinsurers’ advice, industry experience as well as
experience from Discovery Life.
Proactive conservation
Targeted conservation campaigns are run pro-
actively. For example, financial advisors are
notified of clients that do not have certain
features on their policies that are correlated with
good persistency. Financial advisors are thus
encouraged to add such features.
35	Discovery Annual Financial Statements 2022

-- 36 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
Insurance risk 	Description 	How Discovery manages the risk
Modelling and
data risk
Actuarial liabilities are calculated using complex
discounted cash flow models. There is a risk that
the models do not accurately project the policy
cash flows in the future.
The models rely on data from the administration
system and there is thus a further risk that the
data does not accurately reflect the policies
being valued.
Contracts that are short term have simplified
models reducing modelling risk.
The risk is controlled using specialist actuarial
software that is widely used and accepted in the
life insurance industry throughout the world.
This is tailored for Discovery.
The original actuarial models were tested and
verified using an independent but identical
parallel model. Any changes made are externally
and independently reviewed. Parallel models
are developed to test any modelling changes.
The data for the model is extracted from modern
administration systems and subjected to
detailed checks together with high-level
reasonability checks. Discovery does not have
any legacy systems that could impact on the data
quality. Data is checked at each valuation date.
Capital adequacy
requirements and
protection against
adverse
experiences
There is a risk that future premiums, investment
returns and estimates used to calculate liabilities
are insufficient to provide for variations in actual
future experience. Insurance liabilities are
calculated using best estimates plus the addition
of various margins to avoid premature recognition
of profits and to provide for a buffer against
future adverse experience. In addition, Discovery
maintains shareholder capital to meet substantial
deviations in experience beyond those provided
for in the liability calculations.
For discussion on how Discovery manages its
capital adequacy requirements, refer to note 2.1.
Liquidity risk 	Liquidity risk is the risk that an entity will encounter
difficulty in meeting obligations associated with
insurance liabilities due to insufficient cash being
available to meet commitments as and when
they become due. This is exacerbated by timing
mismatches between assets and liabilities.
Discovery maintains sufficient liquid assets to
meet short-term liabilities under base and
stress assumptions. Sufficient liquid assets are
held to allow for the initial cash flow strain when
writing new business.
Contracts that are long-term in nature
Currently, Discovery Life’s and VitalityLife’s
expected outflows are mostly long-term and the
main liquidity requirement is to fund acquisition
expenses on new business and unexpected
fluctuations in benefit payments. As discussed
in note 3.4.3, Discovery invests primarily in
liquid financial assets.
For Discovery Life, large sums assured above a
defined retention level are reinsured, providing
stability in claims experienced and further
reducing liquidity risk.
36	Discovery Annual Financial Statements 2022

-- 37 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
Insurance risk 	Description 	How Discovery manages the risk
Liquidity risk
continued
There is a need to meet liquidity requirements
arising from Discovery Invest’s Guaranteed Plan
book. Liquidity requirements are managed to
ensure a liquidity buffer is maintained to meet
potential outflows if exit rates are higher than
expected. The liquidity risk on the existing
portfolio is thus relatively small.
VitalityLife also receives partial financing for
new business strain from financing reinsurance
treaties with reinsurers.
For discussion on managing liquidity risk, refer
to note 2.2.
Contracts that are short-term in nature
VitalityHealth mostly has expected outflows
which are short-term in nature as the vast
majority of claims are expected to be settled
within 12 months of reporting. The existing
book is mature and is cash generative which
covers liquidity required for the cash flow strain
of writing new business.
Discovery Insure holds the majority of working
and solvency capital in cash or near cash
instruments to minimise liquidity risk. Large sums
assured above a defined retention level are
reinsured, providing stability in claims experience
and further reducing the liquidity risk. Catastrophe
reinsurance further reduces this risk.
Concentration risk 	Claims experience risk
There is a risk that a concentration of risk can
lead to worse than expected experience. The
concentration risk is the highest in group
business, since assured lives live in the same
geographical location and generally work in the
same industry or at the same location.
Discovery has a well-diversified book of business
by source of new business and spread across
brokers and agents.
Furthermore, this risk is mitigated through
catastrophe reinsurance.
For details of diversification refer to note 2.3.
Withdrawal concentration risk
There is a financial risk of the withdrawal of a
block of policies written by a single independent
intermediary.
Operational and
implementation
risk
Operational risk is defined as the risk of loss
arising from inadequate or failed internal
processes, people and systems or from external
events. Discovery offers a wide product range,
which grows over time due to further product
enhancements and development.
In order to mitigate operational risk, Discovery
maintains and follows a set of documented
processes and procedures which are reviewed
internally and externally to be in line with industry
best practice. Testing protocols are implemented
prior to launching new systems/ products or
businesses. Embedded in Discovery’s processes
is the concept of segregation of duties which
ensures that there are multiple checks on outputs
by different areas within the business and
protects against operational and implementation
risk. Discovery does not have any legacy systems
and processes to deal with, thereby reducing
operational risk.
2. 	MANAGEMENT OF INSURANCE RISK continued
37	Discovery Annual Financial Statements 2022

-- 38 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
Insurance risk 	Description 	How Discovery manages the risk
Policy wording/
legal risk
There is a risk that Discovery could be financially
exposed to obligations that differ from
expectations and are not adequately provided for.
The risk could also arise from legal proceedings.
The risk is managed when new products are
developed and all policy wording is reviewed by
legal advisors and external advice is obtained
where necessary to ensure that terms and
conditions are clearly defined and unambiguous.
Regulatory risk 	Discovery operates in a highly regulated
environment which is currently being scrutinised
and questioned by both consumers and
regulators. This has resulted in the constant
review of the in-force regulations and the
interpretation thereof.
The regulatory risk can thus be defined as
the potential detrimental impact unexpected
changes in regulations, or the interpretation
thereof, may have on Discovery.
Although Discovery endeavours to design
insurance and financial solutions which meet
the requirements of the current regulations in
force, the risk does exist that changes in the
regulations or the interpretation of the
regulations, over time may result in the current
products not fully complying with the regulations
in force in future.
This risk is managed through constantly seeking
legal advice on new product developments.
Further, all insurance products issued by
Discovery have to be signed off, including sign-
off from a market conduct perspective.
Depending on the business line, these are
signed off either by the Head of the Actuarial
Function or an Actuarial Committee.
Discovery is a member of industry-wide bodies
that engage in discussions with policymakers
and regulators.
Discovery’s compliance department enhances
regulatory compliance through audits and by
monitoring developments in the regulatory
environment.
Tax risk 	Tax risk is the risk that the actual future tax
liability is different to what is currently expected.
This could be as a result of an incorrect
interpretation or application of tax legislation or
as a result of changes to tax legislation.
External tax advice is obtained as required to
ensure that products are structured in a tax
efficient way.
VitalityLife specific
Tax relief on expenses does not apply to
protection business sold from January 2013
onwards.
Expense risk 	Expense risk is the risk of actual expenses being
higher than expected. Expenses could exceed
expectations due to an increase in expense
inflation or due to a reduction in the number of
in-force policies. A reduction in the assets under
management could be an expense risk due to
the number of fixed costs.
Expenses are monitored on a monthly basis
against budgeted expenses. Any deviation from
the budget is investigated, reported and where
necessary, remedial action is taken.
2. 	MANAGEMENT OF INSURANCE RISK continued
38	Discovery Annual Financial Statements 2022

-- 39 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
Insurance risk 	Description 	How Discovery manages the risk
Reputational risk 	Reputational risk is the risk of negative market
reaction towards Discovery. Discovery may thus
not be able to apply management policies to
reduce risk.
Reputational risk is carefully controlled. Decisions
to repudiate claims are reviewed by a review
committee comprising of a senior underwriter
and claims assessor, representatives of the legal
department and the medical team, as well as a
compliance officer.
Marketing material and policy wording are
reviewed and designed to be clear and
unambiguous to avoid creating unreasonable
policyholder expectations.
All products are approved prior to launch, by
either the Head of the Actuarial Function or
Actuarial Committee, depending on the business
line. Sign-off is also done prior to launch from a
market conduct perspective.
For investment products with insurance risk, the
risk on investment returns is mitigated through
the use of reputable experienced fund managers
and unique, innovative products covering
specific risks.
Discovery Life offers policies that integrate with
the product offerings within the Discovery
Group. The reputational risk to Discovery Life is
thus extended to the reputational risk of the
entire 	Discovery 	Group. 	Discovery 	Life
management reviews all product offerings to
minimise the reputational risk.
Reputational risk may also arise on investment
products with insurance risk, if these products
experience worse investment returns than
competitors. This may lead to lower future new
business and higher surrenders.
Risks significant to long-term insurance
Mismatching and
market risk
Mismatching is the risk that insurance-related
cash outflows (e.g. benefit payments, administration
expenses) do not match expected future cash
inflows (predominately future premiums).
Mismatching risk can also arise when movements
in assets and liabilities are out of line given
changes in market risk, i.e. equity price risk,
interest rate risk or currency risk.
The value of assets and liabilities arising from
insurance contracts are subject to interest rate
risk, thus a risk that a change in the discount
rate could cause a change in the value of the
assets and liabilities arising from insurance
contracts.
For assets arising from contracts, Discovery
covers the insurance related outflows by expected
future cash inflows (predominately future
premiums). This is supported by positive future
net cash flows arising from insurance contracts.
For liabilities arising from insurance contracts,
the insurance related cash outflows are matched
with a combination of a release of policyholder
assets (net of retained fees), investment return
on these assets and cash flows.
For further discussion on how Discovery manages
this risk, refer to note 2.4 more specifically:
– For mismatching risk, refer note 2.4.1 and
2.4.2;
– For interest rate risk, refer note 2.4.3; and
– For currency risk, refer note 2.4.4
2. 	MANAGEMENT OF INSURANCE RISK continued
39	Discovery Annual Financial Statements 2022

-- 40 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
Insurance risk 	Description 	How Discovery manages the risk
Underwriting
experience risk
– Individual life
plans and
investment
products with
insurance risk
For individual life plans, there is a risk that actual
mortality and morbidity experience is higher
than expected. This could arise as a result of the
number of claims or the value of claims being
higher than expected. In addition, there is a risk
that the emergence of a new disease or
epidemic can increase the number of claims.
On guaranteed annuities there is a risk that
mortality experience is lower than expected and
thus income payments continue for longer than
expected. Discovery Life does not offer any
deferred annuities where the annuity rate at a
future point in time is guaranteed for new
entrants.
Investment products with insurance risk are not
directly impacted by mortality and morbidity
risks. The Annuity Integrator’s Ill-health booster
boosts retirement income on severe illness. The
Annuity Integrator’s Longevity booster boosts
retirement income every 10 years. The Life
Booster increases the investment fund value by
between 5% and 15% on death, depending on
Vitality status. The costs of the benefits were
allowed for in the product design and pricing of
the benefits.
The risks are managed through various
mechanisms:
Product design and pricing
Products are carefully designed to minimise
adverse selection. Rating factors are applied to
standard premium rates to differentiate
between different levels of risk. For example,
premiums are differentiated by income,
education level, smoker status, gender, medical
history and age.
– From 	January 	2013 	onwards, 	no
differentiation of premiums or benefits on
the basis of gender is allowed in the UK.
– Discovery Life has the unique ability to take
additional rating factors into account for
example the current medical scheme claims
and lifestyle factors.
All new premium rates are reviewed and
approved by either the Head of Actuarial Function
or Actuarial Committee. Product integration
between the different product offerings in
Discovery helps to attract healthier lives than
average in the market, leading to positive
selection. The product integration incentivises
engagement in the Vitality programme, which
has a positive impact on risk experience.
Selection risk is the risk that worse risks than
expected are attracted and these risks are then
charged inadequate premiums. Selection could
also lead to higher than expected mortality and
morbidity experience on individual life plans or
lower mortality on guaranteed annuity policies.
For certain of the product options offered under
the individual life plans, Discovery has retained
the option to review premium rates annually
throughout the life of the contract because
of uncertainties underlying the value of the
benefits offered. Only premiums that can be
predicted with confidence are guaranteed.
Where guarantees are offered, Discovery
guarantees that premiums can only be reviewed
every 10 years and increased by a maximum of
25% over and above contractual premium
increases. The guarantee provided to the
policyholder will, however, be strengthened
based on the policyholder’s actual annual
historic Vitality status.
Discovery Life predominantly operates in the
high end of the South African insurance market
where the risk of HIV/AIDS is lower than for
the South African market as a whole. The impact
of HIV/AIDS is considered and allowed for
during the product development and pricing.
2. 	MANAGEMENT OF INSURANCE RISK continued
40	Discovery Annual Financial Statements 2022

-- 41 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
Insurance risk 	Description 	How Discovery manages the risk
Underwriting
experience risk
– Individual life
plans and
investment
products with
insurance risk
continued
Underwriting
Underwriting ensures that only insurable risks
are accepted and that premiums reflect the
unique circumstances of each risk.
Financial underwriting is applied to ensure that
the policyholder can justify the amount of cover
applied for. Premium loadings and exclusions
are applied where high risks are identified.
For Integrated policies, Discovery Life can
dynamically adjust certain premiums using
the information from the health claims
experience of a policyholder who is also a
member of the Discovery Health Medical Scheme
and Vitality. This provides Discovery Life with an
advantageous position in the market.
Monthly internal quality assurance audits are
performed on underwriting to minimise the risk
of incorrect underwriting decisions.
Reinsurance
Reinsurance protects against volatility in claims
experience and against an accumulation of risk.
Reinsurance is further utilised on a facultative
basis if uncertainty exists over the terms that
should be offered to a particular risk.
In addition, reinsurers provide specialist advice
when designing new products.
Discovery Life utilises surplus and facultative
reinsurance to reinsure amounts in excess of
defined retention levels. Discovery Life is thus
protected against large individual claims.
In addition, catastrophe reinsurance reduces
the risk of an accumulation of risk due to a single
event. Both individual life and group business
are covered by catastrophe reinsurance which
covers man-made or natural catastrophe events.
For VitalityLife, the life, serious illness, disability
and income protection benefits are reinsured
with a maximum retention of GBP 150 000. The
unemployment benefit offered as part of the
VitalityLife product is fully reinsured.
Experience monitoring
Experience investigations are conducted and
corrective action is taken where adverse
experience is noted. Experience monitoring is
done on at least a quarterly basis, and in some
business lines monthly.
Where there is insufficient historic data to provide
credible results, such as VitalityLife, reliance is
placed on reinsurers’ advice, industry experience
as well as experience from Discovery Life.
2. 	MANAGEMENT OF INSURANCE RISK continued
41	Discovery Annual Financial Statements 2022

-- 42 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
Insurance risk 	Description 	How Discovery manages the risk
Risks significant to short-term insurance
Underwriting
experience risk
The risk is that claims experience turns out to be
worse than anticipated in the pricing of the
product and that claims reserves are insufficient
to meet insurance liabilities as they fall due.
The principal risk is that the frequency and/or
severity of claims are greater than expected.
Insurance events are, by their nature, random
and the actual number and size of events during
any one year may vary from those estimated
and experienced in prior periods.
Frequency of claims can vary depending on, for
instance, the levels of engagement with the
Vitality programme, and severity of claims can
be influenced by new treatments or changes in
medical inflation. In addition to renewal pricing
changes, 	standard 	terms 	and 	conditions
applicable to the company’s products mitigate
the risk of late reporting of claims.
Group Life
Group Life business is reviewed on a contract by
contract basis, with the review period never
exceeding two years. AIDS risk is specifically
allowed for in the pricing of individual groups.
Group business is underwritten on an employer
by employer basis and additional allowance is
made for the impact of industry class, income
and geographic location on expected claims
experience. The free cover limit is the sum
assured that will be given automatically to a
specific life without further specific underwriting.
The free cover limits are set separately for each
scheme depending on the size and cover chosen
by the specific scheme.
VitalityHealth
New business is written in accordance with
approved pricing assumptions. Underwriting
criteria is defined and aligned to the approved
pricing assumptions.
VitalityHealth’s overall premium levels are
determined by its pricing and lapse experience,
as well as the level of new business written.
VitalityHealth can manage the risk of new
business policies through the ability to
underwrite policies at inception or at the point
of claim. Aside from large corporate clients, all
other lives covered were underwritten through
either full medical underwriting, continuation of
previous exclusions (if the policy is moving from
another UK health insurer), or moratorium
conditions which limit claims for a specified
period relating to previous conditions.
VitalityHealth is able to manage the insurance
risk in existing business premiums through the
annual repricing of policies at renewal on a risk-
related basis; this is a key differentiator as to
why the UK market is less susceptible to volatility
from insurance risk. Whilst policyholders can
choose to cancel their contract mid-term
between renewals, this is not experienced in
the SME or corporate products as the terms and
conditions of the contract does not permit
cancellation mid-term unless the customer is
going into administration. Individual contracts
can and do cancel between renewals however
retaining these policies is a key activity for the
business. VitalityHealth is only obligated to
continue to pay for any authorised treatment
whilst premiums are being received from the
policyholder.
2. 	MANAGEMENT OF INSURANCE RISK continued
42	Discovery Annual Financial Statements 2022

-- 43 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
Insurance risk 	Description 	How Discovery manages the risk
Underwriting
experience risk
continued
Discovery Insure
Discovery Insure aims to manage risk through
diversifying the pool of insured risks by
establishing a balanced portfolio of insurance
risks over a wide geographical area. Short-term
insurance risks are priced on an individual
basis, therefore a minimal cross subsidy exists
between risks.
Premiums are calculated using statistical
regression techniques. Insurance risk factors
identified would typically include past insurance
history, type and value of asset covered, measures
taken to protect the asset, primary use of covered
item and various other pertinent factors.
Discovery Insure’s quotation and administration
system calculates risk on an individual basis
based on information captured by brokers and
agents for each risk. Individual risks are
accepted automatically up to cut-off limits which
vary by risk type. Insurance conditions and
exclusions are also automatically set at an
individual risk level.
Individual risks greater than the limit are
automatically referred and underwritten by the
underwriting department. No risks are accepted
which exceed the upper limits of the reinsurance
contracts without the necessary facultative
cover being arranged.
Discovery Insure uses telematics to manage
risk. The telemetry received in respect of
vehicles in which the devices are installed,
highlights speeding, harsh breaking, harsh
cornering and other risk related incidents. By
informing the driver of how they are driving and
in turn rewarding them for driving well, the risk
of an accident is reduced. The ’deep install’
device is also equipped with a stolen vehicle
recovery transponder that increases the
probability of recovering a vehicle should it
be stolen.
Reinsurance – VitalityHealth
VitalityHealth currently utilises reinsurance
to better match the high upfront costs of
acquisition with the profit emergence across the
lifetime of the policies written. VitalityHealth
currently has quota share agreements in place
with two reinsurers with an outstanding balance
of GBP 198.5 million (R3 971 million) at year end
(2021: GBP 156 million (R3 079 million)).
2. 	MANAGEMENT OF INSURANCE RISK continued
43	Discovery Annual Financial Statements 2022

-- 44 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
Insurance risk 	Description 	How Discovery manages the risk
Underwriting
experience risk
continued
Reinsurance – Discovery Insure
Discovery Insure mitigates its insurance risk
through its reinsurance programme which is
structured to protect the company against
material losses to either a single insured risk,
or group of insured risks in the case of a
catastrophe where there would tend to be a
concentration of insured risks.
Furthermore, Discovery Insure reinsures a
portion of the risk it underwrites to protect the
profitability and the capital of the company. A
variety of treaties are entered into in order to
limit losses resulting from individual and
collective insurance risks.
Additional facultative reinsurance is purchased
for certain individual risks that are in excess of
the relevant treaty limits. Discovery Insure only
enters into reinsurance arrangements with
reinsurers that have adequate credit ratings.
Experience monitoring
Across both premiums and claims, recent actual
experience is compared against financial
forecasts, with any deviations investigated. The
results provide a feedback loop into the overall
pricing approach, enabling Discovery to react
quickly to any changes in behaviour.
2.1 	Capital adequacy requirements and protection against adverse experience
Refer to the Directors’ report for a breakdown of Statutory Capital Requirement cover ratios. Discovery manages its capital
requirements in line with the statutory requirements of the relevant Prudential Authorities. During the period Discovery met the
Statutory Capital Requirements.
2.1.1 DISCOVERY LIFE
Discovery Life is required to demonstrate solvency to the Prudential Authority (PA) in South Africa in accordance with the
Insurance Act 18 of 2017. Discovery Life thus needs to maintain sufficient shareholder assets (Own Funds), over and above the
assets required to meet policyholder liabilities (best-estimate liabilities plus a prescribed risk margin), to support a multiple of the
Solvency Capital Requirement (SCR). Discovery Life is required to undertake an internal assessment of its risks and capital needs,
in addition to meeting the minimum capital requirements set by the PA. The SCR is calculated in accordance with the Prudential
Standards as issued by the PA. The SCR calculation is intended to approximate a risk-based capital measure and covers the major
areas of insurance risk. It explicitly covers the following key areas of risk to Discovery Life:
– Lapse and withdrawal risk
– Fluctuations in mortality and morbidity experience including catastrophe risk
– Interest rate risk
– Equity and property risk
– Expense risk
– Operational risk
– Spread and counterparty default risk
– Currency risk
– Concentration risk.
2. 	MANAGEMENT OF INSURANCE RISK continued
44	Discovery Annual Financial Statements 2022

-- 45 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.1 	Capital adequacy requirements and protection against adverse experience continued
2.1.1 DISCOVERY LIFE continued
Discovery Life regularly reviews the capital position and also considers various new business scenarios. Typically, a five-year new
business projection horizon is allowed for and the capital position is assessed at each valuation date during the projection to
ensure an acceptable capital cover is maintained.
Discovery Life has calculated its solvency position in accordance with the Insurance Act and related Prudential Standards since
30 June 2013. A consistent level of solvency cover, comfortably in excess of the statutory minimum, was observed at all valuation
dates.
2.1.2 VITALITYLIFE
The Vitality Life business comprises business underwritten directly by VitalityLife (from 1 January 2016) and business underwritten
on behalf of VitalityLife on Prudential Assurance Company’s (PAC’s) life insurance license (up to 31 December 2015).
Through a number of contractual and loan arrangements, Discovery retains 100% of the insurance risk associated with the
VitalityLife policies underwritten on the PAC life insurance license. All policies are administered by VitalityLife, and they are
managed as a single portfolio. The arrangement with the PAC is accounted for in substance under IFRS as an insurance contract
that Discovery issues.
Accordingly, all information for VitalityLife, other than the segment information, is presented on a combined basis comprising
both the business underwritten by VitalityLife and underwritten on behalf of VitalityLife on the PAC life insurance license.
The business that was underwritten on PAC life insurance license will, as per contractual agreement with PAC, still be valued
under the Solvency I or old capital requirement rules described below until it is transferred to the VLL license. After this date, this
business would need to be fully Solvency II compliant. During the financial period ended 30 June 2022, Discovery and PAC have
finalised a contractual agreement to a long-term deferral of the transfer to the Vitality Life Limited license (the Part VII transfer).
The agreement is such that the Part VII transfer is now deferred for the long-term with options to extend further and for all
intents and purposes should be viewed as an indefinite deferral.
The business written on its own life insurance license within VitalityLife needs to be fully Solvency II compliant. VitalityLife obtained
its own life insurance license at the end of the calendar year 2015. This significant milestone, together with the implementation
of Solvency II in the UK from 1 January 2016, required a change to the capital requirements of VitalityLife.
SOLVENCY I
The Financial Services Authority (FSA) was replaced by two distinct regulators in 2013 namely the Prudential Regulation Authority
(PRA) and the Finance Conduct Authority (FCA). The PRA is a part of the Bank of England and responsible for the prudential regulation
and supervision of insurers. It sets standards and supervises financial institutions. The FCA regulates the financial services industry
in the UK. Their aim is to protect consumers, ensure the industry remains stable and promote healthy competition between financial
services providers. The Prudential Sourcebook for Insurers (INSPRU) contains standards for capital management.
Capital requirements are calculated based on the concept of two pillars:
– Pillar 1, which covers public solvency information that appears within the regulatory returns on the basis of prescriptive rules.
This includes the statutory valuation of liabilities together with a prescribed measure of additional capital, the Long-Term
Insurance Capital Requirement (LTICR); and
– Pillar 2, the Individual Capital Assessment (ICA), which covers a confidential company-specific assessment of solvency. This
assessment is done on a realistic basis with the aim to protect against risks up to the 99.5 percentile over a one-year period.
The LTICR is a minimum required margin for solvency on the statutory valuation basis and covers the following basic risks:
– Mortality risk;
– Expense risk;
– Market risk; and
– Health risk.
The amount of capital that ultimately needs to be held by a life insurance company in the UK is the larger of the Pillar1 and Pillar2
result. VitalityLife is required to provide capital to the Prudential Assurance Company (PAC) equal to one times the Pillar1 capital
requirement, increasing to one and a half times from the Pillar 1 capital requirements from March 2024 onwards. The cover
requirements were observed at all valuation dates.
45	Discovery Annual Financial Statements 2022

-- 46 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.1 	Capital adequacy requirements and protection against adverse experience continued
2.1.2 VITALITYLIFE continued
SOLVENCY II
Capital requirements under Solvency II are calculated using the regulations and guidance published by European Insurance and
Occupational Pensions Authority (EIOPA) and enforced by the PRA in the UK. A Solvency II balance sheet is calculated which has
several components:
– Best estimate liabilities (BEL): policyholder liabilities are calculated on a best estimate basis (excluding any margins) and
discounted at the latest swap curve published by EIOPA;
– Solvency Capital Requirement (SCR): 1-in-200 year stresses are applied to the BEL to stress the key risks and are combined
– correlation matrices;
– Risk Margin (RM): 6% of the SCR run-off projected over time is discounted at the latest swap curve;
– Technical Provisions (TP): the sum of the BEL and the RM; and
– Own Funds: the net assets of the company needed to cover the SCR and other liquidity requirements; a negative TP can be
included in the sum of Own Funds to cover the SCR.
A consistent level of solvency cover was observed at all valuation dates.
2.1.3 VITALITYHEALTH
VitalityHealth maintains shareholder capital to meet substantial deviations in experience and to support business growth.
The objective of VitalityHealth’s capital management policy is to define the principles and guiding philosophy for capital
management that ensures capital and solvency levels are managed effectively in line with the defined risk appetites. The policy
and objectives are reviewed at least annually. Alongside ensuring the Company complies with capital requirements imposed by
its regulator (the PRA), the guiding principles for the policy are to:
– Foster an environment of regulatory compliance within the Company’s culture, strategy and decision making;
– Continually develop and enhance the Group’s regulatory compliance capability;
– Actively communicate the effectiveness and benefits of compliance management to all stakeholders; and
– To provide reasonable and independent assurance to the Company’s key management, board and regulator.
The Company is required to hold sufficient capital (measured in accordance with PRA Rulebook) to meet the PRA capital
requirements. The capital requirements were met at all valuation dates.
With effect from 1 January 2016 the insurance regulatory regime Solvency II was implemented in the UK. Refer to 2.1.2 for
discussion on Solvency II. Under this solvency regime, firms have the opportunity to either follow the standard formula approach,
or apply to the regulators to move away from this. VitalityHealth follows a standard formula, and as such has a Solvency Capital
Requirement in line with that prescribed. Annually, the business publicly discloses a Solvency and Financial Condition Report
(SFCR) alongside private disclosures to the regulators on its Own Risk and Solvency Assessment (ORSA). The standard formula
approach is also annually reviewed to determine its appropriateness for the business and as at 30 June 2022 the standard
formula review determined it was not an inappropriate assessment of the risks present in VitalityHealth.
The actual and projected capital position of the Company is monitored on a regular basis through a number of forums and
governance committees including the Board of Directors as well as through VitalityHealth’s ORSA. In the event that sufficient
capital is not projected to be available, actions would be taken to obtain additional capital or to reduce the amount of risk
accepted and therefore reduce the capital requirement through, for example, reinsurance or investment strategy.
46	Discovery Annual Financial Statements 2022

-- 47 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.1 	Capital adequacy requirements and protection against adverse experience continued
2.1.4 DISCOVERY INSURE
Similar to Discovery Life, Discovery Insure is required to demonstrate solvency to the Prudential Authority (PA) in accordance with
the Insurance Act 18 of 2017. Discovery Insure thus needs to maintain sufficient shareholder assets (Own Funds), over and above
the assets required to meet policyholder liabilities (best-estimate liabilities plus a prescribed risk margin), to support a multiple
of the Solvency Capital Requirement (SCR). In addition, Discovery Insure is required to undertake an internal assessment of its
risks and capital needs, in addition to meeting the minimum capital requirements set by the PA. The SCR is calculated in
accordance with the Prudential Standards as issued by the PA. The SCR calculation is intended to approximate a risk-based
capital measure and covers the major areas of short-term insurance risk. It explicitly covers the following key areas of risk to
Discovery Insure:
– Catastrophe risk
– Premium and reserve risk
– Lapse risk
– Interest rate risk
– Equity and property risk
– Expense risk
– Operational risk
– Spread and counterparty default risk
– Currency risk
– Concentration risk.
The internal assessment of risks and capital needs usually considers, amongst others, the following risks:
– Lapse risk not captured in the SCR
– New business volume risk
– Expense risk over and above ALAE risk
Discovery Insure regularly reviews the capital position and considers various new business scenarios. Typically, a five-year new
business projection horizon is allowed for and the capital position is assessed at each financial year during the projection to
ensure an acceptable capital cover is maintained. The solvency cover was observed at all valuation dates.
2.2 	Liquidity risk
2.2.1 CONTRACTS THAT ARE LONG-TERM IN NATURE
DISCOVERY LIFE AND DISCOVERY INVEST
For Discovery Life and Discovery Invest, the discounted expected embedded value cash flows arising from in-force contracts after
policyholder liabilities have been met, net of tax, as at 30 June were as follows:
Gross of reinsurance
R million 	Total 	Year 1 	Years 2 to 5 	Years 6 to 10 	Years 11 to 20 	Years 21+
2022
Discovery Life 	28 101 	1 690 	5 618 	6 382 	8 221 	6 190
Discovery Invest 	8 602 	547 	2 640 	2 677 	2 354 	384
VitalityLife 	12 830 	2 436 	6 194 	4 597 	1 581 	(1 978)
2021
Discovery Life 	23 560 	(1 174) 	6 721 	6 584 	6 784 	4 645
Discovery Invest 	8 337 	688 	2 318 	2 673 	2 218 	440
VitalityLife1 	11 079 	2 203 	9 861 	2 833 	45 	(3 863)
Net of reinsurance
R million 	Total 	Year 1 	Years 2 to 5 	Years 6 to 10 	Years 11 to 20 	Years 21+
2022
Discovery Life 	23 473 	1 298 	4 003 	4 994 	7 367 	5 811
VitalityLife 	8 818 	743 	2 292 	3 723 	1 705 	355
2021
Discovery Life 	19 441 	(721) 	4 895 	5 079 	5 920 	4 268
VitalityLife1 	8 665 	711 	5 875 	1 573 	277 	229
1 	The comparative numbers have been restated to include Vitality Life.
47	Discovery Annual Financial Statements 2022

-- 48 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.2 	Liquidity risk continued
2.2.1 CONTRACTS THAT ARE LONG-TERM IN NATURE continued
The cash flows in the tables above differ from those disclosed on notes 2.4.1 and 2.4.2 since the cash flows in the tables above
are based on best estimate free cash flows after meeting policyholder liabilities, are discounted at the risk discount rate and are
capped at 40 years as per the Discovery Life and Discovery Invest embedded value methodology. Cash flows arising from
investment management contracts are also included. No allowance has been made for new business and related expenses.
2.2.2 CONTRACTS THAT ARE SHORT-TERM IN NATURE
VITALITYHEALTH
VitalityHealth maintains sufficient liquid assets to meet short-term liabilities and to allow for the initial cash flow strain when
writing new business. Currently, VitalityHealth’s expected liabilities are mostly short-term and the main liquidity requirement is
to fund acquisition expenses on new business, with the existing book mature enough to generate sufficient liquidity to cover this
cash flow strain.
DISCOVERY INSURE
Discovery Insure holds the majority of working and solvency capital in cash or near cash instruments to minimise liquidity risk.
Large sums assured above a defined retention level are reinsured, providing stability in claims experience and further reducing
the liquidity risk. Catastrophe reinsurance further reduces this risk.
2.3 	Concentration risk
2.3.1 CLAIMS EXPERIENCE RISK
DISCOVERY LIFE
Discovery Life maintains a well-diversified portfolio of policies. Reinsurance is further used to protect against the concentration
of risk. Catastrophe reinsurance protects against the accumulation of claims from a single event, for example an airplane crash.
The catastrophe reinsurance for Discovery Life covers single event disasters for up to R870 million where the net of reinsurance
impact is greater than R44 million. For its biggest four group schemes, a further layer of catastrophe reinsurance cover of
R3 400 million in excess of R914 million is in place.
Reinsurance removes the exposure to large individual claims. The following graph demonstrates that the distribution of policies
by sum assured is shifted towards lower sum assured due to the reinsurance cover.
0
40 000
60 000
80 000
100 000
0 – 0.5
Before reinsurance 	After reinsurance
20 000
	Number of Lives
>5.0	4.5 – 5.0	4.0 – 4.5	3.5 – 4.0	3.0 – 3.5	2.5 – 3.0	2.0 – 2.5	1.5 – 2.0	1 – 1.5	0.5 – 1.0
2022 Distribution of Sums Retained: before and after reinsurance (Sum retained – Rm)
Reinsurance results in a reduction in exposure to
large individual sums-at-risk, leading to this transfer
from large to small case sizes.
48	Discovery Annual Financial Statements 2022

-- 49 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.3 	Concentration risk continued
2.3.1 CLAIMS EXPERIENCE RISK continued
DISCOVERY LIFE continued
0
40 000
60 000
80 000
100 000
20 000
2021 Distribution of Sums Retained: before and after reinsurance (Sum retained – Rm)
Number of Lives
0 – 0.5
Before reinsurance 	After reinsurance
>5.0	4.5 – 5.0	4.0 – 4.5	3.5 – 4.0	3.0 – 3.5	2.5 – 3.0	2.0 – 2.5	1.5 – 2.0	1.0 –1.5	0.5 – 1.0
Reinsurance results in a reduction in exposure to large individual sums-at-risk,
leading to this transfer from large to small case sizes
VITALITYLIFE
VitalityLife maintains a well-diversified portfolio of policies. Reinsurance removes the exposure to large individual claims. The
following graph demonstrates that the distribution of policies by sum assured is shifted towards lower sum assured due to the
reinsurance cover. The profile is largely the same as the prior period, although a shift towards higher sums assured due to annual
benefit increases and inflationary impacts on new business was observed as expected.
0
90 000
120 000
150 000
180 000
0 – 25
Before reinsurance 	After reinsurance
60 000
30 000
Number of Lives
>250	225 – 250	200 – 225	175 – 200	150 – 175	125 – 150	100 – 125	75 –100	50 – 75	25 – 50
2022 Distribution of Sums Retained: before and after reinsurance (Sum retained – GBP’000)
Number of Lives
0
60 000
90 000
150 000
180 000
0 – 25
Before reinsurance 	After reinsurance
30 000
>250	225 – 250	200 – 225	175 – 200	150 – 175	125 – 150	75 – 100	50 – 75	25 – 50
2021 Distribution of Sums Retained: before and after reinsurance
120 000
100 – 125
49	Discovery Annual Financial Statements 2022

-- 50 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.3 	Concentration risk continued
2.3.1 CLAIMS EXPERIENCE RISK continued
VITALITYHEALTH
VitalityHealth has the risk of single large medical expense claims arising abroad, or multiple small travel claims due to a single
event which could cause losses. In order to manage these risks VitalityHealth holds a reinsurance policy specifically on travel
benefits which can help to cover the concentration risks from these events. The threshold for a potential claim on the reinsurance
for either of these reasons is GBP 250 000.
DISCOVERY INSURE
There is a risk that a concentration of risk can lead to a worse than expected claims experience. In order to manage this
concentration of insurance risk, Discovery has entered into a catastrophe excess of loss reinsurance treaty that would limit the
loss of the company to pre-determined levels following the occurrence of a localised catastrophe in this area.
Discovery Inure has concentration of policyholders in the main metropolitan areas such as Johannesburg, Pretoria, Cape Town
and Durban. A catastrophic flood, hail, fire or earthquake would result in disproportionate losses in these areas given the
accumulation of risk. Catastrophe reinsurance is used to limit the size of such losses and their impact on the underwriting result.
2.3.2 WITHDRAWAL CONCENTRATION RISK
DISCOVERY LIFE AND VITALITYLIFE
There is a financial risk of the withdrawal of a block of policies written by a single independent intermediary. In order to manage
these risks, Discovery diversifies its book of business by source of new business and spread across its brokers and agents.
Unaudited
Brokers and agents
Maximum exposure to single
intermediary % of total
premium income
2022 	2021 	2022 	2021
Long term insurance
– Discovery Life 	7 500 	7 245 	1.2% 	1.4%
– VitalityLife 	30 199 	29 510 	2.9% 	2.9%
Small concentration (0 – 99 policies)
Medium concentration (100 – 999 policies)
Large concentration (1 000+ policies)
21%	28%
51%
2022 API concentation by intermediary – Discovery Life
Small concentration (0 – 99 policies)
Medium concentration (100 – 999 policies)
Large concentration (1 000+ policies)
20%	28%
52%
2021 API concentation by intermediary – Discovery Life
50	Discovery Annual Financial Statements 2022

-- 51 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.4 	Mismatching and market risk
2.4.1 ASSETS ARISING FROM INSURANCE CONTRACTS
Assets under insurance contracts in the Statement of financial position include assets for Discovery Life, VitalityLife and
VitalityInvest. Reconciliation of the assets under insurance contracts disclosed in the cash flows below to the Statement of
financial position (refer to note 5):
R million 	2022 	2021
Assets arising from insurance contracts relating to:
– Discovery Life 	39 661 	35 014
– VitalityLife 	16 984 	15 371
– VItalityInvest 	– 	98
56 645 	50 483
Cash flows are calculated in accordance with the accounting policies. Contractual premium and benefit increases are recognised
in the cash flow projections.
The expected discounted future cash flows utilised in the calculation of assets arising from insurance contracts are disclosed in
the table below. Discounting is performed using:
– the prevailing risk-free SA gilt yield curve for Discovery Life; and
– a modified passive rate for VitalityLife whereby the one-year average of the risk-free gilt yield is used. The assumption is only
changed if the one-year average changes by more than a predetermined range around the set passive rate.
R million 	Total 	Year 1 	Years 2 to 5 	Years 6 to 10 	Years 11 to 20 	Years 21+
2022
Discovery Life 	39 661 	2 403 	9 267 	8 761 	10 662 	8 568
VitalityLife 	16 984 	3 746 	10 523 	7 587 	7 012 	(11 885)
2021
Discovery Life 	35 014 	589 	10 102 	9 319 	8 926 	6 078
VitalityLife 	15 371 	3 652 	10 131 	6 745 	5 457 	(10 614)
51	Discovery Annual Financial Statements 2022

-- 52 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.4 	Mismatching risk continued
2.4.2 LIABILITIES ARISING FROM INSURANCE CONTRACTS continued
Refer to page 61 for a breakdown of the assets backing these liabilities. A reconciliation of the liabilities arising from insurance
contracts disclosed in the cash flows below to the Statement of financial position (refer to note 18):
R million 	2022 	2021
Long-term insurance contract liabilities with fixed and guaranteed terms (Note 18) 	21 273 	21 764
Long-term insurance contract liabilities with fixed and guaranteed terms: Vitalitylnvest 	(5) 	–
Long-term insurance contract liabilities with fixed and guaranteed terms: Discovery Invest 	21 268 	21 764
Negative insurance liability included in unit-linked insurance contracts 	(5 684) 	(5 117)
Discovery Invest value of liabilities arising from insurance contracts 	15 584 	16 647
The expected discounted future cash flows in the calculation of liabilities arising from insurance contracts are disclosed in the
table below, allowing for compulsory and discretionary margins. Discounting is performed using the prevailing risk free SA gilt
yield curve.
R million 	Total 	Year 1 	Years 2 to 5 	Years 6 to 10 	Years 11 to 20 	Years 21+
2022
Discovery Invest
Long-term insurance
contract liabilities with
fixed and guarantee
terms 	(21 268) 	(4 460) 	(15 450) 	(540) 	(554) 	(264)
Negative insurance
liability included in
unit-linked insurance
contracts 	5 684 	34 	1 724 	2 126 	1 923 	(123)
2021
Discovery Invest
Long-term insurance
contract liabilities with
fixed and guarantee
terms 	(21 764) 	(4 657) 	(16 040) 	(444) 	(381) 	(242)
Negative insurance
liability included in
unit-linked insurance
contracts 	5 117 	170 	1 380 	1 860 	1 742 	(35)
52	Discovery Annual Financial Statements 2022

-- 53 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.4 	MISMATCHING RISK continued
2.4.3 MARKET RISK – INTEREST RATE RISK
DISCOVERY LIFE
For Discovery Life, increased nominal or real interest rates would result in an adverse impact on the present value of future
profits. Cash flows on a material segment of the book are linked to inflation. While this retains cash flows in real terms, this
segment is exposed to real interest rate movements. The balance of the book is exposed to changes in the nominal rates.
VITALITYLIFE
As a long-term insurance provider in the United Kingdom (UK), VitalityLife has significant exposure to long-term interest rate risk,
given the impact on reserves of lower investment rate assumptions related to fixed future premium receipts to meet policy
obligations. Accordingly, lower long-term interest rates and yield assumptions may negatively impact on the valuation of future
policy obligations and result in a valuation loss.
Interest rates in the UK have displayed significant volatility in recent years and after a period of decline have started to rise again.
In recent years, VitalityLife has implemented an interest rate risk mitigation strategy to protect itself against volatility in interest
rates by entering into derivative contracts. This strategy ensures that the VitalityLife business operates well within its pre-
determined risk appetite.
The derivative instruments comprise of:
– Interest rate swaps, with a nominal value of GBP 89.5 million (R1 790 million). This interest rate swap derivative swaps
exposure to variable interest rates in return for a fixed interest rate referenced to the 25-year UK SONIA swap rate (VitalityLife
pays the fixed rate and receives the variable rate). The weighted average (by nominal value) fixed interest rate is 2.434%. The
interest rate swap derivative is in place for an extended period of time; and
– Swaption, with a nominal value of GBP 170.0 million (R3 401 million) that was acquired in the year for GBP 14.2 million (R284
million) and expires June 2024. The swaption gives Discovery the participation in the benefit should interest rates rise above
2.668%.
– Interest rate swaps, with a nominal value of GBP 171.5 million (R3 431 million). This interest rate swap derivative swaps
exposure to variable interest rates in return for a fixed Interest rate reference to the 50-year UK SONIA swap rate (Vitalitylife
receives the fixed rate and pays the variable rate). The weighted average (by nominal value) fixed interest rate is 2.218%. The
interest rate swap derivative is in place for an extended period of time.
53	Discovery Annual Financial Statements 2022

-- 54 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.4 	Mismatching risk continued
2.4.3 MARKET RISK – INTEREST RATE RISK continued
VITALITYLIFE continued
Due to the nature of the underlying exposures, the hedge accounting requirements of IFRS were not met. Therefore, these derivative
instruments were classified at fair value with changes recognised in profit or loss throughout the term which may result in volatility
in the reported IFRS earnings of VitalityLife. As at 30 June, the following mark-to-market positions were recorded:
GBP/Rand million
June 2022 	June 2021
Line item in financial statements 	GBP 	R 	GBP 	R
Statement of Financial Position 	9.0 	179 	(11.8) 	(233)
Interest rate swap valuation 	(Financial liabilities)/Financial assets:
Derivative – financial instruments at fair value
through profit or loss
(3.9) 	(79) 	(11.8) 	(233)
Swaption valuation 	Financial assets:
Derivative – financial instruments at fair value
through profit or loss
10.8 	216 	6.8 	135
Other Payables:
VitatilityLife working capital funding1
12.9 	258 	6.8 	135
Income Statement 	(34.9) 	(707) 	(56.4) 	(1 170)
Fair value remeasurement 	Net fair value (losses)/gains on financial assets
at fair value through profit or loss
(47.8) 	(968) 	(56.4) 	(1 170)
Marketing and administration expenses1 	12.9 	261 	– 	–
Transaction costs 	Marketing and administration expenses 	– 	– 	(0.2) 	(4)
1 The Vitalitylife results are reclassified to account for the contractual arrangement in respect of the business written on the Prudential Assurance
Company license, as on insurance contract which Discovery issues under IFRS 4 Insurance Contracts.
DISCOVERY LIFE AND DISCOVERY INVEST
The outstanding claims and incurred but not reported claims are mostly short-term in nature and have consequently been
matched with cash. Reserves backing Income Continuation Benefits in payment are backed by a combination of cash, money
market, gilts and negative rand reserves of appropriate duration.
The risk arising from the Global Linkage Benefit is fully reinsured and Discovery does not face any net direct market risk.
For Discovery Invest, guaranteed return plan liabilities are backed by a combination of negative rand reserves and bonds of
appropriate duration. As maturity approaches, cash flows from negative reserves are invested in bonds and therefore a
reinvestment risk exists. Furthermore, investment policy fee income is dependent on the underlying value of policyholders’
investments, which may be interest rate sensitive.
2.4.4 MARKET RISK – CURRENCY RISK
All of VitalityLife’s insurance benefits and premiums are Sterling denominated as all business is sold in the UK market. A significant
part of operational expenses are Rand denominated as systems and administration are based in South Africa. This creates a
potential mismatching risk.
The Dollar Life Plan, offered by Discovery Life provides a sum insured in US Dollars. Premiums are paid in Rands but linked to the
Rand/Dollar exchange rate. Certain versions of the Dollar Life Plan provide guarantees on the Rand/Dollar exchange rate for a
specified period, thereby exposing Discovery Life to currency risk.
Other insurance business lines do not have significant currency risk.
54	Discovery Annual Financial Statements 2022

-- 55 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.5 	Sensitivity analysis
The financial impact of the key risks that Discovery is exposed to can be demonstrated by considering the sensitivity of the
financial results to a hypothetical change in the underlying assumptions or prevailing market conditions.
Although the sensitivities demonstrate the impact of a change in assumption, the results generally cannot be extrapolated to
demonstrate the impact on future earnings and earnings forecasts.
For each sensitivity illustrated, all other assumptions have been left unchanged. No allowance has been made for any management
action, for example premium increases, to react to the worse-than-expected experience.
The ranges of sensitivity were chosen for illustration purposes and do not represent the extremes of possible experience. The
sensitivities shown under insurance risks consider a change in the long-term assumption used in the projection model.
The following sensitivities are provided under insurance risk:
❚ 	Lapses: The lapse, surrender and withdrawal rates are increased or decreased across all policies and investment plans;
❚ 	Long-term investment return and inflation: A parallel shift is assumed in the yield curve. The investment return, inflation,
renewal expense inflation and inflation-linked premium increases are adjusted consistently;
❚ 	Renewal expenses: Renewal expense per policy is increased or decreased across all policies and investment plans; and
❚ 	Mortality and morbidity: The mortality rate, disability rate and severe illness rates are increased and decreased across all
policies and investment plans.
2.5.1 DISCOVERY LIFE
Gross exposure 	Net of reinsurance
Assets under
insurance
contracts
R million
Change
from base
assumption
%
Assets under
insurance
contracts
R million
Change
from base
assumption
%
Base: June 2022 assumptions 	39 661 	36 182
Lapses +10% (e.g. from x% to 1.1x%) 	34 937 	(11.9) 	31 602 	(12.7)
Lapses –10% (e.g. from x% to 0.9x%) 	45 366 	14.4 	41 735 	15.3
Investment return and inflation –1% (e.g. from 5% to 4%) 	40 928 	3.2 	37 388 	3.3
Investment return and inflation +1% (e.g. from 5% to 6%) 	38 434 	(3.1) 	35 006 	(3.3)
Expense assumption +10% 	39 094 	(1.4) 	35 614 	(1.6)
Expense assumption –10% 	40 230 	1.4 	36 750 	1.6
Mortality and morbidity +10% 	32 044 	(19.2) 	30 321 	(16.2)
Mortality and morbidity –10% 	47 459 	19.7 	42 212 	16.7
Real curve –1% and inflation +1% 	42 977 	8.4 	39 251 	8.5
Real curve +1% and inflaton –1% 	37 050 	(6.6) 	33 782 	(6.6)
Base: June 2021 assumptions 	35 014 	31 685
Lapses +10% (e.g. from x% to 1.1x%) 	31 065 	(11.3) 	27 875 	(12.0)
Lapses –10% (e.g. from x% to 0.9x%) 	39 746 	13.5 	36 272 	14.5
Investment return and inflation –1% (e.g. from 5% to 4%) 	35 989 	2.8 	32 583 	2.8
Investment return and inflation +1% (e.g. from 5% to 6%) 	34 032 	(2.8) 	30 769 	(2.9)
Expense assumption +10% 	34 498 	(1.5) 	31 166 	(1.6)
Expense assumption –10% 	35 529 	1.5 	32 203 	1.6
Mortality and morbidity +10% 	28 154 	(19.6) 	26 345 	(16.9)
Mortality and morbidity –10% 	41 939 	19.8 	37 092 	17.1
Real curve –1% and inflation +1% 	37 548 	7.2 	33 966 	7.2
Real curve +1% and inflaton –1% 	32 962 	(5.9) 	29 848 	(5.8)
Liabilities arising from insurance contracts consist of outstanding reported claims, IBNR claims and long-term liabilities relating
to fixed and guaranteed contracts and unit-linked contracts. For outstanding reported claims and IBNR claims any deviation from
the best estimate liabilities would have a direct impact on profit.
The above sensitivities reflect the impact on profit or loss if there are no discretionary margins.
55	Discovery Annual Financial Statements 2022

-- 56 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.5 	Sensitivity analysis continued
2.5.1 DISCOVERY LIFE continued
For long-term insurance liabilities relating to fixed and guaranteed contracts and unit-linked contracts (refer to reconciliation on
note 2.4.2), the sensitivities are detailed in the table below:
Liabilities
under
insurance
contracts
R million
Change
from base
assumption
%
Base: June 2022 assumptions 	15 584
Lapses +10% (e.g. from x% to 1.1x%) 	15 609 	0.2
Lapses –10% (e.g. from x% to 0.9x%) 	15 638 	0.3
Investment return and inflation –1% (e.g. from 5% to 4%) 	16 145 	3.6
Investment return and inflation +1% (e.g. from 5% to 6%) 	15 054 	(3.4)
Expense assumption +10% 	15 728 	0.9
Expense assumption –10% 	15 441 	(0.9)
Mortality and morbidity +10% 	15 593 	0.1
Mortality and morbidity –10% 	15 576 	(0.1)
Real curve –1% and inflation +1% 	15 383 	(1.3)
Real curve +1% and inflaton –1% 	15 781 	1.3
Base: June 2021 assumptions 	16 647
Lapses +10% (e.g. from x% to 1.1x%) 	16 692 	0.3
Lapses –10% (e.g. from x% to 0.9x%) 	16 664 	0.1
Investment return and inflation –1% (e.g. from 5% to 4%) 	17 302 	3.9
Investment return and inflation +1% (e.g. from 5% to 6%) 	16 024 	(3.7)
Expense assumption +10% 	16 769 	0.7
Expense assumption –10% 	16 521 	(0.8)
Mortality and morbidity +10% 	16 660 	0.1
Mortality and morbidity –10% 	16 629 	(0.1)
Real curve –1% and inflation +1% 	16 820 	(1.0)
Real curve +1% and inflaton –1% 	16 499 	(0.9)
2.5.2 VITALITYLIFE – ASSETS ARISING FROM INSURANCE CONTRACTS
Gross exposure 	Net of Reinsurance
Assets
arising from
insurance
contracts
R million
Change
from base
assumption
%
Assets
arising from
insurance
contracts
R million
Change
from base
assumption
%
Base: June 2022 assumptions 	16 984 	9 853
Lapses +10% (e.g. from x% to 1.1x%) 	16 525 	(2.7) 	9 413 	(4.5)
Lapses –10% (e.g. from x% to 0.9x%) 	17 451 	2.7 	10 297 	4.5
Investment return and inflation –1% (e.g. from 5% to 4%) 	15 487 	(8.8) 	8 382 	(14.9)
Investment return and inflation +1% (e.g. from 5% to 6%) 	17 919 	5.5 	10 809 	9.7
Expense assumption +10% 	16 595 	(2.3) 	9 465 	(3.9)
Expense assumption –10% 	17 374 	2.3 	10 244 	4.0
Mortality and morbidity +10% 	13 646 	(19.7) 	8 397 	(14.8)
Mortality and morbidity –10% 	20 361 	19.9 	11 302 	14.7
Real curve -1% and inflation +1% 	17 790 	4.7 	10 713 	8.7
Real curve +1% and inflaton –1% 	15 466 	(8.9) 	8 348 	(15.3)
Base: June 2021 assumptions 	15 371 	8 557
Lapses +10% (e.g. from x% to 1.1x%) 	14 890 	(3.1) 	8 141 	(4.9)
Lapses –10% (e.g. from x% to 0.9x%) 	15 884 	3.3 	9 008 	5.3
Investment return and inflation –1% (e.g. from 5% to 4%) 	12 171 	(20.8) 	5 408 	(36.8)
Investment return and inflation +1% (e.g. from 5% to 6%) 	16 578 	7.9 	9 772 	14.2
Expense assumption +10% 	15 124 	(1.6) 	8 309 	(2.9)
Expense assumption –10% 	15 619 	1.6 	8 805 	2.9
Mortality and morbidity +10% 	13 080 	(14.9) 	7 517 	(12.2)
Mortality and morbidity –10% 	17 685 	15.1 	9 573 	11.9
Real curve -1% and inflation +1% 	16 449 	7.0 	9 664 	12.9
Real curve +1% and inflaton –1% 	13 446 	(12.5) 	6 696 	(21.7)
The above sensitivities reflect the impact on profit or loss if there are no discretionary margins.
56	Discovery Annual Financial Statements 2022

-- 57 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
2. 	MANAGEMENT OF INSURANCE RISK continued
2.5 	Sensitivity analysis continued
2.5.3 VITALITYHEALTH – IBNR RESERVES
VitalityHealth’s reserves are set based on the results of a frequency and severity model which looks at the expected cost of
each claim which is authorised for treatment. Historical costs per type of claim and the expected shape of emergence of each
claims costs are compared to the amounts already paid to help determine the appropriate reserve for the business. Within the
monthly reserving process, adjustments to the model results are made where evidence arises that there are changes in
development patterns.
The Reserving Committee considers both the model results and other business indicators when setting the actual reserves and
it is attended by colleagues from across the relevant business areas including operational, clinical and risk specialists.
The IBNR is GBP 43.0 million (R860 million) at 30 June 2022 (2021: GBP 35.2 million (R695 million)), which approximates 1.5 months’
worth of claims – which is the expected delay in claims reporting discussed above. Claims provisions at 30 June 2022 include a
supplier settlement and disputed claims provision reflecting the probability weighted settlement of supplier invoices and claims
in dispute. The total of such provisions is GBP 2.9 million (R58 million) (2021: GBP 2.5 million (R49 million)).
VitalityHealth’s IBNR reserves are sensitive to changes in the business’s invoice processing speeds – which has seen significantly
improved stability over the most recent two years. Currently the IBNR is set using the average expected cost of each claim (in the
prior period the IBNR was set as an 80th percentile reserve in recognition of the volatility in the reserving environment). A 50th
and 95th percentile reserve would result in the following:
Million
2022
Rands
2021
Rands
2022
GBP
2021
GBP
Base case 	846.5 	730.0 	42.3 	35.2
Lower bound 	775.4 	717.6 	38.8 	34.6
Upper bound 	933.1 	871.0 	46.6 	42.0
2.5.4 INSURE – IBNR RESERVES
Insure’s IBNR reserves are set based on the Bornhuetter-Ferguson model – a reserving model widely used in the short-term
insurance industry. As with other traditional chain ladder models, the model assumes stability in the reporting and settlement
delays and an expected loss ratio to arrive at a view of ultimate claims. In contrast, the outstanding claims reserve (OCR) is set
predominantly by claims assessors.
The claims reserve for the personal lines business – made up of both the IBNR and OCR reserves – is R480 million at 30 June 2022
(2021: R332 million). Sensitivity tests were performed with the results on the outlined below (in the prior period the IBNR reserve
was set at the 71st percentile level). Given the OCR is not probabilistic in nature, the sensitivity tests are performed purely on the
IBNR reserve.
R million 	2022 	2021
Base case 	479.8 	331.8
50th percentile 	469.0 	322.1
95th percentile 	505.5 	348.0
57	Discovery Annual Financial Statements 2022

-- 58 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK
Discovery’s activities expose it to a variety of financial risks. Financial risks include market risk, credit risk and liquidity risk.
Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market
prices and investment return. Market risk that could impact on future cash flows and hence the value of a financial instrument
arises from:
❚ 	Equity price risk: The impact of changes in equity prices and dividend income.
❚ 	Interest rate risk: The impact of changes in market interest rates.
❚ 	Currency risk: The impact of changes in foreign exchange rates.
Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge
an obligation.
Liquidity risk is the risk that Discovery will encounter difficulty in meeting obligations associated with financial liabilities due to
insufficient cash or another financial asset being available to meet commitments as and when they become due.
Financial risks are managed by Discovery as follows:
❚ 	Discovery has appointed reputable external asset managers to manage its investments.
❚ 	The Actuarial Committee reviews the overall matching of shareholder and policyholder assets to their respective liabilities.
❚ 	The Capital, Currency, and Investment Committee (CCIC) is a sub-committee of the Group Executive Committee and meets
quarterly to focus on shareholder assets and the performance of asset managers responsible for managing these assets. The
CCIC also sets exposure limits for exposures to individual counterparties.
❚ 	Discovery periodically engages external consultants to review past investment decisions.
❚ 	The Investment Committee is a sub-committee of the CCIC and meets monthly to make operational decisions regarding
Discovery’s liquidity and foreign currency exposure.
58	Discovery Annual Financial Statements 2022

-- 59 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
Discovery’s approach in monitoring credit risk
Discovery’s credit risk rating systems and processes differentiate and quantify credit risk across counterparties and asset classes.
Discovery uses different credit rating approaches to monitor credit risk dependent on the financial assets. For financial assets
with externally rated ratings, e.g. Moody’s, the external rating is always used. For non-Moody’s rated instruments, the following
approaches will apply:
RATING SCALES FOR FUNDS
A credit rating, being a ranking of creditworthiness, is allocated to the obligor. Where external ratings are unavailable, internal
rating assessments are conducted through analysis of the latest financial and other relevant information, in a consistent and
systematic manner. Where external ratings are available, the standard rating classifications used by the external rating agencies
have been applied. The internal rating scale is based on internal definitions and influenced by definitions published by the
external ratings agency, Moody’s. Where applicable, internal ratings are mapped to equivalent external Moody’s rating scales.
The Group’s Internal Rating Scale categories are defined below:
Grading and Group internal rating 	Moody’s Investors Service equivalent of internal rating
Investment grade
Grades Aaa, Aa1, Aa2, Aa3 	Aaa, Aa1, Aa2, Aa3
Grades A1, A2, A3 	A1, A2, A3
Grades Baa, Baa1, Baa2, Baa3 	Baa, Baa1, Baa2, Baa3
Sub-investment grade
Grades Ba, Ba1, Ba2, Ba3, B, B1, B2, B3 	Ba, Ba1, Ba2, Ba3, B
B1, B2, B3
Grades Caa, Caa1, Caa2, Caa3, Ca, Ca1, Ca2, Ca3 	Caa, Caa1, Caa2, Caa3
Ca, Ca1, Ca2, Ca3
Default
Grades C 	C
Moody’s Investor Services define their respective ratings as follows:
Investment grade 	Aaa 	Obligations rated Aaa are judged to be of the highest quality, subject to the lowest level of
credit risk
Aa 	Obligations rated Aaa are judged to be of the highest quality, subject to the lowest level of
credit risk
A 	Obligations rated A are judged to be upper-medium grade and are subject to low credit risk
Baa 	Obligations rated Baa are judged to be medium-grade and subject to moderate credit risk
and as such may possess certain speculative characteristics
Sub-investment grade Ba 	Obligations rated Ba are judged to be speculative and are subject to substantial credit risk
B 	Obligations rated B are considered speculative and are subject to high credit risk
Caa 	Obligations rated Caa are judged to be speculative of poor standing and are subject to very
high credit risk
Ca 	Obligations rated Ca are highly speculative and are likely in, or very near, default, with
some prospect of recovery of principal and interest
Default 	C 	Obligations rated C are the lowest rated and are typically in default, with little prospect for
recovery of principal or interest
A numerical modifier may be added to each generic rating classification. Each modifier indicates the following:
❚ 	the modifier 1 indicates that the obligation ranks in the higher end of its generic rating category.
❚ 	the modifier 2 indicates a mid-range ranking; and
❚ 	the modifier 3 indicates a ranking in the lower end of that generic rating category.
59	Discovery Annual Financial Statements 2022

-- 60 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
Discovery’s approach in monitoring credit risk continued
POOLED FUNDS
The Group invests in funds through which it is also exposed to credit risk of the underlying assets in which the funds are invested.
The Group’s exposure to risk is classified at fund level and not at the underlying asset level. Although funds are not rated, fund
managers are required to invest in credit assets within the defined parameters stipulated in the fund’s mandate. These rules limit
the extent to which fund managers can invest in unlisted and/or unrated credit assets and generally restrict funds to the
acquisition of local currency investment grade assets.
DISCOVERY BANK
Loans and advances to customers are categorised with Discovery Bank’s own internally developed credit models. The Discovery
Bank model uses a 10-point Discovery Risk Grade classification, with each point being in two decrements to further distinguish
risk. The following table summarises how Discovery Bank classifies its loans:
Discovery Risk Category 	Discovery Risk Grades 	Risk of default assessment
Exceptional low risk 	DRG1 – DRG2 	Less than 0.4%
Low risk 	DRG3 – DRG5 	Less than 1.5%
Medium risk 	DRG5 – DRG8 	Less than 6%
High risk 	DRG8 – DRG9 	Less than 24%
Very high risk 	DRG 10 	More than 24%
Categorisation of business in the analysis of financial risk
To assist in the analysis of the financial risks that Discovery and its policyholders are exposed to, the Statement of financial
position has been divided into five categories, based on the nature of the products provided by Discovery and the nature of the
financial assets held to back the policyholder liabilities.
❚ 	Unit-linked investment contracts: this category relates to contracts issued by Discovery where there is a direct relationship
between the returns earned on the underlying portfolio and the returns credited to the contract. Discovery holds the assets
on which the unit prices are based and as a result there is no mismatch. The market risk (including equity price, interest rate
and currency risk) as well as the credit risk for these contracts is therefore borne by the policyholder and not the Discovery
shareholders.
❚ 	Unit-linked insurance contracts: this category relates to insurance contracts issued by Discovery which have a component
that is linked to the units of an underlying portfolio. For this component, Discovery holds the assets on which the unit prices
are based. However, the gross unit liabilities are reduced by the present value of future charges less the present value of
future expenses and risk claims. Under IFRS, the unit-linked component is not accounted for separately from the host
insurance contract. These contracts expose both Discovery shareholders and policyholders to financial risks.
❚ 	Insurance contracts: this category relates to insurance contracts issued by Discovery which Discovery funds with a portfolio
of matching assets, exposing the Discovery shareholders to financial risk. The financial assets in this category include those
financial assets held within specific portfolios matched to specific liabilities, for example claims reserves and claims incurred
but not reported (IBNR).
❚ 	Shareholder financial assets and liabilities: this category includes the financial assets and financial liabilities that expose
the Discovery shareholders to financial risks, including financial assets and cash backing insurance reserves and statutory
capital. This category includes those financial assets that are not held in specific portfolios matched to insurance related
liabilities.
❚ 	Shareholder non-financial assets and liabilities: No financial risk disclosures are required for these items.
60	Discovery Annual Financial Statements 2022

-- 61 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
Categorisation of financial assets continued
The financial assets in each of these categories are sub-categorised into a second tier of classification, namely:
❚ 	Equity portfolios
❚ 	Debt portfolios
❚ 	Money market portfolios
❚ 	Multi-asset portfolios
In applying the definitions below, reliance is placed on the classifications by asset managers.
EQUITY PORTFOLIOS
The following have been defined as equity portfolios:
❚ 	Portfolios that invest a minimum of circa 75% of the market value of the portfolio in equities and generally seek maximum
capital appreciation as their primary goal. These portfolios invest in selected shares across the range of large, mid, and
smaller cap shares. While the managers of these portfolios may subscribe to different investment styles or approaches, their
intent is to produce a risk/return profile that is comparable with the risk/return profile of the overall equities market. The
portfolios in this category offer medium to long-term capital growth as their primary investment objective.
❚ 	Investments or portfolios of equity linked notes.
DEBT (INTEREST-BEARING) PORTFOLIOS
Interest-bearing portfolios are portfolios that invest exclusively in bond, money market investments and other interest earning
securities. These portfolios may not include equity securities, real estate securities or cumulative preference shares.
In addition to the above the inflation-linked bonds have been defined as Debt portfolios. Inflation-linked bonds are essentially
loans where the principal and interest payments are contractually linked to an inflation measure.
MONEY MARKET PORTFOLIOS
Money market portfolios are portfolios that seek to maximise interest income, preserve the portfolio’s capital, and provide
immediate liquidity. This is achieved by investing in money market instruments with a maturity of less than thirteen months while
the average duration of the underlying assets may not exceed 90 days and a weighted average legal maturity of 120 days. The
portfolios are typically characterised as short-term, highly liquid vehicles.
MULTI-ASSET PORTFOLIOS
Multi-asset portfolios are portfolios that invest in a wide spread of investments in the equity, bond, money, and property markets
to maximise total returns, comprising capital and income growth over the long term. These portfolios do not fall within the
thresholds that have been determined for the Equity portfolios or the Debt portfolios.
61	Discovery Annual Financial Statements 2022

-- 62 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
Categorisation of financial assets continued
The following tables reconcile the Group Statement of financial position to the classes of risks and the categories listed on the
previous pages.
Group
R million 	Total
Unit-linked
investment
contracts
Unit-linked
insurance
contracts
Insurance
contracts
Shareholder
Financial
assets and
liabilities
Other
assets and
liabilities
30 June 2022
Assets arising from insurance contracts 	56 645 	– 	– 	56 645 	– 	–
Loans and advances to customers at
amortised cost: 	3 944 	– 	– 	– 	3 944 	–
Investments at amortised cost:
Unlisted:
– Debt 	5 205 	– 	– 	– 	5 205 	–
– Fixed deposits 	1 956 	– 	– 	– 	1 956 	–
Financial instruments mandatorily at
fair value through profit or loss:
Listed:
– Equity portfolios 	53 947 	15 511 	38 024 	252 	160 	–
– Debt portfolios 	47 012 	8 108 	19 439 	18 714 	751 	–
– Money market portfolios 	8 052 	415 	830 	327 	6 480 	–
– Multi-asset portfolios 	21 179 	11 330 	9 689 	93 	67 	–
Unlisted:
– Equity portfolios 	4 001 	171 	3 784 	– 	46 	–
– Debt portfolios 	580 	80 	485 	– 	15 	–
– Money market portfolios 	6 628 	1 180 	2 121 	2 131 	1 196 	–
– Multi-asset portfolios 	95 	– 	87 	– 	8 	–
Derivative financial instruments at
fair value:
– used as cash flow hedges 	17 	– 	– 	– 	17 	–
– not designated as hedging
instruments 	259 	9 	12 	– 	238 	–
Non-current asset held for sale 	171 	– 	– 	– 	– 	171
Receivables:
– Insurance receivables 	7 887 	– 	– 	– 	7 887 	–
– Contract receivables 	1 209 	– 	– 	– 	1 209 	–
– Other receivables 	4 017 	361 	899 	13 	1 369 	1 375
Reinsurance contracts 	511 	– 	– 	511 	– 	–
Cash and cash equivalents 	19 775 	1 092 	3 583 	333 	14 767 	–
Other non-financial assets 	28 134 	– 	834 	– 	– 	27 300
Total assets 	271 224 	38 257 	79 787 	79 019 	45 315 	28 846
Liabilities arising from insurance
contracts 	109 200 	– 	72 002 	37 198 	– 	–
Liabilities arising from reinsurance
contracts 	13 192 	– 	– 	13 192 	– 	–
Deposits from customers 	10 881 	– 	– 	– 	10 881 	–
Borrowings at amortised cost 	20 584 	22 	132 	– 	20 430 	–
Other payables 	15 123 	874 	1 135 	438 	12 264 	412
Investment contracts at fair value
through profit or loss 	37 361 	37 361 	– 	– 	– 	–
Derivative financial instruments at
fair value:
– used as cash flow hedges 	56 	– 	– 	– 	56 	–
– not designated as hedging
instruments 	146 	– 	– 	– 	146 	–
Other non-financial liabilities 	11 126 	– 	– 	– 	– 	11 126
Total liabilities 	217 669 	38 257 	73 269 	50 828 	43 777 	11 538
62	Discovery Annual Financial Statements 2022

-- 63 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
Group
R million 	Total
Unit-linked
investment
contracts
Unit-linked
insurance
contracts
Insurance
contracts
Shareholder
Financial
assets and
liabilities
Other
assets and
liabilities
30 June 2021
Assets arising from insurance contracts 	50 483 	– 	– 	50 483 	– 	–
Loans and advances to customers at
amortised cost: 	3 361 	– 	– 	– 	3 361 	–
Investments at amortised cost:
Unlisted:
– Debt 	4 109 	– 	– 	– 	4 109 	–
– Fixed deposits 	1 495 	– 	– 	– 	1 495 	–
Financial instruments mandatorily at
fair value through profit or loss:
Listed:
– Equity portfolios 	40 508 	13 010 	27 114 	236 	148 	–
– Debt portfolios 	36 452 	5 620 	10 655 	18 674 	1 503 	–
– Money market portfolios 	10 892 	1 004 	1 894 	1 102 	6 892 	–
– Multi-asset portfolios 	33 205 	10 954 	22 083 	114 	54 	–
Unlisted:
– Equity portfolios 	2 854 	52 	2 759 	– 	43 	–
– Debt portfolios 	33 	2 	– 	– 	31 	–
– Money market portfolios 	6 361 	977 	1 911 	3 255 	218 	–
– Multi-asset portfolios 	632 	– 	632 	– 	– 	–
Derivative financial instruments at
fair value:
– used as cash flow hedges 	28 	– 	– 	– 	28 	–
– not designated as hedging
instruments 	221 	3 	4 	– 	214 	–
Receivables:
– Insurance receivables 	6 158 	– 	– 	– 	6 158 	–
– Contract receivables 	1 217 	– 	– 	– 	1 217 	–
– Other receivables 	3 158 	288 	559 	40 	1 302 	969
Reinsurance contracts 	445 	– 	– 	445 	– 	–
Cash and cash equivalents 	20 013 	952 	3 111 	8 	15 942 	–
Other non-financial assets 	25 069 	– 	992 	– 	– 	24 077
Total assets 	246 694 	32 862 	71 714 	74 357 	42 715 	25 046
Liabilities arising from insurance
contracts 	100 977 	– 	64 446 	36 531 	– 	–
Liabilities arising from reinsurance
contracts 	12 525 	– 	– 	12 525 	– 	–
Deposits from customers 	8 985 	– 	– 	– 	8 985 	–
Borrowings at amortised cost 	19 493 	– 	– 	– 	19 493 	–
Other payables at amortised cost 	14 904 	568 	1 154 	404 	12 426 	352
Investment contracts at fair value
through profit or loss 	32 291 	32 291 	– 	– 	– 	–
Derivative financial instruments at
fair value:
– used as cash flow hedges 	461 	– 	– 	– 	461 	–
– not designated as hedging
instruments 	365 	3 	5 	– 	357 	–
Other non-financial liabilities 	10 274 	– 	– 	– 	– 	10 274
Total liabilities 	200 275 	32 862 	65 605 	49 460 	41 722 	10 626
63	Discovery Annual Financial Statements 2022

-- 64 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
The financial risks associated with each category are discussed below.
3.1 	Unit-linked investment contracts
Unit-linked investment contracts relate to contracts where there is a direct relationship between the returns earned on the
underlying portfolio and the returns credited to the contract.
Investments held at risk of
policyholders
R million
Group
2022
Group
2021
30 June 2022
Financial instruments mandatorily at fair value through profit or loss:
Listed:
– Equity portfolios 	15 511 	13 010
– Debt portfolios 	8 108 	5 620
– Money market portfolios 	415 	1 004
– Multi-asset portfolios 	11 330 	10 954
Unlisted:
– Equity portfolios 	171 	52
– Debt portfolios 	80 	2
– Money market portfolios 	1 180 	977
Derivative financial instruments at fair value:
– not designated as hedging instruments 	9 	3
Receivables:
– Other receivables at amortised cost 	361 	288
Cash and cash equivalents 	1 092 	952
Total assets 	38 257 	32 862
Borrowings at amortised cost 	22 	–
Other payables 	874 	568
Investment contracts at fair value through profit or loss 	37 361 	32 291
Derivative financial instruments at fair value:
– not designated as hedging instruments 	– 	3
Total liabilities 	38 257 	32 862
3.1.1 MARKET RISK
EQUITY AND INTEREST RATE RISK
Discovery’s primary exposure to market risk from these contracts is the volatility in asset management fees earned by Discovery,
due to the impact of interest rate, equity price and currency movements on the fair value of the assets held in the linked funds,
on which the investment management fees are based. A increase of 10% in the value of the assets would increase the asset
management fees by R60 million per annum (2021: R55 million). A decrease of 10% in the value of the assets would reduce the
asset management fees by R60 million per annum (2021: R55 million)
In respect of IFRS-defined investment management contracts there may be an associated asset for the costs of obtaining
contracts. There is a risk that in the event of adverse market movements, future expected management fees may reduce and
consequently this asset may not be realised and therefore necessitate impairment. There were no impairments necessary in the
current or previous financial year.
CURRENCY RISK
The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily
with respect to the US dollar and the UK pound. Foreign exchange risk arises from future commercial transactions and recognised
assets and liabilities. The currency risk is borne by the policyholder.
64	Discovery Annual Financial Statements 2022

-- 65 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.1 	Unit-linked investment contracts continued
3.1.2 CREDIT RISK
Credit risk is borne by the policyholder. For the majority of the unit-linked investments, Discovery has invested in mutual funds
in order to provide for obligations under unit-linked investment contract liabilities. Each mutual fund has its own legal constitution
and operates within a mandate that is delegated to the appointed fund manager. Credit risks assumed within the assets held are
controlled by various protection mechanisms within the mandate and in law. Each fund’s trustees or board appoints administrators
who are responsible to ensure that the fund’s mandate and any internal and legislated control procedures are adhered to. In the
event of breach, they are obligated to bring it immediately to the attention of the fund’s trustees or board and management of
the administrators for remedial action.
In the case where unit-linked investment contracts are linked to structured products, Discovery’s policy dictates that these obligations
are matched exactly. At inception of these contracts, assets which have proceeds that exactly match the pay-out under the policy,
with the exception of credit risk, are purchased. Credit risk on these products is therefore also borne by the policyholder.
3.1.3 LIQUIDITY RISK
Certain contracts can be surrendered before maturity for a cash surrender value specified in the contractual terms and conditions.
This surrender value is equal to or less than the carrying amount of the contract liabilities. If all the contracts with this option were
surrendered at the financial year-end, a loss of R792 million (2021: R658 million) would have been recorded in profit or loss. This
loss would result from an impairment to the asset raised for costs of obtaining contracts, but the impact is reduced by the
surrender penalties receivable. A maturity analysis based on the earliest contractual repayment date would present 100%
(2021: 100%) of the policyholder liabilities due within one year. The assets held to match these policyholder liabilities are realisable
in the short-term.
65	Discovery Annual Financial Statements 2022

-- 66 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.2 	Unit-linked insurance contracts
A unit-linked insurance contract is an IFRS-defined insurance contract with a component that is linked to the units of an underlying
portfolio.
Investments held at risk of
policyholders
R million
Group
2022
Group
2021
30 June 2022
Financial instruments mandatorily at fair value through profit or loss:
Listed:
– Equity portfolios 	38 024 	27 114
– Debt portfolios 	19 439 	10 655
– Money market portfolios 	830 	1 894
– Multi-asset portfolios 	9 689 	22 083
Unlisted:
– Equity portfolios 	3 784 	2 759
– Debt portfolios 	485 	–
– Money market portfolios 	2 121 	1 911
– Multi-asset portfolios 	87 	632
Derivative financial instruments at fair value:
– not designated as hedging instruments 	12 	4
Receivables:
– Other receivables 	899 	559
Cash and cash equivalents 	3 583 	3 111
Other assets 	834 	992
Total assets 	79 787 	71 714
Liabilities arising from insurance contracts 	72 002 	64 446
Borrowings at amortised cost 	132 	–
Other payables 	1 135 	1 154
Derivative financial instruments at fair value:
– not designated as hedging instruments 	– 	5
Total liabilities 	73 269 	65 605
The assets are greater than the liabilities as a result of the Negative insurance liability of R5 684 milion (2021: R5 117 million) included in unit-linked
insurance contracts (refer to note 18) and the deferred tax asset of R834 million (2021: R992 million) in relation to the Individual Policyholder Fund.
66	Discovery Annual Financial Statements 2022

-- 67 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.2 	Unit-linked insurance contracts continued
3.2.1 MARKET RISK
Discovery’s primary exposure to market risk from these contracts is the volatility in asset management fees due to the impact of
interest rate, equity price and currency movements on the fair value of the assets held in the linked funds, on which the investment
management fees are based. An increase of 10% in the value of the assets would increase the asset management fees by R147
million per annum (2021: R134 million). A decrease of 10% in the value of the assets would reduce the asset management fees by
R148 million per annum (2021: R134 million).
3.2.2 CREDIT RISK
The credit risk for the unit-linked insurance contracts is similar to the credit risk for the unit-linked investment contracts. Refer to
section 3.1.2 on the detail for the exposure to the credit risk.
3.2.3 LIQUIDITY RISK
All contracts can be surrendered before maturity for a cash surrender value specified in the contractual terms and conditions.
This surrender value is equal to or less than the carrying amount of the contract liabilities. If all the contracts with this option were
surrendered at the financial year-end, a loss of R5 948 million (2021: R5 491 million) would have been recorded in profit or loss.
This loss results from the impairment of assets arising from insurance contracts relating to these contracts, but the impact is
reduced by the surrender penalties receivable.
The assets held to match these policyholder liabilities are highly liquid and are realisable in the short term. A maturity analysis
based on the earliest contractual repayment date is as follows:
Group
R million 	Total
< 1
Year
1 – 2
Years
3 – 5
Years
30 June 2022
Unit-linked insurance contracts 	77 724 	77 507 	98 	119
30 June 2021
Unit-linked insurance contracts 	69 549 	68 947 	122 	480
67	Discovery Annual Financial Statements 2022

-- 68 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.3 	Insurance contracts
For insurance contracts, Discovery funds the insurance liabilities with a portfolio of matching assets.
R million
Group
2022
Group
2021
30 June 2022
Assets arising from insurance contracts 	56 645 	50 483
Financial instruments mandatorily at fair value through profit or loss:
Listed:
– Equity portfolios 	252 	236
– Debt portfolios 	18 714 	18 674
– Money market portfolios 	327 	1 102
– Multi-asset portfolios 	93 	114
Unlisted:
– Money market portfolios 	2 131 	3 255
Receivables:
– Other receivables 	13 	40
Reinsurance contracts 	511 	445
Cash and cash equivalents 	333 	8
Total assets 	79 019 	74 357
Liabilities arising from insurance contracts 	37 198 	36 531
Liabilities arising from reinsurance contracts 	13 192 	12 525
Other payables 	438 	404
Total liabilities 	50 828 	49 460
3.3.1 MARKET RISK
When calculating the liabilities arising from insurance contracts, an increase/decrease in the investments would result in an
increase/decrease in the liability but it may not be an equal Rand value movement, resulting in the difference being accrued to
the shareholders. Discovery aims to closely match liabilities with appropriate assets and maintains sufficient assets to protect
against residual mismatches between assets and liabilities at a 99.5% confidence interval over a one-year time horizon.
3.3.2 CREDIT RISK
Discovery is exposed to credit risk through financial investments comprising money market portfolios and debt portfolios entered
into to match policyholders’ insurance contract liabilities. Discovery is exposed to the issuer’s credit standing on these instruments
which is monitored by the CCIC by setting a minimum credit rating. Discovery has appointed reputable asset managers to manage
these instruments.
68	Discovery Annual Financial Statements 2022

-- 69 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.3 	Insurance contracts continued
3.3.2 CREDIT RISK continued
Group
R million 	Total 	Aaa
Aa1
Aa2
Aa3
A1
A2
A3
Ba1
Ba2
Ba3
Baa1
Baa2
Baa3 	Govt 1
Pooled
funds
30 June 2022
Financial instruments mandatorily
at fair value through profit or loss:
Listed:
– Debt portfolios 	18 714 	1 	2 	12 207 	– 	6 466 	38
– Money market portfolios 	327 	– 	– 	– 	325 	– 	– 	2
Unlisted:
– Money market portfolios 	2 131 	– 	146 	– 	1 967 	– 	18 	–
Reinsurance contracts 	511 	321 	166 	24
Cash and cash equivalents 	333 	– 	– 	1 	332 	– 	– 	–
22 016 	1 	469 	167 	14 855 	– 	6 484 	40
30 June 2021
Financial instruments mandatorily
at fair value through profit or loss:
Listed:
– Debt portfolios 	18 674 	64 	51 	5 	167 	– 	18 383 	4
– Money market portfolios 	1 102 	3 	229 	– 	158 	– 	457 	255
Unlisted:
– Money market portfolios 	3 255 	– 	850 	1 841 	564 	– 	– 	–
Reinsurance contracts 	445 	48 	216 	159 	22 	– 	– 	–
Cash and cash equivalents 	8 	6 	2 	– 	– 	– 	– 	–
23 484 	121 	1 348 	2 005 	911 	– 	18 840 	259
1 These instruments are issued by the South African government.
3.3.3 LIQUIDITY RISK
The liquidity risk for assets and liabilities arising from insurance contracts are discussed in insurance risks in Note 2 Management
of Insurance Risk. The financial investments held at fair value through profit or loss are realisable in the short term.
69	Discovery Annual Financial Statements 2022

-- 70 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities
The shareholders are exposed to financial risk through the following financial assets and liabilities:
Investments held at risk of
shareholders
R million
Group
2022
Group
2021
30 June 2022
Loans and advances to customers at amortised cost 	3 944 	3 361
Investments at amortised cost:
Unlisted:
– Debt 	5 205 	4 109
– Fixed deposits 	1 956 	1 495
Financial instruments mandatorily at fair value through profit or loss:
Listed:
– Equity portfolios 	160 	148
– Debt portfolios 	751 	1 503
– Money market portfolios 	6 480 	6 892
– Multi-asset portfolios 	67 	54
Unlisted:
– Equity portfolios 	46 	43
– Debt portfolios 	15 	31
– Money market portfolios 	1 196 	218
– Multi-asset portfolios 	8 	–
Derivative financial instruments at fair value:
– used as cash flow hedges 	17 	28
– not designated as hedging instruments 	238 	214
Receivables:
– Insurance receivables 	7 887 	6 158
– Contract receivables 	1 209 	1 217
– Other receivables at amortised cost 	1 369 	1 302
Cash and cash equivalents 	14 767 	15 942
Total assets 	45 315 	42 715
Deposits from customers 	10 881 	8 985
Borrowings at amortised cost 	20 430 	19 493
Other payables 	12 264 	12 426
Derivative financial instruments at fair value:
– used as cash flow hedges 	56 	461
– not designated as hedging instruments 	146 	357
Total liabilities 	43 777 	41 722
70	Discovery Annual Financial Statements 2022

-- 71 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.1 MARKET RISK
EQUITY PRICE RISK
INVESTMENTS
Discovery is exposed to equity price risk through its equity investments held that have been classified as investments at fair value
through profit or loss (FVTPL), on the Statement of financial position. To manage its equity risk arising from investments in Equity
portfolios of R206 million (2021: R191 million), the Group diversifies its portfolio and uses experienced asset managers.
For shareholder investments, a reasonable increase of 10% in the equity markets would result in a profit of R40 million before tax
(2021: R62 million). A reasonable decrease of in the equity markets would result in a loss of R40 million before tax
(2021: R62 million). This impact would be recognised in profit or loss and equity. The sensitivity assumes that the equity markets
had increased/decreased by 10% with all other variables held constant.
Discovery is also exposed to equity price risk through its cash-settled share incentive schemes, namely the Phantom share
scheme and the Acquisition share scheme, the details of which are described in note 32. This liability has been included in ‘Other
payables at amortised cost’ in the Statement of financial position. To manage this risk, Discovery has purchased a combination of
total return equity swaps (TRS) and call options from Ba1 (2020: Ba2 – Baa3) South African banks to hedge a portion of its
exposure to changes in the Discovery share price.
With effect from 1 July 2022 the hedges became ineffective. Accordingly, Discovery discontinued hedge accounting under IFRS on
these TRSs and call options. Previously accumulated balances in the hedge reserve will be reclassified to profit or loss during the
future service period.
INTEREST RATE RISK
Sensitivity to changes in interest rates is relevant to financial assets and financial liabilities bearing floating interest rates due to
the risk that future cash flows will fluctuate. However, sensitivity will also be relevant to fixed-rated financial assets and financial
liabilities that are re-measured to fair value. The table below details the specific interest rate risk that the Group is exposed to:
Group
R million
Carrying
amount 	Fixed 	Floating
Non-interest
bearing
30 June 2022
Loans and advances to customers at amortised cost 	3 944 	– 	3 944 	–
Investments at amortised cost:
Unlisted:
– Debt 	5 205 	– 	5 205 	–
– Fixed deposits 	1 956 	1 610 	346 	–
Financial instruments mandatorily at fair value through
profit or loss:
Listed:
– Debt portfolios 	751 	620 	131 	–
– Money market portfolios 	6 480 	2 470 	3 993 	17
– Multi-asset portfolios 	67 	1 	– 	66
Unlisted:
– Debt portfolios 	15 	3 	12 	–
– Money market portfolios 	1 196 	26 	1 170 	–
– Multi-asset portfolios 	8 	– 	– 	8
Derivative financial instruments at fair value:
– used as cash flow hedges 	17 	17 	– 	–
– not designated as hedging instruments 	238 	– 	216 	22
Receivables
– Insurance receivables 	7 887 	– 	– 	7 887
– Contract receivables 	1 209 	– 	– 	1 209
– Other receivables at amortised cost 	1 369 	259 	10 	1 100
Cash and cash equivalents 	14 767 	122 	14 580 	65
Total financial assets 	45 109 	5 128 	29 607 	10 374
Deposits from customers 	10 881 	3 372 	7 360 	149
Borrowings at amortised cost 	20 430 	9 859 	10 571 	–
Other payables at amortised cost 	12 264 	7 381 	26 	4 857
Derivative financial instruments at fair value:
– used as cash flow hedges 	56 	56 	– 	–
– not designated as hedging instruments 	146 	– 	79 	67
Total financial liabilities 	43 777 	20 668 	18 036 	5 073
71	Discovery Annual Financial Statements 2022

-- 72 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
Group
R million
Carrying
amount 	Fixed 	Floating
Non-interest
bearing
30 June 2021
Loans and advances to customers at amortised cost 	3 361 	– 	3 361 	–
Investments at amortised cost:
Unlisted:
– Debt 	4 109 	4 109 	– 	–
– Fixed deposits 	1 495 	1 221 	274 	–
Financial instruments mandatorily at fair value through
profit or loss:
Listed:
– Debt portfolios 	1 503 	1 006 	489 	8
– Money market portfolios 	6 892 	2 953 	3 872 	67
– Multi-asset portfolios 	54 	– 	– 	54
Unlisted:
– Debt portfolios 	31 	1 	30 	–
– Money market portfolios 	218 	25 	193 	–
Derivative financial instruments at fair value:
– used as cash flow hedges 	28 	5 	– 	23
– not designated as hedging instruments 	214 	– 	155 	59
Receivables
– Insurance receivables 	6 158 	– 	– 	6 158
– Contract receivables 	1 217 	– 	42 	1 175
– Other receivables at amortised cost 	1 302 	28 	457 	817
Cash and cash equivalents 	15 942 	894 	14 641 	407
Total financial assets 	42 524 	10 242 	23 514 	8 768
Deposits from customers 	8 985 	3 763 	5 222 	–
Borrowings at amortised cost 	19 493 	10 034 	9 459 	–
Other payables at amortised cost 	12 426 	6 608 	2 	5 816
Derivative financial instruments at fair value:
– used as cash flow hedges 	461 	332 	– 	129
– not designated as hedging instruments 	357 	– 	235 	122
Total financial liabilities 	41 722 	20 737 	14 918 	6 067
72	Discovery Annual Financial Statements 2022

-- 73 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
INVESTMENTS
For shareholder investments, a 1% increase in the local interest rate would result in an increase of R67 million of investment
income from these investments (2021: R9 million). A 1% decrease in the local interest rate would result in a decrease of R67 million
of investment income from these investments (2021: R9 million). The sensitivity assumes that the interest rate had increased/
decreased by 1% with all other variables held constant.
BORROWINGS AT AMORTISED COST AND RELATED HEDGES
Discovery is exposed to interest rate risk through long-term borrowings held with various financial institutions. Refer to note 20
Borrowings at amortised costs for a breakdown of the borrowings, including details of fixed rate and floating rate facilities.
2022 	2021
Group
R million 	Ref
Carrying
value
Facility
value
Carrying
value
Facility
value
Interest rate risk from borrowings from banks
Fixed interest rate loan facilities 	5 737 	5 850 	5 773 	5 850
Floating interest rate facilities with floating-to-fixed
interest rate swap 	i 	5 038 	5 000 	5 034 	5 000
Floating interest rate facilities 	2 411 	5 109 	659 	500
Foreign floating interest rate facilities 	3 122 	4 281 	3 764 	4 224
Total bank borrowings (refer to note 20) 	16 308 	20 240 	15 230 	15 574
i. During prior years and in the current financial year, Discovery entered into long-term borrowing facilities at floating interest
rates, which expose Discovery to cash flow interest rate risk. This risk has been managed by using floating-to-fixed interest
rate swaps. These interest rate swaps have the economic effect of converting the borrowings from floating to fixed rates.
Interest is payable quarterly in arrears, with capital repayable on maturity. The hedge ratio is 1:1.
The Group enters into interest rate swaps that have similar critical terms as the hedged item, such as reference rate, reset
dates, payment dates, maturities, and notional amount. As all critical terms matched during the year, there is an economic
relationship.
Under the Group’s policy, the critical terms of the hedging instrument, such as the settlement dates, maturity dates and
notional amount, are matched with the interest rate risk of the hedged item.
Hedge ineffectiveness for interest rate swaps can arise from:
– day one fair value of the swap,
– events leading to mismatch in terms; and
– the credit value/debit value adjustment on the interest rate swaps which is not matched by the loan.
The fair value movement of the notional cash flow interest rate hedge accumulated in equity is as follows:
Group
R million 	2022 	2021
Balance at beginning of the year 	335 	516
Unrealised (gains)/losses accumulated in equity 	(296) 	(189)
Tax on unrealised losses 	– 	–
Recycled to profit or loss during the current year1 	– 	8
Tax on recycled gains 	– 	–
Balance at end of the year 	39 	335
The cash flow hedge will be recycled to profit or loss as follows:
Recycled to profit or loss within one year 	20 	–
Recycled to profit or loss within two to five years 	19 	232
Recycled to profit or loss within six to ten years 	– 	103
39 	335
1 Disclosed as finance costs in profit or loss.
73	Discovery Annual Financial Statements 2022

-- 74 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
The interest rate swaps held by the Group at 30 June were:
Group
R million
2022 	2021
Nominal
value
Fair value
liability
Nominal
value
Fair value
liability
Maturity date:
21 November 2022 	500 	(7) 	500 	(25)
21 November 2024 	800 	1 	800 	(74)
21 August 2026 	700 	(16) 	700 	(80)
02 March 2023 	1 000 	(14) 	1 000 	(55)
21 August 2023 	500 	13 	500 	5
21 November 2026 	300 	3 	300 	(22)
21 November 2024 	1 200 	(19) 	1 200 	(76)
5 000 	(39) 	5 000 	(327)
Group
R million
2022
Carrying
value
2021
Carrying
value
Term deposits from customers – fixed rate 	3 372 	3 763
Term deposits from customers – variable rates 	1 807 	3 798
On demand deposits from customers – Non Rate sensitive 	149 	–
On demand deposits from customers – variable rate 	5 249 	615
Wholesale NCD's (Negotiable Certificate of Deposit) – variable rate 	304 	809
Total customer deposits Discovery Bank 	10 881 	8 985
NON-HEDGE DERIVATIVE FINANCIAL INSTRUMENTS
I. INTEREST RATE SWAP
VitalityLife has significant exposure to long-term interest rate risk, given the impact on reserves of lower investment rate
assumptions related to fixed future premium receipts to meet policy obligations. Accordingly, lower long-term interest rates
and yield assumptions may negatively impact on the valuation of future policy obligations and result in a valuation loss. Refer
to note 2.4.3 for details of the interest rate mitigation strategy implemented.
In addition to the above, VitalityLife has an exposure to the ’FTSE Actuaries UK Conventional Gilts over 15 Year Index (“the
index”) because of products underwritten by The Prudential Assurance Company on behalf of VitalityLife. To economically
hedge the Vitality UK group’s exposure to the index, Discovery Holdings Europe Limited (DHEL) has been party to a number of
over-the-counter total return interest rate swap derivatives during the financial year. These derivatives provide DHEL with the
capital depreciation/appreciation and coupon payments on a basket of Gilts designed to closely match that of the index in
return for a payment of fixed interest to the counterparty. By 30 June 2022 these derivatives had been exited in DHEL and the
associated index risk is now managed directly on the balance sheet of The Prudential Assurance Company.
As at 30 June 2022 DHEL is party to nil (2021: two) open derivative contracts.
For the derivatives held during the year although these instruments reduce the exposure to the volatility of the index, they did
not qualify for hedge accounting. Accordingly, these derivatives were classified as financial assets or liabilities carried at fair
value through profit or loss.
Fair value adjustments of GBP 77.6 million (net loss) (R1 572 million) have been recognised in ‘Net fair value gains on financial
assets at fair value through profit or loss’ (2021: GBP 38.1 million (net loss) (R792 million)).
74	Discovery Annual Financial Statements 2022

-- 75 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
II. DERIVATIVE INSTRUMENTS USED BY DISCOVERY’S ASSET MANAGERS
Discovery also has interest rate swap agreements and the value of exposure towards these parties was calculated by taking
into consideration the ISDA agreements in place which allow for netting off between positive and negative exposures.
The table below details the Group’s total derivative exposure:
Group
R million
Notional
amount
Fair value
asset
Fair value
liability
June 2022
Interest rate contracts:
– floating for fixed swaps 	5 000 	17 	(56)
5 000 	17 	(56)
June 2021
Interest rate contracts:
– floating for fixed swaps 	5 000 	5 	(332)
5 000 	5 	(332)
75	Discovery Annual Financial Statements 2022

-- 76 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
CURRENCY RISK
The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily
with respect to the US dollar and the UK pound. Foreign exchange risk arises from future commercial transactions and recognised
assets and liabilities. The following table segregates the currency exposure by major currency:
Group
R million 	Total 	Rand
GBP in UK
subsidiary
GBP
other
USD in US
subsidiary
USD
other
Other
currencies
30 June 2022
Loans and advances to customers
at amortised cost 	3 944 	3 944 	– 	– 	– 	– 	–
Investments at amortised cost:
Unlisted:
– Debt 	5 205 	5 205 	– 	– 	– 	– 	–
– Fixed deposits 	1 956 	1 747 	209 	– 	– 	– 	–
Financial instruments mandatorily
at fair value through profit or loss:
Listed:
– Equity portfolios 	160 	66 	12 	1 	– 	65 	16
– Debt portfolios 	751 	130 	613 	– 	– 	3 	5
– Money market portfolios 	6 480 	2 665 	3 815 	– 	– 	– 	–
– Multi-asset portfolios 	67 	15 	1 	– 	– 	51 	–
Unlisted:
– Equity portfolios 	46 	46 	– 	– 	– 	– 	–
– Debt portfolios 	15 	15 	– 	– 	– 	– 	–
– Money market portfolios 	1 196 	1 196 	– 	– 	– 	– 	–
– Money market portfolios 	8 	– 	8 	– 	– 	– 	–
Derivative financial instruments
at fair value:
– used as cash flow hedges 	17 	17 	– 	– 	– 	– 	–
– not designated as hedging
instruments 	238 	22 	216 	– 	– 	– 	–
Receivables
– Insurance receivables 	7 887 	3 095 	4 755 	– 	3 	34 	–
– Contract receivables 	1 209 	886 	– 	– 	322 	– 	1
– Other Receivables 	1 369 	936 	320 	– 	58 	53 	2
Cash and cash equivalents 	14 767 	5 721 	7 659 	164 	295 	822 	106
Total financial assets 	45 315 	25 706 	17 608 	165 	678 	1 028 	130
Deposits from customers 	10 881 	10 732 	– 	32 	– 	72 	45
Borrowings at amortised cost 	20 430 	17 027 	3 272 	– 	131 	– 	–
Other payables 	12 264 	5 289 	6 661 	– 	85 	123 	106
Derivative financial instruments
at fair value:
– used as cash flow hedges 	56 	56 	– 	– 	– 	– 	–
– not designated as hedging
instrument 	146 	68 	78 	– 	– 	– 	–
Total financial liabilities 	43 777 	33 172 	10 011 	32 	216 	195 	151
76	Discovery Annual Financial Statements 2022

-- 77 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
Group
R million 	Total 	Rand
GBP in UK
subsidiary
GBP
other
USD in US
subsidiary
USD
other
Other
currencies
30 June 2021
Loans and advances to customers at
amortised cost 	3 361 	3 361 	– 	– 	– 	– 	–
Investments at amortised cost:
Unlisted:
– Debt 	4 109 	4 109 	– 	– 	– 	– 	–
– Fixed deposits 	1 495 	1 291 	204 	– 	– 	– 	–
Financial instruments mandatorily
at fair value through profit or loss:
Listed:
– Equity portfolios 	148 	48 	16 	– 	– 	70 	14
– Debt portfolios 	1 503 	497 	988 	– 	– 	10 	8
– Money market portfolios 	6 892 	2 817 	4 075 	– 	– 	– 	–
– Multi-asset portfolios 	54 	13 	2 	– 	– 	39 	–
Unlisted:
– Equity portfolios 	43 	20 	– 	– 	– 	23 	–
– Debt portfolios 	31 	31 	– 	– 	– 	– 	–
– Money market portfolios 	218 	218 	– 	– 	– 	– 	–
Derivative financial instruments
at fair value:
– used as cash flow hedges 	28 	28 	– 	– 	– 	– 	–
– not designated as hedging
instruments 	214 	59 	155 	– 	– 	– 	–
Receivables
– Insurance receivables 	6 158 	2 374 	3 736 	– 	– 	48 	–
– Contract receivables 	1 217 	771 	– 	– 	214 	11 	221
– Other financial receivables at
amortised cost 	1 302 	962 	122 	163 	17 	34 	4
Cash and cash equivalents 	15 942 	4 812 	9 508 	119 	443 	1 001 	59
Total financial assets 	42 715 	21 411 	18 806 	282 	674 	1 236 	306
Deposits from customers 	8 985 	8 985 	– 	– 	– 	– 	–
Borrowings at amortised cost 	19 493 	15 368 	4 066 	– 	59 	– 	–
Other financial payables at
amortised cost 	12 426 	3 234 	8 945 	– 	202 	9 	36
Derivative financial instruments
at fair value:
– used as cash flow hedges 	461 	461 	– 	– 	– 	– 	–
– not designated as hedging
instrument 	357 	125 	232 	– 	– 	– 	–
Total financial liabilities 	41 722 	28 173 	13 243 	– 	261 	9 	36
Financial assets and financial liabilities in respect of the Group’s US and UK subsidiaries are accounted for in their functional
currency. Foreign currency movements will be recognised in the foreign currency translation reserve.
The exchange rates at year-end are detailed in the table below (quoted as Rand per foreign currency):
USD 	GBP
30 June 2022 	16.47 	20.00
30 June 2021 	14.28 	19.74
77	Discovery Annual Financial Statements 2022

-- 78 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
SENSITIVITY ANALYSIS
The Group determined that a 10% change is a reasonable expected strengthening/(weakening) of the US dollar and the UK Pound
against all other currencies. The impact on profit or loss and equity at 30 June is shown below. For the purpose of
the analysis, the foreign exchange impact of intergroup balances which eliminate on consolidation has been excluded. The effect
of translation differences which are recognised separately in other comprehensive income has also been excluded. This analysis
assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and
purchases.
Profit or loss 	Equity
R million 	Strengthening 	Weakening 	Strengthening 	Weakening
30 June 2022
USD 	278 	(278) 	278 	(278)
GBP 	14 	(14) 	14 	(14)
30 June 2021
USD 	590 	(590) 	590 	(590)
GBP 	38 	(38) 	38 	(38)
INVESTMENTS
Discovery has offshore assets in its investment portfolios. These offshore investments are made for the purpose of seeking
international diversification. There is a risk to future earnings that the value of these assets reduces due to a strengthening in the
Rand. Performance of foreign currency assets is benchmarked against the MSCI World Index, an international index that represents
large and mid-capitalisation companies across 23 developed market countries. Refer to www.msci.com for further detail.
CURRENCY DERIVATIVE CONTRACTS
To manage its foreign exchange risk arising from future commercial transactions, Discovery enters into various currency
derivative contracts. Discovery entered into these contracts with third party banks which have short term rated risk of P-2 and
P-1, as rated by Moody’s. The fair value of these contracts have been included in financial assets and liabilities. (Refer to note 13).
Discovery entered into these contracts as an economic hedge against foreign currency risk for expenses to be paid in the future.
These transactions are not designated as hedges and as a result gains and losses are recognised in profit or loss. The amount
recognised in profit or loss for the current year was a gain of R78 million (2021: R298 million loss), with a corresponding derivative
asset and liability of R2 million and R1 million respectively, (2021: Derivative asset R58 million and derivative liability R100 million).
The notional value of these contracts are USD 5.3 million. (2021: GBP 119.3 million, USD 39.4 million and EUR 7.9 million).
Currency risk for foreign exchange contracts (FEC’s) are determined with reference to the designated pricing (settlement) currency
of each respective contract. The pricing currency is usually the functional currency of the entity taking out the contract. For the
purposes of currency risk, Discovery discloses FEC contracts using the pricing currency.
BORROWINGS
Discovery has long-term borrowings in the UK, which exposes the Group to currency risks. These risks are managed by aligning
the currency exposure to the underlying operational assets for which these borrowings have been raised. The currency risk is
mitigated as the cash flows emerging from the underlying assets are in the same currency (GBP) as the interest and capital
payments.
DEPOSITS FROM CUSTOMERS
Discovery Bank offers its customers the option to hold deposits in foreign currency of GBP, USD and EUR. These risks are
managed by aligning the currency exposure to the underlying assets. Discovery Bank does so by holding deposits in foreign
currency of GBP, USD and EUR. The currency risk is therefore matched in a 1:1 ratio to not transfer foreign currency risk to the
Group.
78	Discovery Annual Financial Statements 2022

-- 79 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.2 CREDIT RISK
Key areas where Discovery is exposed to credit risk are:
❚ 	Financial investments comprising money market and debt instruments entered into to invest surplus shareholder
funds: Discovery is exposed to the issuer’s credit standing on these instruments which is monitored by the CCIC by setting a
minimum credit rating and maximum exposures per issuer. Discovery has appointed reputable asset managers to manage
these instruments. Information regarding the aggregated credit risk exposure for debt and money market instruments
categorised by credit ratings is provided below.
❚ 	Cash and cash equivalents: This risk is managed by monitoring exposure to external financial institutions against approved
limits per institution. Credit ratings are provided below.
❚ 	Certain accounts within the Statement of financial position category of ’Insurance receivables, contract receivables
and other non-financial receivables’.
❚ 	Reinsurance assets comprising receivables raised for expected recoveries on projected claims (Discovery’s liability as
primary insurer is not discharged) and amounts due from reinsurers in respect of claims already paid: This risk is
limited as risk premiums are paid monthly to reinsurers and claims can be offset against risk premiums. Further, it is expected
that there will be little build-up of actuarial liability on the reinsurers’ side. The risk thus mainly arises following a period of
higher than expected claims. Credit ratings of reinsurers are considered in reinsurance placement decisions. Credit exposure
to reinsurers is also limited through the use of several reinsurers. Reinsurance is placed with reputable international
companies directly or through their national offices. The reinsurance companies used by Discovery are rated A or higher by
A.M. Best, a rating agency with an exclusive insurance industry focus. Refer to www.ambest.com for further detail.
❚ 	Loans and advances to customers at amortised cost, which arises from credit extended to Discovery Bank customers.
79	Discovery Annual Financial Statements 2022

-- 80 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.2 CREDIT RISK CONTINUED
The following table details the aggregated credit risk exposure that the Group is exposed to, categorised by the rating scale noted
in section 3 ‘Discovery’s approach in monitoring credit risk’.
Group
R million 	Total 	Aaa
Aa1
Aa2
Aa3
A1
A2
A3
Baa1
Baa2
Baa3
Ba1
Ba2
Ba3 	Govt1
Inter-
nally
rated
Pooled
funds
30 June 2022
Loans and advances to customers at
amortised cost 	3 944 	– 	– 	– 	– 	– 	– 	3 944 	–
Investments at amortised cost:
Unlisted:
– Debt 	5 205 	– 	– 	– 	– 	– 	5 205 	– 	–
– Fixed deposits 	1 956 	– 	91 	574 	208 	1 083 	– 	– 	–
Financial instruments mandatorily at fair
value through profit or loss:
Listed:
– Debt portfolios 	751 	2 	42 	224 	366 	116 	1 	– 	–
– Money market portfolios 	6 480 	745 	1 348 	1 752 	64 	2 447 	124 	– 	–
Unlisted:
– Debt portfolios 	15 	– 	– 	– 	– 	13 	2 	– 	–
– Money market portfolios 	1 196 	– 	– 	– 	1 184 	12 	– 	–
Derivative financial instruments at fair value:
– used as cash flow hedges 	17 	– 	– 	– 	17 	– 	– 	– 	–
– not designated as hedging instruments 	238 	– 	– 	216 	2 	20 	– 	– 	–
Cash and cash equivalents 	14 767 	– 	7 852 	1 800 	1 011 	1 575 	2 529 	– 	–
34 569 	747 	9 333 	4 566 	1 668 	6 438 	7 873 	3 944
Group
R million
Restated 	Total 	Aaa
Restated
Aa1
Aa2
Aa3
Restated
A1
A2
A3
Baa1
Baa2
Baa3
Ba1
Ba2
Ba3 	Govt1
Inter-
nally
rated
Pooled
funds
30 June 2021
Loans and advances to customers at
amortised cost 	3 361 	– 	– 	– 	– 	– 	– 	3 361 	–
Investments at amortised cost:
Unlisted:
– Debt 	4 109 	– 	– 	– 	– 	– 	4 109 	– 	–
– Fixed deposits 	1 495 	– 	– 	203 	1 292 	– 	– 	– 	–
Financial instruments mandatorily at fair
value through profit or loss:
Listed:
– Debt portfolios 	1 503 	39 	152 	283 	687 	305 	37 	– 	–
– Money market portfolios 	6 892 	1 044 	1 070 	163 	2 928 	1 683 	4 	– 	–
Unlisted:
– Debt portfolios 	31 	– 	– 	– 	– 	31 	– 	– 	–
– Money market portfolios 	218 	– 	14 	21 	3 	180 	– 	– 	–
Derivative financial instruments at fair
value:
– used as cash flow hedges 	28 	– 	– 	– 	23 	5 	– 	– 	–
– not designated as hedging instruments 	214 	– 	– 	155 	37 	22 	– 	– 	–
Cash and cash equivalents2 	15 942 	14 	8 583 	2 453 	1 237 	2 286 	1 369 	– 	–
33 793 	1 097 	9 819 	3 278 	6 207 	4 512 	5 519 	3 361 	–
1 These instruments are issued by the South African government.
2 The note has been restated as some of the cash and cash equivalents was disclosed in the incorrect credit rating group.
Financial instruments included in cash and cash equivalents, fixed deposits and treasury bills have high credit quality based on
the rating of counterparties and/or have relatively short-term maturities. Impairment based on the expected credit loss approach
was assessed and considered immaterial. There are no amounts within these balances which are credit impaired or where there
has been a significant increase in credit risk since initial recognition.
80	Discovery Annual Financial Statements 2022

-- 81 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.2 CREDIT RISK CONTINUED
CREDIT RISK RELATING TO RECEIVABLES
The table below summarises Discovery’s shareholder insurance receivables, contract receivables and other receivables, at 30 June.
This table only relates to shareholder’s credit exposure and will therefore not agree to note 14.
R million
Group
2022
Group
2021
Receivables arising from insurance and reinsurance contracts:
– Premium debtors 	801 	668
– Less provision for impairment of premium debtors 	(81) 	(63)
– Reinsurance debtors 	7 167 	5 553
Contract receivables:
– Closed scheme debtors 	107 	104
– Discovery Health Medical Scheme 	724 	662
– Other contract receivables 	382 	480
– Less allowance for expected credit losses 	(4) 	(29)
Other loans and receivables:
– Agents and brokers 	439 	412
– BEE partners’ rights-issue funding 	– 	1
– Cash-in-transit debtors 	7 	32
– Consolidated unit trust debtors 	2 	1
– FNB-DiscoveryCard receivable 	– 	–
– Loans to BEE initiatives 	256 	220
– Security deposit on derivatives1 	72 	289
– Vitality partner debtors 	148 	112
– Other financial receivables 	837 	696
– Less allowance for expected credit losses 	(392) 	(461)
10 465 	8 677
1 Refer to note 3.7 for an explanation of the nature of the security deposit (cash collateral).
Credit risk relating to receivables is managed as follows:
i. Premium debtors are not rated by Discovery as exposure to any single customer is insignificant. The premium debtors
comprise amounts receivable from individuals and corporates. In addition, Discovery suspends benefits when contributions
are not received. Premium debtors that are past due are handled by a specialist area in business. Where amounts remain
uncollected for more than six months, the debtors are then handed to specialist debt collection agencies.
ii. VitalityHealth makes use of financial reinsurance as a financing tool for new business acquisition costs. The receipt from
the reinsurer is recognised in profit or loss upfront in the year received. GBP 199 million (R3 981 million) (2021: GBP 156 million
(R3 079 million)) is outstanding in respect of cashless reinsurance treaties. The credit ratings of these reinsurers are Aa3.
Refer to note 3.4.2 for detail regarding the management of risk in respect of reinsurance receivables raised for expected
recoveries on projected claims and amounts due from reinsurers in respect of claims already paid. Discovery’s liability as
primary insurer is not discharged.
iii. The Discovery Health Medical Scheme (DHMS) has been rated AAA(za) by Global Credit Ratings. The closed schemes have not
been rated. Payments by DHMS and the other closed schemes are managed by Discovery and are paid by the seventh of the
following month.
iv. Agents and brokers are subject to a comprehensive relationship management programme including credit assessment.
Agents and brokers are not rated by Discovery as exposure to any single intermediary is insignificant. The widespread nature
of the individual amounts combined with this close management relationship reduces credit risk. Most commission claw
backs are offset against future payments and hence the risk of outstanding commission clawbacks is reduced.
81	Discovery Annual Financial Statements 2022

-- 82 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.2 CREDIT RISK CONTINUED
Discovery ages and pursues unpaid accounts on a monthly basis. The ageing of the components of receivables at 30 June was:
Group
R million
Gross
2022
Impairment
2022
Gross
2021
Impairment
2021
Not past due (current) 	9 294 	(111) 	7 901 	(69)
30 days 	267 	(38) 	201 	(22)
60 days 	179 	(23) 	170 	(16)
90 days 	131 	(10) 	149 	(94)
120 days 	95 	(20) 	169 	(13)
150 days 	91 	(10) 	42 	(8)
>150 days 	885 	(265) 	598 	(331)
10 942 	(477) 	9 230 	(553)
Discovery establishes an allowance for expected credit losses that represents its estimate of expected losses in respect of
receivables that are financial assets. The allowance comprises of a specific loss component that relates to individually significant
exposures, and a collective loss component, established for groups of similar assets. The loss allowance is determined based on
historical data of payment statistics for similar financial assets, and where available without undue cost or effort, incorporates
forward-looking information.
For an analysis of the movement in the allowance for expected credit losses as well as provision for impairment of premium
debtors during the year, refer to note 12 Financial assets and note 14 Insurance receivables, contract receivables and other
financial receivables.
3.4.3 LIQUIDITY RISK
Cash flow forecasting is performed in the operating entities of the Group and aggregated by Group finance. Group finance
monitors rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs at all
times so that the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities (refer
to note 20). Such forecasting takes into consideration the Group’s debt financing plans, covenant compliance and, if applicable,
external regulatory or legal requirements – such as capital requirements.
Cash held by the operating entities is managed by Group treasury. Group treasury invests it in interest-bearing accounts, time
deposits and money market deposits, choosing instruments with appropriate maturities or sufficient liquidity to provide sufficient
headroom as determined by the above-mentioned forecasts. For information on the liquidity risk management of contracts with
insurance risk, refer to note 2.2 Liquidity risk.
Discovery Bank manages its liquidity risk by comparing the credit utilisation and expected future utilisation of committed
facilities on its loans and advances against the deposits it holds. Discovery Bank performs normal stresses as well as additional
stresses to ensure that it can meet its obligations continuously. The stresses during the financial period included stresses as a
result of COVID-19 impacts.
82	Discovery Annual Financial Statements 2022

-- 83 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.3 LIQUIDITY RISK continued
The table below analyses the Group’s financial assets and liabilities and net-settled interest rate swap derivative financial liabilities
into relevant maturity groupings based on the remaining period at the reporting date to the contractual maturity date. The
amounts are the undiscounted contractual payments and will therefore not agree to the Statement of financial position.
Group
R million 	Total 	<1 year
1 – 2
year
3 – 5
years
6 – 10
years
> 10
years
30 June 2022
Loans and advances to customers at
amortised cost 	3 944 	2 367 	1 577 	– 	– 	–
Investments at amortised cost 	7 161 	6 927 	234 	– 	– 	–
Investments at fair value through profit or loss 	8 723 	7 651 	149 	393 	114 	416
Derivative financial instruments at fair value 	238 	14 	224 	– 	– 	–
Receivables 	10 465 	6 338 	1 412 	2 006 	668 	41
Cash and cash equivalents 	14 767 	14 767 	– 	– 	– 	–
Total financial assets 	45 429 	38 078 	3 609 	2 433 	824 	485
Deposits from customers 	10 881 	9 381 	1 133 	367 	– 	–
Borrowings net of interest rate swap
– Borrowings 	22 418 	4 635 	5 592 	8 976 	2 744 	471
– Interest rate swap 	311 	117 	90 	104 	– 	–
Other payables at amortised cost 	12 264 	11 970 	117 	44 	7 	126
Derivative financial instruments at fair value 	146 	41 	26 	– 	– 	79
Total financial liabilities 	46 020 	26 144 	6 958 	9 491 	2 751 	676
Group
R million 	Total 	<1 year
1 – 2
year
3 – 5
years
6 – 10
years
> 10
years
30 June 2021
Loans and advances to customers at
amortised cost 	3 361 	2 017 	1 344 	– 	– 	–
Investments at amortised cost 	5 604 	5 604 	– 	– 	– 	–
Investments at fair value through profit or loss 	8 889 	7 279 	656 	279 	375 	300
Derivative financial instruments at fair value 	242 	86 	148 	8 	– 	–
Receivables 	8 677 	5 166 	92 	186 	2 982 	251
Cash and cash equivalents 	15 942 	15 942 	– 	– 	– 	–
Total financial assets 	42 715 	36 094 	2 240 	473 	3 357 	551
Deposits from customers 	8 985 	4 232 	4 449 	304 	– 	–
Borrowings net of interest rate swap
– Borrowings 	21 537 	2 732 	5 577 	10 145 	2 729 	354
– Interest rate swap 	639 	193 	171 	260 	15 	–
Other payables at amortised cost 	12 426 	4 773 	7 188 	124 	– 	341
Derivative financial instruments at fair value 	818 	176 	134 	182 	326 	–
Total financial liabilities 	44 405 	12 106 	17 519 	11 015 	3 070 	695
83	Discovery Annual Financial Statements 2022

-- 84 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.5 	Capital management
The Group’s capital is defined as capital and reserves attributable to as presented on the consolidated statement of financial
position. The Group’s objectives when managing capital are:
❚ 	To comply with the statutory capital requirements required by the regulators of the insurance markets where the Group operates;
refer to Capital section of the directors’ report for the statutory capital requirements
❚ 	To maintain a capital buffer in excess of the statutory capital requirements in order to reduce the risk of breaching the statutory
requirement in the event of deviations from the main assumptions affecting the Group’s insurance businesses.
❚ 	To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements.
❚ 	To achieve an optimal and efficient capital funding profile; and
❚ 	To consider capital management needs both in the short term and over a five-year planning horizon.
Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre
and subsidiaries within South Africa, UK and US. The committee is the governance body for all capital allocation activities across
the Group.
A range of capital raising options are available to manage the capital structure of the Group, which includes the issue of new
shares, debt, reinsurance arrangements and other hybrid instruments.
FINANCIAL LEVERAGE RATIO
As part of the capital management process, the Group monitors its capital structure utilising the Financial Leverage Ratio (FLR).
This ratio is calculated as total debt 1 divided by total debt plus total equity. The Group’s strategy is to maintain a prudent FLR of
28% per the Group Risk Appetite statement. However, the 28% is merely a risk appetite indicator, and not a hard line to indicate
any form of a breach in terms of regulatory or covenant restrictions. The table below summarises the FLR as at 30 June.
R million
Group
2022
Group
2021
– Borrowings at amortised cost (refer to note 20)1 	16 464 	15 230
– Guaranteed deposit facilities 	300 	800
Total debt and guarantees 1 	16 764 	16 030
Total equity 	53 555 	46 419
Financial Leverage Ratio (%) 	23.8% 	25.7%
1. Excluding all IFRS 16 lease liabilities of R4 120 million (2021: R4 263 million).
The FLR at 30 June 2022 is in line with Discovery’s risk appetite.
MINIMUM CAPITAL REQUIREMENTS
For Group subsidiaries that operate in the insurance and financial services sectors, the regulator specifies the minimum amount
and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum required
capital must be maintained at all times throughout the period.
With effect from 1 July 2018, the Insurance Act 18 of 2017 and the related Prudential Standards were implemented in
South Africa. Discovery Life and Discovery Insure are regulated under the Insurance Act, while VitalityHealth and VitalityLife are
regulated under the European Solvency II regulatory regime, which was implemented from 1 January 2016.
84	Discovery Annual Financial Statements 2022

-- 85 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.5 	Capital management continued
DEBT COVENANTS
The following are the key debt covenant ratios and their proximity to breaching the covenant triggers:
Debt covenant and explanation 	Minimum requirement 	2022 	2021
Group Debt to EBITDA Ratio:
– Group debt is contractually defined and means
the aggregate consolidated financial indebtedness
of the Group and excludes items such as the
1 Discovery Place (‘1 DP’) lease and includes
guarantees issued to third parties.
– EBITDA is contractually defined and specifically
includes items such as dividends from associates,
rental paid on 1DP and excludes such items
deemed extraordinary, such as economic
assumption adjustments, and specified FinRe
arrangements.
Less than 2.5 times 	1.83 	2.31
Group financial indebtedness to embedded value
– Group financial indebtedness is as per Group Debt
in the calculation.
Less than 30% of Group
Embedded value
20.3% 	22.6%
Discovery Life Statutory Capital Requirement
(SCR) Cover
SCR cover must be more than 1.1 	1.74 times 	1.83 times
Group embedded value 	Greater than R30billion 	R86 258
million
R74 645
million
New business embedded value must not be negative 	Positive value of new business for
3 consecutive 6-month periods
June 2022:
R1 124 million
Dec 2021:
R937 million
June 2021:
R946 million
June 2021:
R946 million
Dec 2020:
R945 million
June 2020:
R726 million
85	Discovery Annual Financial Statements 2022

-- 86 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.6 	Fair value hierarchy of financial instruments
The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has
three levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical
financial instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing
service or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm’s length
basis.
Level 2: includes financial instruments that are valued using techniques based significantly on observable market data.
Instruments in this category are valued using:
(a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or
(b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on
observable market data.
Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than
observable market data and where at least one input (which could have a significant effect on instruments’ valuation) cannot be
based on observable market data.
R million 	Level 1 	Level 2 	Level 3 	Total
30 June 2022
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	54 271 	3 677 	– 	57 948
– Debt portfolios 	46 672 	920 	– 	47 592
– Money market portfolios 	– 	14 680 	– 	14 680
– Multi-asset portfolios 	– 	21 274 	– 	21 274
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	17 	– 	17
– not designated as hedging instruments 	– 	259 	– 	259
Total financial assets 	100 943 	40 827 	– 	141 770
Non-Financial Assets 	– 	– 	171 	171
Non-current assets held of sale 	– 	– 	171 	171
Financial liabilities
Investment contracts at fair value through profit or loss 	– 	37 361 	– 	37 361
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	56 	– 	56
– not designated as hedging instruments 	– 	146 	– 	146
Total financial liabilities 	– 	37 563 	– 	37 563
NON-FINANCIAL ASSETS MEASURED AT FAIR VALUE
During the current financial period there was a non-recurring fair measurement for the investment in an associate that has been
categorised as a level 3 fair value. Refer to note 11.2.1 for details on the fair value.
There where no transfers between level 1 and level 2 during the current financial period
86	Discovery Annual Financial Statements 2022

-- 87 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.6 	Fair value estimation continued
Group
R million
Restated 	Level 1 	Level 2 	Level 3 	Total
30 June 2021
Financial assets
Financial instruments mandatorily at fair value
through profit or loss:
– Equity portfolios 	40 530 	2 832 	– 	43 362
– Debt portfolios 	34 845 	1 640 	– 	36 485
– Money market portfolios 	– 	17 253 	– 	17 253
– Multi-asset portfolios 	– 	33 837 	– 	33 837
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	28 	– 	28
– not designated as hedging instruments 	– 	221 	– 	221
Total financial assets 	75 375 	55 811 	– 	131 186
Financial liabilities – not designated as hedging
instruments
Investment contracts at fair value through profit or loss 	– 	32 291 	– 	32 291
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	461 	– 	461
– not designated as hedging instruments 	– 	365 	– 	365
Total financial liabilities 	– 	33 117 	– 	33 117
There were no transfers between level 1 and 2 during the current financial year. During the year under review, management
reassessed the observability of significant inputs into fair value determination of money markets and multi-assets portfolios from
level 1 to level 2. The prior period was restated accordingly.
SPECIFIC VALUATION TECHNIQUES USED TO VALUE FINANCIAL INSTRUMENTS IN LEVEL 2
If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial
instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use of
recent arm’s length market transactions, reference to the current fair value of another instrument that is substantially the same,
discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of prices
obtained in actual market transactions.
87	Discovery Annual Financial Statements 2022

-- 88 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.6 	Fair value estimation continued
Valuation techniques used in determining the fair value of assets and liabilities
Instruments 	Valuation technique 	Main inputs and assumptions
Within equity portfolios,
Equity-linked notes
The calculation of the daily value of the equity linked
investments is made by the provider of the note. Discovery
has procedures in place to ensure that these prices are
correct. Aside from the daily reasonableness checks
versus similar funds and movement since the prior day’s
price, the fund values are calculated with reference to a
specific formula or index, disclosed to the policyholders,
which is recalculated by Discovery in order to check if the
price provided by the provider is correct.
For level 2 fair value hierarchy
items:
– discount rate
– spot prices of the underlying
Multi-assets 	The fair values of third-party financial liabilities arising on
the consolidation of mutual funds are determined using
the quoted put (exit) price provided by the fund manager
and discounted for the applicable notice period. The fair
value of a financial liability with a demand feature is not
less than the amount payable on demand, discounted
from the first date on which the amount could be required
to be paid.
For level 2 fair value hierarchy items:
– discount rate
Money Market
instruments
Money market instruments are valued by discounted the
future cash flows using a risk-adjusted discount rate.
For level 2 fair value hierarchy items:
– discount rate, credit spread
Investment contracts at
fair value through profit
or loss
Unit-linked policies: assets which are linked to the
investment contract liabilities are owned by the Group.
The investment contract obliges the Group to use these
assets to settle these liabilities. Therefore, the fair value of
investment contract liabilities is determined with
reference to the fair value of the underlying assets (i.e.,
amount payable on surrender of the policies).
Annuity certain: discounted cash flow models are used to
determine the fair value of the stream of future payments.
For level 2 fair value hierarchy items:
– discount rate
– spot price of underlying
Derivatives 	Standard derivative contracts are valued using market
accepted models and quoted parameter inputs. More
complex derivative contracts are modelled using more
sophisticated modelling techniques applicable to the
instrument. Techniques include:
– Discounted cash flow model
– Black-Scholes model
– Combination technique models
For level 2 fair value hierarchy
items:
– discount rate
– spot prices of the underlying
– correlation factors
– volatilities
– earnings yield
– valuation multiples.
88	Discovery Annual Financial Statements 2022

-- 89 of 219 --

NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.7 	Offsetting financial assets and financial liabilities
FINANCIAL ASSETS
The following financial assets are subject to offsetting:
Group
R million
Gross
financial
assets
Gross
offsetting
financial
liabilities
Net amount
presented
30 June 2022
Cash and cash equivalents 	19 807 	(32) 	19 775
30 June 2021
Cash and cash equivalents 	20 187 	(174) 	20 013
Offsetting of cash and cash equivalents takes place as a result of sweeping arrangements that Discovery has in force with various
financial institutions. No other amounts presented on the financial statements are subject to netting arrangements.
CASH COLLATERAL
To reduce the credit risk exposure from derivative instruments purchased (refer to note 3.4.1), Discovery has entered into
collateral agreements with the relevant financial institutions to post cash collateral periodically, equal to the fair value of the
derivatives. A total of R72 million (2021: R289 million) cash collateral was being held by the various financial institutions and
R245 million (2021: R2 million) was held by Discovery at 30 June 2022.
The posting of the collateral does not result in legal settlement of the outstanding derivative balance. The collateral will only be
used to settle the derivative upon default or bankruptcy of either party. The offsetting requirements of IAS 32 Financial Instruments:
Presentation are therefore not met.
89	Discovery Annual Financial Statements 2022

-- 90 of 219 --

90	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
4. 	SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS
IN APPLYING ACCOUNTING POLICIES
In preparing the annual financial statements, estimates, assumptions and judgements are made that could materially affect the
reported amounts of assets and liabilities within the next financial year. Accounting estimates and judgements are regularly
reviewed and are based on historical experience, current best estimates and expectations of future outcomes as well as
anticipated changes in the environment. The following represents the most material key management assumptions applied by
management in preparing these annual financial statements.
4.1 	Policyholder liabilities assumptions and estimates, including assets arising from
insurance contracts
DISCOVERY LIFE AND VITALITYLIFE
Discovery values its insurance policies issued by Discovery Life and VitalityLife using various methodologies and assumptions.
Accounting policy 13.1 sets out the methodology used in its valuation of the policyholder liabilities, including the use of available
discretionary margins in accounting policy 13.1.1.
The assumptions used are best estimate assumptions, with the addition of explicit compulsory margins required by:
❚ 	SAP 104 of the Actuarial Society of South Africa for Discovery Life; and
❚ 	INSPRU of the Prudential Regulatory Authority (PRA), SAP 104 and Benchmarking information in the UK
Per the accounting policy, the best estimate assumptions and margins are reset at every valuation date to reflect the underlying
profitability of the portfolio. The most recent valuation date is 30 June 2022.
MORTALITY AND MORBIDITY
Assumptions of future mortality and morbidity experience are derived from reinsurers and industry data and compared to actual
past experience. Where appropriate, the assumptions are adjusted to reflect actual past experience or for expected changes in
future experience.
The assumptions are modified for each policy based on actual data from underwriting performed on the policy and compared
against standard industry tables for reasonability. The key mortality and morbidity assumptions are reviewed and benchmarked
against the industry by independent actuarial consultants to ensure that the assumptions are reasonable upon implementing
significant new products for Discovery Life. An adjustment to the standard mortality and morbidity assumptions is made to
reflect the expected impact of engagement in the Vitality programme. It has been observed that higher rates of engagement
result in lower mortality and morbidity claims.
An allowance is made for the impact of AIDS on South African mortality rates. For individual life South African business, a fixed
loading is applied to the expected best estimate mortality rates to allow for the expected effect of AIDS. The loading varies based
on socio-economic class. Discovery Life further operates in the high end of the market, where the AIDS risk is lower than the full
market. The additional loading for AIDS is set in consultation with external independent actuaries and reinsurers.
For Group Life policies, a loading is applied at the underwriting stage to allow for the expected effect of AIDS. The loading varies
based on the industry and geographic area and composition of the group and is derived from advice received from the reinsurers.
The loading then forms the AIDS assumption for Group policies.
The sensitivity of the policyholder liabilities due to changes in mortality and morbidity assumptions are set out in note 2.5.1 for
Discovery Life and note 2.5.2 for VitalityLife.

-- 91 of 219 --

91	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
4. 	SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS
IN APPLYING ACCOUNTING POLICIES
4.1 	Policyholder liabilities assumptions and estimates, including assets arising from
insurance contracts continued
DISCOVERY LIFE AND VITALITYLIFE continued
SURRENDER AND LAPSE RATES
Lapse rates are based on actual past experience where available. The lapse analysis is done by considering the in–force duration
of policies. For durations longer than actual data, lapse rates are set based on expectations of future experience based on
internal and external expert advice as well as available industry benchmarking. The lapse experience investigation covers at least
the last two years of lapse experience to identify trends.
Lapse assumptions are varied between different types of policies where the lapse experience is expected to differ significantly.
Allowance is made for the estimated impact of the economic environment. For Discovery Life, an adjustment is made to the lapse
assumptions to reflect the expected impact of engagement in the Vitality programme because it has been observed that higher
rates of engagement result in lower lapses.
For Discovery Life, the surrender rates are also based on actual past experience where available.
The sensitivity of the policyholder liabilities due to changes in lapse rate assumptions are set out in note 2.5.1 for Discovery Life
and note 2.5.2 for VitalityLife.
ECONOMIC ASSUMPTIONS/INVESTMENT RETURNS
DISCOVERY LIFE
The discount rate for Discovery Life and Invest is based on the risk-free rates at 30 June 2022. The real rate assumption is based on
the average of the real rate curves for the preceding twelve months. This real rate assumption will remain unchanged over time
unless the equivalent single rate, derived based on the weighted duration of the cash flows, moves by more than 25 basis points since
the preceding valuation. The inflation assumption is set as the differential between the assumed nominal and real interest rates.
For comparison purposes, it is noted that the single risk-free rate at 30 June 2022 would have increased to 12.3% (2021: decrease to
11.1%). The implied single real interest rate has also decreased to 4.2% in June 2022 (2021: 4.6%).
Other investment returns and economic assumptions are set relative to this yield curve. The assumptions for Discovery Life are as
follows:
Cash: 	Risk-free – 1.5%
Fixed interest: 	Risk-free
Equity: 	Risk-free + 3.5%
Property: 	Risk-free +1%
The sensitivity of the policyholder liabilities due to changes in real curve assumptions are set out in note 2.5.1.
VITALITYLIFE
The nominal investment return is set as the active market rate on UK long-term swap rates plus a fixed adjustment (based on long-
term averages) for liquidity premium, the gilt/swap spread and cash flow weighting. The best estimate inflation assumption is set in
line with long-term UK inflation expectations and observed real yields consistent with the term of the liabilities. The risk-free rate at
30 June 2022 was set at 2.3% (2021: 0.64%).
The investment fees and tax rates are taken into account in setting the economic assumptions.
The sensitivity of the policyholder liabilities due to changes in real curve assumptions are set out in note 2.5.2.

-- 92 of 219 --

92	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
4. 	SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS
IN APPLYING ACCOUNTING POLICIES continued
4.1 	Policyholder liabilities assumptions and estimates, including assets arising from
insurance contracts continued
ECONOMIC ASSUMPTIONS/INVESTMENT RETURNS continued
EXPENSE ASSUMPTIONS
Renewal expense assumptions are based on the results of the latest expense and budget information. Expenses are considered non-
recurring when they relate to the start-up of a new business area or when they are material and are specific to an event that is not
expected to occur in the future.
The allocation of expenses between initial and renewal is based on the latest expense analysis, where expenses are directly allocated
based on the function performed. Where an expense could relate to both initial and renewal functions, the expenses are allocated
proportionately based on estimates of the functions performed.
Per Discovery’s policy, expenses are projected to increase in line with consumer price inflation.
Non-recurring expenses are excluded from the expense analysis used to derive the assumption.
The sensitivity of the policyholder liabilities due to changes in expense assumptions are set out in note 2.5.1 for Discovery Life and
note 2.5.2 for VitalityLife.
POLICY ALTERATIONS AND AUTOMATIC PREMIUM INCREASES
In calculating policyholder liabilities, allowance is made for overall negative policy alterations over time.
Automatic premium increases could include both contractual and voluntary increases. No allowance is made for voluntary premium
increases when calculating liabilities under insurance contracts.
Contractual premium increases are defined as increases that the policyholder cannot cancel without altering the terms of the benefits
provided under the policy. Contractual increases are included in the calculation of policyholder liabilities.
COVID-19 PROVISIONS FOR DISCOVERY LIFE AND VITALITYLIFE
COVID-19 is expected to transition into an endemic phase considering high immunity of the population in the Discovery client base.
Given this transition, the on financial metrics is expected to be less material compared to the early waves of the COVID-19 pandemic.
Allowance for the remaining short-term and long-term impacts has been incorporated into business as usual reserving for insurance
contracts.

-- 93 of 219 --

93	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
4. 	SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS
IN APPLYING ACCOUNTING POLICIES continued
4.1 	Policyholder liabilities assumptions and estimates, including assets arising from
insurance contracts continued
R million
June
2022
At beginning of the period 	2 800
Movements:
Unwinding, utilisation and release of provisions 	(2 800)
Provisions made during the period, including in respect of new business 	–
Other 	–
At end of the period 	–
CHANGES IN ASSUMPTIONS
Expected profits regarding future options on products are not recognised, but expected losses in respect of such options are
allowed for, in line with actuarial guidance.
Modelling and assumptions changes were made to the valuation at 30 June 2022 to ensure that assumptions are in line with the
best estimate of future experience. For Discovery Life, the total effect of these changes on the Assets arising from insurance
contracts was a decrease in the assets on the Financial Soundness Valuation basis of R1 760 million (2021: R2 537 million
decrease). For VitalityLife, the total effect of these changes was an decrease in the assets of R596 million (2021: R832 million
increase).
In addition to this, for Discovery Life, discretionary margins were reset to reflect the underlying profitability of the overall portfolio.
The reset of margins increased the assets on the Financial Soundness Valuation basis by R377 million (2021: R105 million
increase). Refer to note 5 for an analysis of these changes.
TAXATION
Future tax is allowed according to the current tax legislation and current tax rates. It is assumed that future tax on statutory
profits will be payable at the prevailing company tax rate of 28% (2021: 28%) in South Africa. The South Africa’s National Treasury
announced that the corporate tax rate should reduce to 27% for tax years commencing ending on or after 31 March 2023. The
rate is deemed substantively enacted, and deferred tax has been appropriately adjusted. The prevailing tax rate in the UK is 19%
(2021: 19%). The UK has enacted an increase in the tax rate to 25% effective from 1 April 2023.
Tax amendments for Life Insurance companies introduced a Risk Policy Fund for all new risk business written after 1 July 2016. In
terms of this legislation, Discovery Life elected to move existing risk business to this Fund. As a result of these changes, the
assessed loss in the Individual Policyholder Fund is expected to stop increasing and be utilised over time. Therefore, in terms of
IAS 12 Income Taxes, a value of R834 million (2021: R1 134 million), which was previously implicit in the valuation of insurance
contract liabilities, was recognised explicitly as a deferred tax asset. The value is net of deferred capital gains tax liabilities.
To calculate this value, Discovery Life performed a probability-weighted cash flow forecast of the annual cash flows expected to
arise from the utilisation of the assessed loss. The primary factors that management has considered when arriving at the
probability are the expected market growth and withdrawal rate of the Linked Asset and Guaranteed Endowment book. For
Linked Assets, given the uncertainty inherent in market growth assumptions and the fact that discounting of cash flows is not
permitted by IAS 12, future market growth was assumed to be 0% to calculate the deferred tax asset. The expected income on
the debt portfolio held to match policyholder liabilities has been fully allowed for at current rates. For both the Linked and debt
portfolio, cash flows arising from the tax asset were further reduced to account for the uncertainty of future lapse rates and
product mix as well as the broader economic and legislative environment.
REINSURANCE
All prospective liabilities are valued gross of reinsurance and then adjusted for the expected effect of reinsurance. For outstanding
reported claims and IBNR, a specific allowance is made for reinsurance recoveries.
The Global Linkage Benefit is fully reinsured. The cost of the future reinsurance is dependent on the cost at which the reinsurer
can buy assets to match the liability under this benefit. Assumptions are made around the cost at which the reinsurer can
purchase these benefits based on the current and historical costs of these assets.
FINANCIAL SOUNDNESS VALUATION
The sensitivity of the policyholder liabilities on the Financial Soundness Valuation basis is set out in note 2.5.1. The sensitivity of
the policyholder liabilities on the INSPRU basis is set out in note 2.5.2.

-- 94 of 219 --

94	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
4. 	SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS
IN APPLYING ACCOUNTING POLICIES continued
4.2 	Annual assessment of goodwill impairment
Refer to note 10 Goodwill for a breakdown of business acquisitions resulting in goodwill.
Discovery annually assesses goodwill allocated to the respective businesses as set out in note 10.
Based on the work performed for the financial years ended 30 June 2022 and 30 June 2021, management considered that there
is a very low risk of material adjustment to the carrying amount of goodwill allocated to VitalityHealth and VitalityLife within the
next financial year. Accordingly, no further information is included within this note, as this no longer meets the requirement of
significant estimation uncertainty under IAS 1 Presentation of Financial Statements.
DISCOVERY BANK
The Discovery Bank CGU comprise the various assets that collectively produce independent cash flows for Discovery Bank.
Discovery Bank’s income streams comprise interest earned on loans to customers, interest on excess cash invested, fees (e.g.,
banking fees, interchange fees and transaction fees) from banking. For the financial years ended 30 June 2021 and 30 June 2020,
the recoverable amount of the Discovery Bank cash-generating unit (CGU) was determined based on fair value less costs to sell.
Inherent in the determination of fair value less costs to sell is estimation uncertainty. The recoverable amount is the fair value
less costs to sell using the income approach.
In determining the assets to attribute to the Discovery Bank CGU, Discovery considered the assets required to perform banking
operations, including the banking license costs, the internally developed software in use, and the goodwill associated with the
DiscoveryCard business acquisition and related assets and liabilities. Therefore, the valuation also supports the recoverability of
goodwill, intangible assets and deferred tax.
Management has reviewed its business forecast, which comprises:
– A detailed 10-year business plan. The 10-year plan considers regulatory capital requirements, macro-economic forecasts and
customer behaviour assumptions when forecasting a statement of financial position, income statement and resultant equity
cash flows to/from shareholders. The 10-year period used to assess impairment is longer than the standard 5-year forecast
model generally applied in Discovery’s impairment testing. The business is still in the start-up phase, resulting in a 5-year
forecast not adequately reflecting the business plan. Management can project beyond the 5-years due to the insights from the
DiscoveryCard business it acquired.
– The terminal value was calculated using an extended cash flow forecasting method until the growth in earnings has stabilised
in year 20 and a final value considering perpetual terminal growth. This terminal value was discounted to year 10.
– As a reasonability check, Discovery Bank translates the value of the business at year 10 into a Price-Earnings (PE) multiple,
which it benchmarks against Discovery’s PE ratio and other emerging banks within the South African environment. The ratio
was determined to be within range.
– In the near term, expected credit losses and customer spending patterns were stressed for the impact of COVID-19 and post
COVID-19, also considering the expected impact of the inflationary environment.

-- 95 of 219 --

95	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
4. 	SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS
IN APPLYING ACCOUNTING POLICIES continued
4.2 	Annual assessment of goodwill impairment continued
The key assumptions used by Discovery in the estimation are as follows:
– Conservative customer growth, targeting an achievable level of customers in year 10. After that, the customer base is treated
as stable. From the point of stability in year 20, the projected growth in profits is estimated at a conservative 5.55% (2021:
5.0%) considering long-term inflation and long-term nominal GDP estimations. The increase in growth projections is based on
the growth over the past financial year.
– System-build costs and intangible assets acquired in the business combination have been amortised over 10 years
(2021: 10 years). Useful lives range between 10 and 11 years (2021: between 10 and 11 years).
– The discount rate applied to the cashflows comprises the following:
Group
2022
Group
2021
Risk-free rate based on 10-year SA bond curve 	10.60% 	8.90%
Beta factor: The beta factor is a weighted average of large SA banks and Discovery 	1.07 	1.09
Discount rate applied 	17.97% 	16.38%
For the year ended 30 June 2022, management has engaged independent external valuation experts to benchmark the key
assumptions and ratios within the South African market. This exercise determined that the assumptions to be within acceptable
ranges.
Management has further performed stress tests by increasing the discount rate to 19% while simultaneously decreasing the
terminal growth rate to 5%. Again, no impairment was triggered with these stressed scenarios.
Based on management’s assessment, Discovery did not identify any impairments in respect of the Discovery Bank CGU.

-- 96 of 219 --

96	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
5. 	ASSETS ARISING FROM INSURANCE CONTRACTS
R million
Group
2022
Group
2021
Long-term insurance contracts – gross 	56 645 	50 483
Less: ceded to reinsurers (refer to note 19) 	(10 610) 	(10 143)
Long-term insurance contracts – net 	46 035 	40 340
Current 	5 127 	2 754
Non-current 	40 908 	37 586
46 035 	40 340
Movement in assets arising from insurance contracts
Balance at beginning of the year 	40 340 	36 999
Movement for the year:
Expected movement in policyholder liabilities 	(1 362) 	(2 102)
Unwinding of discount rate 	3 108 	2 711
New business written 	3 370 	3 607
Experience variances 	1 350 	1 433
Economic 	185 	115
Operational 	1 165 	1 318
Modelling and method changes 	(179) 	(346)
Changes in assumptions 	(1 086) 	(1 359)
Economic 	169 	789
Operational 	(1 255) 	(2 148)
Changes in margins1 	377 	105
Translation differences 	117 	(708)
Balance at end of the year 	46 035 	40 340
1 In line with accounting policy 13.1.1, the best estimate assumptions and margins are reset at every valuation date to reflect the underlying
profitability of the overall portfolio. Assumptions and margins are not set on new business in isolation but on a portfolio level.

-- 97 of 219 --

97	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
6. 	PROPERTY AND EQUIPMENT
Group
R million
Land and
buildings
Furniture,
fittings and
equipment
Computer
equipment
and
operating
systems
Leasehold
improve-
ments
Motor
Vehicles
Telematics
devices 	Total
Year ended 30 June 2022
Opening carrying amount 	3 071 	45 	324 	638 	18 	92 	4 188
Translation differences 	16 	– 	4 	5 	– 	– 	25
Additions 	95 	5 	211 	39 	4 	59 	413
Disposals
– Cost 	(24) 	– 	– 	(10) 	(12) 	(3) 	(49)
– Accumulated depreciation 	9 	– 	– 	1 	9 	2 	21
Derecognition
– Cost 	(12) 	(10) 	(302) 	(38) 	(11) 	(60) 	(433)
– Accumulated depreciation 	10 	10 	302 	37 	11 	51 	421
Impairment
Depreciation charge 	(299) 	(15) 	(171) 	(116) 	(8) 	(41) 	(650)
Lease modification 	(125) 	– 	– 	– 	– 	– 	(125)
Closing carrying amount 	2 741 	35 	368 	556 	11 	100 	3 811
At 30 June 2022
Cost 	3 969 	168 	875 	1 018 	63 	269 	6 362
Accumulated depreciation 	(1 228) 	(133) 	(507) 	(462) 	(52) 	(169) 	(2 551)
Carrying amount 	2 741 	35 	368 	556 	11 	100 	3 811
Year ended 30 June 2021
Opening carrying amount 	3 437 	70 	298 	740 	21 	77 	4 643
Translation differences 	(46) 	(2) 	(7) 	(9) 	– 	– 	(64)
Additions 	8 	2 	231 	20 	7 	63 	331
Disposals
– Cost 	(26) 	– 	(37) 	– 	– 	(4) 	(67)
– Accumulated depreciation 	– 	– 	20 	– 	– 	3 	23
Derecognition
– Cost 	9 	(117) 	(262) 	– 	(1) 	(34) 	(405)
– Accumulated depreciation 	(9) 	115 	259 	– 	1 	28 	394
Impairment
– Cost 	(6) 	– 	(3) 	(133) 	– 	– 	(142)
– Accumulated depreciation 	1 	– 	1 	123 	– 	– 	125
Depreciation charge 	(297) 	(23) 	(176) 	(103) 	(10) 	(41) 	(650)
Closing carrying amount 	3 071 	45 	324 	638 	18 	92 	4 188
At 30 June 2021
Cost 	4 011 	173 	942 	1 015 	82 	273 	6 496
Accumulated depreciation 	(940) 	(128) 	(618) 	(377) 	(64) 	(181) 	(2 308)
Carrying amount 	3 071 	45 	324 	638 	18 	92 	4 188
Derecognition
In Discovery Insure, when policies relating to motor vehicle insurance lapse, the telematics devices installed in those vehicles are
not always recovered. The value of these unrecovered units are derecognised.

-- 98 of 219 --

98	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
6. 	PROPERTY AND EQUIPMENT continued
LEASED ASSETS
The table above includes the following assets which are leased under a finance lease:
R million
Group
2022
Group
2021
Land and buildings 	2 480 	2 891
Computer equipment and operating systems 	11 	70
Leasehold improvements 	23 	112
Motor vehicles 	2 	–
Total 	2 516 	3 073
7. 	INTANGIBLE ASSETS
Group
R million
Software
development
Business
acquisitions:
Identifiable
Intangibles
Banking
license 	Total
Year ended 30 June 2022
Opening carrying amount 	5 911 	431 	29 	6 371
Translation differences 	109 	5 	– 	114
Additions 	1 567 	– 	– 	1 567
Amortisation charge 	(1 252) 	(59) 	– 	(1 311)
Impairment
– Cost 	(49) 	– 	– 	(49)
– Accumulated amortisation 	49 	– 	– 	49
Derecognition1
– Cost 	(546) 	– 	– 	(546)
– Accumulated amortisation 	344 	– 	– 	344
Closing carrying amount 	6 133 	377 	29 	6 539
Year ended 30 June 2022
Cost 	10 663 	1 872 	29 	12 564
Accumulated amortisation 	(4 530) 	(1 495) 	– 	(6 025)
Carrying amount 	6 133 	377 	29 	6 539
1 	Included in derecognition for the year is an amount of R164 million resulting from the IFRIC interpretation on capitalisation of costs associated with
configuration or customisation costs in a cloud arrangement. R75 million has been recognised in profit and loss and presented in salaries, wages
and allowances (refer to note 31) and R89 million was recognised in prepayments (refert to note 14) of which R45 million has been expensed at
30 June 2022. Accordingly, the headline earnings per share has not been adjusted to reflect the derecognition as a result of this interpretation.
BUSINESS ACQUISITIONS
Intangibles identified in the acquisition of business combinations are amortised over their remaining useful lives and only tested
for impairment if an indication of impairment arises. There was no indication of impairment for the current reporting period.
Included in the value of business acquisitions are:
❚ 	Customer contracts represented by value-in-force business acquired in the Standard Life Healthcare and PrimeMed business
combinations. The carrying amount as at 30 June 2022 is R277 million (2021: R316 million); and
❚ 	Client relationships and Core Deposit Funding Benefit acquired in the DiscoveryCard business combination. The carrying
amounts as at 30 June 2022 are R87 million and R13 million respectively (2021: R100 million and R15 million).
BANKING LICENSE
– During the 2018 financial year, Discovery incurred costs of R29 million in respect of the application for a banking license.
Discovery has capitalised these costs in terms of IAS 38 Intangible Assets. This asset has an indefinite useful life.

-- 99 of 219 --

99	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
7. 	INTANGIBLE ASSETS continued
Group
R million
Software
development
Business
acquisitions:
Identifiable
Intangibles
Banking
license 	Total
Year ended 30 June 2021
Opening carrying amount 	5 825 	527 	29 	6 381
Translation differences 	(218) 	(30) 	– 	(248)
Additions 	1 587 	– 	– 	1 587
Amortisation charge 	(1 200) 	(66) 	– 	(1 266)
Impairment
– Cost 	(56) 	– 	– 	(56)
– Accumulated amortisation 	12 	– 	– 	12
Derecognition
– Cost 	(1 267) 	– 	– 	(1 267)
– Accumulated amortisation 	1 228 	– 	– 	1 228
Closing carrying amount 	5 911 	431 	29 	6 371
Year ended 30 June 2021
Cost 	9 496 	1 850 	29 	11 375
Accumulated amortisation 	(3 585) 	(1 419) 	– 	(5 004)
Carrying amount 	5 911 	431 	29 	6 371

-- 100 of 219 --

100	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
8. 	DEFERRED ACQUISITION COSTS
R million
Group
2022
Group
2021
Balance at beginning of the year 	585 	632
Translation differences 	6 	(46)
Additions 	1 524 	1 667
Deferred acquisition costs amortised 	(1 475) 	(1 668)
Balance at the end of the year 	640 	585
9A. 	ASSETS ARISING FROM CONTRACTS WITH CUSTOMERS AND
CONTRACT LIABILITIES
Where either party to a contract has performed, Discovery presents either a contract asset or contract liability, depending on the
relationship between Discovery’s performance and the customer’s payment. Unconditional rights to consideration is presented
separately as a receivable.
Group
R million
Assets
arising from
contracts
with
customer1
Costs of
obtaining
contracts 1
Contract
liabilities
Contract
receivables 2
Year ended 30 June 2022
Balance at beginning of the year 	162 	1 086 	(776) 	1 217
Accrued income recognised during the year 	111 	– 	– 	–
Payments received 	(45) 	– 	– 	(12 100)
Costs of obtaining new contracts 	– 	456 	– 	–
Amortised during the year 	– 	(252) 	– 	–
Contract liabilities recognised in the current year 	– 	– 	(534) 	–
Revenue recognised in the year 	– 	– 	404 	12 016
Provision of impairment of contract receivables 	– 	– 	– 	24
Foreign exchange revaluations 	– 	– 	– 	7
Translation differences 	28 	3 	(38) 	45
Balance at end of the year 	256 	1 293 	(944) 	1 209
Year ended 30 June 2021
Balance at beginning of the year 	108 	846 	(808) 	1 413
Accrued income recognised during the year 	112 	– 	– 	–
Payments received 	(35) 	– 	– 	(11 287)
Costs of obtaining new contracts 	– 	488 	– 	–
Amortised during the year 	– 	(243) 	– 	–
Contract liabilities recognised in the current year 	– 	– 	(413) 	–
Revenue recognised in the year 	– 	– 	391 	11 182
Provision of impairment of contract receivables 	– 	– 	– 	11
Foreign exchange revaluations 	– 	(2) 	– 	(21)
Translation differences 	(23) 	(3) 	54 	(81)
Balance at end of the year 	162 	1 086 	(776) 	1 217
1 Presented as assets arising from contracts with customers.
2 Presented as part of insurance receivables, contract receivables and other receivables.

-- 101 of 219 --

101	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
9A. 	ASSETS ARISING FROM CONTRACTS WITH CUSTOMERS AND
CONTRACT LIABILITIES continued
The contract liability primarily relates to the advance consideration received from customers for the initial advisor fees, for which
revenue will be recognised over the expected terms of the arrangement. It further includes the Discovery Miles liability on the
Vitality Programme.
The transaction price is allocated to remaining performance obligations, which represents the fixed revenue in future for stand
ready services, to provide Intellectual Property services for VitalityOne System.
Group
R million
Contract
amount
for future
service 	< 1 year 	2 – 3 years 	4 – 5 years 	> 5 years
Year ended 30 June 2022
Provision of stand ready Intellectual Property services 	3 148 	439 	910 	675 	1 124
Total 	3 148 	439 	910 	675 	1 124
Group
R million
Contract
amount
for future
service 	< 1 year 	2 – 3 years 	4 – 5 years 	> 5 years
Year ended 30 June 2021
Provision of stand ready Intellectual Property services 	2 374 	368 	786 	681 	539
Total 	2 374 	368 	786 	681 	539
Where performance obligations are discharged within 12 months or where contracts are cancellable giving 12 months or less
notice, without the payment of a significant penalty, a practical expedient has been applied. Discovery has excluded these contracts
from the disclosures above. Contracts that include variable considerations have also not been included in the table above.
9B. 	REVENUE
Also refer to accounting policy 20 Revenue recognition. Discovery Group’s Revenue includes ‘Fee income from administration
business’, ‘Vitality Income’ and ‘Banking fee and commission income’.
The split of revenue per geographical region and reportable segment can be viewed in Note 1, Segmental information.
The split of revenue according to the timing of satisfaction of performance obligation, i.e. ‘over time’ or a ‘point-in-time’ is as
follows:
R million
Group
2022
Group
2021
Fee income from administration business 	10 971 	10 077
– Over time 	10 548 	9 630
– Point-in-time 	423 	447
Intellectual Property Fees: Fee income from administration business 	1 781 	1 623
– Over time 	1 781 	1 623
Vitality Income 	3 495 	3 340
– Over time 	2 348 	2 348
– Point-in-time 	1 147 	992
Banking fee and commission income 	853 	633
– Over time 	389 	272
– Point-in-time 	464 	361

-- 102 of 219 --

102	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
10. 	GOODWILL
Goodwill is not amortised, but is tested on an annual basis for impairment. Any impairment is recognised immediately in profit
or loss and is not subsequently reversed.
The table below sets out the goodwill allocated to the respective cash generating units (CGU’s) which is expected to benefit from
the synergies of the combination. Impairment of goodwill is assessed at this CGU level.
R million
Goodwil per cash generating unit
Value in functional currency on
date of acquisition 	2022 	2021
Goodwill
– Vitality Health1, 2, 5, 6 	GBP 100.3 million 	2 007 	1 980
– VitalityLife1, 5, 7 	GBP 23.4 million 	468 	462
– Discovery Bank3 	R 2 417 million 	2 417 	2 417
– Discovery Administration Services4 	R 20 million 	20 	20
Total 	4 912 	4 879
1 GBP 96.7 million and GBP 23.4 million of the goodwill was allocated to VitalityHealth and VitalityLife respectively as at 31 July 2010.The goodwill
arose from the acquisition of Standard Life Healthcare and related capital restructure of the Prudential joint venture.
2 GBP 2.5 million goodwill from the acquisition of Insure Your Health (25 March 2013) and GBP 1.1 million of goodwill from the acquisition of KYS
Paid Limited (30 April 2014) were allocated to the VitalityHealth CGU.
3 R2 417 million goodwill from the acquisition of the DiscoveryCard business on 1 March 2019 was allocated to the Discovery Bank CGU.
4 In October 2020, Discovery acquired Liberty Health Administration, a wholly owned subsidiary, which performs medical aid administration for
specified medical aids. Liberty Health Administration has been renamed to Discovery Administration Services Proprietary Limited as of 11 August 2021.
5 As part of the annual assessment of impairment, Discovery has done significant stresses on the Goodwill of VitalityHealth and VitalityLIfe. The
value-in-use considers the ‘value-in-force’ business as well as new business. The value-in-use is calculated as the present value of the best-estimate
pre-tax cash flows of the CGU for the in-force policies at the valuation date and 10 years of new business. The outcome of the working indicated
that the recoverable amount significantly exceeds the carrying amount of the CGUs, with little risk of impairment.
6 Net exchange rate differences of R27 million (2021: R171 million) were recognised in the financial year ended 30 June 2022.
7 Net exchange rate differences of R6 million (2021: R40 million) were recognised in the financial year ended 30 June 2022.

-- 103 of 219 --

103	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
11. 	EQUITY-ACCOUNTED INVESTEES
R million
Group
2022
Group
2021
Carrying value of material interest in associates and joint ventures – Ping An Health 	4 499 	2 198
Carrying value of material interest in associated and joint ventures – CMT 	1 263 	1 127
Carrying value of individually immaterial interest in associates 	112 	134
Carrying value of individually immaterial interest in joint ventures 	134 	–
Investment in equity-accounted investees 	6 008 	3 459
11.1 	Material interests in associates and joint ventures
The table below provides summarised financial information for the Group’s material joint ventures and associates. The
information disclosed reflects the amounts presented in the financial statements of the relevant associates and joint ventures
and not Discovery’s share of those amounts.
PING AN HEALTH INSURANCE COMPANY OF CHINA, LIMITED (PING AN HEALTH OR PAH)
Ping An Health offers policyholders in China cover for a range of private healthcare-related claims. PAH is a strategic partnership
for the group, providing access to new clients and markets in China.
As announced in the 30 June 2021 and 31 December 2021 results announcements, during the year ended 30 June 2022, the group
contributed R1.5 billion of additional capital to Ping An Health. This capital contribution represents the Group’s proportionate
24.99% shareholding and the additional capital should support the business growth and regulatory requirements for the
foreseeable future.
Given that the final regulatory approval by the Chinese Banking and Insurance Regulatory Commission was prolonged, the capital
has been funded in the interim by way of a bridge facility and internal resources.
CAMBRIDGE MOBILE TELEMATICS INC. (CMT)
A United States of America based leading telematics technology provider. This partnership provides the group with expertise in
the telematics environment that Discovery Insure harnesses to manage its insurance risk.
Ping An Health 	CMT
Ownership structure 	Equity-accounted associate 	Equity-accounted associate
Nature 	Insurance 	Telematics technology
Place of business 	China 	USA
R million 	2022 	2021 	2022 	2021
% of ownership interest at end of year 	24.99% 	24.99% 	8.85% 	8.96%
Summarised statement of comprehensive income
Revenue 	29 540 	25 484 	2 285 	1 537
Net profit/(loss) 	1 637 	1 884 	(521) 	80
Other comprehensive income/(loss) 	69 	(8) 	– 	–
Total comprehensive income/(loss) 	1 706 	1 876 	(521) 	80
Summarised statement of financial position
Current assets 	19 048 	16 482 	3 852 	3 292
Non-current assets 	39 144 	21 584 	11 686 	9 824
Current liabilities 	(6 526) 	(5 400) 	(1 054) 	(538)
Non-current liabilities 	(34 833) 	(24 941) 	(604) 	(308)
Net assets 	16 833 	7 725 	13 880 	12 270
Reconciliation to carrying amounts:
Opening net assets 	7 725 	6 093 	12 270 	5 749
Profit/(loss) for the year 	1 637 	1 884 	(521) 	80
Other comprehensive income/(loss) 	69 	(8) 	– 	–
Increase in share capital and share premium 	5 950 	425 	267 	7 352
Foreign exchange gains/(losses) 	1 452 	(669) 	1 864 	(911)
Closing net assets 	16 833 	7 725 	13 880 	12 270
Group’s share of net assets 	4 207 	1 931 	1 228 	1 099
Goodwill 	292 	267 	35 	28
Carrying value at 30 June 	4 499 	2 198 	1 263 	1 127

-- 104 of 219 --

104	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
11. 	EQUITY-ACCOUNTED INVESTEES continued
11.2 	Individually immaterial associates and joint ventures
11.2.1 INDIVIDUALLY MATERIAL TRANSACTIONS
REVERSAL OF IMPAIRMENT OF INVESTMENT IN AIA VITALITY (PTY) LTD AND CLASSIFICATION AS
HELD FOR SALE
Discovery Vitality Australia (Pty) Limited (DVA), a wholly-owned subsidiary of Vitality Group International Inc. (VGI), has an associate
investment in AIA Vitality (Pty) Limited (AIAV). The value of AIAV is directly influenced by AIA Health Australia (Pty) Limited (AIAH), an
Australian health insurance joint venture between GMHBA Limited and VGI and AIA Australia via its indirect interest through AIAV.
Discovery was approached regarding a potential offer to buy Discovery Vitality’s interest in AIAV. On 1 June 2022 Discovery
Executive management confirmed the acceptance of an unconditional offer to purchase Discovery Vitality’s interest in AIA Vitality.
Accordingly, management committed to a plan to sell the investment in AIAV and the investment in AIAV was classified as a non-
current asset held for sale as of 1 June 2022.
REVERSAL OF PREVIOUS IMPAIRMENT
During the previous financial reporting period, the Group recognised an impairment of AIAV in the amount of AUD12.5million
(R149 million). During the current period, there were internal and external indicators that the impairment had reversed. The offer
made confirmed that there was a reversal of the previous recognised impairment. Accordingly the Group reversed impairments
to the value of AUD 12.5 million (R134 million). In order to determine the reversal, the recoverable amount was measured at fair
value less cost to sell.
NON-CURRENT ASSETS HELD FOR SALE
The investment in AIAV was reclassified from equity-accounted investments to non-current assets held for sale in accordance with
IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. At date of reclassification, there were no additional impairment
losses or reversals due to reclassifcation. At 30 June 2022, the disposal group was stated at fair value less costs to sell.
The disposal group comprises of:
– Investment in AIAV equity accounted investment 	AUD 15 million (R171 million)
MEASUREMENT OF FAIR VALUE
The non-recurring fair value measurement for the investment in AIAV of AUD 15 million (R171 million) has been categorized as a
level 3 fair value due to the binding offer being subject to significant unobservable inputs. Discovery used the binding offer
without adjustment as the fair value and therefore there are no quantitative unobservable inputs developed when measuring the
fair value.
FORMATION OF AMPLIFY HEALTH
On 15 February 2022 Discovery announced its new venture with AIA Group Limited (AIA) to form Amplify Health. Amplify Health’s
vision is to be Asia’s leading digital health technology and integrated solutions business, transforming how individuals, corporates,
payors, and providers experience and manage health insurance and healthcare delivery, improving the health and wellness
outcomes of patients and communities across Asia.
Discovery owns 25% of AmplifyHealth with AIA owning the balance of 75%. Discovery has classified the investment in AmplifyHealth
as an associate which it equity-accounts for.
Discovery will continuously transfer its full health technology stack along as well as provide for transfer of skilled personnel.
Discovery will assign, for the region, ownership of the Health IP and the Vitality IP (excluding China, Hong Kong, Macau and Japan,
given its partnerships in those markets) to AmplifyHealth. This will ensure the AmplifyHealth has end-to-end capability.
Discovery will earn revenue for the technology it sells and will develop and sell in the future on this arrangement, in addition to
its participation in AmplifyHealth.
11.2.2 SUMMARY OF FINANCIAL INFORMATION
The table below provides summarised information of the aggregate amounts of the Group’s share of total income:
Group
R million
Associates 	Joint ventures
2022 	2021 	2022 	2021
Aggregate amount of the Group’s share of profit/(loss) 	(21) 	40 	137 	1
Reversal of impairment/(impairment) of equity-accounted
investments 	134 	(149) 	– 	–

-- 105 of 219 --

105	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
12. 	FINANCIAL ASSETS
The Group’s investment in financial assets are summarised by measurement category in the table below:
R million 	Notes
Group
2022
Group
2021
Financial assets at fair value through profit or loss – mandatorily: 	141 494 	130 937
– Equity portfolios 	57 948 	43 362
– Debt portfolios 	47 592 	36 485
– Money market portfolios 	14 680 	17 253
– Multi-asset portfolios 	21 274 	33 837
Financial assets at amortised cost 	11 105 	8 965
Investments at amortised cost1 	7 161 	5 604
– South African Treasury Bills 	5 205 	4 109
– Deposits 	1 956 	1 495
Loans and advances to customers at amortised cost 	3 944 	3 361
Total investments 	152 599 	139 902
Listed 	130 192 	121 057
Unlisted 	22 407 	18 845
152 599 	139 902
Shareholder investments: 	19 828 	17 854
– Investments at amortised cost 	3 	11 105 	8 965
– Investments at fair value through profit and loss – mandatorily 	8 723 	8 889
Policyholder investments: 	132 771 	122 048
– Investments at fair value through profit and loss – mandatorily 	132 771 	122 048
Total Investments 	152 599 	139 902
1 The fair value of instruments at amortised cost approximates the carrying amount due to the relatively short term nature of the instrument.

-- 106 of 219 --

106	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
12. 	FINANCIAL ASSETS continued
12.1 	Loans and advances to customers
Group
R million 	2022 	2021
Loans and advances (gross) – unsecured 	4 308 	3 795
Accrued interest 	39 	31
Total Gross advances 	4 347 	3 826
Less: IFRS9 Expected credit losses (ECL) 	(403) 	(465)
Total net loans and advances 	3 944 	3 361
12.1.1 LOANS AND ADVANCES PER CREDIT RISK RATING
Group
R million 	DRG 1 – 4 	DRG 5 – 7 	DRG 8 – 10 	Not rated 	Total
As at 30 June 2022
Stage 1 	2 166 	1 272 	309 	– 	3 747
Stage 2: SICR1 	4 	24 	271 	5 	304
Stage 2: Arrears 	– 	1 	2 	62 	65
Stage 3 	2 	4 	10 	176 	192
Total gross advances 	2 172 	1 301 	592 	243 	4 308
As at 30 June 2021
Stage 1 	1 633 	1 197 	302 	83 	3 215
Stage 2: SICR1 	1 	6 	259 	4 	270
Stage 2: Arrears 	10 	21 	35 	5 	71
Stage 3 	22 	52 	147 	18 	239
Total gross advances 	1 666 	1 276 	743 	110 	3 795
1 Significant increase in credit risk.
The analysis above excludes accrued interest.
Discovery risk grade (DRG) is an internal client rate allocated on the basis of their risk profile. An adjusted DRG is allocated for the
purposes of calculating the expected credit losses.
Loans and advances classified as ‘not rated’ pertain to loans and advances migrated from DiscoveryCard which have not been
through Discovery Bank credit assessment, and have not been assigned a DRG. To determine the ECL on these customers,
information from the DiscoveryCard back book is used.

-- 107 of 219 --

107	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
12. 	FINANCIAL ASSETS continued
12.1.2 RECONCILIATION OF THE EXPECTED CREDIT LOSS (ECL)
As at 30 June 2022
Group
R million
Stage 1
(12-month
ECL)
Stage 2
(Lifetime ECL,
but no
missed
payments)
Stage 2
(Lifetime
ECL,
and missed
payments)
Stage 3
(Lifetime
ECL,
and credit
impaired,
default) 	Total
30 June 2022
Balance at beginning of the year 	192 	41 	24 	208 	465
Total changes in ECL due to changes
in balances of advances 	(16) 	2 	10 	(134) 	(138)
New loans originated and acquired 	3 	1 	– 	– 	4
Repayments and other movements2 	(16) 	2 	10 	30 	26
Change in ECL due to derecognition
other than write-off 	(3) 	(1) 	– 	(6) 	(10)
Change in ECL due to write-off3 	– 	– 	– 	(158) 	(158)
176 	43 	34 	74 	327
Transfers between stages1
Transfer (to)/from stage 1 	– 	(4) 	11 	51 	58
Transfer (to)/from stage 2: SICR 	(3) 	– 	1 	10 	8
Transfer (to)/from stage 2: Arrears 	(2) 	– 	– 	29 	27
Transfer (to)/from stage 3 	(4) 	(2) 	(11) 	– 	(17)
Balance at end of the year 	167 	37 	35 	164 	403
30 June 2021
Balance at beginning of the year 	81 	52 	26 	23 	182
Total changes in ECL due to changes
in balances of advances 	101 	23 	23 	11 	158
New loans originated and acquired1 	64 	25 	24 	4 	117
Repayments and other movements2 	41 	– 	– 	8 	49
Changes in ECL due to derecognition
other than write-off 	(4) 	(2) 	(1) 	(1) 	(8)
182 	75 	49 	34 	340
Transfers between stages 3
Transfer (to)/from stage 1 	14 	(25) 	2 	59 	50
Transfer (to)/from stage 2: SICR 	– 	– 	(1) 	46 	45
Transfer (to)/from stage 2: Arrears 	(4) 	– 	– 	69 	65
Transfer (to)/from stage 3 	– 	(9) 	(26) 	– 	(35)
Balance at end of the year 	192 	41 	24 	208 	465
1 Discovery Bank’s policy is to transfer accounts between stages based on the ECL stage at the end of the reporting period. Therefore, exposures can
be transferred directly from stage 3 to stage 1 as the curing requirements would have been satisfied during the reporting period. The expected
credit loss recognised on new exposures originated during the reporting period (which are not included in opening balances) are recognised in
new loans originated and acquired based on the exposures ECL stage as at the end of the month the account comes on book. Any change in
status will be reflected in the transfers between stages as described above.
2 During the year ending 30 June 2022, management has adjusted for the effects of COVID 19 in considering forward looking macroeconomic
factors. The adjustment specifically associated with these factors resulted in an increase in ECL of R 28.6 Million (2021:R 24.1million).
3 The contractual amount outstanding on financial asset that were written off during the year ended 30 June 2022 and that are still subject to
enforcement activity is R158 million (2021: R 8 million).

-- 108 of 219 --

108	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
13. 	DERIVATIVE FINANCIAL INSTRUMENTS
R million
Group
2022
Assets
Group
2022
Liabilities
Group
2021
Assets
Group
2021
Liabilities
Derivatives used as cash flow hedges:
Equity price risk derivatives 	– 	– 	23 	(129)
Interest rate swaps 	17 	(56) 	5 	(332)
Derivatives not designated as hedging instruments:
Equity price risk derivatives 	19 	(66) 	1 	(22)
Interest rate swaps 	– 	(79) 	27 	(243)
Swaptions 	216 	– 	135 	–
Currency derivative contracts 	24 	(1) 	58 	(100)
276 	(202) 	249 	(826)
Current 	36 	(62) 	93 	(176)
Non-current 	240 	(140) 	156 	(650)
276 	(202) 	249 	(826)
The effects of the derivatives used in cash flow hedges on the Group’s financial position and performance are as follows:
Year ended 30 June 2022
Group
R million
Notional
amount of
the hedging
instrument
Carrying amount
of the hedging
instrument
Line item
in the
Statement
of financial
position
where the
hedging
instrument
is presented
Changes
in fair value
of hedging
instrument
used for
calculating
hedge
ineffective-
ness
Ineffective-
ness
recognised
in profit
or loss
Line item in
which hedge
ineffectiveness
is presented
in profit or loss	Assets 	Liabilities
Interest rate risk 	5 000 	17 	(56) 	(295) 	–
Interest rate swaps 	5 000 	17 	(56)
Financial
Asset-
Derivative/
Financial
Liability-
Derivative 	(295) 	–
Net fair value
gains on
financial assets
at fair value
through profit
or loss
Refer to note 3.4.1 for a detailed description of the derivative financial instruments listed above.
Group
R million
Changes in
the value of
the hedging
instrument
recognised
in other
comprehen-
sive income
Amount
reclassified
from the
cash flow
hedge
reserve to
profit or
loss
Line item
in which
the
recycled
amount is
presented
in profit
or loss
Carrying amount of the
hedged item
Changes in
fair value of
hedged item
used for
calculating
hedge
ineffective-
ness
Cash flow
hedge
reserve	Assets 	Liabilities
Interest rate risk 1 	295 	– 	– 	– 	(5 038) 	(185) 	(40)
Interest rate
swaps
295 	– 	– 	– 	(5 038) 	(185) 	(40)
1 The interest rate risk derivatives have been recycled to the ‘Cash flow hedges – gains recycled to profit or loss’ line item in the SOCI.

-- 109 of 219 --

109	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
13. 	DERIVATIVE FINANCIAL INSTRUMENTS continued
Year ended 30 June 2021
Group
R million
Notional
amount of
the hedging
instrument
Carrying amount
of the hedging
instrument
Line item in the
Statement
of financial
position
where the
hedging
instrument
is presented
Changes
in fair value
of hedging
instrument
used for
calculating
hedge
ineffective-
ness
Ineffective-
ness
recognised
in profit
or loss
Line item in
which hedge
ineffectiveness
is presented
in profit or loss	Assets 	Liabilities
Equity price risk 	851 	23 	(129) 	(171) 	(8)
Total return swaps 	791 	18 	(129) 	Financial
Asset-
Derivative/
Financial
Liability-
Derivative
(174) 	(11) Net fair value
gains on
financial assets
at fair value
through profit
or loss
Call options 	60 	5 	– 	Financial
Asset-
Derivative
3 	3 	Net fair value
gains on
financial assets
at fair value
through profit
or loss
Interest rate risk 	5 000 	5 	(332) 	(189) 	–
Interest rate swaps 	5 000 	5 	(332) 	Financial
Asset-
Derivative/
Financial
Liability-
Derivative
(189) 	– 	Net fair value
gains on
financial assets
at fair value
through profit
or loss
Refer to note 3.4.1 for a detailed description of the derivative financial instruments listed above.
Group
R million
Changes in
the value of
the hedging
instrument
recognised
in other
comprehen-
sive income
Amount
reclassified
from the
cash flow
hedge
reserve to
profit or
loss
Line item in
which the
recycled
amount is
presented in
profit or loss
Changes in
fair value of
hedged item
used for
calculating
hedge
ineffective-
ness
Cash flow
hedge
reserve
Carrying amount of the
hedged item
Assets 	Liabilities
Equity price risk 1 	171 	(82) 	– 	(364) 	230 	(10)
Total return swaps 	174 	(90) 	Cash flow
hedges-gains
recycled to
profit or loss
– 	(360) 	233 	(8)
Call options 	(3) 	8 	Cash flow
hedges-gains
recycled to
profit or loss
– 	(4) 	(3) 	(2)
Interest rate risk 2 	189 	(8) 	– 	(5 034) 	(202) 	(335)
Interest rate
swaps
189 	(8) 	Cash flow
hedges-gains
recycled to
profit or loss
– 	(5 034) 	(202) 	(335)
1 The equity price risk derivatives have been recycled to the cash flow hedges – gains recycled to profit or loss line items in the SOCI.
2 The interest rate risk derivatives have been recycled to the cash flow hedges – gains recycled to profit or loss line item in the SOCI.

-- 110 of 219 --

110	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
14. 	INSURANCE RECEIVABLES, CONTRACT RECEIVABLES AND OTHER
RECEIVABLES
R million
Group
2022
Group
2021
Receivables arising from insurance and reinsurance contracts: 	7 887 	6 158
– Premium debtors 	801 	668
– Less provision for impairment of premium debtors 	14.1 	(81) 	(63)
– Reinsurance debtors 	7 167 	5 553
Contract receivables 	9A 	1 209 	1 217
– Closed scheme debtors 	107 	104
– Discovery Health Medical Scheme 	724 	662
– Other contract receivables 	382 	480
– Less allowance for expected credit losses 	14.2 	(4) 	(29)
Other non-financial receivables1 	1 375 	969
– Prepayments 	1 022 	851
– Value-added tax asset 	158 	53
– Other debtors 	195 	65
Other financial receivables: 	2 642 	2 189
– Agents and brokers 	439 	412
– BEE partners’ rights-issue funding 	– 	1
– Cash-in-transit debtors 	443 	220
– Consolidated unit trust debtors 	770 	587
– Loans to BEE initiatives 	256 	220
– Security deposit on derivatives2 	72 	289
– Vitality partner debtors 	148 	112
– Other debtors 	906 	809
– Less allowance for expected credit losses 	14.2 	(392) 	(461)
Total insurance receivables, contract receivables and other receivables 	13 113 	10 533
Current 	8 822 	7 110
Non-current 	4 291 	3 423
13 113 	10 533
1 These non-financial assets have been excluded from the risk disclosures presented in note 3.
2 To reduce the credit risk exposure from the hedge derivative instruments purchased, Discovery has entered into collateral agreements with the
relevant financial institutions to post cash collateral periodically, equal to the fair value of the derivatives. The posting of the collateral does not
result in legal settlement of the outstanding derivative balance. The collateral will only be used to settle the derivative upon default or bankruptcy
of either party.
The carrying values approximate the fair value due to the short term nature of these receivables, or for longer term receivables,
they are interest bearing at market rates and fully secured.

-- 111 of 219 --

111	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
14. 	INSURANCE RECEIVABLES, CONTRACT RECEIVABLES AND OTHER
RECEIVABLES continued
14.1 	Provision for impairment of premium debtors
Group
R million 	<30 days
30 – 60
days
60 – 120
days
more than
120 days 	Total
Year ended 30 June 2022
Balance at beginning of the year 	26 	16 	16 	6 	64
Increase in provision 	2 	25 	22 	7 	56
Amount utilised during the period 	(3) 	(19) 	(11) 	(6) 	(39)
Translation difference 	* 	* 	* 	* 	*
Balance at end of the year 	25 	22 	26 	7 	80
Year ended 30 June 2021
Balance at beginning of the year 	46 	33 	7 	7 	93
Increase in provision 	– 	– 	11 	8 	19
Amount utilised during the period 	(20) 	(17) 	(6) 	(6) 	(49)
Translation difference 	* 	* 	* 	* 	*
Balance at end of the year 	26 	16 	12 	9 	63
* Amount is less than R500 000.
14.2 	Reconciliation of expected credit losses (ECL)
Group
R million
General model 	Simplified model
Stage 1
(12-month
ECL)
Stage 2
(Lifetime
ECL)
Stage 3
(Lifetime
ECL/credit
impaired)
Not
Credit
impaired
90 days
past due/
credit
impaired 	Total
Year ended 30 June 2022
Balance at beginning of the year 	11 	8 	230 	98 	143 	490
Increase in provision 	1 	2 	2 	33 	39 	77
Amount utilised during the period 	(4) 	– 	(4) 	(26) 	(140) 	(174)
Translation difference 	* 	* 	* 	2 	1 	3
Balance at end of the year 	8 	10 	228 	107 	43 	396
Year ended 30 June 2021
Balance at beginning of the year 	48 	8 	249 	123 	57 	485
Increase in provision 	3 	– 	22 	8 	201 	234
Amount utilised during the period 	(40) 	– 	(41) 	(33) 	(101) 	(215)
Translation difference 	* 	* 	* 	* 	(14) 	(14)
Balance at end of the year 	11 	8 	230 	98 	143 	490
* Amount is less than R500 000.
15. 	REINSURANCE CONTRACTS
R million
Group
2022
Group
2021
Reinsurers’ share of insurance contract liabilities 	511 	445
Current 	511 	445
Amounts due from reinsurers in respect of claims paid and reported by the Group on the contracts that are reinsured are
included in Insurance receivables, contract receivables and other receivables (refer to note 14).

-- 112 of 219 --

112	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
16. 	CASH AND CASH EQUIVALENTS
R million
Group
2022
Group
2021
Cash at bank and in hand 	17 625 	17 984
Short-term deposits 	2 150 	2 029
19 775 	20 013
The fair value of cash and cash equivalents approximates the carrying amount due to the relatively short term nature of
the instrument.
17. 	SHARE CAPITAL AND SHARE PREMIUM
17.1 	Ordinary share capital and share premium
Issued 	Treasury shares
Group
R million
Share
capital
Share
premium
Discovery
Health
BEE
share trust 	LTIP
Total
outstanding
At 1 July 2020 	1 	10 214 	(14) 	(53) 	– 	10 148
Share movements:
– new issue 	– 	907 	– 	– 	– 	907
– treasury shares delivered 	– 	– 	– 	3 	– 	3
– treasury shares purchased 	– 	– 	– 	– 	(907) 	(907)
At 30 June 2021 	1 	11 121 	(14) 	(50) 	(907) 	10 151
Share movements:
– new issue 	– 	443 	– 	– 	– 	443
– treasury shares delivered 	– 	24 	– 	3 	– 	27
– treasury shares purchased 	– 	– 	– 	– 	(443) 	(443)
At 30 June 2022 	1 	11 588 	(14) 	(47) 	(1 350) 	10 178
Treasury shares
Number of shares 	Company
Discovery
Health
BEE
share trust 	LTIP
Total
outstanding
At 1 July 2020 	658 290 736 	(680 268) 	(966 460) 	– 	656 644 008
Share movements:
– new issue 	7 477 865 	– 	– 	– 	7 477 865
– treasury shares delivered 	– 	– 	160 499 	– 	160 499
– treasury shares purchased 	– 	– 	– 	(7 477 865) 	(7 477 865)
At 30 June 2021 	665 768 601 	(680 268) 	(805 961) 	(7 477 865) 	656 804 507
Share movements:
– new issue 	3 194 870 	– 	– 	– 	3 194 870
– treasury shares delivered 	– 	– 	152 104 	– 	152 104
– treasury shares purchased 	– 	– 	– 	(3 194 870) 	(3 194 870)
At 30 June 2022 	668 963 471 	(680 268) 	(653 857) (10 672 735) 	656 956 611
The total authorised number of ordinary shares is 1 billion (2021: 1 billion), with a par value of 0.1 cent per share.
SHARE ISSUE IN 2022 FINANCIAL REPORTING PERIOD
Discovery issued 3 194 870 shares for a cash consideration of R442 616 476. This was a specific issuance, to the Discovery Long-
Term Incentive Plan Trust.

-- 113 of 219 --

113	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
17. 	SHARE CAPITAL AND SHARE PREMIUM continued
17.2 	Preference share capital
R million
Group
2022
Group
2021
Authorised
40 000 000 A no par value preference shares 	– 	–
20 000 000 B preference shares of R100 each 	2 000 	2 000
20 000 000 C no par value preference shares 	– 	–
2 000 	2 000
Issued
8 000 000 B preference shares of R100 each 	800 	800
Share issue costs 	(21) 	(21)
At 30 June 	779 	779
The B preference shares are non-compulsory, non-cumulative, non-participating, non-convertible, voluntarily redeemable (at
option of Discovery) preference shares and were issued at a coupon rate of 85% of prime rate. With the introduction of dividend
withholding tax on 1 April 2012, the coupon rate on the preference shares was increased to 100% of the prime rate.
18. 	LIABILITIES ARISING FROM INSURANCE CONTRACTS
R million
Group
2022
Group
2021
Gross
– claims reported and loss adjustment expenses 	12 662 	11 234
– claims incurred but not reported 	2 118 	2 074
– IFA liability 	100 	82
– unearned premiums 	1 007 	1 091
– additional unexpired risk reserve 	– 	300
– unit-linked insurance contracts 	72 040 	64 432
– with fixed and guaranteed terms 	21 273 	21 764
Total liabilities arising from insurance contracts, gross 	109 200 	100 977
Recoverable from reinsurers
– claims incurred but not reported 	(501) 	(439)
– unearned premiums 	(10) 	(6)
Total reinsurers’ share of liabilities arising from insurance contracts (refer to note 15) 	(511) 	(445)
Net
– claims reported and loss adjustment expenses 	12 662 	11 234
– claims incurred but not reported 	1 617 	1 635
– IFA liability 	100 	82
– unearned premiums 	997 	1 085
– additional unexpired risk reserve 	– 	300
– unit-linked insurance contracts 	72 040 	64 432
– with fixed and guaranteed terms 	21 273 	21 764
Total liabilities arising from insurance contracts, net 	108 689 	100 532
Current 1 	92 917 	83 914
Non-current 	15 772 	16 618
108 689 	100 532
1 Includes R77 724 million (2021: R69 549 million) which is repayable to policyholders on demand. For contractual maturity refer to note 3.2.3.

-- 114 of 219 --

114	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
18. 	LIABILITIES ARISING FROM INSURANCE CONTRACTS continued
Movements in the liabilities are as follows:
Group
R million
2022 	2021
Gross 	Reinsurance 	Net 	Gross 	Reinsurance 	Net
Claims reported and loss
adjustment expenses and IBNR
Notified claims 	11 234 	– 	11 234 	9 290 	– 	9 290
Incurred but not reported 	2 074 	(439) 	1 635 	1 754 	(394) 	1 360
Balance at beginning of the year 	13 308 	(439) 	12 869 	11 044 	(394) 	650
Cash paid for claims settled in the year 	(13 601) 	73 	(13 528) 	(11 636) 	29 	(11 607)
Increase/(decrease) in liabilities:
– arising from current year claims 	16 545 	(183) 	16 362 	14 994 	(171) 	14 823
– arising from prior year claims 	(1 500) 	50 	(1 450) 	(908) 	79 	(829)
Translation differences 	28 	(2) 	26 	(186) 	18 	(168)
Balance at end of the year 	14 780 	(501) 	14 279 	13 308 	(439) 	12 869
Notified claims 	12 662 	– 	12 662 	11 234 	– 	11 234
Incurred but not reported 	2 118 	(501) 	1 617 	2 074 	(439) 	1 635
Balance at end of the year 	14 780 	(501) 	14 279 	13 308 	(439) 	12 869
IFA liability
Balance at beginning of the year 	82 	– 	82 	69 	– 	69
Increase in the year 	42 	– 	42 	28 	– 	28
Cash paid 	(24) 	– 	(24) 	(15) 	– 	(15)
Balance at end of the year 	100 	– 	100 	82 	– 	82
Provisions for unearned premiums
Balance at beginning of the year 	1 091 	(6) 	1 085 	1 548 	(6) 	1 542
Increase in the year 	1 625 	(10) 	1 615 	1 496 	(6) 	1 490
Release in the year 	(1 725) 	6 	(1 719) 	(1 857) 	6 	(1 851)
Translation differences 	16 	– 	16 	(96) 	– 	(96)
Balance at end of the year 	1 007 	(10) 	997 	1 091 	(6) 	1 085
Additional unexpired risk reserve
Balance at beginning of the year 	300 	– 	300 	– 	– 	–
(Decrease)/increase in the year 	(300) 	– 	(300) 	300 	– 	300
Translation differences 	– 	– 	– 	– 	– 	–
Balance at end of the year 	– 	– 	– 	300 	– 	300
R million
Group
2022
Group
2021
Unit-linked insurance contracts
Balance at beginning of the year 	64 432 	49 752
Premiums received 	17 726 	16 198
Fair value adjustment 	(608) 	8 338
Withdrawals 	(7 609) 	(7 747)
Fees 	(1 416) 	(1 234)
Movement in negative insurance liability 	(567) 	(223)
Translation differences 	82 	(652)
Balance at end of the year 	72 040 	64 432
Balance is made up as follows:
Unit-linked liabilities 	77 724 	69 549
Negative insurance liability 	(5 684) 	(5 117)
72 040 	64 432
With fixed and guaranteed terms
Balance at beginning of the year 	21 764 	19 998
Expected movement in policyholder liabilities 	(4 324) 	(4 201)
Unwinding of discount rate 	968 	888
New business written 	3 187 	4 396
Experience variances 	(322) 	683
Balance at end of the year 	21 273 	21 764

-- 115 of 219 --

115	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
19. 	LIABILITIES ARISING FROM REINSURANCE CONTRACTS
R million
Group
2022
Group
2021
Financial reinsurance 	2 582 	2 382
Reinsurance recoveries relating to assets arising from insurance contracts (refer to note 5) 	10 610 	10 143
13 192 	12 525
Balance at beginning of the year 	12 525 	12 465
Increase in liability 	577 	664
– gross increase in liability 	(458) 	(266)
– receipt arising from reinsurance contracts1 	2 597 	2 926
– reinsurance premiums paid 	(1 562) 	(1 996)
Translation differences 	90 	(604)
Balance at end of the year 	13 192 	12 525
Current 	2 131 	919
Non-current 	11 061 	11 606
13 192 	12 525
1 In the prior financial period, Discovery Life Limited entered into a financial reinsurance treaty, with risk transfer, resulting in a cash inflow of
R500 million.
The liabilities arising from reinsurance contracts releases with the associated underlying insurance contracts.
20. 	BORROWINGS AT AMORTISED COST
R million 	Ref
Group
2022
Group
2021
Borrowings from banks 	(i) 	16 308 	15 230
Lease liabilities 	(ii) 	4 120 	4 263
Bank overdraft 	156 	–
Balance at end of the year 	20 584 	19 493
Current 	3 940 	2 065
Non-current 	16 644 	17 428
Balance at end of the year 	20 584 	19 493
For variable rate loans, the carrying amount approximates the fair value because the variable rate is set on market related terms.
For fixed rate loans, the fair value is R6 122 million relative to the carrying value of R5 737 million.
(i) 	Borrowings from banks
MOVEMENT ANALYSIS OF BORROWINGS
R million
Group
2022
Group
2021
Balance at beginning of the year 	15 230 	15 456
Loans raised 	3 261 	1 839
Loans repaid 	(2 087) 	(1 753)
Interest accrued 	1 037 	971
Interest paid 	(1 188) 	(941)
Raising fees capitalised 	(3) 	(39)
Translation differences 	58 	(303)
Balance at end of the year 	16 308 	15 230

-- 116 of 219 --

116	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
20. 	BORROWINGS AT AMORTISED COST continued
(i) 	Borrowings from banks continued
SA BORROWING FACILITIES
DISCOVERY LIMITED
Carrying value
R million
Facility amount
R million 	Variable rate
Interest
per annum
Capital repayment
and maturity date
Group
2022
Group
2021
Listed DMTN4
500 	3-month Jibar + 161bps 	9.71% 1,3 At maturity – 21 November 2022 	503 	503
500 	3-month Jibar + 205bps 	6.30%1,3 At maturity – 21 August 2023 	503 	503
200 	– 	10.46%2 At maturity – 21 November 2024 	202 	202
800 	3-month Jibar + 191bps 	10.31%1,3 At maturity – 21 November 2024 	805 	804
1 200 	3-month Jibar + 191bps 	9.21%1,3 At maturity – 21 November 2024 	1 217 	1 220
700 	3-month Jibar + 180bps 	10.29%1,3 At maturity – 21 August 2026 	704 	703
300 	3-month Jibar + 180bps 	9.40%1,3 At maturity – 21 November 2026 	303 	302
792 	3-month Jibar +173bps 	– At maturity– 21 May 2027 	792 	–
226 	3-month Jibar +180bps 	– At maturity– 21 May 2029 	226 	–
Unlisted DMTN4,5
1 100 	– 	8.92%3 	At maturity – 10 March 2023 	1 104 	1 103
2 500 	– 	9.62%3 	At maturity – 22 February 2025 	2 520 	2 519
Other
1 000 	3-month Jibar + 245bps 	10.28%1,3 At maturity – 02 March 2023 	1 003 	999
500 	3-month Jibar + 86bps 	5.85%6 At maturity – 30 June 2022 	– 	659
1 400 	3-month Jibar + 125bps3 	– 	At maturity – 12 October 2022 	702 	–
11 718 	10 584 	9 517
1 The interest rate has been fixed through interest rate swaps.
2 Interest is payable semi-annually in arrears.
3 Interest payable quarterly in arrears.
4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017.
5 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank syndicated loans through the issue of unlisted DMTN
notes. The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market
on an ongoing basis..

-- 117 of 219 --

117	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
20. 	BORROWINGS AT AMORTISED COST continued
(i) 	Borrowings from banks continued
SA BORROWING FACILITIES
DISCOVERY CENTRAL SERVICES
Carrying value
R million
Facility amount
R million
Interest rate
per annum
Capital repayment and
maturity date
Group
2022
Group
2021
1 400 	10.60%1 	At maturity – 20 December 2023 	1 417 	1 423
650 	11.56%2 	Instalments – 29 October 2027 	494 	526
691 	3-month Jibar + 1.9% 	At maturity – 30 June 2027 	691 	–
1 500 	3-month Jibar + 1.45% 	At maturity – 8 June 2024 	– 	–
4 241 	2 602 	1 949
1 Interest payable quarterly in arrears.
2 Instalments of interest and capital is monthly.
UK BORROWING FACILITIES
UK BORROWINGS
Carrying value
GBP (Rand) million
Facility amount
GPB million 	Variable rate
Capital repayment
and maturity date
Group
2022
Group
2021
80 	SONIA + 2.73%1 	Instalments – 31 July 2023 	GBP 42 	(R847) GBP 73 (R1 435)
34 	SONIA + 1.31%1 	At maturity – 19 October 2022 	GBP 14 	(R276) GBP 26 	(R512)
100 	SONIA + 2.38%1 	At maturity – 31 July 2023 	GBP 100 (R1 999) GBP 89 (R1 817)
214 	GBP 156 (R3 122) GBP 188 (R3 764)
1 Interest payable quarterly in arrears.
(ii) 	Leases
R million
Group
2022
Group
2021
Balance at beginning of the year 	4 263 	4 380
New leases entered into 	138 	57
Interest payable 	426 	436
Repayments 	(600) 	(613)
Modifications 	(126) 	46
Translation difference 	19 	(43)
Balance at end of the year 	4 120 	4 263
Total payments for leases for the year is R825 million (2021: R815 million).
During the 2018 financial year Discovery took occupation of a new head office building under a finance lease. A lease liability and
related asset (refer to note 6) of R3 155 million was raised. At year end, R3 373 million (2021: R3 388 million) remained outstanding.
Finance charges of R366 million (2021: R366 million) have been recognised in profit or loss and repayments of R381 million
(2021: R348 million) have been made.

-- 118 of 219 --

118	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
21. 	INVESTMENT CONTRACTS AT FAIR VALUE THROUGH PROFIT OR LOSS
R million
Group
2022
Group
2021
The movements during the year were as follows:
Balance at beginning of the year 	32 291 	23 012
Deposits received 	11 769 	12 527
Account balances paid on withdrawal and other terminations in the year 	(6 739) 	(6 882)
Fair value adjustment 	40 	3 634
Balance at end of the year 	37 361 	32 291
Current1 	37 361 	32 291
1 There is no maturity profile for these liabilities as this will depend on policyholder behaviour. Contractually, policyholders may disinvest on
demand.
The benefits offered under the Group’s unit-linked investment contracts are based on the return of selected equities, debt securities
and money market securities. The Group communicates the actual performance of these contracts to its contract holders.
Investment contracts at fair value through profit or loss are exactly matched with related assets and managed collectively as a
pool. Discovery’s credit risk is not reflected in the measurement of the assets or consequently the liability, which is measured with
reference to the underlying assets. Own credit risk has been assessed and determined to be immaterial.
22. 	OTHER PAYABLES
R million
Group
2022
Group
2021
Commissions payable 	251 	213
Consolidated unit trust payables 	512 	659
Digicore payable 	– 	9
Due to reinsurers 	651 	448
Expired hedge payables 	6 	21
Intermediary payables 	130 	99
Payables and accrued liabilities 	3 672 	3 146
Payroll creditors 	987 	929
Policyholder unallocated funds 	1 180 	961
Security deposits on derivatives 	245 	2
Unsettled trades 	580 	376
VitalityLife working capital funding1 	5 477 	6 809
Other financial payables 	1 020 	880
Other non-financial payables2 	412 	352
– Value-added tax liability 	258 	193
– Premiums and fees received in advance 	154 	159
Balance at end of the year 	15 123 	14 904
Current 	14 827 	7 238
Non-current 	296 	7 666
15 123 	14 904
1 Includes the ‘deposit back’ of GBP 236 million (R4 780 million) (2021: GBP 315 million (R6 210 million)) related to the level premium reinsurance
treaty in respect of business written on Prudential Assurance Company’s (Prudential’s) life license, payable to the reinsurer.
2 Value-added tax liabilities and premiums received in advance are non-financial liabilities and have been excluded from the risk disclosures
presented in note 3.

-- 119 of 219 --

119	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
23. 	DEPOSITS FROM CUSTOMERS
R million
Group
2022
Group
2021
Term deposits from customers – fixed rate 	3 372 	3 763
Term deposits from customers – variable rates 	1 807 	3 798
On demand deposits from customers – non rate sensitive 	149 	–
On demand deposits from customers – variable rate 	5 249 	615
Wholesale NCD's (Negotiable Certificate of Deposit) – variable rate 	304 	809
Total customer deposits 	10 881 	8 985
24. 	DEFERRED TAX
R million
Group
2022
Group
2021
Deferred tax asset – non-current 	4 455 	3 948
Deferred tax liability – non-current 	(9 335) 	(8 814)
Total 	(4 880) 	(4 866)

-- 120 of 219 --

120	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
24. 	DEFERRED TAX continued
Deferred taxation comprises:
Charge for the year
Group
R million
Balance at
beginning of
the year
Recognised
in Profit or
loss
Recognised
in other
comprehensive
income
Recognised
in Equity
Translation
differences
Balance
at end of
the year
Year ended 30 June 2022
Assessed loss in Company Policyholder's Fund 	185 	(25) 	– 	– 	– 	160
Assessed loss in Individual Policyholder's Fund 	1 134 	(300) 	– 	– 	– 	834
Assessed loss in subsidiaries 	2 439 	158 	– 	– 	103 	2 700
Financial Instruments and share based payments 	169 	(181) 	(3) 	– 	– 	(15)
Deferred acquisition costs 	(227) 	19 	– 	– 	2 	(206)
Contract liability 	70 	10 	– 	– 	9 	89
Difference between wear and tear and depreciation and leases 	(276) 	(11) 	– 	– 	(12) 	(299)
Intangible asset recognised on acquisition of business 	(57) 	53 	– 	– 	2 	(2)
Prepayments 	(14) 	11 	– 	– 	(3)
Provisions 	340 	26 	– 	17 	3 	386
Difference between accounting and tax balances arising from insurance
contracts 	(8 929) 	449 	– 	– 	– 	(8 480)
Other 	300 	(141) 	– 	– 	(203) 	(44)
(4 866) 	68 	(3) 	17 	(96) 	(4 880)
Charge for the year
Group
R million
Balance at
beginning of
the year
Recognised
in Profit or
loss
Recognised
in OCI
Recognised
in business
combinations
Translation
differences
Balance
at end of
the year
Year ended 30 June 2021
Assessed loss in Company Policyholder's Fund 	203 	(18) 	– 	– 	– 	185
Assessed loss in Individual Policyholder's Fund 	854 	280 	– 	– 	– 	1 134
Assessed loss in subsidiaries 	2 373 	242 	– 	6 	(182) 	2 439
Financial instruments and share based payments 	96 	91 	(16) 	– 	(2) 	169
Deferred acquisition costs 	(166) 	(60) 	– 	– 	(1) 	(227)
Contract liability 	18 	64 	– 	– 	(12) 	70
Difference between wear and tear and depreciation and leases 	(171) 	(112) 	– 	– 	7 	(276)
Intangible asset recognised on acquisition of business 	(74) 	12 	– 	– 	5 	(57)
Prepayments 	(40) 	26 	– 	– 	– 	(14)
Provisions 	225 	119 	– 	– 	(4) 	340
Difference between accounting and tax balances arising from insurance
contracts 	(8 681) 	(248) 	– 	– 	– 	(8 929)
Other 	360 	(97) 	– 	– 	37 	300
(5 003) 	299 	(16) 	6 	(152) 	(4 866)

-- 121 of 219 --

121	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
24. 	DEFERRED TAX continued
Assessed losses
Discovery did not recognise deferred tax assets in respect of the following assessed losses:
R million
Group
2022
Group
2021
Better Health Insurance Advice Ltd 	37 	33
Cogence (Pty) Ltd 	2 	–
Discovery Central Services (Pty) Ltd 	4 062 	2 854
Discovery Group Europe Limited 	52 	46
Discovery Life – Individual Policyholder's Fund 	7 907 	7 992
Discovery Partner Markets Service PTE Ltd 	33 	46
Discovery Vitality Australia (Pty) Ltd 	47 	28
Grove Nursing Services (Pty) Ltd 	43 	39
Medical Services Organisation International (Pty) Ltd 	3 	–
Southern Rx (Pty) Ltd 	109 	93
Vitality Healty Workplace Ltd 	17 	16
12 312 	11 147
A deferred tax asset has been partly recognised on assessed losses in the Discovery Life Individual Policyholder Fund. Refer to
note 4.1.
The Group recognises deferred tax assets on carried forward losses to the extent that there are sufficient estimated future taxable
profits and/or taxable temporary differences against which the tax losses can be utilised.
25. 	EMPLOYEE BENEFITS
R million
Group
2022
Group
2021
Leave pay
Balance at beginning of the year 	315 	284
Additional provisions raised 	299 	312
Used during the year 	(262) 	(253)
Paid to terminated employees 	(32) 	(27)
Translation differences 	– 	(1)
Balance at end of the year 	320 	315
Current 	269 	262
Non-current 	51 	53
320 	315

-- 122 of 219 --

122	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
26. 	NET INSURANCE PREMIUM REVENUE
R million
Group
2022
Group
2021
Health 	9 744 	8 599
Recurring premiums 	11 299 	11 262
Reinsurance premiums 	(1 555) 	(1 840)
Accelerated reinsurance premiums1 	– 	(823)
Individual life and invest 	33 195 	32 364
Recurring premiums 	30 302 	28 023
Single premiums 	9 335 	10 016
Reinsurance premiums 	(6 442) 	(5 675)
Group life 	2 411 	2 062
Recurring premiums 	2 634 	2 249
Reinsurance premiums 	(223) 	(187)
Short-term insurance 	5 170 	4 358
Recurring premiums 	5 212 	4 385
Reinsurance premiums 	(42) 	(27)
50 520 	47 383
Insurance premium revenue 	58 782 	55 935
Outward reinsurance premiums 	(8 262) 	(7 729)
Accelerated reinsurance premiums 	– 	(823)
50 520 	47 383
1 Refer to note 42 Accelerated reinsurance premiums.
27. 	INVESTMENT INCOME
R million
Group
2022
Group
2021
At amortised cost interest income using the effective interest rate method 	17 	17
Cash and cash equivalents interest income using the effective interest rate method 	279 	263
296 	280
Attributable to:
– shareholders 	164 	141
– policyholders 	132 	139
296 	280

-- 123 of 219 --

123	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
28. 	NET FAIR VALUE (LOSSES)/GAINS ON FINANCIAL ASSETS AT FAIR
VALUE THROUGH PROFIT OR LOSS
R million
Group
2022
Group
2021
Investment income 	3 128 	2 535
– Interest 	2 528 	2 233
– Dividends 	600 	302
Mutual fund distributions 	1 371 	1 228
Hedge ineffectiveness 	– 	8
Net fair value (losses)/gains1 	(6 324) 	8 120
(1 825) 	11 891
1 The comparative period has been restated to combine the line items Net realised (losses)/gains and Net fair value (losses)/gains into a single line item.
29. 	NET CLAIMS AND POLICYHOLDERS’ BENEFITS
R million
Group
2022
Group
2021
Health insurance claims 	4 322 	3 991
Gross claims 	5 644 	5 315
Less: Reinsurance recoveries 	(1 322) 	(1 324)
Individual life insurance claims 	7 502 	6 380
Death 	6 499 	5 076
Disability 	4 484 	3 801
Payback benefits 	1 930 	1 588
Less: Recapture of reinsurance 	(89) 	–
Less: Reinsurance recoveries 	(5 322) 	(4 085)
Group life insurance claims 	2 594 	2 569
Death 	1 747 	1 606
Disability 	1 076 	1 262
Payback benefits 	10 	8
Less: Reinsurance recoveries 	(239) 	(307)
Individual investment benefits 	13 284 	12 913
Surrenders 	12 590 	12 232
Guaranteed payments 	65 	56
Annuity payments 	629 	625
Short-term insurance claims 	3 198 	2 325
Gross claims 	3 533 	2 403
Less: Reinsurance recoveries 	(335) 	(78)
30 900 	28 178
Claims and policyholders’ benefits 	38 207 	33 972
Insurance claims recovered from reinsurers 	(7 218) 	(5 794)
Recapture of reinsurance 	(89) 	–
Net claims and policyholders’ benefits 	30 900 	28 178
30. 	ACQUISITION COSTS
R million
Group
2022
Group
2021
Commission and other costs of obtaining contracts 	4 823 	5 032
Movement in deferred acquisition costs (refer to note 8) 	(49) 	1
4 774 	5 033

-- 124 of 219 --

124	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
31. 	MARKETING AND ADMINISTRATION EXPENSES
R million
Group
2022
Group
2021
Auditors remuneration
Audit fees 	113 	90
Fees for other services 	1 	2
Prior year 	(8) 	–
106 	92
Lease charges
Short-term leases 	69 	59
Low value item leases 	156 	143
225 	202
Staff costs including executive directors1
Salaries, wages and allowances2 	8 456 	7 516
Medical aid fund contributions 	482 	451
Defined contribution provident fund contributions 	401 	366
Social security levies 	304 	263
Share-based payment expenses
– equity-settled 	326 	330
– cash-settled 	93 	195
– loss/(gain) on cash flow hedge 	22 	(6)
Staff training 	69 	36
Recruitment fees 	51 	29
Temporary staff 	537 	382
Provision for leave pay 	37 	59
Other 	168 	114
10 946 	9 735
Other operating costs
Amortisation of software (note 7)3 	1 252 	1 200
Building related and office costs 	518 	508
Depreciation of property and equipment (note 6) 	650 	650
Loss on derecognition of property and equipment and intangible assets 	50 	51
Losses/(gains) on disposal of property and equipment 	3 	(3)
Gains on disposal of intangible assets 	(131) 	–
Impairment of property and equipment and intangible assets 	– 	61
Allowance for expected credit losses on receivables 	(79) 	(11)
Insurance 	51 	44
IT systems and consumables 	2 183 	2 123
Marketing and distribution costs 	1 743 	1 344
Non-executive directors fees 	37 	30
Professional fees 	895 	774
Vitality benefit expenses 	3 694 	3 259
Other operating expenses 	3 066 	2 620
13 932 	12 650
Total marketing and administration expenses 	25 209 	22 679
1 Executive directors’ and prescribed officers’ remuneration is included in employee costs. Refer to Directorate for detailed disclosure.
2 Included in salaries, wages and allowance, is an amount of R75 million related to the derecognition of Software development, resulting from the
IFRIC interpretation on capitalisation of costs associated with configuration or customisation costs in a cloud arrangement. Refer to note 7..
3 The transactions relating to business combinations are not included in marketing and administration expenses as it is disclosed separately in the
income statement.

-- 125 of 219 --

125	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
32. 	SHARE-BASED PAYMENTS AND LONG TERM INCENTIVES
Incentive schemes
Discovery operates various share-based payment and long term incentive arrangements. The details of these arrangements are
described below:
1. BEE STAFF SHARE TRUST
In 2005, 5 290 000 shares in Discovery Limited’s shares were issued to the BEE staff share trust for current and future
employees. These shares had all been allocated during prior years. Additional shares have been purchased in prior years, for
future allocation to employees. The trusts consist of two components; the allocation scheme and the option scheme as
described below.
Allocation scheme
Shares have been allocated to senior black employees based on level of seniority and length of past service. The shares vest
to employees two, three, four and five years after allocation at a rate of 25% per annum. On each vesting date, the trustees
shall distribute to the employees the allocated shares to which the employee may be entitled.
Option scheme
Options granted to black employees may be exercised two, three, four and five years after the option is granted at a rate of
25% per annum. Any options not exercised by the end of the fifth year from the grant date shall lapse. On exercise of the
option, the employee pays cash to the trust for the full purchase price of the option.
2. DISCOVERY’S PHANTOM SCHEME
Participants earn a cash bonus based on allocation of bonus scheme units which in turn are linked to the performance of the
Discovery Limited share price. The bonus is earned if the participant is employed on each vesting date. For units issued in
September, the vesting of the units is two, three, four and five years after allocation of the bonus units. The bonus may not
be carried forward.
The 2017 – 2018 allocations were pre-determined combinations of units that replicate the economics of a Discovery Limited
share and units that replicate the economics of a call option over a Discovery Limited share.
3. DISCOVERY’S LONG-TERM INCENTIVE PLAN (EQUITY SETTLED)
The Discovery Long-term incentive plan (LTIP) was introduced in the financial year ended 30 June 2020 and replaced the cash-
settled Discovery Phantom scheme (see point 2 above) with an equity-settled LTIP.
Participants will receive Discovery Limited shares subject to performance criteria and if the participant is employed on each
vesting date. The performance conditions are aligned to the organic growth methodology of the Group and will vest from
between the 3rd and 5th anniversary of these awards.
4. ACQUISITION SCHEMES
There are various schemes offered to franchise directors, agents and employees where participants are allocated share units
which replicate the economics of a Discovery Limited share. The share units are settled as a cash bonus on vesting. The
bonus is earned if the participant is employed on the vesting date. The vesting periods on the schemes vary from two to five
years. The bonus may not be carried forward.
5. DISCOVERY BANK SCHEME
Participants will receive Discovery Limited shares subject to the ‘Value Created’, which references the growth in the value of
Discovery Bank business after capital invested and interest. These awards vests from between the 3rd and 7th anniversary of
the market launch date of Discovery Bank, and each vesting is settled in three equal instalments over three years, if the
participant is employed on each vesting date.
OTHER LONG TERM INCENTIVE SCHEMES
The following schemes are long term staff incentives where the value is determined with reference to something other than the
Discovery Limited share price. These schemes are accounted for in terms of IAS 19: Employee benefits.
6. THE VITALITYHEALTH AND VITALITYLIFE PHANTOM SHARE SCHEME
Participants earn a cash bonus based on allocation of bonus scheme units which in turn are linked to the performance of
VitalityLife and VitalityHealth, and more specifically the Value of In Force (ViF) of VitalityLife and the Embedded Value (EV) of
VitalityHealth. The bonus is earned if the participant is employed on each vesting date. For units issued, the vesting of the
units is two, three and four years after allocation of the bonus units. The bonus may not be carried forward.

-- 126 of 219 --

126	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
32. 	SHARE-BASED PAYMENTS AND LONG TERM INCENTIVES continued
7. OTHER DEVELOPMENT SEGMENT SCHEMES
Various other long term incentive schemes exist in the Discovery Group in the development segments. These schemes are
individually and in aggregate immaterial and as a result no further information is disclosed.
The share/option schemes mentioned in bullet 1, 3 and 5 have been classified as equity-settled schemes and therefore a share-
based payment reserve has been recognised. The schemes mentioned in bullets 2 and 4 have been classified as cash-settled
schemes and a liability is raised in terms of IFRS 2. The other long term incentive schemes, have been accounted for in terms of
IAS 19.
The following is a summary of the terms and conditions of the units granted:
Date granted
Share/
Option
price
Final
vesting
date
Shares
under
option at
beginning
of year
Share/
Options
granted
during
year
Share/
Options
vested
during
year
Share/
Options
cancelled
or adjusted
during year
Shares
under
option
at end
of year
1. BEE staff share trust
01/07/2015 – 30/06/2016 	R0.00 	30/09/2021 	415 	– 	(415) 	– 	–
01/07/2016 – 30/06/2017 	R0.00 	31/03/2022 	31 351 	– 	(31 064) 	– 	287
01/07/2016 – 30/06/2017 	R113 	30/09/2021 	1 062 	– 	(1 062) 	– 	–
01/07/2016 – 30/06/2017 	R122.5 	30/09/2021 	72 556 	– 	(70 834) 	– 	1 722
01/07/2017 – 30/06/2018 	R0.00 	22/05/2023 	32 412 	– 	(16 952) 	(10 805) 	4 655
01/07/2018 – 30/06/2019 	R0.00 	30/04/2024 	17 520 	– 	(5 901) 	(5 665) 	5 954
01/07/2019 – 30/06/2020 	R0.00 	30/09/2025 	74 095 	– 	(25 824) 	(1 077) 	47 194
01/07/2020 – 30/06/2021 	R0.00 	31/03/2026 	29 935 	– 	(3 473) 	(4 866) 	21 596
01/07/2021 – 30/06/2022 	R0.00 	30/09/2027 	– 	131 344 	– 	(15 716) 	115 628
2. The Discovery Limited
phantom scheme
01/07/2016 – 30/06/2017 	R0.00 	30/09/2022 	498 544 	– 	(371 909) 	(67 738) 	58 897
01/07/2016 – 30/06/2017 	R115 	30/09/2022 	93 785 	– 	(93 524) 	(261) 	–
01/07/2017 – 30/06/2018 	R0.00 	30/09/2023 	1 100 973 	– 	(356 175) 	(103 980) 	640 818
01/07/2017 – 30/06/2018 	R141.65 	30/09/2023 	339 799 	– 	(169 264) 	(6 977) 	163 558
01/07/2018 – 30/06/2019 	R0.00 	31/03/2024 	1 369 206 	– 	(346 395) 	(135 495) 	887 316
3. Discovery LTIP
(equity settled)
01/07/2019 – 30/06/2020 	R0.00 	30/09/2024 	3 457 020 	– 	– 	(407 180) 	3 049 840
01/07/2020 – 30/06/2021 	R0.00 	30/09/2025 	3 870 645 	– 	– 	(214 500) 	3 656 145
01/07/2021 – 30/06/2022 	R0.00 	30/09/2025 	– 	3 478 348 	– 	(126 113) 	3 352 235
4. Acquisition schemes
01/07/2016 – 30/06/2017 	R0.00 	30/06/2022 	34 788 	– 	(31 511) 	(3 277) 	–
01/07/2017 – 30/06/2018 	R0.00 	30/06/2023 	64 955 	– 	(32 212) 	(7 840) 	24 903
01/07/2018 – 30/06/2019 	R0.00 	30/06/2024 	576 583 	– 	(494 905) 	(17 950) 	63 728
01/07/2019 – 30/06/2020 	R0.00 	30/06/2025 	742 543 	– 	(48 815) 	(35 660) 	658 068
01/07/2020 – 30/06/2021 	R0.00 	30/06/2026 	803 027 	– 	(7 734) 	(27 879) 	767 414
01/07/2021 – 30/06/2022 	R0.00 	30/06/2027 	– 	717 351 	– 	– 	717 351

-- 127 of 219 --

127	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
32. 	SHARE-BASED PAYMENTS AND LONG TERM INCENTIVES continued
The Black-Scholes model was used to calculate the fair value of the following options based on the assumptions in the below
table:
Spot price
Risk free
interest rate 	Exercise price 	Option term 	Volatility
Dividend
yield
Phantom scheme
01/07/2017 – 30/06/2018 	R128.10 	4.98% 	R141.65 	0.25 years 	29.1% 	0%
The VitalityHealth and VitalityLife phantom share scheme is cash settled and thus repriced at each reporting date. The value of
the shares and options allocated are dependent on the performance of VitalityLife and VitalityHealth, more specifically the ViF of
VitalityLife and the EV of VitalityHealth.
The Discovery Limited phantom scheme, and Acquisition schemes are cash-settled and are thus repriced at each reporting date.
The Discovery LTIP is equity-settled, and accordingly Discovery determines the grant date fair value at the date of allocating the
grant to the employee. The grant date fair value is then recognised over the vesting period. The significant assumptions in
determining the grant date fair value were as follows:
Spot price
Risk free
interest rate 	Volatility 1 	Vesting period 	Dividend yield
Discovery LTIP
01/07/2019 – 30/06/2020 	R113.81 	6.68% – 7.01% 	30.89% 	3 – 5 years 	2.21% – 2.52%
01/07/2020 – 30/06/2021 	R125.52 – R153.54 	3.9% – 5.02% 37.02% – 42.21% 	3 – 5 years 	2.26% – 2.57%
01/07/2021 – 30/06/2022 	R135.94 	5.76%-6.57% 	36.77% 	3 – 5 years 	2.29% – 2.46%
1 The expected volatility is based on both the historical average share price and implied volatility derived from traded options over the groups
ordinary shares of maturity similar to those of the employee share options.
33. 	FINANCE COSTS
R million
Group
2022
Group
2021
Interest expense on:
– Borrowings measured at amortised cost using the effective interest method 	1 037 	973
– Release from other comprehensive income 	– 	(8)
– Lease liabilities (IFRS 16) 	426 	436
– Interest on other payables using the effective interest method 	195 	247
1 658 	1 648
34. 	FOREIGN EXCHANGE GAINS/(LOSSES)
R million
Group
2022
Group
2021
Net foreign exchange gains/(losses) 	155 	(389)
The net foreign exchange gains and losses arised primarily from foreign denomintated loans, some of which are internal.
The total amount of foreign exchange gains/ (losses) recognised in profit or loss is a gain of R221 million (2021: R396 million
losses) presented with various lines associated with the underlying transaction.

-- 128 of 219 --

128	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
35. 	TAXATION
R million
Group
2022
Restated 1
Group
2021
Charge for the year:
Current taxation 	1 533 	1 274
Normal taxation
– prior year (over)/ under provision 	(22) 	–
– current year charge 	1 550 	1 236
Capital gains taxation 	5 	38
Deferred taxation 	(68) 	(299)
Total income tax expense recognised in profit or loss 	1 465 	975
% 	%
Taxation rate reconciliation
Statutory rate 	28.0 	28.0
Non-taxable income: Equity-accounted profit or loss and dividend income 	(2.7) 	(3.1)
Non-taxable income: Other individually immaterial 	(0.3) 	(1.4)
Non-deductible expenditure: Including items of a capital nature and non-deductible
provisions 	4.0 	4.5
Non-deductible expenditure: Other individually immaterial 	* 	*
Subsidiary current period losses for which no deferred tax asset was recognised, net of of
deferred tax assets on losses recognires for prior period losses 	3.1 	4.2
PAC arrangement 	(7.4) 	(5.3)
Insurance policyholder funds I-E taxes and related DTA recognitions 	2.0 	(1.7)
Accounting gains and losses taxable at CGT rates 	0.1 	1.3
CFC imputations and WHT not recovered 	0.7 	1.4
Additional tax allowances 	(0.3) 	(0.6)
Prior year under provision 	0.1 	0.9
Tax rate changes 	(4.6) 	(2.2)
Tax rate differences 	(1.6) 	(2.8)
Effective taxation rate 	21.1 	23.2
* Amount is less than 0.1%
1 As part of the enhancement in tax transparency reporting, Discovery has enhanced the reporting categories. The prior period has been restated to
align with the current year approach.
For South African entities that are in a tax paying position, tax has been provided at 28% (2021: 28%). Discovery uses the South
African tax rate in respect of its tax rate reconciliation as Discovery Limited (holding company listed on the JSE) is domiciled in
South African and the most significant operations are in South Africa. The South Africa’s National Treasury announced that the
corporate tax rate should reduce to 27% for tax years commencing ending on or after 31 March 2023. The rate is deemed
substantively enacted, and deferred tax has been appropriately adjusted.
Taxation in respect of the South African life insurance operations is determined in accordance with the rates and basis applicable
to section 29A of the Income Tax Act at the reporting date.

-- 129 of 219 --

129	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
36. 	EARNINGS PER SHARE
CHANGE IN PRESENTATION OF RECONCILIATION OF HEADLINE EARNINGS AND NORMALISED
HEADLINE EARNINGS
For the year ended 30 June 2022, the headline earnings and normalised headline earnings reconciliations have been amended to
enhance the presentation thereof. The presentation of prior periods have been restated accordingly to enable comparability.
R million
Group
2022
Group
2021
Earnings per share (cents):
– basic 	825.5 	480.7
– diluted 	817.8 	475.4
Headline earnings per share (cents):
– basic 	792.4 	454.7
– diluted 	785.0 	449.7
Normalised headline earnings per share (cents):
– basic 	885.5 	518.7
– diluted 	877.3 	512.9
Number of shares used in calculation
Weighted number of shares in issue ('000) 	656 901 	656 710
Diluted weighted number of shares ('000) 	663 082 	664 073
HEADLINE EARNINGS RECONCILIATION
Headline earnings per share is disclosed per the JSE Listing Requirements and is calculated in accordance with the circular titled
Headline Earnings issued by SAICA, as amended from time to time. Headline earnings per share is based on the net profit after
tax attributable to ordinary shareholders adjusted for items of a capital nature and the weighted average number of ordinary
shares in issue.
Group 2022 	Group 2021
R million 	Gross 	Tax 	Net 	Gross 	Tax 	Net
Profit attributable to the ordinary shareholders 	5 422 	3 157
Adjusted for:
– gain on disposal of intangible assets 	(131) 	29 	(102) 	– 	– 	–
– loss on derecognition of intangible assets 	37 	(5) 	32 	39 	(8) 	31
– loss on derecognition of property and equipment 	13 	(1) 	12 	11 	(2) 	9
– loss/ (gain) on disposal of property and
equipment 	3 	– 	3 	(3) 	1 	(2)
– impairment of intangible assets 	– 	– 	– 	44 	(3) 	41
– impairment of property and equipment 	– 	– 	– 	17 	(2) 	15
Adjustments attributable to equity-accounted
investments:
– gain on dilution and disposal of equity-accounted
investments 	(33) 	4 	(29) 	(554) 	140 	(414)
– (reversal of impairment)/impairment of equity-
accounted investments1 	(134) 	– 	(134) 	149 	– 	149
Headline earnings 	5 204 	2 986
1 Impairment reversal was supported by a firm offer to purchase the equity accounted investment.

-- 130 of 219 --

130	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
36. 	EARNINGS PER SHARE continued
EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS
NORMALISED HEADLINE EARNINGS RECONCILIATION
Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policy 28.
Group 2022 	Group 2021
R million 	Gross 	Tax 	Net 	Gross 	Tax 	Net
Headline earnings 	5 204 	2 986
Adjusted for:
– Economic assumption adjustments net of
discretionary margins and interest rate
derivatives 	84 	(74) 	10 	519 	(136) 	383
– 	gain on economic assumption adjustments
net of discretionary margins 	(169) 	(26) 	(195) 	(790) 	112 	(678)
– 	loss on fair value changes on VitalityLife
interest rate derivative 	253 	(48) 	205 	1309 	(248) 	1061
– Loss/(gain) on fair value changes in the time
value of swaption contract in VitalityLife 	454 	(87) 	367 	(139) 	248 	(113)
– other 	233 	2 	235 	407 	(257) 	150
– amortisation of intangible assets arising
from business combinations 	59 	(13) 	46 	66 	(13) 	53
– gain on disposal of intangible assets1 	131 	(29) 	102 	– 	– 	–
– recognition of deferred tax assets on
assessed losses not recognised in previous
periods 	– 	-14 	(14) 	– 	(152) 	(152)
– loss/ (gain) on fair value changes on foreogn
exchange contracts not designated as
hedges 	2 	(1) 	1 	304 	(85) 	219
– restructuring costs 	– 	– 	– 	33 	(6) 	27
– transaction costs related to the Vitality Life
interest rate derivative 	– 	– 	– 	4 	(1) 	3
– increase or decrease in deferred tax
balances resulting from use of different tax
rates on items that were excluded from
normalised headline earnings 	– 	59 	59 	– 	– 	–
– increase or decrease in deferred tax
balances resulting from use of different tax
rates on items that were excluded from
normalised headline earnings 	– 	59 	59 	– 	– 	–
Adjustments attributable to equity-accounted
investments:
– 	amortisation of intangible assets arising
from business combinations 	41 	– 	41 	– 	– 	–
Normalised headline earnings 	5 816 	3 406
* Amount is less than R500 000

-- 131 of 219 --

131	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
37. 	CASH FLOW INFORMATION
37.1 Cash generated by operations
R million
Group
2022
Group
2021
Cash generated by operations
Profit before taxation 	6 944 	4 195
Adjusted for:
Investment income 	(4 795) 	(4 043)
Realised loss/(gain) on financial assets 	3 574 	216
Finance costs 	1 658 	1 648
Premiums, claims and investment charges for liabilities under investment contracts 	5 030 	5 645
Non-cash items:
Allowance for expected credit losses 	(79) 	(11)
Amortisation of intangibles from business combinations 	59 	66
Amortisation of software 	1 252 	1 200
Assets arising from contracts with customers 	141 	131
Contract liabilities movement 	130 	22
Deferred acquisition costs 	(49) 	1
Derecognition and impairment of property and equipment 	12 	29
Derecognition and impairment of intangible assets 	170 	83
Depreciation 	650 	650
Fair value adjustment to liabilities under investment contracts 	40 	3 634
(Gain)/loss from derivatives 	(89) 	(136)
Gain on dilution and disposal of equity-accounted investments 	(33) 	(554)
Hedge ineffectiveness 	– 	8
(Reversal of impairment)/impairment of equity-accounted investment 	(134) 	149
Gain on disposal of intangible assets 	(131) 	–
Loss/(gain) on disposal of property and equipment 	3 	(3)
Provision for employee benefits 	37 	59
Share-based payment expenses – cash settled 	93 	330
Share-based payment expenses – equity settled 	326 	195
Share of profits from equity-accounted investments 	(422) 	(523)
Transfer to assets under insurance contracts 	(5 786) 	(545)
Transfer to assets under reinsurance contracts 	(63) 	(56)
Transfer to liabilities under insurance contracts 	6 935 	17 941
Transfer to liabilities under reinsurance contracts 	577 	(1 755)
Economic assumption differences net of discretionary margins 	(169) 	(790)
Translation differences 	(166) 	395
Unearned premiums 	(100) 	(360)
Unrealised losses/(gains) on investments at fair value through profit or loss 	2 860 	(8 336)
Working capital changes:
Deposits from customers 	1 897 	6 558
Loans and advances to customers 	(679) 	(1 513)
Loans and receivables including insurance receivables 	(2 361) 	(205)
Trade and other payables 	3 611 	2 132
Cash generated by operations 	20 943 	26 457

-- 132 of 219 --

132	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
37. 	CASH FLOW INFORMATION continued
37.2 	Taxation paid
R million
Group
2022
Group
2021
Balance at beginning of the year 	22 	(611)
Taxation charged for the year in the income statement 	(1 465) 	(975)
Adjustment for movement in deferred taxation 	(68) 	(299)
Reallocation to separately disclosable items 	20 	195
Translation differences 	3 	(5)
Balance at end of the year 	307 	(22)
Taxation paid 	(1 181) 	(1 717)
37.3 	Movement in borrowings
R million
Group
2022
Group
2021
Balance at beginning of the year excluding bank overdraft 	19 493 	19 836
Leased assets acquired and IFRS 16 transition 	138 	56
Increase in borrowings 	3 261 	1 839
Raising fees capitalised 	(3) 	(39)
Interest accrued on borrowings 	1 463 	1 407
Interest paid on borrowings 	(1 188) 	(941)
Repayment of borrowings 	(2 687) 	(2 366)
Modification to lease assets 	(126) 	46
Translation differences 	77 	(345)
Balance at end of the year excluding overdrafts with banks 	20 428 	19 493
38. 	COMMITMENTS
Capital commitments
R million
Group
2022
Group
2021
Capital expenditure approved but not contracted for at the reporting date as follows:
– Property and Equipment 	41 	–
– Intangible assets 	120 	140
– Developments costs for Discovery Bank 	394 	325
555 	464
Also refer to Capital section of Directors’ report.

-- 133 of 219 --

133	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
39. 	DIVIDENDS PER SHARE
39.1 	Dividends per ordinary share
Due to the uncertain and potentially volatile environment caused by the COVID-19 pandemic, Discovery did not pay out any
ordinary dividends for the year ended 30 June 2022.
39.2 	Dividends per preference share
The dividends paid in 2022 totalled R56 million and comprised a final dividend of 347.12329 (277.69863 net of withholding
tax) cents per share paid on 27 September 2021 and an interim dividend of 355.75342 (284.60274 net of withholding tax)
cents per share paid on 14 March 2022.
The dividends paid in 2021 totalled R63 million and comprised a final dividend of 433.21918 (346.57534 net of withholding
tax) cents per share paid on 28 September 2020 and an interim dividend of 354.52055 (283.61644 net of withholding tax)
cents per share paid on 15 March 2021.
40. 	CONTINGENCIES
The Group is not exposed to material contingencies at 30 June 2022.
41. 	RELATED PARTIES
41.1 	List of related parties as defined
SUBSIDIARIES
Details of subsidiaries directly and indirectly owned by Discovery Limited are contained in Company note 2. In addition, Annexure
A sets out all subsidiary and other investments held within Discovery Group.
ASSOCIATES AND JOINT VENTURES
Details of Discovery’s material associates and joint ventures are contained in note 11.
KEY MANAGEMENT PERSONNEL
Key management personnel have been defined as directors of Discovery Limited, Discovery Health Proprietary Limited and
Discovery Life Limited, as these businesses constitute the majority of the Discovery Group.
A list of the directors and prescribed officers of Discovery Limited can be found in the Directors’ report. Also refer to Annexure C
for Directorate remuneration.
To the extent specific transactions have occurred between Discovery and key management personnel, including close family
members of key management, (as defined in IAS 24 Related Party Disclosures) the details are included in the aggregate disclosure
contained below under key management and where significant, full details of all relationships and terms of the transactions are
provided.

-- 134 of 219 --

134	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
41. 	RELATED PARTIES continued
41.2 	Transactions with related parties
CAMBRIDGE MOBILE TELEMATICS INC. (CMT)
Discovery Insure paid fees monthly to CMT for the collation and interpretation of data and the translating of driving behavior into
scorable events. Fees paid for the year totaled R16 million (2021: R11 million).
KEY MANAGEMENT PERSONNEL OF DISCOVERY LIMITED, FAMILIES OF KEY MANAGEMENT (AS
DEFINED IN IAS 24) AND ENTITIES SIGNIFICANTLY INFLUENCED OR CONTROLLED BY KEY
MANAGEMENT
INSURANCE CONTRACTS
Aggregated insured cover 	Premiums received 	Claims paid
R’000 	2022 	2021 	2022 	2021 	2022 	2021
Life insurance 	1 098 794 	1 016 334 	8 419 	6 347 	– 	–
Short-term insurance 	882 273 	630 404 	3 327 	2 723 	1 300 	1 622
Short-term health insurance 	– 	– 	12 	79 	7 	27
INVESTMENT CONTRACTS
Investment values 	Premiums received 	Withdrawal benefits 	Investment returns
R’000 	2022 	2021 	2022 	2021 	2022 	2021 	2022 	2021
Investment contracts 	86 526 	116 523 	13 461 	56 328 	11 902 	19 216 	6 778 	6 522
VITALITY LOYALTY PROGRAMME
Premiums received 	Amounts paid
R’000 	2022 	2021 	2022 	2021
Vitality benefits 	272 	79 	4 460 	571
During the 2021 financial year, the DiscoveryCard benefits were migrated to Discovery Vitality. There are, therefore, no transaction
for 2022.
DISCOVERY BANK
Loans 	Savings 	Fees
R’000 	2022 	2021 	2022 	2021 	2022 	2021
Discovery Bank 	2 259 	1 345 	26 399 	32 141 	287 	244
During the 2021 financial year DiscoveryCard migrated to Discovery Bank.
Key management personnel, their families (as defined in IAS 24) and entities significantly influenced or controlled by key
management accrued 444 903 Discovery miles as part of the Vitality Reward Programme (previously DiscoveryCard loyalty
programme) for the year ended 30 June 2022 (2021: 149 388).
Aggregate shareholdings of key management personnel, their families (as defined in IAS 24) and entities significantly influenced
or controlled by key management, in Discovery Limited as at 30 June 2022 was 78 169 727ordinary shares (2021: 78 620 184
ordinary shares).
During the current financial year, the following transaction occurred between Discovery and key management personnel, their
families (as defined in IAS 24) and entities significantly influenced or controlled by key management:
❚ 	Sponsorship and enterprise development grants to the value of R0.7 million (2021: R1.9 million) were made to organisations
where members of key management personnel have significant influence.

-- 135 of 219 --

135	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
41. 	RELATED PARTIES continued
41.3 	Major customers and other Discovery entities not part of Discovery Group
DISCOVERY HEALTH MEDICAL SCHEME (DHMS)
Discovery Health administers DHMS and provides managed care services for which it charges an administration fee and a managed
healthcare fee respectively. These fees are determined on an annual basis and approved by the trustees of DHMS. The fees totaled
R6 804 million (2021: R6 403 million). Discovery offers the members of DHMS access to the Vitality programme. Discovery Health
also provides wellness services to DHMS. The fees received for these services totaled R28 million (2021: R12 million).
Discovery Third Party Recovery Services (DTPRS) paid DHMS R14.5 million (2021: R10 million) to purchase all the risks and rewards
of ownership to the claims due from the Road Accident Fund up to 14 January 2022 (2021: 15 January 2021). DTPRS also provides a
service to DHMS to recover all claims that are due from the Compensation for Occupational Injuries and Diseases. DTPRS received
R19.5 million (2021: R22 million) for this service. DTPRS owes DHMS R5.7 million (2021: R3 million) at year-end.
Discovery Vitality receives monthly contributions from DHMS members that have activated the Vitality Wellness programme through
various product integrations. The membership fees totaled R1 686 million for the year ended 30 June 2022 (2021: R1 660 million).
DHMS owes the Discovery Group R679 million (2021: R650 million) at year-end.
Discovery Central Services receives monthly rent from DHMS for office space at 1 Discovery Place which totalled R9 million for the
year ended 30 June 2022, (2021: R 7 million).
CLOSED SCHEMES
Discovery Health administers the following restricted membership medical schemes:
– Anglo Medical Scheme 	– Malcor Medical Scheme
– Anglovaal Group Medical Scheme 	– Multichoice Medical Aid Scheme (previously known as Naspers Medical Fund)
– Bankmed Medical Scheme 	– Netcare Medical Scheme
– BMW Employees Medical Aid Society 	– Remedi Medical Scheme
– Engen Medical Benefit Fund 	– Retail Medical Scheme
– Glencore Medical Scheme 	– SAB Medical Aid Scheme
– LA Health Medical Scheme 	– TFG Medical Scheme
– Libcare Medical Scheme 	– Tsogo Sun Group Medical Scheme
– Lonmin Medical Scheme 	– UKZN Medical Scheme
Discovery Health charges these schemes administration fees which are determined on an annual basis and approved by the
trustees of the respective closed schemes. The fees totaled R1 212 million (2021: R1 174 million).
DTPRS paid Bankmed R2 million (2021: R3 million) to purchase all the risks and rewards of ownership for the claims due from the
Road Accident Fund up to 31 December 2021 (2021: 20 October 2020). DTPRS also provides a service to Bankmed to recover all
claims that are due from the Compensation for Occupational Injuries and Diseases. DTPRS received R0.5 million (2021:
R0.4 million) for this service.
Discovery Vitality receives monthly contributions from the closed scheme members that have activated the Vitality Wellness
programme through various product integrations. The membership fees totaled R86 million (2021: R91 million). Amounts due to
the Discovery Group at year-end totaled R101 million (2021: R104 million).
DISCOVERY FRANCHISES
Discovery has established a network of 27 franchises in order to establish a national footprint for its products. Discovery has paid
R229 million (2021: R251 million) in fees to the franchises.
The franchises participate in the Acquisition Scheme (refer to note 31 for further details). During the year, R15 million (2021: R17
million) was accrued for in terms of this scheme.
THE DISCOVERY FOUNDATION
The Discovery Foundation, which is an independent shareholder of Discovery, received contributions of R3 million from
Discovery in the current year, no contributions or fees were received during the prior year.

-- 136 of 219 --

136	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
41. 	RELATED PARTIES continued
41.3 	Major customers & other Discovery entities not part of Discovery Group continued
THE DISCOVERY FUND
A fund for sustainable non-governmental healthcare projects, especially in primary healthcare. These projects complement the
delivery of primary and preventative care in the public sector and help to relieve the burden on state facilities.
The Discovery Fund received contributions from Discovery of R24 million during the year (2021: R24 million). Discovery also paid
a management fee of R2 million (2021: R4 million).
DISCOVERY RETIREMENT FUNDS
In February 2020 the Discovery Limited Board appointed the Discovery Retirement Funds comprising funds underwritten by
Discovery Life and registered as the Discovery Life Pension Umbrella Fund and the Discovery Life Provident Umbrella Fund, as
retirement fund provider to the Discovery Staff.
At 30 June 2021 the Discovery Staff Pension Fund and Discovery Staff Provident Fund, the two standalone Funds previously
providing retirement benefits to Discovery Staff, were in the process of moving their members’ assets across to the Discovery
Retirement Funds (Umbrella Pension and Provident Funds underwritten and administered by Discovery Life) through a Section
14 transfer. At that stage assets of the Discovery Staff Pension Fund amounting to R1 787 million were transferred across to the
Discovery Retirement Funds. The movement of the assets of the Discovery Staff Provident Fund amounting to R1 773 million was
transferred in October 2021. The Boards of the Discovery Staff Pension and Provident Funds have now resolved to close these
Funds and this process is now underway.
Contributions to the Discovery Retirement Funds by Discovery Staff during the year amounted to R520 million (2021: R497
million). The Discovery Retirement Funds have R4 334 million of assets under administration on behalf of Discovery Staff, R4 159
million is invested in unit linked insurance policies with Discovery Life (2021: R2 288 million). R3 732 million (2021: R1 969 million)
of the unit linked insurance policies are in turn linked to unit trusts managed by Discovery Life Collective Investments.
42. 	ACCELERATED REINSURANCE PREMIUMS – VITALITYHEALTH
VitalityHealth uses quota share reinsurance treaties as one of the mechanisms to manage initial acquisition cost strain and
underwriting experience risk. During the prior financial year, VitalityHealth modified certain of its existing quota share reinsurance
treaties to adjust the repayment profile thereof. The modification resulted in VitalityHealth making additional repayments of GBP
39.7 million (R823 million) in the prior financial year, with GBP19.8 million of reduced repayments in the financial year ended 30
June 2022 and 2023 respectively. The net impact in profit or loss over the three-year period to 30 June 2023, is nil.
43. 	DIVIDENDS PAID DURING THE CURRENT AND PRIOR FINANCIAL YEAR
B preference shares
Payment date 	Nature and financial period 	Dividend declared per share
14 March 2022 	Interim dividend Financial year 2022 	355.75342
(284.60274 cents net of dividend withholding tax)
27 September 2021 	Final dividend Financial year 2021 	347.12329 cents
(277.69863 cents net of dividend withholding tax)
15 March 2021 	Interim dividend Financial year 2021 	354.52055 cents
(283.61644 cents net of dividend withholding tax)
Ordinary shares
While the Group’s capital position remains robust, in light of the uncertain future impact of COVID-19 and the volatile global
macro-economic environment, the Discovery Board has decided to retain its prior stated position and has decided not to declare
an ordinary final dividend for the year ended 30 June 2022. The reintroduction of an ordinary dividend will be considered on an
ongoing basis.

-- 137 of 219 --

137	Discovery Annual Financial Statements 2022
NOTES TO THE GROUP ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
44. 	EVENTS AFTER REPORTING DATE
B preference share cash dividend declaration
On 1 September 2022, the directors declared a final gross cash preference share dividend of 382.26027 cents (305.80822 cents
net of dividend withholding tax) per B preference share for the period 1 January 2022 to 30 June 2022, payable from the income
reserves of the Company. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt.
The issued preference share capital at the declaration date is 8 million B preference shares.
The salient dates for the dividend will be as follows
Last day of trade to receive a dividend 	Tuesday, 20 September 2022
Shares commence trading “ex” dividend 	Wednesday, 21 September 2022
Record date 	Friday, 23 September 2022
Payment date 	Monday, 26 September 2022
B Preference share certificates may not be dematerialised or rematerialised between Wednesday, 21 September 2022 and Friday,
23 September 2022, both days inclusive.
Ordinary share cash dividend declaration:
While the Group’s capital position remains robust, in light of the uncertain future impact of COVID-19 and the volatile global
macro-economic environment, the Discovery Board has decided to retain its prior stated position and has decided not to declare
an ordinary final dividend for the year ended 30 June 2022. The reintroduction of an ordinary dividend will be considered on an
ongoing basis.
Competition Commission investigation
As reported in the media, the Competition Commission launched a search and seizure exercise at multiple life insurance company
premises on 25 August 2022. The purpose of this was to collect information as part of an investigation covering Sanlam, Old
Mutual, Hollard, Bidvest Life (FMI), BrightRock, Momentum, the Professional Provident Society, Liberty, and Discovery. While
Discovery is yet to receive detailed insight into the Competition Commission’s complaint, the investigation appears to be in
respect of alleged price fixing in the life insurance industry, including group risk cover and retirement fund investments.
The process will evolve, but upfront it is important that Discovery states it’s position on this matter:
❚ 	Discovery is an organisation built on purpose and values, and it places the utmost importance on our compliance with the
laws and regulations that govern it.
❚ 	Discovery is a fiercely competitive organisation - Discovery innovates and disrupt markets in which it operate, striving to offer
its customers products that are more efficient, better value for money and more sustainable. The strength of its competitive
force is evidenced by the scale of market share Discovery has taken across every market it has entered.
❚ 	Discovery does not collude with competitors, and never will.
❚ 	Discovery strongly respect and support the country’s regulatory bodies, and Discovery will comply fully with the Commission’s
requests and processes.

-- 138 of 219 --

DISCOVERY
COMPANY ANNUAL
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE
2022

-- 139 of 219 --

R million 	Notes
Company
2022
Company
2021
Assets
Deferred tax asset 	13 	82 	113
Investments in subsidiaries 	2 	29 027 	27 458
Investment in associate 	3 	2 584 	1 097
Financial assets
– Loans to subsidiaries 	5 	8 397 	8 758
– Loans to BEE partners 	6 	186 	149
– Other receivables 	7 	185 	112
– Derivatives at fair value through profit or loss 	4 	18 	27
Cash and cash equivalents 	20.5 	607 	93
Total assets 	41 086 	37 807
Equity
Capital and reserves
Ordinary share capital and share premium 	8.1 	10 293 	10 281
Perpetual preference share capital 	8.2 	779 	779
Other reserves 	1 129 	510
Retained earnings 	8 003 	7 926
Total equity 	20 204 	19 496
Liabilities
Financial liabilities
– Borrowings at amortised cost 	9 	10 584 	8 858
– Financial guarantee contracts 	21 	25 	27
– Trade and other payables 	11 	10 216 	8 147
– Loans from subsidiaries 	12 	– 	853
– Derivatives at fair value through profit or loss 	10 	56 	426
Current tax liability 	1 	*
Total liabilities 	20 882 	18 311
Total liabilities and equity 	41 086 	37 807
* Amount is less than R500 000.
COMPANY STATEMENT OF FINANCIAL POSITION
at 30 June 2022
139	Discovery Annual Financial Statements 2022

-- 140 of 219 --

R million 	Notes
Company
2022
Company
2021
Investment income1 	14 	1 049 	3 845
At amortised cost interest income, using the effective interest rate 	688 	574
Dividends received from subsidiaries and equity-acccounted investments 	361 	3 271
Other income 	15 	57 	61
Net fair value losses on financial instruments at fair value through
profit or loss 	16 	(2) 	(307)
Marketing and administration expenses 	17 	(19) 	(14)
Movement in allowance for expected credit losses 	18 	* 	18
Profit from operations 	1 085 	3 603
Finance costs 	(937) 	(867)
Foreign exchange gains/(losses) 	16 	(169)
Profit before tax 	164 	2 567
Taxation 	19 	(31) 	112
Profit for the year 	133 	2 679
Attributable to:
– ordinary shareholders 	77 	2 616
– preference shareholders 	56 	63
133 	2 679
* Amount is less than R500 000.
1 During the current period, in line with the requirements of IAS 1, interest income using the effective interest rate method has been disclosed separately on the
face of the Income Statement. Investment income has therefore been disaggregated with Dividend income and Interest income calculated using the effective
interest rate method now disclosed separately. The comparative numbers have been restated accordingly.
R million
Company
2022
Company
2021
Profit for the year 	133 	2 679
Items that are or may be reclassified subsequently to profit or loss:
Cash flow hedges 	295 	182
– unrealised gains 	295 	189
– gains reclassified to profit or loss 	– 	(7)
Other comprehensive income for the year, net of tax 	295 	182
Total comprehensive income for the year 	428 	2 861
Attributable to:
– ordinary shareholders 	372 	2 798
– preference shareholders 	56 	63
428 	2 861
COMPANY INCOME STATEMENT
for the year ended 30 June 2022
COMPANY STATEMENT OF OTHER COMPREHENSIVE INCOME
for the year ended 30 June 2022
140	Discovery Annual Financial Statements 2022

-- 141 of 219 --

R million 	Notes
Company
2022
Company
2021
Cash flow from operating activities 	492 	1 029
Cash generated/(utilised) by operations 	20.1 	1 067 	(1 420)
Dividends received 	237 	3 271
Interest received 	102 	96
Interest paid 	(914) 	(829)
Taxation paid 	20.2 	* 	(89)
Cash flow from investing activities 	(2 078) 	(1 569)
Increase investment in subsidiary 	20.3 	(1 559) 	(884)
Increase investment in associate 	(1 487) 	(106)
Increase in loans granted to subsidiaries 	5 	(1 789) 	(2 274)
Proceeds from settlement of subsidiary loans 	5 	2 757 	1 695
Cash flow from financing activities 	2 106 	445
Proceeds from treasury shares 	9 	10
Proceeds from issuance of ordinary shares 	443 	–
Proceeds from long-term borrowings 	20.4 	2 410 	498
Repayment of long-term borrowings 	20.4 	(700) 	–
Dividends paid to preference shareholders 	(56) 	(63)
Net increase/(decrease) in cash and cash equivalents 	520 	(95)
Cash and cash equivalents at beginning of the year 	93 	188
Exchange losses on cash and cash equivalents 	(6) 	–
Cash and cash equivalents at end of the year 	20.5 	607 	93
* Amount is less than R500 000
COMPANY STATEMENT OF CASH FLOWS
for the year ended 30 June 2022
141	Discovery Annual Financial Statements 2022

-- 142 of 219 --

Company
R million
Share
capital
and share
premium
Preference
share
capital
Hedging
reserve
Share-
based
payment
reserve
Retained
earnings 	Total
Year ended 30 June 2021
At beginning of the year 	10 331 	779 	(516) 	520 	5 085 	16 199
Total comprehensive income for the year 	– 	63 	182 	– 	2 616 	2 861
Profit for the year 	– 	63 	– 	– 	2 616 	2 679
Other comprehensive income 	– 	– 	182 	– 	– 	182
Transactions with owners 	(50) 	(63) 	– 	324 	225 	436
Issue of shares 	907 	– 	– 	– 	– 	907
Increase in treasury shares 	(957) 	– 	– 	(5) 	67 	(895)
Gain on common control transaction 	– 	– 	– 	– 	158 	158
Employee share option schemes:
– Value of employee services 	– 	– 	– 	329 	– 	329
Dividends paid to preference shareholders 	– 	(63) 	– 	– 	– 	(63)
Balance at 30 June 2021 	10 281 	779 	(334) 	844 	7 926 	19 496
Year ended 30 June 2022
At beginning of the year 	10 281 	779 	(334) 	844 	7 926 	19 496
Total comprehensive income for the year 	– 	56 	295 	– 	77 	428
Profit for the year 	– 	56 	– 	– 	77 	133
Other comprehensive income 	– 	– 	295 	– 	– 	295
Transactions with owners 	12 	(56) 	– 	324 	– 	280
Issue of shares 	443 	– 	– 	– 	– 	443
Increase in treasury shares 	(443) 	– 	– 	– 	– 	(443)
Delivery of treasury shares 	3 	– 	– 	(3) 	– 	–
Proceeds from treasury shares 	9 	– 	– 	– 	– 	9
Employee share option schemes:
– Value of employee services 	– 	– 	– 	327 	– 	327
Dividends paid to preference shareholders 	– 	(56) 	– 	– 	– 	(56)
Balance at 30 June 2022 	10 293 	779 	(39) 	1 168 	8 003 	20 204
COMPANY STATEMENT OF CHANGES IN EQUITY
for the year ended 30 June 2022
142	Discovery Annual Financial Statements 2022

-- 143 of 219 --

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The principal accounting policies applied in the preparation of these separate financial statements are consistent with those set out in
Annexure B. In addition to those policies, the following policies apply specifically to these separate financial statements.
1. 	Investment in subsidiaries and associates
The company is directly and indirectly the holding company of subsidiaries and investments as set out in Annexure A. Investments
in subsidiaries and associates are accounted for at cost less impairment. Cost is adjusted to reflect changes in consideration
arising from contingent consideration amendments. Cost also includes directly attributable cost of the investment.
Discovery assesses at each reporting date whether there is objective evidence that the investment in subsidiaries and associates
are impaired. If such evidence of impairment exists, Discovery calculates the amount of impairment as the difference between
the recoverable amount of the investment and its carrying value.
1.1 	COMMON CONTROL TRANSACTIONS
Common control transactions refer to business combinations in which all the combining entities or businesses are ultimately
controlled by the same party (or parties) before and after the combination. This includes businesses which are associates and
joint ventures. Discovery Limited applies book value accounting to account for common control transactions. Discovery Limited
will dispose of its investment at the carrying amount. Any difference between the consideration received and the carrying amount
of the investment disposed of is recognised as an equity transaction with shareholders in equity. No gain or loss is recognised in
profit or loss on disposal.
2. 	Financial guarantee contracts
The Company accounts for financial guarantee contracts (FGCs) in accordance with IFRS 9 Financial Instruments (IFRS 9). The
Company issues FGCs to assist in securing funding for its subsidiaries.
FGCs are contracts which require the Company, as the issuer of the contract, to make specified payments to reimburse the holder
for a loss that the holder incurs because the specified debtor fails to make payment when it is due under the original or modified
terms of the debt instrument.
The Company measures the FGC:
❚ 	Initially at fair value; and
❚ 	Subsequently at the higher of:
– The amount of expected credit losses determined under IFRS 9 (calculation 1); and
– The amount initially recognised less, when appropriate, the cumulative amount of income recognised under the principles
of IFRS 15 Revenue from Contracts with Customers (calculation 2).
2.1 	INITIAL RECOGNITION
In instances where the Company issues FGCs for the debt of a related entity in the Discovery Group, the Company determines
the fair value. These FGCs are seen as transactions in a capacity as shareholder and are treated as capital contributions.
In some instances, the other Discovery Group entity can also pay a premium to the issuer of the FGCs. The Company then
determines if the price represents the fair value, or whether there is still an additional cost of the FGC that the Company should
recognise.
In the instance where the Company does not receive all the premiums upfront, it recognises the FGC using a net approach. The
net approach requires that the Company presents the financial guarantee as its fair value less all future premiums.
COMPANY ACCOUNTING POLICIES
for the year ended 30 June 2022
143	Discovery Annual Financial Statements 2022

-- 144 of 219 --

COMPANY ACCOUNTING POLICIES continued
for the year ended 30 June 2022
2. 	Financial guarantee contracts continued
2.2 	SUBSEQUENT MEASUREMENT
The Company recognises financial guarantee fee income as follows:
❚ 	Amortises the fair value recognised on initial recognition over the period that the FGC is outstanding, being generally the
period of the underlying debt;
❚ 	Recognises any premiums received for issuing the FGC as financial guarantee fee income; and
❚ 	Where the Company has applied the net approach, the Company adjusts for the premiums subsequently received to ensure
it takes into account all premiums in using calculation 2.
The Company calculates the lifetime expected credit losses for purposes of calculation 1.
Where the outcome is such that calculation 1 is more than calculation 2, differences are recognised and presented as part of
expected credit losses.
Where the outcome is such that calculation 2 is more than calculation 1, no adjustments are required. Any previously recognised
expected credit losses can be reversed, but limited to the total value previously recognised.
2.3 	DERECOGNITION
The Company derecognises FGCs when the FGC is extinguished, expires or the underlying debt is extinguished.
At the date of derecognition:
❚ 	Where the FGC is extinguished in exchange for a new FGC to the same holder and in respect of the same guaranteed entity,
the FGC derecognised is seen as compensation for the new FGC; or
❚ 	In all other instances, the FGC is derecognised with an associated gain or loss in profit or loss.
3. 	Share based payments
Also refer to Accounting Policies 17 'Employee benefits' set out in Annexure B and Group note 32 'Share-based payments and
long-term incentives'.
Two of the schemes that Discovery operates, namely the BEE staff share trust and Discovery long-term incentive plan (equity
settled), are both equity-settled share-based payment arrangements in accordance with the requirements of IFRS 2 Share-based
Payment. In these schemes, Discovery Limited grants the awards to the employees within the Discovery Group of entities.
Discovery classifies the share-based payment transaction according to whether the entity has the obligation to settle. As it is
Discovery Limited’s shares being awarded to employees, Discovery classifies the transaction as equity-settled.
Under IFRS, Discovery does not consider any repayment or recharge arrangements in determining the classification of these
group share-based payment. Any recharge payments Discovery receives from its subsidiaries is treated as a return on capital
from the subsidiary. Any excess of recharge above the carrying amount of investment in subsidiary is recognised immediately as
dividend income.
Discovery manages two share trusts. Discovery treats the share trusts set up to facilitate the share-based payment arrangements
as an agent, i.e., an extension of Discovery. In other words, shares held by the trust is treated as treasury shares of Discovery
Limited.
❚ 	BEE Staff Share Trust: Shares and option to acquire shares have been allocated to senior black employees based on level of
seniority and length of past service. The trust will hold shares until the date of vesting of the shares to the employee or
exercise date of the option.
❚ 	Discovery LTIP Trust: Participants will receive Discovery Limited shares subject to performance criteria and if the participant
is employed on each vesting date. The trust will hold shares until the date of vesting of the shares to the employee. Per the
LTIP Trust deed, the LTIP Trust recharges the costs of the shares acquired for the employees to the relevant subsidiary whose
employees are awarded the shares. The recharge is upfront.
144	Discovery Annual Financial Statements 2022

-- 145 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS
for the year ended 30 June 2022
1. 	MANAGEMENT OF FINANCIAL RISK
The Company’s activities expose it to a variety of financial risks. Financial risks include market risk, credit risk and liquidity risk.
Refer to Group Note 3 ”Management of financial risk” for a detailed explanation of financial risks and how they are managed.
1.1 	Interest rate risk
Sensitivity to changes in interest rates is relevant to financial assets or liabilities bearing floating interest rates due to the risk that
future cash flows fluctuate. However, sensitivity will also be relevant to fixed-rated financial assets and financial liabilities that are
re-measured to fair value.
The table below details the specific interest rate risk that the Company is exposed to:
Company
R million
Carrying
amount 	Fixed 	Floating
Non-interest
bearing
At 30 June 2022
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	1 	– 	– 	1
– Used as cash flow hedges1 	17 	17 	– 	–
Loan to subsidiaries 	8 397 	2 216 	6 181 	–
Loans to BEE partners 	186 	– 	184 	2
Other receivables 	176 	– 	– 	176
Cash and cash equivalents 	607 	– 	607 	–
Total financial assets 	9 384 	2 233 	6 972 	179
Borrowings at amortised cost 	10 584 	3 826 	6 758 	–
Derivative financial instruments at fair value:
– Used as cash flow hedges1 	56 	56 	– 	–
Financial guarantee contracts 	25 	– 	– 	25
Trade and other payables 	10 216 	– 	– 	10 216
Total financial liabilities 	20 881 	3 882 	6 758 	10 241
At 30 June 2021
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	22 	– 	– 	22
– Used as cash flow hedges1 	5 	5 	– 	–
Loan to subsidiaries 	8 758 	2 001 	6 428 	329
Loans to BEE partners 	149 	– 	149 	–
Other receivables 	112 	– 	– 	112
Cash and cash equivalents 	93 	7 	86 	–
Total financial assets 	9 139 	2 013 	6 663 	463
Borrowings at amortised cost 	8 858 	3 824 	5 034 	–
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	94 	– 	– 	94
– Used as cash flow hedges 	332 	332 	– 	–
Financial guarantee contracts 	27 	– 	– 	27
Trade and other payables 	8 147 	– 	– 	8 147
Loans from subsidiaries 	853 	– 	723 	130
Total financial liabilities 	18 311 	4 156 	5 757 	8 398
1 For further information on the use of interest rate swaps to manage the interest rate risk of Discovery Limited, refer to the following notes in the
Group financials, which equally apply to Discovery Limited:
– Note 3.4 Shareholder financial assets and liabilities, "Borrowings at amortised cost and related hedges", page 72 – 73.
For those finanical assets at amortised cost, a change of 1% in the interest rate would result in an increase/decrease of R69 million
(2021: R19 million) in interest income and R56 million (2021: R58 million) in finance costs. The sensitivity is based on the
assumption that the interest rate has increased/decreased by 1% with all other variables held constant.
145	Discovery Annual Financial Statements 2022

-- 146 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
1. 	MANAGEMENT OF FINANCIAL RISK continued
1.2 	Currency risk
The Company operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily
with respect to the US dollar and the UK pound. Foreign exchange risk arises from future commercial transactions and recognised
assets and liabilities.
The following table segregates the currency exposure by major currency:
Company
R million 	Total 	Rand 	GBP 	USD
At 30 June 2022
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	1 	1 	– 	–
– Used as cash flow hedges 	17 	17 	– 	–
Loans to subsidiaries 	8 397 	6 621 	1 776 	–
Loans to BEE partners 	186 	186 	– 	–
Other receivables 	176 	143 	33 	–
Cash and cash equivalents 	607 	526 	59 	22
Total financial assets 	9 384 	7 494 	1 868 	22
Borrowings at amortised cost 	10 584 	10 584 	– 	–
Derivative financial instruments at fair value:
– Used as cash flow hedges 	56 	56 	– 	–
Financial guarantee contracts 	25 	17 	8 	–
Other payables 	10 216 	10 216 	* 	–
Total financial liabilities 	20 881 	20 873 	8 	–
At 30 June 2021
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	22 	22 	– 	–
– Used as cash flow hedges 	5 	5 	– 	–
Loans to subsidiaries 	8 758 	7 020 	1 738 	–
Loans to BEE partners 	149 	149 	– 	–
Other receivables 	112 	66 	46 	–
Cash and cash equivalents 	93 	22 	52 	19
Total financial assets 	9 139 	7 284 	1 836 	19
Borrowings at amortised cost 	8 858 	8 858 	– 	–
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	94 	94 	– 	–
– Used as cash flow hedges 	332 	332 	– 	–
Financial guarantee contracts 	27 	19 	8 	–
Other payables 	8 147 	8 147 	– 	–
Loans from subsidiaries 	853 	853 	– 	–
Total financial liabilities 	18 311 	18 303 	8 	–
* Amount is less than R500 000.
A 10% increase or decrease in the respective foreign exchange rates of GBP: ZAR would result in additional gains of R186 million
(2021: R196 million), or in the case of decrease, a loss of R186 million (2021:R196 million, recognised in profit or loss.
1.3 	Credit risk
Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge
an obligation. The credit risk associated with Cash and cash equivalents is managed by monitoring exposure to external financial
institutions against limits set by the CCIC.
146	Discovery Annual Financial Statements 2022

-- 147 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
1. 	MANAGEMENT OF FINANCIAL RISK continued
1.3 	Credit risk continued
CREDIT EXPOSURE FOR DEBT INSTRUMENTS, MONEY MARKET INSTRUMENTS AND CASH AND CASH
EQUIVALENTS
The following table provides information regarding the credit risk exposure categorised by Moody’s credit ratings. These assets
are all in stage 1 for purposes of determining expected credit losses.
Company
R million 	Total 	Aaa 	Aa1-3 	A1-3 	Baa1-3 	Ba1-3
Internally
rated/
assessed
At 30 June 2022
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	1 	– 	– 	– 	– 	1 	–
– Used as cash flow hedges 	17 	– 	– 	– 	– 	17 	–
Loans to subsidiaries 	8 397 	– 	– 	– 	– 	– 	8 397
Loans to BEE partners 	186 	– 	– 	– 	– 	– 	186
Other receivables 	176 	– 	– 	– 	– 	– 	176
Cash and cash equivalents 	607 	– 	– 	– 	– 	607 	–
9 384 	– 	– 	– 	– 	625 	8 759
At 30 June 2021
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	22 	– 	– 	– 	– 	22 	–
– Used as cash flow hedges 	5 	– 	– 	– 	– 	5 	–
Loans to subsidiaries 	8 758 	– 	– 	– 	– 	– 	8 758
Loans to BEE partners 	149 	– 	– 	– 	– 	– 	149
Other receivables 	110 	– 	– 	– 	– 	– 	110
Cash and cash equivalents 	93 	3 	6 	1 	– 	83 	–
9 137 	3 	6 	1 	– 	110 	9 017
Long-term credit ratings were used in the above credit risk analysis.
Discovery Limited has issued financial guarantees as security of loans incurred by subsidiaries in the group. The maximum
credit risk that Discovery Limited is exposed to on these contracts is the carrying amount, which amounted to R6 917 million
(2021: R6 522 million). For majority of the issued financial guarantees, Discovery Limited is co-guarantor with Discovery Health
(Pty) Ltd and Discovery Vitality (Pty) Ltd.
Loans to subsidiaries and financial guarantees do not have external credit ratings. Credit ratings are internally assigned to
subsidiaries and the financial guarantees relative to the Discovery Group ratings. Loans to BEE partners are not assigned formal
credit ratings externally or internally. These loans are structured considering creditworthiness of the individual partners, and the
purpose of the BEE relationship. These loans are managed and monitored on an individual basis, and ECL is accordingly
recognised on an individual basis using management’s best estimate.
1.4 	Liquidity risk
Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities due to
insufficient cash available to meet commitments as and when due.
Liquidity is managed through the Group Treasury Management function, which considers the liquidity position at the respective
Company level as well as the overall Group position. As part of this assessment, the liquidity position in each entity is optimised
and takes account of available credit facilities to the Group within the Board approved maximum financial leverage ratio. The
Company is in the process of refinancing short term borrowings as part of its ongoing debt capital management activities. The
group structure is conducive for the Company to receive dividends and other forms of funding from underlying subsidiaries to
enable it to meet its short-term obligations.
Cash flow forecasting is performed by the Company and liquidity requirements are monitored to ensure it has sufficient cash to
meet operational needs. Such forecasting takes into consideration the Company’s debt financing plans and covenant compliance.
Cash held by the Company is invested in interest-bearing accounts, term deposits and money market deposits with appropriate
maturities or sufficient liquidity to provide headroom as determined by the above-mentioned forecasts. At the reporting date,
the Company had money market funds and cash and cash equivalents of R607 million (2021: R93 million).
147	Discovery Annual Financial Statements 2022

-- 148 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
1. 	MANAGEMENT OF FINANCIAL RISK continued
1.4 	Liquidity risk continued
The table below analyses Discovery Limited’s financial liabilities into relevant maturity groupings based on the remaining period
at the reporting date to the contractual maturity date. These amounts do not agree to the Statement of financial position as these
are the undiscounted contractual payments.
Company
R million 	Total 	<1 year
1 – 2
years
3 – 5
years
6 – 10
years
At 30 June 2022
Borrowings 	12 416 	4 013 	1 036 	7 110 	257
Derivative financial instruments:
– used as cash flow hedges 	311 	117 	90 	104 	–
Trade and other payables 	10 216 	10 216 	– 	– 	–
22 943 	14 346 	1 126 	7 214 	257
Financial guarantees 	6 917 	6 917 	– 	– 	–
29 860 	21 263 	1 126 	7 214 	257
At 30 June 2021
Borrowings 	10 842 	643 	3 186 	5 995 	1 018
Derivative financial instruments:
– used as cash flow hedges 	635 	193 	171 	260 	11
– not designated as hedging instruments 	94 	94 	– 	– 	–
Trade and other payables 	8 147 	8 147 	– 	– 	–
Loans from subsidiaries:
– interest free loans 	130 	– 	– 	130 	–
– interest-bearing loans 	766 	766 	– 	– 	–
20 614 	9 843 	3 357 	6 385 	1 029
Financial guarantees 	6 522 	6 522 	– 	– 	–
27 136 	16 365 	3 357 	6 385 	1 029
1.5 	Fair value estimation
Discovery Limited’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy
has three levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical
financial instruments. An active market is a market in which transactions for the asset or liability take place with sufficient
frequency and volume to provide information on an ongoing basis. Quoted prices are readily and regularly available from an
exchange, dealer, broker, industry group, pricing service or regulatory agency and those prices represent actual and regularly
occurring market transactions on an arm’s length basis.
Level 2: includes financial instruments that are valued using techniques based significantly on observable market data.
Instruments in this category are valued using:
(a) Quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or
(b) Valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on
observable market data.
Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than
observable market data and where at least one input (which could have a significant effect on instrument’s valuation) cannot be
based on observable market data.
148	Discovery Annual Financial Statements 2022

-- 149 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
1. 	MANAGEMENT OF FINANCIAL RISK continued
1.5 	Fair value estimation continued
Company
R million 	Total 	Level 1 	Level 2 	Level 3
At 30 June 2022
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	1 	– 	1 	–
– Used as cash flow hedges 	17 	– 	17 	–
Total financial assets 	18 	– 	18 	–
Derivative financial instruments at fair value:
– Used as cash flow hedges 	56 	– 	56 	–
Total financial liabilities 	56 	– 	56 	–
At 30 June 2021
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	22 	– 	22 	–
– Used as cash flow hedges 	5 	– 	5 	–
Total financial assets 	27 	– 	27 	–
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	94 	– 	94 	–
– Used as cash flow hedges 	332 	– 	332 	–
Total financial liabilities 	426 	– 	426 	–
2. 	INVESTMENTS IN SUBSIDIARIES
Issued ordinary
capital
R million
Effective
percentage holding
%
Investment
in subsidiaries3
R million
2022 	2021 	2022 	2021 	2022 	2021
Cogence 	* 	– 	100 	100 	* 	–
Discovery Bank Holdings Company 	8 771 	7 689 	100 	100 	8 996 	7 896
Discovery Connect Distribution Services 	555 	555 	100 	100 	551 	554
Discovery Central Services 	* 	* 	100 	100 	34 	42
Discovery Finance Company Europe Limited1 	393 	393 	100 	100 	394 	394
Discovery Group Europe Limited 1 	14 080 	13 802 	100 	100 	14 063 	13 790
Discovery Health 	271 	271 	100 	100 	216 	243
Discovery Insure 	2 402 	2 402 	100 	100 	1 442 	1 463
Discovery Life 	1 416 	1 416 	100 	100 	1 486 	1 510
Discovery Life Collective Investments 	15 	15 	100 	100 	15 	15
Discovery Life Investment Services 	203 	3 	100 	100 	203 	3
Discovery Mauritius Asset Management 	1 	1 	100 	100 	1 	1
Discovery Vitality 	* 	* 	100 	100 	– 	–
Discovery Partner Markets Asia
Private Limited2 	211 	211 	100 	100 	113 	113
Vitality Group International Inc4 	3 319 	3 319 	100 	100 	1 513 	1 434
Balance at the end of the year 	29 027 	27 458
* Amount is less than R500 000.
1 Incorporated in England and Wales.
2 Incorporated in Singapore.
3 Investments in subsidiaries include cost less impairments plus the value of share options issued to subsidiary staff.
4 Incorporated in the United States of America.
Refer to Company note 20.3 for a detailed movement analysis.
149	Discovery Annual Financial Statements 2022

-- 150 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
3. 	INVESTMENT IN ASSOCIATE
R million
% ownership interest 	Company
2022
Company
2021	2022 	2021
Investment at cost:
– Ping An Health Insurance Company in China, Limited 	25% 	25% 	2 584 	1097
Refer to Group note 11 for disclosure of the investment in associate.
4. 	DERIVATIVES AT FAIR VALUE THROUGH PROFIT OR LOSS
R million
Company
2022
Company
2021
Interest rate swap – used as cash flow hedge 	17 	5
Derivatives not designated as hedging instrument 	1 	22
Total 	18 	27
Current 	1 	22
Non-current 	17 	5
Total 	18 	27
Refer to the Group note 3.4.1 for a detailed description of the derivative financial instruments listed above.
5. 	LOANS TO SUBSIDIARIES1
R million
Company
2022
Company
2021
Balance at beginning of the year 	8 758 	7 856
Additional loan granted 	1 789 	2 274
Repayment of loans
– capital portion 	(2 757) 	(1 695)
– interest portion 	(93) 	–
Interest receivable 	676 	475
Movement in allowance for expected credit losses 	1 	–
Exchange differences 	23 	(152)
Balance at end of the year 	8 397 	8 758
Discovery Group Europe Ltd 	2 265 	2 200
Discovery Health (Pty) Ltd 	3 408 	3 120
Discovery Central Services (Pty) Ltd 	2 724 	3 109
Discovery Life Investment Services (Pty) Ltd 	– 	329
Balance at end of the year 	8 397 	8 758
Current 	3 214 	3 109
Non-current 	5 183 	5 649
8 397 	8 758
1 All loans to subsidiaries are measured at amortised cost, which approximates to fair value, as the loans bear interest at market related terms.
150	Discovery Annual Financial Statements 2022

-- 151 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
5. 	LOANS TO SUBSIDIARIES continued
GBP denominated
Discovery Limited has granted GBP denominated loans to subsidiaries, the terms are as follows:
Carrying value
GBP/ Rand million
Subsidiary
the loan was
granted to
Original
loan
value
GBP
million 	Variable rate
Capital repayment
and maturity date
Company 2022 	Company 2021
Rand 	GBP 	Rand 	GBP
DGEL 	11.9
3-month Libor +
400bps
At maturity –
31 July 2025 	319 	16.0 	301 	15.3
DGEL 	24.7
3-month Libor +
600bps
At maturity –
1 April 2027 	491 	24.6 	485 	24.6
DGEL 	6.0
3-month Libor +
600bps
At maturity –
1 November 2027 	120 	6.0 	118 	6.0
DGEL 	10.5
3-month Libor +
600bps
At maturity –
1 June 2028 	209 	10.5 	207 	10.5
DGEL 	9.0
3-month Libor +
600bps
At maturity –
21 August 2028 	179 	9.0 	177 	9.0
DGEL 	6.5
3-month Libor +
600bps
At maturity –
24 November 2028 	130 	6.5 	128 	6.5
DGEL 	2.8
Bank of England base
rate + 615bps
At maturity –
1 March 2029 	56 	2.8 	55 	2.8
DGEL 	7.1
Bank of England base
rate + 615bps
At maturity –
1 June 2029 	142 	7.1 	140 	7.1
DGEL 	6.5
Bank of England base
rate + 615bps
At maturity –
31 July 2029 	130 	6.5 	128 	6.5
1 776 	89.0 	1 739 	88.3
DGEL – Discovery Group Europe Limited
ZAR denominated
Discovery Limited has granted ZAR denominated loans to subsidiaries, the terms are as follows:
Carrying value
Rand million
Subsidiary the loan was
granted to
Original
loan
value
GBP
million 	Variable rate
Capital repayment and
maturity date
Company
2022
Company
2021
Discovery Group Europe
Limited 	268 	3-month Jibar + 200bps 	At maturity – 11 November 2022 	489 	461
Discovery Health1 	727 	3-month Jibar + 240bps 	At maturity – 30 June 2026 	1 192 	1 119
Discovery Health1 	92 	At maturity – 9 September 2027 	167 	151
Discovery Health1 	282 	At maturity – 9 September 2027 	507 	458
Discovery Health1 	235 	At maturity – 15 December 2027 	413 	373
Discovery Health1 	173 	At maturity – 28 March 2027 	296 	267
Discovery Health1 	288 	At maturity – 30 June 2027 	480 	433
Discovery Health1 	212 	At maturity – 3 July 2027 	353 	319
Discovery Central Services 	2 932 	South African prime
lending rate
On demand 	2 724 	3 109
Discovery Life Investment
Services
330 	On demand 	– 	329
6 621 	7 019
1 Interest payable quarterly in arrears, with the option available for Discovery Health to capitalise the interest to the value of the loan.
For the loans to Discovery Group Europe Limited, interest of R136 million was earned in respect of these loans in the current financial
year (2021: R130 million) and R23 million foreign exchange gains was recognised in profit and loss (2021: R152 million gain).
151	Discovery Annual Financial Statements 2022

-- 152 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
6. 	LOANS TO BEE PARTNERS 1
R million
Company
2022
Company
2021
Balance at the beginning of the year 	149 	116
Interest receivable 	9 	4
Additional loan granted 	35 	48
Repayment of loans 	(7) 	(19)
Balance at the end of the year 	186 	149
Current 	186 	149
Balance at the end of the year 	186 	149
1 All loans to BEE partners are measured at amortised cost, which approximates to fair value.
R186 million (2021: R148 million) is a bridge loan due from Mohau Equity Partners. The loan accrues interest at prime rate less
2% and there is no fixed term to this loan.
Financial assistance was provided to Discovery's BEE Partners in April 2015 to assist them in following their rights in terms of the
Discovery Limited's rights issue. Interest accrued at a rate of prime less 0.5%. The outstanding balance of R1 million was fully
repaid in the current financial year.
7. 	OTHER RECEIVABLES
R million
Company
2022
Company
2021
Intercompany receivables 	176 	110
Prepayments 	9 	2
Balance at the end of the year 	185 	112
Intercompany receivables include:
Congence 	4 	–
Discovery Bank 	29 	–
Discovery Connect Distribution Services 	6 	–
Discovery Finance Company Europe 	14 	39
Discovery Group Europe 	3 	–
Discovery Holdings Europe 	19 	7
Discovery Insure 	43 	64
Discovery Vitality 	58 	–
Balance at the end of the year 	176 	110
8. 	SHARE CAPITAL AND SHARE PREMIUM
8.1 	Ordinary share capital and share premium
Issued 	Treasury Shares
R million
Share
capital
Share
premium
BEE
Share
Trust
Long-term
incentive plan
Total
Outstanding
Issued
At 1 July 2020 	1 	10 331 	(54) 	– 	10 278
Share movements:
– shares issued 	* 	906 	– 	– 	906
– treasury shares delivered 	– 	– 	3 	– 	3
– Ttreasury shares purchased 	– 	– 	– 	(906) 	(906)
At 30 June 2021 	1 	11 237 	(51) 	(906) 	10 281
Share movements:
– shares issued 	* 	443 	– 	– 	443
– treasury shares delivered 	– 	8 	4 	– 	12
– treasury shares purchased 	– 	– 	– 	(443) 	(443)
At 30 June 2022 	1 	11 688 	(47) 	(1 349) 	10 293
* Amount is less than R500 000.
152	Discovery Annual Financial Statements 2022

-- 153 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
8. 	SHARE CAPITAL AND SHARE PREMIUM continued
8.1 	Ordinary share capital and share premium continued
Treasury Shares
R million 	Company
BEE
Share
Trust
Long-term
incentive plan
Total
Outstanding
Issued
At 1 July 2020 	658 290 736 	(966 460) 	– 	657 324 276
Share movements:
– shares issued 	7 477 865 	– 	– 	7 477 865
– treasury shares delivered 	– 	160 499 	– 	160 499
– Ttreasury shares purchased 	– 	– 	(7 477 865) 	(7 477 865)
At 30 June 2021 	665 768 601 	(805 961) 	(7 477 865) 	657 484 775
Share movements:
– shares issued 	3 194 870 	– 	– 	3 194 870
– treasury shares delivered 	– 	152 104 	– 	152 104
– treasury shares purchased 	– 	– 	(3 194 870) 	(3 194 870)
At 30 June 2022 	668 963 471 	(653 857) 	(10 672 735) 	657 636 879
The total authorised number of ordinary shares is 1 billion (2020: 1 billion), with a par value of 0.1 cent per share.
8.2 	Preference share capital
R million
Company
2022
Company
2021
Authorised
40 000 000 A no par value preference shares 	– 	–
20 000 000 B preference shares of R100 each 	2 000 	2 000
20 000 000 C no par value preference shares 	– 	–
2 000 	2 000
Issued
8 000 000 B preference shares of R100 each 	800 	800
Share issue costs 	(21) 	(21)
At 30 June 2022 	779 	779
The preference shares are non-compulsory, non-cumulative, non-participating, non-convertible, voluntarily redeemable (at
option of Discovery Limited) preference shares and were issued at a coupon rate of 85% of prime rate. With the introduction of
dividend withholding tax on 1 April 2012, the coupon rate on the preference shares was increased to 100% of the prime rate.
9. 	BORROWINGS AT AMORTISED COST
R million
Company
2022
Company
2021
Borrowings from banks1 	10 584 	8 858
Current 	3 312 	54
Non-current 	7 272 	8 804
Balance at the end of the year 	10 584 	8 858
1 Collateral in the form of financial guarantees by Discovery Health, Discovery Vitality and Discovery Central Services has been given to secure these
borrowings.
The borrowings were acquired for general corporate purposes in order to fund the various growth initiatives within the Group.
CREDIT RATING
In April 2022 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s Global scale long-term issuer rating of Ba3 and
the national scale long- term issuer rating at A1.za. The outlook changed to stable from negative, aligned to the outlook of the
country.
153	Discovery Annual Financial Statements 2022

-- 154 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
9. 	BORROWINGS AT AMORTISED COST continued Carrying value
R million
Facility amount
R million 	Variable rate
Interest
per annum
Capital repayment and
maturity date
Company
2022
Company
2021
Listed DMTN4,6
500 	3-month Jibar + 161bps 	9.71%1,3 At maturity – 21 November 2022 	503 	503
500 	3-month Jibar + 205bps 	6.30%1,3 	At maturity – 21 August 2023 	503 	503
200 	– 	10.46%2 	At maturity – 21 November 2024 	202 	202
800 	3-month Jibar + 191bps 	10.31%1,3 At maturity – 21 November 2024 	805 	804
1 200 	3-month Jibar + 191bps 	9.21%1,3 At maturity – 21 November 2024 	1 217 	1 220
700 	3-month Jibar + 180bps 	10.29%1,3 	At maturity – 21 August 2026 	704 	703
300 	3-month Jibar + 180bps 	9.40%1,3 At maturity – 21 November 2026 	303 	302
792 	3-month Jibar + 173bps 	At maturity – 21 May 2027 	792 	–
226 	3-month Jibar + 180bps 	At maturity – 21 May 2029 	226 	–
Unlisted DMTN4,5
1 100 	– 	8.92%3 	At maturity – 10 March 2023 	1 104 	1 103
2 500 	– 	9.62%3 	At maturity – 22 February 2025 	2 520 	2 519
Other
1 400 	3-month Jibar + 125bps 	At maturity – 12 October 2022 	702 	–
1 000 	3-month Jibar + 245bps 	10.28%1,3 At maturity – 2 March 2023 	1 003 	999
11 218 	10 584 	8 858
1 The interest rate has been fixed through interest rate swaps.
2 Interest is payable semi-annually in arrears.
3 Interest payable quarterly in arrears.
4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017.
5 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank syndicated loans through the issue of unlisted DMTN
notes. The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market
on an ongoing basis.
The borrowings are unsecured senior debt and are not callable or convertible. Interest is payable quarterly in arrears other than
footnote 2 in the table above. Refer to company note 20.4 for movement analysis and Group Note 20.
10. 	DERIVATIVES AT FAIR VALUE THROUGH PROFIT OR LOSS
R million
Company
2022
Company
2021
Interest rate swap – used as cash flow hedges1 	56 	332
Derivatives not designated as hedging instruments 	– 	94
Balance at the end of the year 	56 	426
Current 	21 	94
Non-current 	35 	332
Balance at the end of the year 	56 	426
1 For further information, refer to Group Note 13, which sets out information on the 'Interest Rate Swaps' which equally apply to the Company.
154	Discovery Annual Financial Statements 2022

-- 155 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
11. 	TRADE AND OTHER PAYABLES
R million
Company
2022
Company
2021
Accrued expenditure 	11 	10
Dividends due to shareholders 	10 	9
Intercompany payables 	10 195 	8 128
10 216 	8 147
Intercompany payables include:
– Discovery Health (Pty) Ltd 	i 	5 430 	3 078
– Discovery Life Limited 	ii 	4 765 	4 839
– Discovery Vitality (Pty) Ltd 	– 	211
10 195 	8 128
i. 	Discovery Limited receives funds from Discovery Health (Pty) Ltd through a loan account, based on operational requirements.
The loan is interest free and is settled as and when sufficient cash becomes available.
ii. 	Discovery Limited received funds from Discovery Life Limited in 2020 to assist with operational requirements. The loan is
interest-free and is settled as and when sufficient cash becomes available.
The amortised cost of the trade and other payables approximate the fair value due to the short-term nature of these payables.
12. 	LOANS FROM SUBSIDIARIES
R million
Company
2022
Company
2021
Discovery Life Limited 	– 	853
– 	853
13. 	DEFERRED TAX ASSET
R million
Company
2022
Company
2021
Deferred tax asset – non-current 	82 	113
Movement summary:
Balance at beginning of the year 	113 	(1)
Income statement charge 	(31) 	112
Increase in treasury shares 	– 	2
Balance at end of the year 	82 	113
Deferred taxation comprises:
Assessed losses 	67 	106
Section 6 quat credits 	15 	6
Unrealised gains on financial instruments 	(1) 	(1)
Realised capital losses 	1 	2
82 	113
* Amount is less than R500 000.
155	Discovery Annual Financial Statements 2022

-- 156 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
14. 	INVESTMENT INCOME1
R million
Company
2022
Company
2021
At amortised cost interest income, using the effective interest rate 	688 	574
Dividends received from subsidiaries and equity-accounted investments 	361 	3 271
1 049 	3 845
Dividends received from subsidiaries and equity-accounted investments:
– AIA Vitality (Hong Kong) 	– 	34
– Discovery Central Services 	117 	–
– Discovery Health 	– 	3 000
– Discovery Insure 	30 	–
– Discovery Life Collective Investments 	– 	200
– Discovery Mauritius Asset Management 	7 	–
– Discovery Partner Markets Services 	– 	16
– Discovery Vitality 	207 	21
361 	3 271
1 Investment income for Discovery Limited is seen as Revenue.
15. 	OTHER INCOME
R million
Company
2022
Company
2021
Guarantee fees 	i 	53 	54
Amortisation of financial guarantee contract 	ii 	3 	7
Other income 	1 	–
57 	61
i. Discovery Limited issued guarantees in respect of Discovery Finance Company Europe Limited and Discovery Holdings Europe
Limited obligations. A guarantee fee is charged by Discovery Limited to Discovery Finance Company Europe Limited of
R25 million and Discovery Holdings Europe Limited of R28 million.
ii. Amortisation of initial financial guarantee contracts over the term of the loan. Refer to Company note 21 for a list of all the
guarantees that Discovery Limited has issued.
16. 	NET FAIR VALUE LOSSES ON FINANCIAL INSTRUMENTS AT FAIR VALUE
THROUGH PROFIT OR LOSS
R million
Company
2022
Company
2021
Fair value losses on non-hedge derivatives 	2 	307
2 	307
17. 	MARKETING AND ADMINISTRATION EXPENSES
R million
Company
2022
Company
2021
Marketing and administration expenses comprises:
– Audit fees 	6 	7
– Professional fees 	11 	4
– Other 	2 	3
19 	14
156	Discovery Annual Financial Statements 2022

-- 157 of 219 --

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
18. 	MOVEMENT IN ALLOWANCE FOR EXPECTED CREDIT LOSSES1
R million
Company
2022
Company
2021
Financial guarantee contracts:
– Discovery Bank 	* 	*
– Discovery Central Services 	* 	25
– Discovery Finance Company Europe 	* 	(7)
* 	18
* Amount is less than R500 000.
1 In determining the expected credit loss, Discovery assigned risk ratings to subsidiaries relative to Discovery Limited where a Moody’s rating was not
available. All these loans are high quality.
12 month
credit losses
Lifetime
credit losses 	Total
30 June 2022
Balance at beginning of the year 	16 	– 	16
Increase in allowance 	* 	– 	*
Balance at end of the year 	16 	– 	16
30 June 2021
Balance at beginning of the year 	34 	– 	34
Increase in allowance 	(18) 	– 	(18)
Balance at end of the year 	16 	– 	16
* Amount is less than R500 000.
19. 	TAXATION
R million
Company
2022
Company
2021
Charge for the year:
Current taxation 	* 	–
Normal taxation
– prior year under/ (over) provision 	* 	–
– current year charge 	* 	–
Deferred taxation 	(31) 	112
– prior year under/(over) provision 	* 	–
– current year charge 	(31) 	112
Total income tax (expense)/credit recognised in profit or loss 	(31) 	112
* Amount is less than R500 000.
% 	%
Taxation rate reconciliation
Effective taxation rate 	18.8 	4.4
Capital profits and dividend income 	61.0 	(35.7)
Exempt income 	– 	(0.1)
Disallowed expenditure: Capital in nature 	(44.1) 	3.1
Prior year under provision 	0.5 	–
Taxable Income: International tax adjustments 	(6.5) 	0.3
Change in tax rate 	(1.5) 	–
Difference in tax rate 	(0.2) 	–
Standard rate of taxation 	28.0 	(28.0)
Tax has been provided at 28% (2021: 28%) for Company Income Tax and at 40% (2021: 40%) for the respective Trust Tax. The
Company uses the South African tax rate in respect of its tax rate reconciliation as Discovery Limited (holding company listed on
the JSE) is domiciled in South African and the most significant operations are in South Africa. On 23 February 2022, the Minister
of Finance announced that the Corporate Income Tax rate would reduce from 28% to 27% with effect from years of assessment
ending on or after 31 March 2023. These rates are substantively enacted.
157	Discovery Annual Financial Statements 2022

-- 158 of 219 --

20. 	CASH FLOW INFORMATION
20.1 	Cash generated/(utilised) by operations
R million
Company
2022
Company
2021
Profit before taxation 	164 	2 567
Adjusted for:
Interest received 	(688) 	(574)
Dividends received 	(361) 	(3 271)
Finance costs 	937 	867
Non-cash items:
Movement in expected credit losses 	* 	(18)
Amortisation of financial guarantee contracts 	(3) 	(7)
Fair value (gains)/losses on derivatives not designated as hedging instruments 	(73) 	307
Unrealised foreign exchange (gains)/losses 	(16) 	169
Working capital changes:
Loans and receivables 	1 105 	197
Trade and other payables and loans from subsidiaries 	2 	(1 657)
1 067 	(1 420)
* Amount is less than R500 000.
20.2 	Taxation paid
R million
Company
2022
Company
2021
Balance at beginning of the year 	* 	(89)
Current taxation charged for the year in the income statement 	* 	–
Balance at end of the year 	1 	*
* 	(89)
* Amount is less than R500 000.
20.3 	Increase investment in subsidiary
R million
Company
2022
Company
2021
Balance at beginning of the year 	27 458 	25 658
Value of share options issued to subsidiary staff 	327 	330
Financial guarantee contracts raised 	1 	1
Deemed dividends 	125 	–
Long-term incentive plan share recharges 	(443) 	–
Non-cash restructure of investment in subsidiary 	– 	427
Common control transaction (asset for share) 	– 	158
Balance at end of the year 	(29 027) 	(27 458)
Increase in investment in subsidiary 	(1 559) 	(884)
20.4 	Long-term borrowings
R million
Company
2022
Company
2021
Balance at beginning of the year 	8 858 	8 356
Interest accrued 	686 	640
Interest paid 	(683) 	(636)
Increase in borrowings 	2 418 	500
Raising fees capitalised 	(8) 	(2)
Raising fees amortised 	13 	–
Repayment of borrowings 	(700) 	–
Balance at end of the year 	10 584 	8 858
NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
158	Discovery Annual Financial Statements 2022

-- 159 of 219 --

20.5 	Cash and cash equivalents
R million
Company
2022
Company
2021
Cash at bank and in hand 	93 	78
Short-term deposits 	514 	15
607 	93
21. 	FINANCIAL GUARANTEE CONTRACTS
R million
Company
2022
Company
2021
Discovery Limited has provided guarantees for the following subsidiaries:
Discovery Finance Co Europe Limited 	i 	3 	3
Discovery Central Services 	ii 	16 	18
Discovery Holdings Europe Limited 	iii 	5 	5
Discovery Bank 	iv 	1 	1
Balance at the end of the year 	25 	27
.
i 	Discovery Limited has issued a guarantee for 2 facilities in respect of the obligations of Discovery Finance Company Europe
Limited for the amount of GBP 80 million and GBP 34 million. As at 30 June 2022, Discovery Finance Company Europe Limited
owed GBP 56 million (2021: GBP 99 million) in respect of these borrowing facilities.
ii Discovery Central Services entered into borrowing facilities for an amount of R650 million to fund the systems build of
Discovery Bank. The full amount has been drawn down and the balance outstanding at 30 June 2022 is R494 million (2021:
R526 million). Discovery Central Services entered into a 5 year borrowing facility for an amount of R1.4 billion. These funds
were acquired for general corporate purposes and the full amount has been drawn down and the balance outstanding at 30
June 2022 is R1 417 million (2021: R1 423 million). During the current year, a new facility of R691 million was entered into and
the full amount has been drawn down and the balance outstanding at 30 June 2022 is R691 million.
iii During 2020, Discovery Holdings Europe Limited entered into borrowing facilities for an amount of GBP 55 million, which was
increased to GBP 100 million in 2021 to fund its operations. This facility has been guaranteed by Discovery Limited.
iv Discovery Limited issued a guarantee for a facility in respect of the obligations of Discovery Bank for the amount of R300 million
(2021: R800 million).
22. 	EVENTS AFTER REPORTING DATE
Refer to Group note 44 for a list of the events after reporting date.
NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS continued
for the year ended 30 June 2022
159	Discovery Annual Financial Statements 2022

-- 160 of 219 --

DISCOVERY
ANNEXURES

-- 161 of 219 --

ANNEXURE A – GROUP STRUCTURE
for the year ended 30 June 2022
Discovery is directly and indirectly the holding company of:
Audited information 	Classification
Pecentage
Holding
at 30 June
2022 	Country
Discovery Limited which holds the interest in:
Cogence Proprietary Limited 	Subsidiary 	100% 	South Africa
Discovery Bank Holdings Limited which holds the interest in: 	Subsidiary 	100% 	South Africa
– Discovery Bank Limited 	Subsidiary 	100% 	South Africa
Discovery Central Services Proprietary Limited which holds the interest in: 	Subsidiary 	100% 	South Africa
– Glucode (Pty) Limited 	Associate 	25% 	South Africa
Discovery Connect Distribution Services Proprietary Limited 	Subsidiary 	100% 	South Africa
Discovery Finance Company Europe Limited 	Subsidiary 	100% 	United Kingdom
Discovery Group Europe Limited which holds the interest in: 	Subsidiary 	100% 	United Kingdom
– Discovery Holdings Europe Limited which holds the interest in: 	Subsidiary 	100% 	United Kingdom
○ Better Health Insurance Advice Limited 	Subsidiary 	100% 	United Kingdom
○ Healthcode Limited 	Associate 	20% 	United Kingdom
○ Vitality Corporate Services Limited 	Subsidiary 	100% 	United Kingdom
○ Vitality Invest Trustee Company Limited 	Subsidiary 	100% 	United Kingdom
○ Vitality Life Limited which holds the interest in: 	Subsidiary 	100% 	United Kingdom
– Vitality Health Insurance Limited which holds the interest in: 	Subsidiary 	100% 	United Kingdom
○ Vitality Health Limited 	Subsidiary 	100% 	United Kingdom
– Discovery Offshore Holdings No.2 Limited 	Subsidiary 	100% 	United Kingdom
Discovery Health, which holds the interest in: 	Subsidiary 	100% 	South Africa
– Discovery Administration Services Proprietary Limited 	Subsidiary 	100% 	South Africa
– Discovery Third Party Recovery Services Proprietary Limited 	Subsidiary 	100% 	South Africa
– Discovery Healthcare Service Proprietary Limited which holds the
interest in: 	Subsidiary 	100% 	South Africa
○ Discovery Medical suppliers Proprietary Limited 	Subsidiary 	100% 	South Africa
○ Grove Nursing Services Proprietary Limited 	Subsidiary 	100% 	South Africa
○ Southern Rx Distributors Proprietary Limited 	Subsidiary 	100% 	South Africa
– Medical Services Organisation International Proprietary Limited which
holds an interest in: 	Subsidiary 	70% 	South Africa
○ Mediguide Africa Proprietary Limited 	Associate 	25% 	South Africa
○ Medical Services Organisation Proprietary Limited 	Subsidiary 	51% 	Swaziland
– Medical Services Organisation International Limited which holds an
interest in: 	Subsidiary 	70% 	Isle of Man
○ Global Access Health Network SARL 	Subsidiary 	80% 	Democratic
Republic
of Congo
○ MSOI Health Risk Managers Limited 	Subsidiary 	85% 	Nigeria
– Quantium Health SA Proprietary Limited 	Joint venture 	50% 	South Africa
Discovery Insure Limited which holds an interest in: 	Subsidiary 	100% 	South Africa
– Bi-Me Proprietary Limited 	Associate 	33% 	South Africa
– Discovery Telematics Services Proprietary Limited which holds an
interest in: 	Subsidiary 	100% 	South Africa
○ Advinne Technologies Proprietary Limited 	Associate 	25% 	South Africa
Discovery Life Limited 	Subsidiary 	100% 	South Africa
Discovery Life Collective Investments Proprietary Limited 	Subsidiary 	100% 	South Africa
Discovery Life Investment Services Proprietary Limited which holds an interest in: 	Subsidiary 	100% 	South Africa
– Discovery Life Nominees Proprietary Limited 	Subsidiary 	100% 	South Africa
Discovery Mauritius Asset Management which holds an interest in: 	Subsidiary 	100% 	Mauritius
– Discovery International Collective Investments PLC 	Subsidiary 	100% 	Mauritius
Discovery Partner Markets Asia Private Limited which holds an interest in: 	Subsidiary 	100% 	Singapore
– Discovery Partner Market Services Private Limited which holds an
interest in: 	Subsidiary 	100% 	Singapore
○ Vitality (Shangai) Business Consulting Services Company Limited 	Subsidiary 	100% 	China
Discovery Vitality Proprietary Limited 	Subsidiary 	100% 	South Africa
Ping An Health Insurance Company of China Limited 	Associate 	25% 	China
Vitality Group International Incorporated which holds an interest in: 	Subsidiary 	100% 	United States
– AIA Vitality (Hong Kong) Limited 	Joint venture 	44% 	Hong Kong
– Amplify Health Asia Private Limited 	Associate 	25% 	Singapore
– Cambridge Mobile Telematics Incorporated 	Associate 	9% 	United States
– Discovery Vitality Australia Proprietary Limited which holds an interest in: 	Subsidiary 	100% 	Australia
○ Quantium Health Proprietary Limited which holds an interest in: 	Joint venture 	50% 	Australia
– Health Outcomes Australia Proprietary Limited 	Joint venture 	100% 	Australia
– Quantium Health Hong Kong Proprietary Limited 	Joint venture 	100% 	Hong Kong
○ AIA Vitality Proprietary Limited which holds an interest in: 	Associate 	27% 	Australia
– My Own Support Proprietary Limited which holds the interest in: 	Associate 	100% 	Australia
○ AIA Health Insurance Proprietary Limited 	Associate 	100% 	Australia
– The Vitality Group Incorporated 	Subsidiary 	100% 	United States
– Vitality International Health Insurance Company Limited 	Subsidiary 	100% 	Isle of Man
– Vitality Management Company Limited Liability Company 	Subsidiary 	100% 	United States
161	Discovery Annual Financial Statements 2022

-- 162 of 219 --

ANNEXURE A – GROUP STRUCTURE continued
for the year ended 30 June 2022
In addition to the above subsidiaries, Discovery consolidates unit trusts which are deemed to be under the Group’s control in terms
of IFRS 10 Consolidated Financial Statements. The consolidated unit trusts include:
Discovery Aggressive Dynamic Asset Optimiser Fund of Funds 	Discovery Target Retirement 2025 Fund
Discovery Balanced Fund 	Discovery Target Retirement 2030 Fund
Discovery Cautious Balanced Fund 	Discovery Target Retirement 2035 Fund
Discovery Conservative Dynamic Asset Optimiser Fund of Funds 	Discovery Target Retirement 2040 Fund
Discovery Diversified Income Fund 	Discovery Target Retirement 2045 Fund
Discovery Equity Fund 	Discovery Target Retirement 2050 Fund
Discovery Flexible Property Fund 	Discovery Target Retirement 2055 Fund
Discovery Global Equity Feeder Fund 	Discovery Target Retirement 2060 Fund
Discovery Global Real Estate Securities Feeder Fund 	Discovery Global Multi Asset Fund (previously named
Discovery Global Value Equity Feeder Fund 	Discovery Worldwide Best Ideas Fund)
Discovery Moderate Balanced Fund 	Discovery Strategic Bond Fund
Discovery Moderate Dynamic Asset Optimiser Fund of Funds 	Discovery Global Conservative Fund (Mauritius)
Discovery Money Market Fund 	Discovery Global Moderate Fund (Mauritius)
Discovery Target Retirement 2015 Fund 	Discovery Global Growth Portfolio Fund (Mauritius)
Discovery Target Retirement 2020 Fund
162	Discovery Annual Financial Statements 2022

-- 163 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES
for the year ended 30 June 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The principal accounting policies applied in the preparation of these consolidated and separate financial statements are set out below. These
policies have been consistently applied to all the years presented. Other interpretations, amendments and annual improvements effective
for the first time in the current year have been considered and have no impact on the current reporting period.
1. 	Basis of presentation
The consolidated and separate Annual Financial Statements have been prepared in accordance with International Financial
Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), its interpretations adopted by the
IASB, the South African Institute of Chartered Accountants (SAICA), Financial Reporting Guides as issued by the Accounting Practices
Committee, the JSE Listings Requirements, JSE Debt Listings Requirement as well as the South African Companies Act. They have
been prepared in accordance with the going concern principle using the historical cost basis except where otherwise stated in the
accounting policies below.
The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also
requires management to exercise its judgement in the process of applying Discovery’s accounting policies. The areas involving a
higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial
statements, are outlined in Group note 4 to the Annual Financial Statements.
All monetary information and figures presented in these financial statements are stated in millions of Rand (R million), unless
otherwise indicated.
NEW STANDARDS AND AMENDMENTS WHICH BECAME EFFECTIVE DURING THE FINANCIAL YEAR
The following new standards, amendments and interpretations became effective during the periods which had a significant
impact on recognised amounts:
Title and
Effective date 	Scope 	Potential impact
Interpretation:
Cloud-based
arrangements
The IFRS Interpretations Committee clarified that in a
cloud service contract, the customer needs to assess
whether the implementation service is distinct from
the service of receiving access to the software. Based
on the committee’s decision, implementation costs will
need to be expensed as incurred or capitalised.
Discovery has identified specific implementation
costs capitalised in previous financial years as
intangible assets. Under the new interpretation,
these costs will be expensed. Due to the impact
being immaterial, the full cumulative costs were
expensed in the current financial reporting
period.
New standards and amendments to published standards not yet effective
❚ 	Discovery has not early adopted any accounting standards, amendments or annual improvements issued but not yet effective.
❚ 	The accounting standards, amendments and annual improvements described below are those that are expected to have an
impact on Discovery’s results and/or disclosures. Accounting standards, amendments and annual improvements not
mentioned below are not expected to have a significant impact on recognised amounts.
❚ 	For discussion on IFRS 17, please refer to accounting policy note 29.
2. 	Consolidation
The consolidated financial statements include the assets, liabilities and results of the operations of the holding company and its
subsidiaries, joint ventures and associates.
2.1 	BUSINESS COMBINATIONS
The acquisition method of accounting is used to account for business combinations by the Group. The consideration transferred
for the acquisition of a business is the fair values of the assets transferred, the liabilities incurred and the equity interests issued
by the Group. The consideration transferred includes the fair value of any asset or liability resulting from a contingent
consideration arrangement. Acquisition-related costs are expensed as incurred.
Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at
their fair values at the acquisition date. On an acquisition-by-acquisition basis, Discovery recognises any non-controlling interest
in the acquiree either at fair value or at the non-controlling interest’s proportionate share of the acquiree’s net assets. The excess
of the consideration transferred, being the amount of any non-controlling interest in the acquiree and the acquisition-date fair
value of any previous equity interest in the acquiree over the fair value of the identifiable net assets acquired, is recorded as
goodwill. If this is less than the fair value of the net assets of the subsidiary acquired in the case of a bargain purchase, the
difference is recognised directly in profit or loss.
163	Discovery Annual Financial Statements 2022

-- 164 of 219 --

2. 	Consolidation continued
2.2 	CONSOLIDATION OF ENTITIES IN WHICH THE GROUP HOLDS LESS THAN 50%
Discovery analysed its relationships with the Discovery Unit Trusts and has determined that it has significant power to direct the
relevant activities of the funds, has sufficient exposure to the variable returns of the funds and the ability to use its power over
the investee to affect its returns. This analysis concluded that Discovery has control of the Discovery Unit Trusts even if the
economic interest is less than 50% and is therefore required to consolidate these funds.
Discovery controls these unit trusts as it has right to the variable returns in the form of fund management fees that it receives
from its involvement with the funds. Furthermore, Discovery exercises control over these unit trust through the setting of the
mandates as well as the appointment of the independent trustees. Discovery can, within the regulatory framework, also amend
the mandates and change the independent trustee.
Of the 27 (2021: 27) Discovery Unit Trusts consolidated at 30 June 2022 Discovery holds less than a 50% economic interest in
1 (2021: 1) of these funds. Refer to page 25 for a list of consolidated unit trusts.
2.3 	SUBSIDIARIES
Subsidiaries are all entities (including structured entities) over which Discovery has control. Discovery controls an entity when it
is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns
through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to Discovery.
Consolidation is discontinued from the date on which control ceases.
Intra-group transactions, balances and unrealised gains on intra-group transactions are eliminated. Unrealised gains or losses
are also eliminated. Subsidiaries’ accounting policies have been changed where necessary to ensure consistency with the policies
adopted by Discovery. Intra-group foreign exchange gains or losses arising on intra-group balances do not eliminate.
2.4 	ASSOCIATES AND JOINT ARRANGEMENTS
ASSOCIATES AND JOINT VENTURE
Associates are entities over which Discovery has the ability to exercise significant influence but not control over the financial and
operational policies. Significant influence is determined based primarily on percentage voting rights, generally between 20% and
50%, together with other factors such as board participation and participation in the policy-making process. In certain instances,
Discovery holds less than 20% equity interests, but holds rights that still give it significant influence. These are equity accounted.
A joint venture is a joint arrangement whereby the parties have joint control of an arrangement and have rights to the net assets
of the arrangement.
Discovery recognises its interest in an associate or a joint venture as an investment and accounts for that investment using the
equity method. Under the equity method, on initial recognition the investment in an associate or a joint venture is recognised at
cost. The carrying amount is adjusted to recognise Discovery’s share of the post-acquisition profit or loss of the investee and is
recognised in profit or loss. Distributions received from an investee reduce the carrying amount of the investment. Dividends
received from the investee are presented as part of investing activities in the Statement of cash flows. Adjustments to the carrying
amount may also be necessary for changes in Discovery’s proportionate interest in the investee arising from changes in the
investee’s other comprehensive income. Such changes include those arising from foreign exchange translation differences.
Discovery’s share of those changes is recognised in other comprehensive income. Discovery will discontinue the use of the equity
method from the date when its investment ceases to be an associate or a joint venture.
Discovery discontinues equity accounting when the carrying amount of the investment in an associate or a joint venture reaches
zero, unless it has incurred obligations, guaranteed obligations or made payments on behalf of the associate or the joint venture.
Discovery resumes equity accounting only after its share of the profits equals the share of losses not recognised. Discovery increases
the carrying amount of investments with its share of the associate’s or joint venture’s income when equity accounting is resumed.
Discovery’s investment in an associate or a joint venture includes goodwill identified on acquisition. Discovery assesses at each
reporting date whether there is objective evidence that an associate or a joint venture is impaired. If such evidence of impairment
exists, Discovery calculates the amount of impairment as the difference between the recoverable amount of the investment and
its carrying value.
Unrealised gains or losses on transactions between Discovery and its associates or joint ventures are eliminated to the extent of
the Group’s interest in these entities unless the transaction provides evidence of an impairment of the asset transferred.
Accounting policies of associates and joint ventures have been changed where necessary to ensure consistency with the policies
adopted by the Group. The carrying amount of equity-accounted investments are tested for impairment (see accounting policy 9.3
for the policy on impairment).
ANNEXURE B – GROUP ACCOUNTING POLICIES continued
164	Discovery Annual Financial Statements 2022

-- 165 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
2. 	Consolidation continued
2.4 	ASSOCIATES AND JOINT ARRANGEMENTS continued
ASSOCIATES AND JOINT VENTURE continued
A decrease in interest while an investment continues to be classified as an associate can also result from a dilution. The gain or
loss on the dilution of in an equity-accounted investee is calculated as the difference between:
❚ 	the entity’s ownership interest in the new assets received by the investee for the subscription of the new shares (e.g. the cash
paid by the other party); and
❚ 	the reduction in ownership interest in the previous carrying amount.
JOINT OPERATIONS
A joint operation is a joint arrangement whereby the parties have joint control of an arrangement and rights to the assets and
obligations for the liabilities relating to the arrangement.
Discovery recognises its share of those assets, liabilities, revenues and expenses that the operators incur jointly.
3. 	Foreign currency translation
3.1 	FUNCTIONAL AND PRESENTATION CURRENCY
Items included in the financial statements of each of Discovery’s entities are measured using the currency of the primary
economic environment in which the entity operates (the functional currency). The consolidated financial statements are
presented in Rand, which is the presentation currency of Discovery Limited.
3.2 	TRANSACTIONS AND BALANCES
Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the
transactions. Foreign exchange gains and losses resulting from:
❚ 	The settlement of trading transactions is included in the results of operating activities in profit or loss;
❚ 	The settlement of financing transactions and from the translation at year-end exchange rates of assets and liabilities
denominated in foreign currencies are recognised in profit or loss as foreign exchange gains and losses; and
❚ 	Qualifying cash flow hedges are deferred in the statement of other comprehensive income and are recycled to profit or loss
in the periods in which the hedged item affects profit or loss.
3.3 	GROUP COMPANIES
The results and financial position of all Discovery entities (none of which has the currency of a hyperinflationary economy) that
have a functional currency different from the presentation currency are translated into the presentation currency as follows:
❚ 	Assets and liabilities for each Statement of financial position presented are translated at the closing rate at the date of that
statement of financial position;
❚ 	Income and expenses for each Income statement are translated at average exchange rates (unless this average is not a
reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and
expenses are translated at rates at the date of the transactions); and
❚ 	All resulting exchange differences are recognised as a separate component of equity, namely the foreign currency
translation reserve.
On consolidation, exchange differences arising from the translation of the net investment in foreign entities are recognised in the
foreign currency translation reserve in the Statement of other comprehensive income. When a foreign operation is partially
disposed of or sold, such exchange differences are recognised in profit or loss as part of the gain or loss on sale. Goodwill and
fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and
translated at the closing rate.
165	Discovery Annual Financial Statements 2022

-- 166 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
4. 	Property and equipment
Items of property, and equipment are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation
and any accumulated impairment losses.
Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only when it is
probable that future economic benefits associated with the item will flow to Discovery and the cost of the item can be measured
reliably. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.
If significant parts of an item of property, and equipment have different useful lives, then they are accounted for as separate
items (major components) of property, and equipment. Property and equipment are depreciated using the straight-line method
to allocate their cost to their residual values over their estimated useful lives, as follows:
Owner occupied property 	40 years
Leasehold improvements 	Shorter of estimated life or period of lease
Leased asset 	3 – 15 years
Computer equipment 	3 – 7 years
Furniture, fittings and building fit out 	5 – 15 years
Motor vehicles 	4 years
Telematics devices 	2 – 5 years
The assets’ residual values and useful lives are reviewed at each reporting period and adjusted if appropriate. An asset’s carrying
amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated
recoverable amount. The recoverable amount is the higher of the asset’s fair value less costs to dispose and value-in-use.
Gains or losses on disposals are determined by comparing the proceeds with the carrying amount. These are recorded in profit
or loss.
5. 	Intangible assets
5.1 	COMPUTER SOFTWARE DEVELOPMENT COSTS
Items of computer software development costs are measured at cost, less accumulated and any accumulated impairment losses.
Costs associated with maintaining computer software programmes are recognised as an expense as incurred. Development
costs that are directly attributable to the design and testing of identifiable software products controlled by Discovery are
recognised as intangible assets when the following criteria are met:
❚ 	It is technically feasible to complete the software product so that it will be available for use;
❚ 	Management intends to complete the software product and use or sell it;
❚ 	There is an ability to use or sell the software product;
❚ 	It can be demonstrated how the software product will generate probable future economic benefits;
❚ 	Adequate technical, financial and other resources to complete the development and to use or sell the software product are
available; and
❚ 	The expenditure attributable to the software product during its development can be reliably measured.
Directly attributable costs that are capitalised as part of the software product, include the software development employee costs
and an appropriate portion of directly attributable overheads. For cloud computing arrangements, implementation costs that do
not meet the requirements to be capitalised as an asset is expensed as incurred.
Other development expenditures that do not meet these criteria are recognised as an expense as incurred. Development costs
previously recognised as an expense are not recognised as an asset in a subsequent period.
Computer software development costs are recognised as assets from the point where the recognition criteria above are satisfied,
and are amortised once the asset is ready for use, over their useful lives (between three and ten years). The amortisation is
reflected under marketing and administration expenses in profit or loss.
If significant parts of computer software development costs have different useful lives, then they are accounted for as separate
items (major components) of computer software development costs. Computer software development costs recognised as
assets are amortised over their useful lives.
Software applications 	3 – 7 years
Core Systems 	15 years (2021: 11 years)
166	Discovery Annual Financial Statements 2022

-- 167 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
5. 	Intangible assets continued
5.2 	OTHER INTANGIBLE ASSETS
Discovery does not recognise costs incurred to internally developed trademarks, patents and similar rights and assets, including
franchises and management contracts. These costs are recognised in profit or loss in the period in which they are incurred.
Purchased intangible assets which represent rights to receive future profits are capitalised at their fair values, represented by the
estimated net present value of future cash flows relating to existing business, or at a value as determined by an independent
valuer. These intangible assets are amortised into profit or loss as profits are expected to emerge and only tested for impairment
if an indication of impairment arises.
Intangible assets acquired as part of business combinations were capitalised at their fair value, represented by the estimated net
present value of future cash flows relating to existing business, or at a value as determined by an independent valuer. These
intangible assets are amortised over their useful lives and only tested for impairment if an indication of impairment arises.
6. 	Deferred acquisition costs
The direct costs of acquiring new business, which are expected to be recovered out of future revenue margins, are deferred over
the period in which the related performance obligations are satisfied and recognised as an asset in the Statement of financial
position. The accounting policies relating specifically to deferred acquisition costs for insurance are detailed in accounting policies 13.
7. 	Goodwill
Goodwill arises on the acquisition of businesses and represents the excess of the consideration transferred, the amount of any
non-controlling interest in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the
fair value of the identifiable net assets acquired.
Goodwill is reviewed for impairment annually or more frequently if events or changes in circumstances indicate a potential
impairment. The carrying value of the cash generating unit (CGU) containing the goodwill is compared to the recoverable amount,
which is the higher of value in use and the fair value less costs of disposal. Any impairment is recognised immediately as an
expense and is not subsequently reversed.
For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the CGUs, or groups
of CGUs that is expected to benefit from the synergies of the combination. Each unit or group of units to which the goodwill is
allocated represents the lowest level within the entity at which the goodwill is monitored for internal management purposes.
Goodwill is monitored at the operating segment level.
8. 	Impairment of non-financial assets
Goodwill is tested annually for impairment or more frequently if events or changes in circumstances indicate that goodwill may
be impaired.
Other assets, including equity accounted investments, intangible assets and costs of obtaining contracts, other than those
relating to insurance contracts (see accounting policy 13), are reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount may not be recoverable. Such indicators include continued losses, changes in
technology, market, economic, legal and operating environments.
An impairment loss is recognised for the amount by which the asset’s carrying amount exceeds its recoverable amount. The
recoverable amount is measured using the higher of the fair value less costs to sell and the value-in-use. Value-in-use is the
present value of projected cash flows covering the remaining useful life of the asset. An impairment loss is recognised in profit or
loss immediately.
Other assets, other than goodwill, that suffered an impairment are reviewed for possible reversal of the impairment at the end
of each reporting period.
9. 	Financial instruments
Discovery initially recognises financial instruments when it becomes party to the contract.
Financial instruments are measured at initial recognition at fair value net of directly attributable transaction costs, unless the
financial instrument is classified as fair value through profit or loss. For instruments classified at fair value through profit or loss
attributable transaction costs are immediately expensed.
167	Discovery Annual Financial Statements 2022

-- 168 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
9. 	Financial instruments continued
9.1 	FINANCIAL ASSETS
9.1.1 	RECOGNITION, CLASSIFICATION, MEASUREMENT AND DERECOGNITION
At initial recognition, the Group considers the appropriate classification as at Amortised cost (AC); Fair value through profit or loss
(FVTPL) or Fair value through other comprehensive income (FVOCI) for debt instruments. Discovery considers:
❚ 	Whether the contractual cash flows of the financial asset are solely payments of principal and interest (SPPI). Such contractual
cash flows are consistent with a basic lending arrangement, and compensate Discovery for the elements of time value of
money, credit risk and other basic lending risks and a profit margin. Examples of such instruments include Treasury Bills,
Government Bonds, cash and fixed term deposits. It excludes instruments such as equity-linked financial assets or puttable
investments in unit trusts; and
❚ 	The business model for holding the financial assets.
Based on the criteria above, Discovery will classify a debt instrument as at:
❚ 	Amortised cost, if the financial asset meets the SPPI criterion and is held for the purpose to collect the contractual cash flows.
Examples of this include loans and advances to customers (e.g. credit card advances) and fixed term deposits;
❚ 	Fair value with changes in other comprehensive income (debt instruments), if the financial asset kie
❚ 	kmeets the SPPI criterion and is held either to collect contractual cash flows or for sale. Discovery currently does not hold
financial assets in this category. However, specified associates do have certain of their debt instruments in the category.
❚ 	Fair value through profit or loss, for all other financial assets that do not meet the criteria above (mandatorily). In addition,
Discovery can designate financial assets into this category if this will reduce measurement inconsistencies (i.e. ‘accounting
mismatch’) (designated). Discovery’s business includes, amongst others, providing unit-linked insurance, unit-linked
investment and non-linked insurance products to customers. Financial assets and liabilities in these portfolios are managed
to achieve the objectives of the portfolio and to ensure that liabilities are appropriately matched with assets. In considering
whether the objective of a portfolio is to collect contractual cash flows or to trade in financial instruments, Discovery considers
the purpose for which instruments are held, the methods of risk management in a portfolio, the manner of performance
reporting on a portfolio and the basis for determining compensation to managers for asset performance. For those financial
assets backing insurance contracts, Discovery measures these financial assets at fair value through profit or loss. Unit-linked
investment contracts are also mandatorily classified at fair value through profit or loss.
For equity instruments Discovery is permitted to make the irrevocable election to present changes in fair value in other
comprehensive income, however cumulative gains or losses recognised cannot be reclassified to profit or loss on disposal. This
election is available on an instrument-by-instrument basis. This election has only been made in the accounting records of
specified associates. All other equity instruments are measured at FVTPL.
Subsequent measurement
Amortised cost (AC) 	These instruments are measured at amortised cost using the effective interest
method. Movements in the balance of the instrument relate to expected credit
losses, interest income and foreign exchange gains and losses which are
recognised on profit or loss.
Fair value through
profit or loss (FVTPL)
These instruments are measured at fair value with gains and losses recognised in
other comprehensive income and are never reclassified to profit or loss.
Dividends are recognised in profit or loss.
Fair value through other comprehensive
income (FVOCI) – equity
These instruments are measured at fair value with gains and losses recognised in
other comprehensive income. Dividends are recognised in profit or loss.
Fair value through other comprehensive
income (FVOCI) – debt
These instruments are measured at fair value with changes in fair value recognised
in other comprehensive income. Discovery recognises interest using effective
interest method, movements in the balance related to expected credit losses,
interest income and foreign exchange gains and losses in profit or loss. On
derecognition, gains and losses accumulated in OCI are reclassified to profit
or loss
There are no financial assets that have been designated at fair value through profit or loss.
The business model for managing a group of financial instruments is expected to remain stable, in rare instances where the
business model changes there can be a reclassification of the business model. Any reclassifications are applied prospectively
from the first day of the first reporting period after the change in business model, with no restatement of any previously
recognised gains, losses or interest. Discovery has not had any changes in business models in the current reporting period and
consequently there have been no reclassifications.
Financial assets are derecognised when the rights to receive cash flows from them have expired or where they have been
transferred and Discovery has also transferred substantially all risks and rewards of ownership.
168	Discovery Annual Financial Statements 2022

-- 169 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
9. 	Financial instruments continued
9.1 	FINANCIAL ASSETS continued
9.1.2 	EXPECTED CREDIT LOSSES
Expected credit losses are recognised on the following items:
❚ 	Debt instrument at amortised cost, which includes treasury bills, banking loans and advances and fixed deposits. This also
includes loan commitment for undrawn credit facilities;
❚ 	Lease receivables;
❚ 	Financial guarantee contracts;
❚ 	Other receivables which are financial assets at amortised cost; and
❚ 	Contract receivables and contracts assets with non-insurance customers and cash and cash equivalents.
Discovery has a multitude of different debtors and loans included in other receivables which are financial assets, which do not
represent a homogeneous group of assets. The approach to determining credit losses varies according to the asset type, past bad
debt experience and the potential to incorporate forward looking information. In certain instances, financial assets have been
grouped based on shared characteristics (i.e. debt payment pattern similarities, financial instruments with collateral, debtor
type), and expected credit losses determined on a collective basis.
The general expected credit loss approach requires that Discovery assess the credit risk of the instrument and determine whether
there has been a significant increase in credit risk since initial recognition.
❚ 	Where there has not been a significant increase in credit risk since initial recognition expected credit losses are measured as
the 12-month expected credit losses.
❚ 	Where there has been a significant increase in credit risk, expected credit losses are recognised as the life-time credit losses.
Discovery measures expected credit losses on:
❚ 	financial assets that are not credit-impaired at the reporting date as the present value of all cash shortfalls (i.e. the difference
between the cash flows due to the entity in accordance with the contract and the cash flows that Discovery expects to receive);
❚ 	financial assets that are credit-impaired at the reporting date: as the difference between the gross carrying amount and the
present value of estimated future cash flows; and
❚ 	undrawn loan commitments: as the present value of the difference between the contractual cash flows that are due to Discovery
if the commitment is drawn down and the cash flows that Discovery expects to receive (adjusted using a credit conversion factor).
Discovery does not recognise expected credit losses on Treasury Bills issued by the South African Reserve Bank as well as cash
and cash equivalents receivable on demand due to the assessment that it is immaterial
SIGNIFICANT INCREASE IN CREDIT RISK
At each reporting date, Discovery assesses whether the credit risk on a financial asset has increased significantly since initial
recognition. When making the assessment, an entity shall use the change in the risk of a default occurring over the expected life
of the financial instrument instead of the change in the amount of expected credit losses.
Qualitative 	Quantitative
❚ 	when contractual payments are more than 30 days past due
the presumption is applied in conjunction with Discovery Risk
Grade (DRG).
❚ 	the eligibility rules used in the credit underwriting and account
management strategies are considered as triggers of
significant increase in credit risk, since they provide a view in
terms of how the client performs on their other credit facilities
outside Discovery Bank. The rules comprise of a list of statuses
at the bureau such as: judgements; adverse; deceased; and
debt counselling statuses.
❚ 	performing (up-to-date and current) accounts that have
shown deterioration with respect to Discovery Bank risk
grades will also be regarded as a significant increase in credit
risk.
Currently the Discovery Bank is not considering the
quantitative triggers of significant increase in credit risk
due to lack of origination data on the back book (ie
DiscoveryCard joint venture data). As the book in
Discovery Bank matures it will be in a position to perform
the assessment.
169	Discovery Annual Financial Statements 2022

-- 170 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
9. 	Financial instruments continued
9.1 	FINANCIAL ASSETS continued
9.1.2 	EXPECTED CREDIT LOSSES continued
CREDIT IMPAIRED AND DEFAULT
Discovery considers a financial instrument to be credit-impaired where current circumstances and economic conditions indicate
that the expected future cash flows from a financial instrument may not be recoverable. These circumstances include but are not
limited to evidence of financial or operational challenges for the debtor and missed contractual payments.
Default is defined on a facility level and considers both quantitative and qualitative factors as provided in the Basel capital
framework. The qualitative criterion requires banks to identify credit deterioration before the exposure becomes delinquent
“unlikeliness to pay” events, while the quantitative criterion requires banks to look at the material delinquency status.
The following factors are what constitutes default from a qualitative and quantitative perspective, and it is in line with the
South African Reserve Bank definition.
Qualitative 	Quantitative
❚ 	The borrower is placed in debt counselling/debt review;
❚ 	The borrower is deceased;
❚ 	The facility has undergone a distressed restructure/special
arrangement;
❚ 	The facility has been transferred to charge off/legal status; or
❚ 	The client is under debt review;
❚ 	The client is insolvent; or
❚ 	The facility is written off
A material amount on the facility is 90 days or more in
arrears, whereby material is set to avoid technical defaults.
WRITE-OFF
Discovery Bank will reduce the gross carrying amount of a financial asset when it has no reasonable expectation of recovering a
financial asset in its entirety or a portion thereof. Currently the write-off point is based on time in default and is set as 12 months
in default. To ensure the appropriateness of the write-off point, the proposed write-off point will be assessed on an annual basis
and both time in default and recency of repayments will be considered.
Where Discovery has no reasonable expectation of recovery of a debt the amount is written off, this is considered to occur when
all avenues of legal recourse to recover the debt have been unsuccessful.
9.2 	FINANCIAL LIABILITIES
At initial recognition, the Group considers the appropriate classification as at Amortised costs (AC) or Fair value through profit or
loss (FVTPL).
Financial liabilities are measured at FVTPL if:
❚ 	is it is held for trading; or
❚ 	if the financial liabilities are part of a group of financial assets and financial liabilities which are managed and performance
evaluated on a fair value basis. These include financial liabilities held within the portfolios of unit-linked insurance and unit-
linked investments.
All other financial liabilities in Discovery, which are in scope of IFRS 9, are measured at amortised cost.
Qualitative 	Subsequent measurement
Amortised cost (AC) 	These instruments are measured at amortised cost using the effective interest method. Interest
income and foreign exchange gains and losses are recognised in profit or loss.
Fair value through profit
or loss (FVTPL)
These instruments are measured at fair value with gains and losses and any interest recognised
in profit or loss.
Discovery has investment contracts which have financial risk, and are consequently recognised and measured in terms of IFRS 9
rather than IFRS 4 Insurance Contracts. These contracts are classified at fair value through profit or loss. The policies are linked to
the return on underlying financial assets and are directly matched. The movement on Discovery’s own credit risk is considered
immaterial. The remaining financial liabilities are carried at amortised cost.
Financial liabilities are derecognised when the obligation is extinguished.
170	Discovery Annual Financial Statements 2022

-- 171 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
9. 	Financial instruments continued
9.3 	OFFSET
Financial assets and liabilities are offset and the net amount reported in the Statement of financial position when there is a legally
enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and
settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable
in the normal course of business and in the event of default, insolvency or bankruptcy of Discovery or the counterparty.
9.4 	MODIFICATIONS
Where an existing financial asset or liability is replaced by another with the same counterparty on substantially different terms,
or the terms of an existing financial asset or liability are substantially modified, such an exchange or modification is treated as a
derecognition of the original asset or liability and the recognition of a new asset or liability at fair value, including calculating a
new effective interest rate, with the difference in the respective carrying amounts being recognised in other gains and losses on
financial instruments within non-interest revenue. The date of recognition of a new asset is consequently considered to be the
date of initial recognition for impairment calculation purposes.
If the terms are not substantially different for financial assets or financial liabilities, the group recalculates the new gross carrying
amount by discounting the modified cash flows of the financial asset or financial liability using the original effective interest rate.
The difference between the new gross carrying amount and the original gross carrying amount is recognised as a modification
gain or loss within credit impairments (for distressed financial asset modifications) or in other gains and losses on financial
instruments within non-interest revenue (for all other modifications).
In assessing whether a financial asset was substantially modified, Discovery performs a qualitative assessment to determine if
the terms were substantially modified. In assessing whether a financial liability has been substantially modified, Discovery
performs both a qualitative and quantitative (10% threshold) assessment to determine if the terms were substantially modified.
For discussion on modifications as a result of the interbank offered rates (IBOR) reforms, refer to accounting policy 10.4.
10. 	Derivative financial instruments
Derivative financial instruments are classified as held for trading unless they are designated as effective hedging instruments.
Discovery initially recognises derivative financial instruments in the Statement of financial position at fair value on the date which
a derivative contract is entered into (the best evidence of fair value on day one is the transaction price) and subsequently re-
measures these instruments to fair value. The method of recognising the resulting fair value gain or loss depends on whether the
derivative is designated as a hedging instrument, and if so, the nature of the item being hedged. Fair values are obtained from
quoted prices in active markets, including recent market transactions, and valuation techniques, including discounted cash flow
models and options pricing models, as appropriate. All derivatives are carried as assets when the fair value is positive and as
liabilities when the fair value is negative.
Discovery is permitted to designate certain derivatives as either:
❚ 	Hedges of the fair value of recognised assets or liabilities or firm commitments (fair value hedges); or
❚ 	Hedges of highly probable forecast transactions (cash flow hedges).
Discovery documents at the inception of the transaction the relationship between hedging instruments and hedged items, as well
as its risk management objective and strategy for undertaking various hedge transactions. Discovery also documents its
assessment, both at hedge inception and on an ongoing basis, of whether the derivatives that are used in hedging transactions are
expected to be and have been highly effective in offsetting changes in fair values or cash flows of hedged items. Discovery continues
to apply hedge accounting, as permitted in IFRS, consistent with IAS 39 Financial Instruments: Recognition and Measurement.
10.1 	CASH FLOW HEDGE
Discovery recognises the effective portion of fair value changes of derivatives that are designated as cash flow hedges in the cash
flow hedging reserve in the Statement of other comprehensive income. The gain or loss relating to the ineffective portion is
recognised immediately in profit or loss, within net fair value gains on financial assets at fair value through profit or loss in the
income statement.
Amounts accumulated in the Statement of other comprehensive income are recycled to profit or loss in the period in which the
hedged item will affect profit or loss. Where the forecast transaction or a foreign currency firm commitment results in the
recognition of a non-financial asset or liability, the gains and losses previously deferred are transferred from the Statement of
other comprehensive income and included in the initial measurement of the cost of the non-financial asset or liability. Where the
forecast transaction subsequently results in the recognition of a financial asset or liability, gains or losses deferred in equity are
transferred from the statement of other comprehensive income when the financial asset or liability is sold or impaired.
When a hedging instrument expires or is sold, or when a hedge no longer meets the criteria for hedge accounting, any cumulative
gain or loss existing in equity at that time remains in equity and is recognised when the forecast transaction is ultimately
recognised in profit or loss. When a forecast transaction is no longer expected to occur, the cumulative gain or loss that was
reported in equity is immediately transferred to profit or loss.
171	Discovery Annual Financial Statements 2022

-- 172 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
10. 	Derivative financial instruments continued
10.2 	DERIVATIVES THAT DO NOT QUALIFY FOR HEDGE ACCOUNTING
Certain derivative instruments do not qualify for hedge accounting. Changes in the fair value of all such derivative instruments
are recognised immediately in profit or loss, within net fair value gains on financial assets at fair value through profit or loss in
the income statement.
10.3 	HEDGING RESERVE
The hedging reserve includes the cash flow hedge reserve. The cash flow hedge reserve is used to recognise the effective portion
of gains or losses on derivatives that are designated and qualify as cash flow hedges. Amounts are subsequently recycled to profit
or loss as follows:
❚ 	For the effective portion recycled for hedges relating to share-based payments, as part of marketing and administration
expenses (staff costs); and
❚ 	For the effective portion recycled for hedges relating to interest rate risk, as part of finance costs.
10.4 	INTERBANK OFFERED RATES (IBOR) REFORMS
A fundamental reform of major interest rate benchmarks is being undertaken globally, including the replacement of some IBORs
with alternative nearly risk-free rates (referred to as ’IBOR reform’). The Group has exposures to IBORs on its financial instruments
which has been or will be replaced or reformed as part of these market-wide initiatives, such as Libor and Jibar.
The United Kingdom has seen a change from the GBP Libor to the Reformed Sterling Overnight Index Average (SONIA). The South
African Reserve Bank has indicated its intention to move away from Jibar and to create an alternative reference rate for South
Africa. However, there is currently no indication when the designated successor rate will be made available.
The IBOR reforms will generally result in changes in the basis for determining the contractual cash flows of financial assets and
financial liabilities, including derivatives.
For financial assets and liabilities measured at amortised cost, an entity will update the effective interest rate only if:
❚ 	The change is necessary as a direct consequence of reform; and
❚ 	The new basis for determining the contractual cash flows is economically equivalent to previous basis.
For the purpose of cash flow hedges (see accounting policy 10.1), in determining whether a forecast transaction is highly probably,
an entity will assume that the interest rate benchmark on which the hedged cash flows are based is not altered as a result of IBOR
reforms. The Group anticipates that IBOR reform will impact some of its Jibar risk management and hedge accounting relationships
in the longer term. However, as noted, there is no indication of a designated successor rate for Jibar.
11. 	Cash and cash equivalents
Cash and cash equivalents comprise:
❚ 	Cash in hand;
❚ 	Deposits held at call and short notice; and
❚ 	Balances with banks.
Cash and cash equivalents only include items held for the purpose of meeting short-term cash commitments rather than for
investing or other purposes. Cash and cash equivalents have a maturity of less than three months from the date of acquisition.
Cash and cash equivalents are carried at amortised cost (or in specified instances at fair value through profit or loss) which due
to their short-term nature approximates fair value.
Due to Discovery’s sweeping arrangements in force with various financial institutions, positive and negative cash balances are
presented on a net basis for the purpose of presenting cash and cash equivalents in the statement of cash flows.
12. 	Share capital
Shares are classified as equity when there is no contractual obligation to transfer cash or other financial assets to the holder.
Incremental costs directly related to the issue of new shares or options are shown in equity as a deduction from the proceeds,
net of tax.
Where any Group company purchases Discovery Limited equity share capital (treasury shares), the consideration paid, including
any directly attributable incremental costs (net of income taxes), is deducted from equity attributable to Discovery Limited equity
holders. Where such shares are subsequently sold, reissued or otherwise disposed of, any consideration received is included in
equity attributable to Discovery Limited equity holders, net of any directly attributable incremental transaction costs and the
related income tax effects.
172	Discovery Annual Financial Statements 2022

-- 173 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
13. 	Insurance contracts
Insurance contracts are those contracts that transfer significant insurance risk. Such contracts may also transfer financial risk.
Discovery defines significant insurance risk as the possibility of having to pay benefits, on the occurrence of an insured event, that
are significantly more than the benefits payable if the insured event did not occur.
Discovery developed its accounting policies for insurance contracts before the adoption of IFRS 4. As provided for in IFRS 4,
Discovery continues to apply these same accounting policies for the recognition and measurement of obligations arising from
insurance contracts that it issues and reinsurance contracts that it holds.
13.1 	RECOGNITION AND MEASUREMENT
Insurance contracts are classified into four main categories, depending on the duration of the risk and the type of risk insured.
13.1.1 INDIVIDUAL LIFE INSURANCE
These contracts insure against a comprehensive spectrum of risks, including life, disability, severe illness and income continuation
cover. These contracts are long-term in nature.
VALUATION OF POLICYHOLDER LIABILITIES
For the published accounts, the actuarial value of policyholder liabilities is determined based on a prospective discounted cash
flow valuation basis calculated as the difference between the present value of future benefit payments plus expenses and the
present value of future premiums. Best estimate assumptions regarding the future expected claims experience, premium
income, expenses and commission are used. Where the same policy includes both insurance and investment components and
where the policy is classified as an insurance policy, the liability for the insurance benefits and investment benefits are separately
calculated. These components of the liability are not unbundled for reporting purposes. (Refer to accounting policy 14 for the
recognition and measurement of investment benefit liabilities).
Where the value of policyholder liabilities is negative in aggregate, this is shown as assets arising from insurance contracts.
Applying the valuation basis using the best estimate assumptions described above, would result in a gain at initial recognition.
Compulsory and discretionary margins are therefore added to the best estimate assumption to avoid the premature recognition
of future profits. At initial recognition, profits are recognised to the extent of the actual acquisition costs incurred but considering
the premium loadings available on the total portfolio to recoup acquisition costs.
Discretionary and compulsory margins are therefore added to the best estimate assumptions within the following framework.
❚ 	All margins are at least equal to the compulsory margins prescribed by regulations;
❚ 	For the discount rate and lapse rate margins, the direction of the margins may vary based on policy type and duration to
ensure that the margin is in the conservative direction, overall;
❚ 	Given the level of uncertainty in the best estimate assumptions for lapse, mortality and morbidity, margins are added to
protect against future possible adverse experience;
❚ 	Additional margins are added to allow for the release of profit over the term of the policy;
❚ 	Margins are released over the term of a policy in line with the risk borne;
❚ 	The best estimate assumptions and margins are reset at every valuation date to reflect the underlying profitability of the
portfolio. Changes to assumptions, models and benefits are therefore offset at the portfolio level through an increase in
discretionary margin (or release if sufficient discretionary margin exists). The impact of experience variances (with the
exception of lapse and mortality experience) on the end-of-period prospective liability recognised in respect of in-force
policies is offset at the portfolio level against an increase in discretionary margin (or release if sufficient discretionary margin
exists). The impact of experience variances on the in-period cash flows is accounted for in profit or loss for the period and not
offset through changes in discretionary margins;
❚ 	Where insurance contracts are backed by assets, other than negative reserves, changes in economic assumptions are
recognized directly in profit or losses;
❚ 	Discovery has established a procedure to utilise the available discretionary margin in a specified order. First, Discovery will
utilise available discretionary margins to absorb all experience items on in-force policies. This is after in period experience
variances which are recognised immediately in profit or loss as noted above. Secondly, Discovery utilises available discretionary
margins to offset non-economic assumption variances, model, and benefit changes. Lastly, the discretionary margins are
utilised to offset economic assumption changes. In subsequent periods;
❚ 	Where there are insufficient discretionary margins to offset losses arising from negative changes in non-economic
assumptions, models and benefit and or negative changes in economic assumptions, those losses in excess of the discretionary
margin are recognised immediately in profit or loss; and
❚ 	In subsequent periods, positive changes in economic assumptions and positive variance in non-economic assumptions,
models and benefits are first recognised separately in profit or loss to extent that it reverses related losses previously
recognised in profit or loss. This is in the reversed sequence in which the negative variances were utilised against discretionary
margin and any excess previously recognised in profit or loss.
173	Discovery Annual Financial Statements 2022

-- 174 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
13. 	Insurance contracts continued
13.1 	RECOGNITION AND MEASUREMENT continued
13.1.1 INDIVIDUAL LIFE INSURANCE continued
Contractual premium and benefit increases are included in the valuation of the policyholder liability. It is further assumed that
no voluntary benefits are taken up where a future take-up of these benefits would reduce the liability. This is in line with South
African actuarial guidance which requires that expected profits in respect of future options that may be taken up by policyholders
should not be recognised in the policyholder liability.
The actuarial liabilities are calculated gross of reinsurance. The expected impact of reinsurance is valued separately.
The valuation basis meets the requirement of the liability adequacy test as required by IFRS 4 for individual life insurance and no
additional tests are performed.
The liability estimates are reviewed at every reporting period and any changes in estimates to the liability are reflected in profit
or loss as they occur.
PREMIUM REVENUE
For individual life insurance contracts, premiums are recognised as revenue when due. Premiums are shown net of premium
discounts received, premiums provided for as bad debts and before the deduction of commission. Premiums exclude taxes
and levies.
INSURANCE BENEFITS AND CLAIMS
Insurance benefits and claims relating to individual life insurance contracts are recognised in profit or loss based on the estimated
liability for benefits owed to the contract holder. Death, disability and severe illness and surrender claims are accounted for when
notified. These claims include claims reported but not yet validated. The estimate is determined taking into account the likelihood
of the claim being valid and the expected severity of the claim given that the claim is valid. The proportion to be included is
estimated separately for each benefit type. An estimate of the expected claim amount is charged to profit or loss and included in
liabilities under insurance contracts. Maturity and income disability are recorded as incurred. Liabilities are held to reflect
incurred but not yet reported (IBNR) claims. The IBNR liabilities are modified to reflect actual current operating conditions. The
liabilities are calculated gross of reinsurance. An asset is then raised to allow for the expected recoveries from reinsurers.
ACQUISITION COSTS
Acquisition costs for these contracts represent commission and other costs that relate to the securing of new contracts and the
renewing of existing contracts. The valuation basis for valuing insurance contracts makes implicit allowance for the deferral of
acquisition costs and hence no explicit deferred acquisition cost asset is recognised in the Statement of financial position. These
are expensed in profit or loss.
13.1.2 GROUP LIFE INSURANCE
These contracts insure against a comprehensive spectrum of protection benefits on a group basis. Life cover, severe illness,
disability and income continuation benefits are offered. These contracts are short-term in nature.
PREMIUM REVENUE
For group life insurance contracts, premiums are recognised as revenue when due. Premiums are shown net of premiums
provided for as bad debts, before the deduction of commission and exclude taxes and levies.
INSURANCE BENEFITS AND CLAIMS
Insurance benefits and claims relating to group life insurance contracts are recognised in profit or loss based on the estimated
liability for benefits owed to the contract holder. Death, disability and severe illness and surrender claims are accounted for when
notified. These claims include claims reported but not yet validated. The estimate is determined taking into account the likelihood
of the claim being valid and the expected severity of the claim given that the claim is valid. The proportion to be included is
estimated separately for each benefit type. An estimate of the expected claim amount is charged to profit or loss and included in
liabilities under insurance contracts. Maturity and income disability are recorded as incurred. Liabilities are held to reflect IBNR
claims. The IBNR is modified to reflect actual current operating conditions. The liabilities are calculated gross of reinsurance. An
asset is then raised to allow for the expected recoveries from reinsurers.
ACQUISITION COSTS
Acquisition costs for group life insurance contracts comprise all direct costs arising from the sale of insurance contracts.
Commissions are expensed as incurred.
13.1.3 HEALTH INSURANCE
These contracts insure policyholders against healthcare-related claims.
PREMIUM REVENUE
Health insurance premiums received in respect of annual contracts are recognised proportionally over the period of the coverage. The
portion of the premium received on in-force contracts that relates to unexpired risks at the reporting period is reported as unearned
premiums within liabilities arising from insurance contracts. The unearned premium income is amortised on a straight- line basis.
174	Discovery Annual Financial Statements 2022

-- 175 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
13. 	Insurance contracts continued
13.1 	RECOGNITION AND MEASUREMENT continued
13.1.3 HEALTH INSURANCE continued
INSURANCE BENEFITS AND CLAIMS
Benefits payable under health insurance contracts are accounted for as incurred. Liabilities are held to reflect IBNR claims. The
IBNR calculation is performed using the chain ladder approach. This allows for the historic patterns of claims payment in
determining the likely future emergence of claims. The IBNR is further modified to reflect current operational conditions or known
events. The liabilities are calculated gross of reinsurance. An asset is then raised to allow for the expected recovery from reinsurers.
DEFERRED ACQUISITION COSTS
The direct costs (commissions) of acquiring short-term health insurance business which are incurred during the year, but which
are expected to be recoverable out of future revenue margins, are deferred and disclosed as an asset in the Statement of
financial position (gross of tax). The costs are deferred over the period of the contract and amortised on a straight-line basis in
line with unearned premiums.
FINANCIAL REINSURANCE
Where a financial reinsurance contract is taken out to protect against lapses, all acquisition costs related to the policy are
effectively deferred over the period of the reinsurance contract.
13.1.4 SHORT-TERM INSURANCE
These monthly contracts insure policyholders against a comprehensive spectrum of short-term risks including, but not limited to,
motor vehicle and household cover.
PREMIUM REVENUE
Short-term insurance premiums received in respect of monthly contracts are recognised as revenue when due. Premiums are
shown before the deduction of commission, less the fuel cash back rewards described below, and exclude value-added tax.
UNEARNED PREMIUM PROVISION
An unearned premium provision is created at the commencement of each insurance contract and is released as the risk covered
by the contract expires. The Unearned Premium Provision, represents a proportion of premiums underwritten in the current
year, which relate to risks which have not expired by the end of the financial year. This is calculated on a time-proportionate basis
for even risks. Therefore, the unearned premium is released over the period of insurance using a method which approximates
the time period of the risk covered. The unearned premium provision is calculated on a gross basis.
REINSURANCE COMMISSION INCOME
Reinsurance commission income is recognised in profit or loss over the period of the related direct insurance business assumed.
INSURANCE BENEFITS AND CLAIMS
Claims are accounted for as incurred and consist of claims paid, movement in the provision for outstanding claims and related
claims handling expenses.
The provision for outstanding claims is based on estimates of the cost of settling all claims incurred but unpaid at the reporting
date, whether reported or not. Related anticipated reinsurance recoveries are disclosed separately as assets in the Statement of
financial position and are included in recoveries from reinsurers in profit or loss.
SALVAGE AND SUBROGATION RECOVERIES
Certain short-term insurance contracts allow Discovery to sell property acquired as a result of a claim (salvage). Discovery may
also have the legal right to pursue third parties for payment of some or all of the costs (subrogation).
The estimated salvage and subrogation reimbursements are treated as a reduction in the measurement of claims liability.
ACQUISITION COSTS
Acquisition costs for these contracts comprise all direct costs arising from the sale of insurance contracts and are recognised in
profit or loss for monthly policies and deferred in acquisition costs for future periods, over the term of the contract.
175	Discovery Annual Financial Statements 2022

-- 176 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
13. 	Insurance contracts continued
13.1 	RECOGNITION AND MEASUREMENT continued
13.1.4 SHORT-TERM INSURANCE continued
INSURE FUNDER ACCOUNT (IFA)
This relates to a benefit on a short-term insurance product. A fuel cash back can be used to either reduce the premium that the
policyholder is required to pay for the month in question or can be doubled and paid into an IFA.
Where the policyholder has used the fuel cash back to reduce the monthly premium, the reduction has been shown in insurance
premium revenue in profit or loss as incurred.
If the policyholder has elected to double the fuel cash back and paid it into an IFA, an IFA liability is raised. The IFA liability is
calculated using a discounted cash flow approach and is disclosed in liabilities arising from insurance contracts in the Statement
of financial position and the movement is disclosed in the transfer to liabilities under insurance contracts.
When the member uses funds in the IFA to pay for his excess or other costs, the excess is paid by Discovery and an expense is
included in claims in the income statement.
Where the member withdraws the funds after three years, the member is paid out in cash and an expense is disclosed against
insurance premium revenue in the income statement.
13.2 	EMBEDDED DERIVATIVES ARISING FROM INSURANCE CONTRACTS
A unit-linked insurance contract is an insurance contract with an embedded derivative linking payments on the contract to units
of an investment fund purchased with the consideration received from the contract holders. This embedded derivative meets the
definition of an insurance contract and is therefore not accounted for separately from the host insurance contract. The liability
for such contracts is adjusted for all changes in the fair value of the underlying assets.
Discovery does not separately measure embedded derivatives that meet the definition of an insurance contract or options to
surrender insurance contracts for a fixed amount (or amount based on a fixed amount and an interest rate). All other embedded
derivatives are separated and carried at fair value if they are not closely related to the host insurance contract and meet the
definition of a derivative. Embedded derivatives that are separated from the host contract are fair valued through profit or loss.
13.3 	LIABILITY ADEQUACY TEST
At the reporting date, liability adequacy tests are performed to ensure the adequacy of the contract liabilities net of related
deferred acquisition costs. In performing these tests, current best estimates of future contractual cash flows and claims handling
and administration expenses are used. Any deficiency is immediately charged to profit or loss initially by writing off deferred
acquisition costs and by subsequently establishing a provision for losses arising from the liability adequacy test.
13.4 	REINSURANCE CONTRACTS
Contracts entered into by Discovery with reinsurers under which Discovery is compensated for insured events on one or more
contracts that meet the classification requirements for insurance contracts are classified as reinsurance contracts. Contracts that
do not meet these classification requirements are classified as financial assets.
Amounts recoverable from or due to reinsurers are measured consistently with the amounts associated with the reinsured
insurance contracts and in accordance with the terms of each reinsurance contract.
The amounts Discovery is required to pay under its reinsurance contracts held are recognised as reinsurance liabilities (liabilities
arising from reinsurance contracts).
Outward reinsurance premiums are recognised as an expense and are accounted for when due under the reinsurance contract. The
amounts due to Discovery under its reinsurance contracts are recognised as reinsurance assets (classified within insurance receivables).
Discovery assesses its reinsurance assets for impairment on an annual basis.
In certain cases there is a net gain or loss at inception of a reinsurance contract:
❚ 	Where these amounts relate directly to a reimbursement of expenses the gain is disclosed as a recovery of expenses from
reinsurers; or
❚ 	Other gains or losses are amortised over the life of the reinsurance contract on a consistent basis as the profit is expected to
emerge on the underlying policies but considering the contractual terms and intent of the specific reinsurance contract.
In certain cases there is a net gain or loss upon early termination of a reinsurance contract. Where these amounts result directly
from the termination, they are recognised as at the termination date and disclosed as recapture of reinsurance in profit or loss.
13.5 	RECEIVABLES AND PAYABLES RELATED TO INSURANCE CONTRACTS
Receivables and payables are recognised when due. These include amounts due to and from agents, brokers and insurance
contract holders. Amounts due are measured consistently and where applicable, provisions for impairments are recognised.
176	Discovery Annual Financial Statements 2022

-- 177 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
14. 	Investment contracts
Investment contracts are those contracts that transfer financial risk without significant insurance risk. Financial risk refers to the
risk of a possible future change in the value of an asset or financial instrument due to a change in interest rate, commodity price,
index of prices, foreign exchange rate or other measurable variables.
Discovery issues investment contracts without fixed benefits (e.g. unit-linked and structured products) and investment contracts
with fixed and guaranteed benefits (e.g. term certain annuity).
VALUATION OF POLICYHOLDER LIABILITIES
Investment contracts without fixed benefits are financial liabilities whose fair value is dependent on the fair value of the underlying
financial assets and derivatives (unit-linked) which are classified at fair value through profit or loss. Discovery designates these
investment contracts to be measured at fair value through profit or loss because it eliminates or significantly reduces a
measurement or recognition inconsistency that would otherwise arise from measuring assets or liabilities or recognising the
gains and losses on them on different bases. See accounting policy 7 for the financial assets backing these liabilities.
Discovery’s main valuation techniques incorporate all factors that market participants would consider and are based on
observable market data. The fair value of a unit-linked financial liability is determined using the current unit price that reflects the
fair values of the financial assets contained within Discovery’s unitised investment funds linked to the financial liability. The fair
value of the financial liabilities is obtained by multiplying the number of units attributed to each policyholder at the reporting date
by the unit price for the same date.
For investment contracts with fixed and guaranteed terms, valuation techniques are used to establish the fair value at inception
and at each reporting date. Valuation techniques include discounted cash flow analysis using current market rates of interest and
reference to other instruments that are substantially the same.
PREMIUM REVENUE
All premiums received under investment contracts are recorded as deposits to investment contract liabilities and claims incurred
on investment contracts are recorded as deductions from investment contract liabilities.
FEES ON INVESTMENT CONTRACTS
Service fee income on investment management contracts is recognised over time as and when the related performance obligation
is satisfied. Refer accounting policy note 20. Fees on investment contracts are included in fee income from administrative business.
A deferred revenue liability (DRL) is recognised as a contract liability to contracts with customers in respect of upfront fees for
financial advice, investment management and other services which are directly attributable to a contract that are charged for
securing the investment management service contract. The DRL is then released to revenue when the performance obligations
are satisfied, which corresponds to the underlying expected profit signature of the contract.
Regular fees are charged to the customer monthly either directly or by making a deduction from invested funds.
COSTS OF OBTAINING CONTRACTS
Deferred acquisition costs on investment contracts represent the contractual customer relationship and the right to receive
future investment management fees. Incremental costs directly attributable to securing rights to receive policy fees for services
sold with investment contracts, are recognised as an asset where they can be identified separately and measured reliably and it
is probable that they will be recovered. An incremental cost is one that would not have been incurred if the Group had not
secured the investment contract.
The asset represents the Group’s contractual right to benefit from providing asset management services and is amortised over
the expected life of the contract as the entity recognises the related revenue.
15. 	Borrowings
Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently measured at
amortised cost. Any difference between the proceeds and the redemption value is recognised in profit or loss over the period of
the borrowings using the effective interest method.
Fees paid on the establishment of loan facilities are recognised as transaction costs against the loan to the extent that it is
probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw-down occurs. To the
extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a
prepayment and amortised over the period of the facility to which it relates.
Preference shares, which are mandatorily redeemable on a specific date, are classified as liabilities. The dividends on these
preference shares are recognised in profit or loss as finance costs using the effective interest method.
177	Discovery Annual Financial Statements 2022

-- 178 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
16. 	Deferred income tax
Discovery calculates deferred income tax on all temporary differences using the Statement of financial position approach.
Deferred tax liabilities or assets are calculated by applying corporate tax rates that have been substantively enacted to the
temporary differences between the tax values of assets and liabilities and their carrying amount, where such temporary
differences are expected to result in taxable or deductible amounts in determining taxable income for future periods when the
carrying amount of the assets or liabilities are recovered or settled.
Discovery recognises deferred tax assets if the directors of Discovery consider it probable that future taxable income will be
available against which the tax losses can be utilised.
Temporary differences arise primarily from the difference between accounting and tax balances arising from insurance contracts,
depreciation of property and equipment, effect of accounting for leases, revaluation of certain financial assets and liabilities,
provisions for leave pay, provisions for share-based payments and tax losses carried forward. For leases, Discovery assesses the
lease asset and lease liability together as a single transaction and assesses the temporary difference on a net basis.
Deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a
business combination that at the time of the transaction affects neither accounting nor taxable income.
Deferred tax related to cash flow hedges, which are charged or credited directly to the statement of other comprehensive income,
is also credited or charged directly to the statement of other comprehensive income and is subsequently recognised in profit or
loss when the gain or loss is realised.
Deferred income tax assets and liabilities are offset when:
❚ 	There is a legally enforceable right to offset current tax assets against current tax liabilities; and
❚ 	When the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on either the
taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.
If offsetting does not apply, Discovery separately discloses the deferred tax asset and deferred tax liability.
17. 	Employee benefits
17.1 	SHORT-TERM EMPLOYEE BENEFITS
Short-term employee benefits are expensed as the related service is provided. A liability is recognised for the amount expected
to be paid if Discovery has a present legal or constructive obligation to pay this amount as a result of past service provided by the
employee and the obligation can be estimated reliably.
17.2 	POST-EMPLOYMENT BENEFITS
Discovery operates defined contribution schemes, the assets of which are held in separate private trustee-administered funds.
Discovery pays contributions to these funds on a mandatory basis. These funds are registered in terms of the Pension Funds Act,
1956, and membership is compulsory for all Discovery employees. Qualified actuaries perform annual valuations. Discovery has
no further payment obligations once the contributions have been paid. The contributions are recognised as an employee benefit
expense when they are due.
17.3 	SHARE-BASED COMPENSATION
Discovery operates equity-settled and cash-settled share-based compensation plans.
EQUITY-SETTLED SHARE-BASED COMPENSATION PLANS
Discovery expenses the fair value of the employee services received in exchange for the grant of the options, over the vesting period
of the awards, as employee costs, with a corresponding credit to a share-based payment reserve in the Statement of changes in
equity. The total value of the services received is calculated with reference to the fair value of the options on grant date.
The fair values of the options are determined excluding non-market vesting conditions. These vesting conditions are included in the
assumptions of the number of options expected to vest. At each reporting date, Discovery revises its estimate of the number of
options expected to vest. Any changes to the estimated number of options are recognised in profit or loss immediately.
CASH-SETTLED SHARE-BASED COMPENSATION PLANS
Discovery recognises employee services received in exchange for cash-settled share-based payments at the fair value of the
liability incurred and expenses these services over the vesting period of the benefits, as employee costs.
The liability is re-measured at each reporting period to its fair value, with all changes recognised immediately in profit or loss.
178	Discovery Annual Financial Statements 2022

-- 179 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
17. 	Employee benefits continued
17.4 	LEAVE PAY
Discovery accrues in full the employees’ rights to annual leave entitlement in respect of past service. This is expensed over the
period the services are rendered.
17.5 	PROFIT SHARE AND BONUS PLAN
Discovery operates several other profit sharing and bonus compensation arrangements and recognises these when a constructive
obligation has been created by past practice. These are calculated with reference to predetermined formulae. The Group has
other deferred compensation schemes in place where employees are incentivised based on a variable other than the share price
of Discovery Limited, such as embedded value, value of in-force and earnings multiples. Discovery recognises a liability and the
related expense is included in employee costs in profit or loss.
18. 	Trade and other payables
Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from
suppliers. Trade payables are classified as current liabilities if payment is due within one year or less from the reporting date. If
not, they are presented as non-current liabilities.
Trade payables are recognised initially at fair value and subsequently measured at amortised cost using the effective
interest method.
19. 	Contingent liabilities
Discovery discloses a contingent liability when:
❚ 	It has a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-
occurrence of one or more uncertain future events not wholly within the control of the entity; or
❚ 	It has a present obligation that arises from past events but not recognised because:
– It is not probable that an outflow of resources will be required to settle an obligation; or
– The amount of the obligation cannot be measured with sufficient reliability.
20. 	Revenue recognition
The Group’s primary source of revenue arises on the sale of insurance contracts which are accounted for under IFRS 4 Insurance
Contracts and are excluded from the scope of IFRS 15 Revenue from Contracts with Customers. IFRS 15 is applicable to the Group’s
revenue from administration business, Vitality income and banking fee and commission income.
IFRS 15 requires that once contracts have been identified, the entity identifies the performance obligations in the contract. This
is determined on the basis of whether the customer can benefit from the promised good or service individually or together with
other readily available resources and whether the performance obligation is distinct in the context of the contract. For the Group,
most contracts contained a single performance obligation.
The timing of revenue recognition is dependent on whether the entity transfers control over the good or service over time or at a point
in time. In determining the appropriate timing for revenue recognition, the Group considers whether the customer benefits as the
entity performs. For most revenue types, Group entities provide stand ready services to customers, where customers benefit as the
entities services are consumed. In limited instances where revenue is not recognised over time it is recognised at a point in time when
control transfers. For revenue recognised over time the stand ready service is recognised straight line over the term of the contract.
In determining the amount of revenue to recognise, the Group considers any uncertainty created through variable consideration
contained in the contract, and constrains the recognition of revenue in order to recognise revenue only to the extent that it is highly
probably that a significant reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty is
resolved. The Group also considers the impact of the timing of receiving payments for revenue transactions and determines whether
a significant financing component should be taken into account in the measurement of the transaction price. As the Group’s contracts
routinely include single performance obligations, there is limited complexity in allocating transaction prices to performance obligations.
Payment terms vary across the different revenue types earned by the Group.
Where contracts with customers involve a third party, the Group considers whether it is acting as the principal or the agent in the
delivery of the promised goods or services to the customer. This assessment is based on whether the Group controls the goods
or services before it is transferred to the customer.
For certain contracts with customers, Discovery receives income in advance of discharging the related performance obligation. In
these instances, the amount is recognised as a contract liability incurred in the acquisition or fulfilment of a contract. Discovery
considers whether there are costs incurred for the acquisition or fulfilment of a contract. These costs are recognised as an asset
and amortised over the expected period over which performance obligations under the contract are satisfied. Contract costs
incurred that are considered to be of a general and administrative nature, that are not explicitly recovered from the customer,
are expensed as incurred.
Where the transaction price included in a contract is payable less than 12 months from the date of satisfying the related
performance obligation the practical expedient is applied in that a significant financing component is not recognised. Similarly,
where costs of obtaining a contract would be amortised over 1 year or less, the costs are not recognised as a separate asset.
179	Discovery Annual Financial Statements 2022

-- 180 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
20. 	Revenue recognition continued
Fee income from
administration business 	Vitality Income
Banking fee and commission
income
Nature of
performance
obligations
Fee income is recognised on health
administration and managed care services
rendered. Fee income is also generated
on asset administration and fees earned
on use of intellectual property. In the
respective business these are considered
revenue and are seen as single performance
obligations in the respective legal entities.
These are separated by underlying
reported entity in the segmental report
shown in note 1.
Vitality income includes the
fee income that members of
corporations pay to access the
Vitality benefit, as well as
various activation fees for
activating additional benefits.
The performance obligation
relates to access to the Vitality
rewards 	programme 	and
partner benefits provided to
members.
Banking fee and commission
income includes banking service
fees for banking services. The
performance obligation relates
to the access to banking and
banking 	services 	rendered.
Commission income relates to
the interchange fees which
Discovery 	Bank 	earns 	on
transactions using debit or
credit cards. The performance
obligation relates to settlement
of transactions via the card
network.
When does
control pass –
Point in time
(PIT) vs over
time
Performance 	obligation 	to 	provide
administration services are considered
stand ready services, the customer
obtains control over the service as the
entity makes its services available on an
“as and when” basis. As a result, revenue
is recognised over time, as the respective
entity makes the services available, based
on the passage of time.
Performance obligations to
provide access to benefits
are considered stand ready
services as the customers
obtains benefits over the
duration 	of 	the 	contract
and when required by the
customers. 	As 	a 	result
revenue is recognised over
time based on the passage
of time.
The 	performance 	obligation
associated with the banking fee
and commission income passes
over time because the client
obtains substantially all of the
remaining benefits from the
service over the period of the
month for which the banking
fee was charged.
When are
amounts
payable
Amounts 	are 	billed 	on 	health
administration 	and 	managed 	care
business at the end of the respective
month with amounts paid within 30 days.
For fees on asset administration business,
amounts are disinvested for the units
held at the end of the related month.
Certain fees for example advisor fees are
received upfront but are deferred as a
contract liability over the expected term
of the entity’s performance.
Amounts are billed either
monthly, 	payable 	within
30 days, or billed on activation
of 	the 	benefit, 	payable
immediately.
Banking 	fees 	are 	charged
monthly 	and 	payment 	is
immediate. Interchange income
is charged at a point of payment
and settled daily in batch
format.
180	Discovery Annual Financial Statements 2022

-- 181 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
20. 	Revenue recognition continued
Fee income from
administration business 	Vitality Income
Banking fee and commission
income
Variable
consideration
and estimates
There is no potential for amounts of
revenue to vary relating to discounts or
rebates on the health administration
business.
For the asset administration business, fees
are determined with reference to assets
under management at a point in time.
There are no benchmark performance
based fees. The nature of the integrated
products that Discovery sells related to
the invest business allows for fee
discounts and rebates to be determined
based on client behaviour.
Revenue is estimated and recognised
in line with the constraint on variable
consideration, only to the extent that it is
highly probable that there will not be a
significant reversal of revenue already
recognised once the uncertainty is resolved.
The fee discounts and rebates are
determined 	according 	to 	a 	fixed
methodology incorporating policyholder
specific information including Vitality status.
Discovery has experience in estimating
these amounts, which are based on a
limited number of outcomes. There is no
financing component.
There are no adjustments to
the transaction price as a result
of any variable consideration.
There 	is 	no 	significant
financing component.
There are no adjustments to
the transaction price as a result
of any variable consideration.
There is no significant financing
component.
Costs to
capitalise
Where costs are incurred directly to secure
a new health administration customer,
and the contract is expected to exceed 12
months, the costs are capitalised and
amortised over the expected term of the
contract. Costs are routinely incurred on
the asset administration business related
to commission and other incremental
costs of entering into the contract. These
are capitalised and recognised over the
expected duration of the customer
relationship. These assets are tested for
impairment to the extent that the carrying
amount of the asset exceeds the expected
remaining net cash inflows from the
customer contract.
In respect of the Apple watch
benefit, Discovery incurs costs
upfront to purchase the device
and provide it to the customer.
These costs are deferred and
recognised over the two year
term of the benefit.
None.
INSURANCE PREMIUM REVENUE
Insurance premium revenue includes individual life insurance premiums, group life insurance premiums, health insurance
premiums and short-term insurance premiums. These are accounted for as described in accounting policy 13.
181	Discovery Annual Financial Statements 2022

-- 182 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
21. 	Other non-revenue income
21.1 	INVESTMENT INCOME
Investment income comprises dividends and interest received from assets held at amortised cost and cash and cash equivalents.
Discovery recognises dividends when Discovery’s right-to-receive payment is established. This is on the “last day to trade” for
listed shares and on the “date of declaration” for unlisted shares. Dividend income includes scrip dividends, irrespective of
whether there is an option to receive cash instead of shares.
Interest is accounted for on an accrual basis using the effective interest method.
21.2 	NET FAIR VALUE GAINS ON FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS
Net fair value gains on financial assets at fair value through profit or loss include gains arising from interest, dividends and net
realised and unrealised gains on financial assets held at fair value through profit or loss.
22. 	Leases
IDENTIFICATION OF A LEASE
At inception of a contract, Discovery assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the
contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess
whether a contract conveys the right to control the use of an identified asset, Discovery uses the definition of a lease in IFRS 16.
Contracts where the service provider has a substantive right to substitute the asset for an alternative asset during the lease term
is not regarded as a lease, but instead a service contract. Accordingly, these contracts are not accounted for in accordance with
IFRS 16. For Discovery, such contracts include items such as vending machines.
22.1 	AS A LESSEE
At commencement or on modification of a contract that contains a lease component, Discovery allocates the consideration in the
contract to each lease component on the basis of its relative stand-alone prices. However, for the leases of property Discovery has
elected not to separate non-lease components and account for the lease and non-lease components as a single lease component.
Discovery recognises a right-of-use asset and a lease liability at the lease commencement date. Discovery presents right-of-use
assets in ‘Property and equipment’ and lease liabilities in ‘Borrowings at amortised cost’ in the Statement of financial position.
Discovery leases the following assets with a range of lease terms:
– Large offices 	5 – 15 years
– Small offices/Franchise offices (SA only) 	1 – 3 years
– Computer equipment (e.g. servers) (SA only) 	3 – 4 years
– Motor vehicles (UK only) 	3 years
MEASUREMENT
LEASE LIABILITY
The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date,
discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the lessee’s incremental
borrowing rate. Generally, Discovery uses its incremental borrowing rate as the discount rate.
Discovery determines its incremental borrowing rate by obtaining interest rates from various external financing sources and
makes certain adjustments to reflect the terms of the lease and type of the asset leased. The incremental borrowing rates were
calculated for each legal entity within Discovery that entered into lease arrangements. The incremental borrowing rate considers
a base interest rate reflective of the jurisdiction in which the legal entity operates (South Africa, United Kingdom and United
States of America), the term of the lease arrangement and the nature of the assets.
182	Discovery Annual Financial Statements 2022

-- 183 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
22. 	Leases continued
22.1 	AS A LESSEE continued
Lease payments included in the measurement of the lease liability comprise the following:
❚ 	fixed payments, including in-substance fixed payments;
❚ 	variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
❚ 	amounts expected to be payable under a residual value guarantee; and
❚ 	the exercise price under a purchase option that Discovery is reasonably certain to exercise, lease payments in an optional
renewal period if Discovery is reasonably certain to exercise an extension option, and penalties for early termination of a lease
unless Discovery is reasonably certain not to terminate early.
Extension or termination options are included in a number of the building leases across Discovery. These terms are used to
maximise operational flexibility in terms of managing contracts. In determining the lease term, management considers all facts
and circumstances that create an economic incentive to exercise an extension option, or not exercise a termination option.
Extension options (or periods after termination options) are considered in the lease term when there is reasonable certainty that
those options will be exercised.
The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in
future lease payments arising from a change in an index or rate, if there is a change in Discovery’s estimate of the amount
expected to be payable under a residual value guarantee, if Discovery changes its assessment of whether it will exercise a
purchase, extension or termination option or if there is a revised in-substance fixed lease payment. When the lease liability is
remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in
profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.
RIGHT-OF-USE ASSET
The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease
payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle
and remove the underlying asset or to restore the underlying asset, less any lease incentives received. Discovery receives
incentives such as reimbursements for installations or rent-free periods.
The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of
the lease term, unless the lease transfers ownership of the underlying asset to Discovery by the end of the lease term or the cost
of the right-of-use asset reflects that Discovery will exercise a purchase option.
In that case the right-of-use asset will be depreciated over the useful life of the underlying asset, which is determined on the same
basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any,
and adjusted for certain remeasurements of the lease liability.
SHORT-TERM LEASES AND LOW VALUE ITEMS
Discovery has elected not to recognise right-of-use assets and lease liabilities for leases of low-value assets and short-term
leases. Discovery recognises the lease payments associated with these leases as an expense on a straight-line basis over the
lease term.
Leases of low value assets relate to those categories of assets which at inception of the lease typically have a value, if bought new,
of no more than approximately R70 000. For Discovery, these categories include computer equipment such as desktops, laptops,
monitors and related IT peripherals.
Short-term leases are those leases with a lease term of less than 12 months.
22.2 	AS A LESSOR
At inception or on modification of a contract that contains a lease component, Discovery allocates the consideration in the
contract to each lease component on the basis of their relative standalone prices.
CLASSIFICATION
To classify the lease, Discovery makes an overall assessment of whether the lease transfers substantially all of the risks and
rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an
operating lease.
As part of this assessment, Discovery considers indicators such as whether the lease is for the major part of the economic life of
the asset, the specialised nature of the asset and the present value of lease payments.
183	Discovery Annual Financial Statements 2022

-- 184 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
22. 	Leases continued
22.2 	AS A LESSOR continued
Discovery leases out portions of its leased property in the form of subleases. Discovery has classified these leases as operating
leases.
MEASUREMENT
As Discovery is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the
lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the
underlying leased asset.
If an arrangement contains lease and non-lease components, Discovery applies IFRS 15 Revenue from Contracts with Customers
to allocate the consideration in the contract.
Discovery recognises lease payments received under operating leases as income on a straightline basis over the lease term as
part of ‘other income’.
23. 	Marketing and administration expenses
Marketing and administration expenses include marketing and development expenditure, all other non-acquisition related
expenditure and benefits paid under the Vitality programme. These costs are expensed in profit or loss as incurred.
24. 	Finance costs
Finance costs (net of investment income earned on the temporary investment of specific borrowings pending their expenditure
on qualifying assets) directly attributable to the acquisition, construction or production of assets that necessarily take a substantial
period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are
substantially ready for their intended use or sale. All other finance costs are recognised as an expense in profit or loss on an
accrual basis using the effective interest method.
In addition, finance costs include any recycled gains or losses from other comprehensive income arising from cash flow hedges
of interest rates, amortisation of financing related fees such as loan commitment fees and letter of credit fees as well as
modification gains and losses on borrowings.
25. 	Direct and indirect taxes
Direct taxes include South African and foreign jurisdiction corporate tax payable and are disclosed as taxation in profit or loss.
Indirect taxes include various other taxes paid to central and local governments, including value-added tax and skills development
levies. Indirect taxes are included as part of marketing and administration expenses in profit or loss.
The charge for current tax is based on the results for the year as adjusted for items which are non-taxable or disallowed. It is
calculated using taxation rates that have been enacted or substantively enacted by the reporting date, in each particular
jurisdiction within which the Discovery entities operate.
Taxation in respect of the South African life insurance operations is determined in accordance with the rates and basis applicable
to section 29A of the Income Tax Act at the reporting date.
26. 	Dividend distribution
Dividend distribution to Discovery Limited’s shareholders is recognised as a liability in the Group’s financial statements in the
period in which the dividends are approved.
184	Discovery Annual Financial Statements 2022

-- 185 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
27. 	Non-current assets held for sale
Non-current assets, or disposal groups comprising assets and liabilities, are classified as held-for-sale if it is highly probable that
they will be recovered primarily through sale rather than through continuing use. Such assets, or disposal groups, are generally
measured at the lower of their carrying amount and fair value less costs to sell.
Any impairment loss on a disposal group is allocated first to goodwill, and then to the remaining assets and liabilities on a pro
rata basis, except that no loss is allocated to inventories, financial assets, deferred tax assets, employee benefit assets, investment
property or biological assets, which continue to be measured in accordance with the Group’s other accounting policies.
Impairment losses on initial classification as held-for-sale or held-for-distribution and subsequent gains and losses on
remeasurement are recognised in profit or loss.
Once classified as held-for-sale, intangible assets and property and equipment are no longer amortised or depreciated, and any
equity-accounted investee is no longer equity accounted. Interest and other expenses attributable to the liabilities of a disposal
group classified as held for sale continue to be recognised.
Non-current assets and liabilities classified as held for sale are presented separately from the other assets and liabilities in the
balance sheet.
28. 	Normalised headline earnings
Discovery assesses its performance using Normalised Headline Earnings, an alternative non-IFRS profit measure, alongside its
IFRS profit. Management considers that Normalised Headline Earnings Per Share (NHEPS) is an appropriate alternative
performance measure to enhance the comparability and understanding of the financial performance of Discovery.
Non-IFRS measures are not uniformly defined or used by all entities and may not be comparable with similarly labelled measures
and disclosures provided by other entities. Discovery has set out its policy to calculate NHEPS below.
Discovery calculates headline earnings in accordance with the latest SAICA Circular ‘Headline Earnings’. NHEPS is calculated by
starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal
operations as follows:
❚ 	Once-off transactions, for example, debt restructuring costs resulting from the DiscoveryCard business transaction,
restructuring costs and transaction costs related to interest rate derivatives.
❚ 	Unusual items – Discovery considers items to be unusual when they have limited predictive value and it is reasonable that
items of similar nature would not necessarily arise for several future annual reporting periods. These adjustments include
those gains or losses associated with changes in economic assumptions recognised in profit or loss, net of any gains or losses
on derivatives to offset such changes in economic assumptions. Adjustments are shown net of tax; or
❚ 	Income or expenses not considered to be part of Discovery’s normal operations, for example, amortisation of intangibles
from business combinations, fair value (gains)/losses certain foreign exchange contracts not designated as hedges and
specified foreign exchange gains or losses.
In addition, specified items may be included in NHEPS that may otherwise be included if the income is considered part of
Discovery's normal operations, for example 'gains on disposal of intellectual property', if the sale arises from the monetisation of
intellectual property rights. Management is responsible for the calculation of NHEPS and determining the inclusions and
exclusions in accordance with the policy. The Discovery Limited Audit Committee (DLAC) reviews the normalised headline
earnings for transparency and consistency.
185	Discovery Annual Financial Statements 2022

-- 186 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
28. 	Normalised headline earnings continued
During the financial period, Discovery has made the following adjustments in the determination of NHEPS:
Adjustment 	Explanation
Changes in economic
assumptions in excess of
available discretionary margin
(in future, this will also include
the reversals of economic
assumptions recognised in
profit or loss)
Economic assumptions include changes associated with interest rates as well as
currency exchange rates. The adjustment reflects changes in economic assumptions for
the time value of money and forex rates and the effect on insurance contracts resulting
from changes in the long-term interest rates as well as forex rates.
Under IFRS, where there are insufficient discretionary margins to offset losses arising
from negative changes in economic assumptions, those losses in excess of the
discretionary margin are recognised immediately in profit or loss. In subsequent
periods, positive changes in economic assumptions are first recognised separately in
profit or loss to the extent that it reverses related losses previously recognised in profit
or loss before it increases discretionary margins.
The effect of these economic assumptions is unusual and provides little predictive value
for future periods. This is because the value is dependent on available discretionary
margins at a given point in time and the long-term interest rates which could vary
period to period – thereby introducing volatility and inability to be predictive on results
during future periods. These adjustments are therefore excluded in assessing the
normal business operations of Discovery.
Intrinsic fair value changes on
specified derivatives to offset
changes in economic
assumptions
Long-term insurance business lines, for example VitalityLife enters into interest rate
derivative instruments to offset the impact of changes in economic assumptions on
insurance contracts.
The adjustment reflects the intrinsic value of fair value gains or losses on these derivative
instruments. The intrinsic value of fair value gains or losses on these derivative
instruments are excluded from NHEPS to be consistent with the treatment of the
changes in economic assumptions recognised in profit or loss.
186	Discovery Annual Financial Statements 2022

-- 187 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
28. 	Normalised headline earnings continued
Adjustment 	Explanation
Fair value (gains)/losses on
foreign exchange contracts not
designated as a hedge
The adjustment reflects fair value gains or losses on foreign exchange contracts entered
in anticipation of future capital injections in foreign operations, such as UK Composite
or Ping An Transfer. These derivative instruments are not designated as a hedge and as
a result, the fair value adjustments are recognised in profit or loss.
The fair value adjustments of these derivative instruments can result in volatility in
profit or loss and is therefore excluded in assessing the normal business operations of
Discovery as it relates specifically to a future once-off transaction.
Amortisation of intangibles from
business combinations
The adjustment reflects the amortisation of intangible assets which arose from the
purchase of various subsidiaries within Discovery and recognised in accordance with
IFRS 3 Business Combinations.
Intangible assets recognised from business combinations provide little predictive value
of the earnings from the business, as these assets will not be reacquired, renewed, or
replaced once depleted. Discovery also infrequently acquires businesses. The
amortisation of these assets is therefore excluded in assessing the normal business
operations of Discovery.
Deferred tax assets raised on
assessed losses
The adjustment reflects the initial recognition of deferred tax assets in respect of
assessed losses in prior financial periods, after evaluating that there is future taxable
income that will arise in the respective business.
The initial recognition of this deferred tax asset results in a once-off income recognised
in profit or loss. It provides no predictive value in assessing the normal business
operations of Discovery.
Initial expenses related to the
Prudential Book Transfer
The adjustment reflects professional fees and legal fees of the book transfer incurred in
anticipation of the Prudential Book Transfer.
As these expenses relate to a future once-off transaction it provides no predictive value
in assessing the normal business operations of Discovery and has therefore been
excluded from earnings.
Restructuring Costs 	The adjustment reflects restructuring costs which are once-off costs incurred to
restructure specified business areas.
These transaction costs are infrequent and therefore excluded in assessing the normal
business operations of Discovery.
Transaction costs related to
interest rate derivatives
Transaction costs paid to acquire specified derivative instruments to offset changes in
economic assumptions excluded from NHEPS.
These transaction costs are infrequent and therefore excluded in assessing the normal
business operations of Discovery.
Changes in tax balances
as a result of use of different
tax rates
The adjustments reflects the changes in current and deferred tax balances resulting
from the use of different tax rates that related to items that were excluded from
normalized headlines earnings in the current or prior periods.
Gain on disposal of intangible
assets - Vitality Group
International
The adjustments include those gains on disposal of intangible assets, e.g. in the
AmplifyHealth deal, where Vitality Group International monetised a specified regional
right to an initial component of its intellectual property rights via sale as opposed to a
licensing arrangement.
These gains are part of normal operations for Discovery.
187	Discovery Annual Financial Statements 2022

-- 188 of 219 --

29. 	IFRS 17 Insurance Contracts (standard issued not yet effective)
IFRS 17 INSURANCE CONTRACTS
The Effective date of IFRS 17 is for reporting periods beginning on or after 1 January 2023, with comparative restatement for 2022.
For the Discovery Group, IFRS 17 is therefore mandatory effective from 1 July 2023. IFRS 17 provides comprehensive guidance on
accounting for insurance contracts issued, reinsurance contracts held, and investment contracts with discretionary participation
features.
IFRS 17 requires the standard to be applied either retrospectively (full or modified retrospective) or using the fair value approach.
Given the availability of reliable and accurate data and actuarial models Discovery has elected to apply IFRS 17 retrospectively.
The retrospective approach will require Discovery to identify, recognise and measure groups of insurance contracts as if IFRS 17
had always applied. The retrospective approach has provided Discovery with the benefit of hindsight in how the results will be
impacted by model assumption changes, changes in the discount rates and unexpected stresses such as the financial crisis in
2009 and the COVID-19 pandemic. Based on the work completed the impact of retrospective restatement in terms of impact is
limited for short-term business, and more pronounced for long-term insurers
IFRS 17 IMPLEMENTATION PROGRESS
The group has progressed well with the conceptual design decisions and the system and model build required to implement IFRS
17. Management has undertaken a financial impact assessment to better understand the transitional balance sheet to be
presented as the opening balance adjustment as at 1 July 2022. This was a high-level exercise to estimate and evaluate of the
impact of IFRS 17 on the 30 June 2021 balances sheet, as well as other statement impacts for 2021. The transitional impact, taking
into account the financial year ended 30 June 2022, will be undertaken following the finalisation of the results for the year-end 30
June 2022. The exercise included the entities within Discovery Group impacted by IFRS 17 and the insurance contracts throughout
the Group. The assessment was based on the current working assumptions, however this was not a complete exercise as there
remain several interpretation items across the auditing and industry communities relating to the standard that have not been
resolved.
In South Africa National Treasury has released draft tax legislation to cater for the transition to IFRS 17 which indicates the
intention to retain an ‘adjusted IFRS’ tax basis, and phase-in the transitional tax impact over 6 years for long-term insurers and 3
years for short-term insurers. In the United Kingdom the indication is that government intends to spread the transitional impact
for Life Insurers over a 10 year period.
Accordingly, Discovery will delay the publishing of the quantative impact until a more accurate and reliable estimate can be
provided, which is expected in the latter part of the 2023 financial year.
It is anticipated that the impact of IFRS 17 will only be fully quantified with reasonable certainty during the financial year ending
30 June 2023 (being a combination of transition values as well as revenue recognition patterns). The group expects to be fully
prepared to start a parallel run during 2022, during which the new IFRS 17 processes will be run and embedded, and the working
assumptions refined and signed-off. Ongoing training initiatives are ensuring that various relevant stakeholders are familiar with
the implications and requirements of this new standard.
At this stage, the impact of IFRS 17 on regulatory capital is expected to be minimal given that the group has fully adopted the SAM
basis and, other than possible second order taxation implications, IFRS 17 should not impact regulatory capital assessment.
ANNEXURE B – GROUP ACCOUNTING POLICIES continued
188	Discovery Annual Financial Statements 2022

-- 189 of 219 --

29. 	IFRS 17 Insurance Contracts (standard issued not yet effective)
IFRS 17 IMPLEMENTATION PROGRESS continued
PROJECT GOVERNANCE
The Group CFO heads up the IFRS 17 Executive Working Committee which comprises of the respective Insurance business CFOs,
Chief Actuaries, and IT specialist. The IFRS 17 Executive Working Committee is supported by a Technical Advisory Group comprising
of IFRS Specialists, Actuaries, Financial Managers, and Tax.
The Executive Working Committee is responsible for providing overall strategic direction to the project and monitor progress and
interdependencies with other group initiatives. The committee is also providing policy guidance and technical support for the
implementation in its subsidiaries.
The Executive Working Committee report into the Group Finance and Capital Committee (FCC) in its capacity as a sub-committee
of the Group Executive Committee and recommends and suggest its final proposal to the IFRS 17 Governance Committee.
KPMG Inc, as current joint auditor, and Deloitte and Touche as proposed joint auditor following the mandatory audit firm rotation
for PricewaterhouseCoopers, have been engaged to provide the external audit assurance for IFRS 17 in their capacity as the
external auditors for the financial year ending 30 June 2024, the first year that Discovery will apply IFRS 17. A combined assurance
approach is being followed whereby group internal audit and external audit are incrementally testing the new IFRS 17 landscape,
and control improvements have already been identified for implementation.
Finance and Capital Committee
The FCC will ensure robust management of the Operating Model across the Group to ensure delivery of the Group strategy.
Those policies, methodology and judgements which have a significant impact on IFRS 17 or contentious issues should be
presented for decision making to the FCC. The FCC will also receive feedback on progress of IFRS 17 project and the key risks for
delivering on the project.
Governance committee
The IFRS 17 Governance Committee comprises members of the Discovery Limited Audit Committee, Discovery Limited Actuarial
Committee, UK Composite Audit Committee and UK Composite Actuarial Committee. It may also include other non-executive
directors on the Discovery Limited or UK Composite boards.
The IFRS 17 Governance Committee is a subset of the Discovery and UK Composite Audit and Actuarial Committees, that allows more
efficient decision making and enables the representatives of these committees to ensure appropriate rigour and debate into the more
complex matters, consistency in application, decisions and progress of the project and to assist the respective committees to discharge
their obligations on the IFRS 17 project.
Project focus:
The IFRS 17 project team will focus on the following key areas during the next financial reporting period:
❚ 	Complete the system development and key controls for implementation of IFRS 17
❚ 	Produce and request business sign-off
❚ 	External audit of transition balances
❚ 	Commence with the IFRS 4/ IFRS 17 parallel runs
❚ 	Finalise and produce as part of parallel run IFRS 17 compliant financial statements
❚ 	Finanalise management reporting, and where applicable, key performance measures
❚ 	Continue engaging with the executive with training initiatives to ensure robust implementation of IFRS 17,
❚ 	Finalise business-as-usual future financial and data governance processes and financial reporting controls.
189	Discovery Annual Financial Statements 2022

-- 190 of 219 --

29. 	IFRS 17 Insurance Contracts (standard issued not yet effective) continued
IFRS 17 OVERVIEW
INSURANCE CONTRACT DEFINITION
The definition for an insurance contract has remained largely the same between IFRS 4 and IFRS 17 and thus there has not been
a significant change in contracts identified as insurance contracts under IFRS 4 vs IFRS 17 within Discovery. An insurance contract
is defined as a contract under which one party (the issuer) accepts significant insurance risk from another party (the policyholder)
by agreeing to compensate the policyholder if a specified uncertain future event (the insured event) adversely affects the
policyholder. IFRS 17 requires the significant insurance risk to be determined on a present value (discounted) basis, unlike IFRS
4. The significance of insurance risk is also assessed on a contract-by-contract basis.
Discovery is ensuring that in the transition to IFRS 17 it appropriately reassesses its products to define more clearly when
significant insurance risk is transferred or not by introducing a threshold to better differentiate between insurance and investment
contract, consistent with IFRS 17. Within industry, several entities apply a 10% threshold to establish significant insurance risk and
the Discovery threshold will most likely fall within this range. This may result in some products with a small amount of insurance
risk not being in the scope of insurance contracts.
UNIT OF ACCOUNT
In terms of IFRS 17 the unit of account is a group of insurance contracts. The manner contracts are grouped affects the timing of
recognition of profit for insurance services but does not affect the measurement of the cash flows to fulfil the insurance contracts.
Applying IFRS 17 the unit of account is split at the ‘portfolio’ level, profitability level as well as at the inception date (refer to the
image below.)
Portfolio
Insurance contracts that are subject to similar risks and managed together
Annual cohorts grouped into one of the following:
Onerous at initial Recognition
(Onerous)
Other
(Profitable as risk)
At initial recognition, no
significant possibility of becoming
onerous (Profitable)
MEASUREMENT OF INSURANCE CONTRACTS
IFRS 17 introduces a default measurement model referred to as the General Measurement Model (GMM). The GMM does not
distinguish insurance contracts between short-term or long-term insurance products. Rather, IFRS 17 introduces modifications
to the general model (i.e., the Variable Fee Approach (VFA)) and simplifications to the general model (the Premium Allocation
Approach (PAA)).
ANNEXURE B – GROUP ACCOUNTING POLICIES continued
190	Discovery Annual Financial Statements 2022

-- 191 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
29. 	IFRS 17 Insurance Contracts (standard issued not yet effective) continued
IFRS 17 OVERVIEW continued
GENERAL MEASUREMENT MODEL
The main measurement principles under the GMM are as follows:
1. The total liability/asset of a group of insurance contracts comprises the Liability for Remaining Coverage (LRC) and Liability
for incurred claims (LIC). The LRC and LIC are measured as a sum of the following components:
i. 	Fulfillment cash flows which comprise:
a. Estimates of expected future cash flows (inflows and outflows) over the life of the contract. The cashflows include
insurance acquisition cashflows
b. An adjustment to reflect the time value of money – i.e. discounting – and the financial risks related to the expected
cash flows
c. 	An explicit risk adjustment for non-financial risk: to reflect the compensation that the entity requires for bearing the
uncertainty about the amount and timing of cash flows that arise from non-financial risk, also referred to as risk
adjustment
ii. 	A contractual service margin (CSM) representing unearned profit an entity will recognise as it provides service under the
insurance contracts in the group. The CSM is a component that is applicable only to the LRC and not the LIC.
2. 	The basic revenue recognition principle under IFRS 17 is that no profit is recognised on initial recognition of a group of
insurance contracts. This is achieved by setting up the CSM on initial recognition of the group of insurance contract equal
to the expected profit on initial recognition. However, a loss must be recognised for a group of contracts that is onerous
upon initial recognition, which is consistent with the principles of other IFRS on onerous contracts.
3. 	The revenue and profit are recognised as insurance contract services are performed under the contract. In broad terms,
insurance contract services related to the provision of risk cover to the policy holder.
The diagram below provides a view of the liability/(asset) for a group of insurance contracts at initial measurement:
Cash flows within contract boundary
Future
cash
inflow
Future
cash
outflows
Discounting
Non-financial
risk adjustment
Contractual
service margin
(i.e., future
profits)
Subsequent to initial recognition, the liability of a group of insurance contracts comprises the LRC (fulfilment cash flows and CSM)
as well as the LIC (claims and expenses already incurred but not yet paid).
The diagram below reflects how changes in the LRC and LIC are recognised in profit or loss, and the accounting policy election
available for the treatment of changes in financial risk.
191	Discovery Annual Financial Statements 2022

-- 192 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
29. 	IFRS 17 Insurance Contracts (standard issued not yet effective) continued
IFRS 17 OVERVIEW continued
GENERAL MEASUREMENT MODEL continued
Fulfillment
cash inflows OCI
P/L
CSM
CSM allocation
Financial risk assumptions (e.g., interest rates)
Past and current service
Future service
Reclassify
Either
Or
Within the Discovery Group the following entities will have portfolios that apply the GMM:
❚ 	Discovery Life – Discovery Life Plan polices (whole of life insurance products) are considered to be a single portfolio
❚ 	Discovery Invest – the general endowment products are considered to be a single portfolio
❚ 	VitalityLife – Vitality Life whole of life and term products are considered to be separate portfolios and the PAC Book will be
treated as a separate portfolio
Similarities with current Discovery policy
❚ 	Discovery values the policyholder liabilities using a prospective discounted cash flow valuation basis. The best estimate non-
economic assumptions under IFRS 17 and IFRS 4 are unchanged.
❚ 	Discovery applies compulsory and discretionary margins to the best estimate assumptions to avoid the recognition of future
profits at initial recognition. In broad terms, this is similar to the risk adjustment and contract service margin respectively that
is required in IFRS 17
❚ 	The present value of the best estimate cash flows are calculated using market-consistent economic assumptions with
reference to a yield curve. Under IFRS 4 Discovery discounts at a nominal discount rate equal to the JSE nominal bond curve.
Under IFRS 17 Discovery is considering to discount using current risk-free discount rates. The likely source of SA risk-free
curves is the JSE nominal bond curve, similar to IFRS 4 today. The likely source of the UK risk-free curves are those aligned to
in the Solvency II reporting.
Differences with current Discovery policy
❚ 	Discovery currently applies the definition of portfolio in a broader sense while IFRS 17 will apply in a more granular fashion,
particularly the cohorting. This will reduce the extent of cross subsidisation within a portfolio.
❚ 	The risk adjustment is conceptually similar to the compulsory margin under IFRS 4. However the confidence level and method
of calculation for the risk adjustment is not prescribed in IFRS 17.
❚ 	The CSM is conceptually similar to the discretionary margin but is released over time in each reporting period with reference
to coverage units. The number of coverage units in a group is the quantity of insurance contract services provided by the
contracts in the group, determined by considering, for each contract, the quantity of benefits provided and its expected
coverage period.
192	Discovery Annual Financial Statements 2022

-- 193 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
29. 	IFRS 17 Insurance Contracts (standard issued not yet effective) continued
DISCOUNT RATE
Discounting adjusts the estimates of expected cash flows to reflect the time value of money and the financial risks associated with
those cash flows, to the extent that the financial risks are not already included in the cash flow estimates.
The following table shows which discount rate to is apply throughout the measurement of a group of insurance contracts, and
the general objective of how to determine that discount rate.
Point in time cost incurred 	Accounting implication
Fulfilment cash flows 	Current discount rates
CSM interest accretion for contracts without direct
participation features
Discount rates determined on initial recognition of the group,
i.e. locked-in at inception
Adjustments to the CSM for changes in the fulfilment cash
flows for contracts without direct participation features
Discount rates determined on initial recognition of the group,
i.e. locked-in at inception
Adjustments to the CSM for changes in the fulfilment cash
flows for direct participating contracts that do not vary based
on the returns on underlying items, excluding the change in
the effect of the time value of money and financial risks 	Current discount rates
For groups applying the PAA, liability for remaining coverage
adjustment for the time value of money
Discount rates determined on initial recognition of the group.
However, discounting is not required where there is no
significant finance component.
VARIABLE FEE APPROACH (MODIFIED MODEL)
For insurance contracts with direct participation features, the Variable Fee Approach(VFA) applies. The variable fee approach
modifies the treatment of the contractual service margin to accommodate direct participating contracts.
When applying the variable fee approach, the entity’s share of the fair value changes of the underlying items is included in the
contractual service margin. As a consequence, the fair value changes are not recognised in profit or loss in the period in which
they occur but over the remaining life of the contract.
The initial measurement of the VFA is the same as per the GMM measurement model, the differences in the measurement will
occur on the subsequent treatment. Refer to the diagram below that provides an overview of the subsequent measurement.
Fulfillment
cash inflows 	OCI
CSM
CSM allocation
Obligation to pay the policyholder the fair value
of underlying items
Other effects of discounting and
Financial risk assumptions (e.g., interest rates)
Entity’s share of the fair value of underlying items
Past and current service
Future service
OR
EITHER
P/L
P/L
Changes in fulfilment cash flows
Within the Discovery Group the unit linked products and the Discovery Retirement OptImiser products offered by Discovery Life
will apply the VFA measurement model.
193	Discovery Annual Financial Statements 2022

-- 194 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
29. 	IFRS 17 Insurance Contracts (standard issued not yet effective) continued
VARIABLE FEE APPROACH (MODIFIED MODEL) continued
SIMILARITIES AND DIFFERENCES WITH CURRENT DISCOVERY POLICY
The initial measurement of the portfolios measured based on the VFA is the same as the GMM and the similarities and differnces
to the Discovery policy have been identified above under the GMM section.
PREMIUM ALLOCATION APPROACH (SIMPLIFIED MODEL)
Under the Premium Allocation Approach (PAA) the general measurement model may be simplified for certain contracts to
measure the Liability for Remaining Coverage (LRC). The LRC under the PAA is not based on the components as identified under
the GMM, rather based on the LRC is measured as:
❚ 	Premiums received
❚ 	Minus insurance acquisition cash flows (applicable only if the entity has elected to defer the insurance acquisition cash flows)
❚ 	Plus/Minus any assets or liabilities previously recognised.
In addition to the simplification on the measurement of the LRC, the PAA provides the following simplifications:
a) An entity may elect not to adjust the LRC, LIC and onerous contracts for the time value of money (i.e., no discounting)
b) An entity may elect to expense insurance acquisition cash flows when incurred. If entity elects to defer the insurance
acquisition cash flows, the insurance acquisition cash flows are amortised over the expected duration of the insurance contract,
which includes expected renewal periods.
This simplified approach is permitted at inception of the group of insurance contracts if one of the following criteria has been
met:
❚ 	The insurance contract has a coverage period of one year or less, or
❚ 	The entity reasonably expects that the PAA would produce a measurement of the liability for remaining coverage for a group
of insurance contracts that would not differ materially from the measurement that would be achieved by applying the general
measurement requirements.
Based on the criteria above the PAA, products that have a short-term coverage period are best suited to elect the PAA. Within the
Discovery Group the following entities will have insurance and reinsurance portfolios that are measured using the PAA:
❚ 	Discovery Group Life contracts
❚ 	Discovery Insure – Discovery Insure issues the following insurance, Personal lines for motor and household, Business
insurance, Medical gap and trauma cover, and travel insurance.
❚ 	Vitality Health Private medical insurance contracts
SIMILARITIES AND DIFFERENCES WITH CURRENT DISCOVERY POLICY
❚ 	The LRC for the PAA is similar to the unearned premium reserve profile.
❚ 	The PAA allows an entity to elect not to take the impact of discounting into the measurement of the liabilities/assets arising
from insurance contract. The principle of not discounting is consistent with Discovery's current treatment under IFRS 4
❚ 	Under the PAA an entity is allowed to recognise an asset for insurance acquisition cash flows, similar to the deferred acquisition
cost (DAC) asset recognised under IFRS 4. However, the period over which insurance acquisition cashflows is amortised is
different. IFRS 17 allows an entity to consider renewal periods beyond the contract boundary of the insurance contract.
❚ 	Unlike IFRS 4, the measurement of the LIC in IFRS 17 requires the calculation of a risk adjustment.
194	Discovery Annual Financial Statements 2022

-- 195 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
29. 	IFRS 17 Insurance Contracts (standard issued not yet effective) continued
INSURANCE ACQUISITION CASH FLOWS
IFRS 17 has defined acquisition costs as the costs incurred in selling, underwriting, and starting a group of insurance contracts
that are directly attributable to the portfolio of insurance contract. The insurance acquisition cashflows also includes the allocation
of insurance cash flows directly attributable to the portfolio to which the insurance contract belongs.
There are various accounting implications of the requirements under the GMM for insurance acquisition cash flows based on the
point in time at which the acquisition cash flow has been incurred. The table below provides an overview of the accounting
implications:
Point in time cost incurred 	Accounting implication
Costs incurred before the group of insurance contract is
recognised
Step 1: entity recognises as an asset any insurance acquisition
cash flows relating to a group of existing or future insurance
contracts that it incurs.
Step 2: These assets and liabilities are derecognised when the
group of insurance contracts to which the cash flows are
allocated is recognised, as part of determining the CSM on
initial recognition.
Costs expected to be paid after the related group of insurance
contract is recognised
The insurance acquisition cash flows are included as part of
the fulfilment cash flows of that group.
Cost is paid or the liability to pay them is incurred at the date
of initial recognition
The insurance acquisition cash flows are in effect deducted
from the CSM at that date.
The requirements to recognise an asset for insurance acquisition cash flows are relevant when the PAA is applied, unless the
entity has elected to expense the insurance acquisition cash flows as they are incurred. This accounting policy election is allowed
at the portfolio level.
For portfolios measured the PAA model, if an entity has elected not to immediately expense the acquisition cash flows, a portion
of the acquisition costs can be deferred and recognised in anticipated future renewal periods.
SIMILARITIES WITH CURRENT DISCOVERY POLICY
Under the Discovery Group’s IFRS 4 accounting policy, profits are recognised at initial recognition to the extent of the actual
acquisition costs incurred but considering the premium loadings available on the total portfolio to recoup acquisition costs –the
interpretation of the policy is to add compulsory and discretionary margins to achieve a broadly zero IFRS profit on new business
at initial recognition at a portfolio level (i.e., allowing for offsets between individual policies).
IFRS 17 classifies acquisition expenses as either directly or not directly attributable. While sufficient margin is released on
profitable policies to cover directly attributable acquisition expenses (and ensure a zero profit at initial recognition in line with
current policy), expenses which are not directly attributable must be immediately expensed through profit and loss –the extent
of these expenses is likely to differ to the value allowed for under IFRS 4.
Based on the above the Discovery policy closely aligns with the requirements of IFRS 17 for the initial recognition of the expenses,
i.e., no initial profit recognised for business that is profitable at initial recognition. The application of the policy was done at a total
level under IFRS 4, while it will be applied at a policy level under IFRS 17. The Discovery policy therefore aligns with requirements
for business that is profitable at initial recognition, however the losses incurred on policies at initial recognition will be immediately
reflected in the profit or loss under IFRS 17.
DIFFERENCES WITH CURRENT DISCOVERY POLICY
The expenses allocated under IFRS 4 has been an area of significant judgement with no IFRS standard definition. While IFRS 17
introduces requirements regarding the expenses which can be allocated to a portfolio of business, there remains diversity in
practice over the types of costs and the amounts identified as insurance acquisition cash flows, depending on the type of contract
or the jurisdiction.
195	Discovery Annual Financial Statements 2022

-- 196 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
29. 	IFRS 17 Insurance Contracts (standard issued not yet effective) continued
REINSURANCE CONTRACTS
IFRS 17 represents a significant change from IFRS 4 in the accounting for the reinsurance contract. Common existing practice
under IFRS 4 is to account for reinsurance contracts held using a ‘mirroring approach’, essentially matching reinsurance contract
revenue, costs, assets, and liabilities to the underlying insurance contracts. Under IFRS 17, a reinsurance contract held is
accounted for as a standalone contract, independent of the accounting for the underlying insurance contracts.
IFRS 17 OVERVIEW
REINSURANCE CONTRACT DEFINITION
The definition for an insurance contract has remained largely the same between IFRS 4 and IFRS 17 and thus there has not been
a significant change in contracts identified as reinsurance contracts under IFRS 4 vs IFRS 17 within Discovery. A reinsurance
contract is defined as a type of insurance contract that is issued by an entity (the reinsurer) to compensate another entity (the
cedant) for claims arising from insurance contract(s) issued by the cedant.
REINSURANCE CONTRACT UNIT OF ACCOUNT
An entity should divide portfolios of reinsurance contracts held by applying the same criteria as for insurance contracts issued
discussed in the insurance contracts section above, i.e. the unit of account is the group of reinsurance contracts.
MEASURMENT OF INSURANCE CONTRACT
For reinsurance contracts issued the requirements of the GMM will apply similar to the requirements of the insurance contracts,
while for reinsurance contracts held the requirements of the GMM will apply with certain modifications. An entity has the option
to apply the PAA if the eligibility criteria are met at initial recognition, while the VFA modeL cannot be applied to reinsurance
contracts.
PRESENTATION AND DISCLOSURE
IFRS 17 introduces the following presentation and disclosure principles and line items:
❚ 	Insurance revenue, derived from change in LRC
❚ 	Insurance services expenses is a new line item that comprises:
– The incurred claims and other incurred insurance service expenses,
– Amortisation of the insurance acquisition cash flows,
– Changes in fulfilment cash flows that relate to past services, i.e., relating to the LIC
– Changes in fulfilment cash flows that relate to future service, but which do not adjust the CSM
❚ 	Investment components are excluded from insurance revenue and insurance services expenses
❚ 	Insurance finance income and expenses is presented separately from insurance revenue; and
❚ 	Entities can choose to disaggregate the presentation of insurance finance income or expenses between profit or loss and
other comprehensive income (OCI).
SIMILARITIES WITH CURRENT DISCOVERY POLICY
The presentation on the Statement of Financial Position is not expected to differ significantly for the portfolios measured using
the GMM/VFA. The difference will arise from a change to the components of the assets and liabilities arising from insurance and
reinsurance contracts.
Portfolios of insurance contracts issued that are either assets or liabilities, and portfolios of reinsurance contracts held that are
either assets or liabilities, are presented separately in the statement of financial position as currently presented.
DIFFERENCES WITH CURRENT DISCOVERY POLICY
The level of aggregation is relevant not only for measurement purposes but also for presentation purposes. Entities must be able
to identify the position – i.e., asset or liability – of each portfolio of contracts, in order to ensure the appropriate presentation, by
aggregating all of the groups of contracts within each portfolio.
IFRS 17 requires separate presentation of amounts relating to insurance contracts issued and reinsurance contracts held in the
primary statements.
196	Discovery Annual Financial Statements 2022

-- 197 of 219 --

ANNEXURE B – GROUP ACCOUNTING POLICIES continued
29. 	IFRS 17 Insurance Contracts (standard issued not yet effective) continued
STATEMENT OF FINANCIAL POSITION
The portfolios measured using the PAA will no longer present the premiums receivable and unearned premiums reserve will
separately. The balances will be included in the measurement of the liabilities/(assets) arising from insurance contracts.
For the portfolios measured using the GMM/VFA IFRS 17 allows and entity to elect to disaggregate insurance finance income or
expenses between profit or loss and other comprehensive income (OCI).
STATEMENT OF PROFIT OR LOSS
For the GMM/VFA measurement models the revenue under IFRS 4 is premiums. This will change as under IFRS 17, as revenue is
a derived number for the amount the company has earned over the period to cover the expected claims and expenses, the
acquisition cash flows, an amount for the underlying risk and an amount to reflect the profit recognised on the services provided
in the period.
❚ 	Under IFRS 4 disclosure includes Premiums, Claims and Transfer of reserves (this is the release of the profit margin).
❚ 	Whereas under IFRS 17 the requirement will be to disclose Revenue, less Claims. The transfer of reserves is encapsulated in
the revenue components under IFRS 17 and will not be disclosed separately.
IFRS 17 introduces a new insurance metric with the Insurance service result line item in the Statement of profit or loss. The
Insurance service result introduces the concept of a margin for insurance entities.
NOTES TO THE FINANCIAL STATEMENTS
IFRS 4 provides for similar disclosures to those required by IFRS 17, however many of these disclosures for example reconciliations
of changes in the insurance and reinsurance liabilities or assets are typically presented at a very high level only with little or no
disaggregation.
IFRS 17 requires an entity to disclose reconciliations in the notes to the financial statements that show how the amounts disclosed
on the face of the statement of financial position (i.e., the net carrying amount of contracts within the scope of IFRS 17) changed
during the reporting period because of cash flows and income and expenses recognised in the statement of financial performance.
Separate reconciliations are required for insurance contracts issued and reinsurance contracts held.4
Separate reconciliations are required for different portfolio of contracts. For example, those portfolios subject to the general
model and the premium allocation approach, or portfolios in different geographical regions with different risk management.
PRESENTATION OF INSURANCE FINANCE INCOME OR EXPENSE
The effect of, and changes in, the time value of money and financial risk (including that arising from the passage of time) are
presented as insurance finance income or expense within the income statement. Except for insurance finance income or
expenses arising from insurance contracts under the variable fee approach when risk mitigation is applied, an entity can choose
as an accounting policy to present the insurance finance income or expense:
❚ 	in profit or loss; or
❚ 	disaggregated between profit or loss and OCI (the OCI option).
Once elected, the accounting policy will need to be applied consistently at the level of a portfolio of insurance contracts.
When determining whether to apply the OCI option, entities will consider the expected accounting mismatches that may arise
and the potential ways to mitigate them. Entities that deem it more appropriate not to reflect the volatility in profit or loss that
arises from the insurance liability and the assets that manage it are likely to consider options that allow this volatility to be
presented in OCI.
Discovery Life is considering to make use of the election to disaggregate Insurance Finance Income and Expenses between profit
and loss and other comprehensive income (OCI) when such presentation better reflects the underlying economic substance of
the contract. Under IFRS 4, where inputs of economic assumptions changes are impacting porfit or loss, these impacts are
excluded in the presentation of "Normalised" performance measures. The election to reflect such changes in OCI will similarly
provide a more reliable measure in profit or loss and therfore likely to be applied for certain portfolios or groups of insurance
contracts by Discovery.
197	Discovery Annual Financial Statements 2022

-- 198 of 219 --

ANNEXURE C – DIRECTORATE
REMUNERATION AND FEES
Payment to directors for the year ended 30 June 2022 for services rendered are set out in the table below. It should be noted that these
payments reflect cash payments made to directors during the financial year and therefore all variable pay components are reflective of
performance measurements relating to previous periods. The variable pay components relating to the current year under review are
physically paid in the following financial year and are analysed in detail in the Group’s annual remuneration report and are more reflective
of the performance of the period under review.
Payments to directors for the year ended 30 June 2022 for services rendered are as follows:
R’000
Services
as
directors 1
Basic
salary
Perfor-
mance
bonus
Phantom
scheme
payments
Provident
fund
contri-
butions
Other
benefits1 	Total
Executive
A Gore 	– 	7 611 	8 172 	– 	1 107 	387 	17 277
HD Kallner 	– 	5 650 	6 891 	– 	282 	174 	12 997
NS Koopowitz2 	– 	19 428 	21 286 	8 664 	81 	552 	50 011
Dr A Ntsaluba 	– 	4 749 	5 216 	– 	356 	290 	10 611
A Pollard3 	– 	7 343 	6 684 	2 057 	122 	336 	16 542
B Swartzberg 	– 	5 314 	5 933 	2 532 	555 	237 	14 571
DM Viljoen 	– 	5 019 	5 381 	2 995 	780 	183 	14 358
Sub-total 	– 	55 114 	59 563 	16 248 	3 283 	2 159 	136 367
Non-executive
ME Tucker4 	6 539 	– 	– 	– 	– 	– 	6 539
HL Bosman6 	1 743 	– 	– 	– 	– 	– 	1 743
Dr BA Brink 	614 	– 	– 	– 	– 	– 	614
SE De Bruyn 	591 	– 	– 	– 	– 	– 	591
R Farber 5 	3 219 	– 	– 	– 	– 	3 633 	6 852
WM Hlala 	1 102 	– 	– 	– 	– 	– 	1 102
FN Khanyile 	1 500 	– 	– 	– 	– 	– 	1 500
D Macready 	1 851 	– 	– 	– 	– 	– 	1 851
DR TV Maphai 	1 797 	– 	– 	– 	– 	– 	1 797
T Mboweni 	209 	– 	– 	– 	– 	– 	209
M Schreuder 	1 621 	– 	– 	– 	– 	– 	1 621
B Van Kralingen7 	348 	– 	– 	348
SV Zilwa8 	2 176 	– 	– 	– 	– 	– 	2 176
Sub-total 	23 310 	– 	– 	– 	– 	3 633 	26 943
Total 	23 310 	55 114 	59 563 	16 248 	3 283 	5 792 	163 310
Less: paid by subsidiaries 	23 310 	55 114 	59 563 	16 248 	3 283 	5 792 	163 310
Paid by holding company 	– 	– 	– 	– 	– 	– 	–
1 “Other benefits” comprise medical aid contributions, travel, other allowances and fees from group subsidiaries.
2 Salary and incentive are paid in GBP
3 Salary and incentive are paid in USD.
4 Director's fees for services rendered are paid in GBP.
5 Director's fees for services rendered by R Farber were paid in AUD components.
6 Director's fees for services rendered by HL Bosman were paid to Rand Merchant Insurance Holdings Limited.
7 Director’s fees for services rendered are paid in USD.
8 Participated in Discovery Limited 2015 BEE transaction, which loan outstanding to the Company was fully settled during the financial year.
198	Discovery Annual Financial Statements 2022

-- 199 of 219 --

ANNEXURE C – DIRECTORATE continued
REMUNERATION AND FEES continued
Payment to directors for the year ended 30 June 2021 for services rendered are set out in the table below. It should be noted that these
payments reflect cash payments made to directors during the financial year and therefore all variable pay components are reflective of
performance measurements relating to previous periods. The variable pay components relating to the current year under review are
physically paid in the following financial year and are analysed in detail in the Group’s annual remuneration report and are more reflective
of the performance of the period under review.
Payments to directors for the year ended 30 June 2021 for services rendered are as follows:
R’000
Services
as
directors 1
Basic
salary 1
Perfor-
mance
bonus
Phantom
scheme
payments
Provident
fund
contri-
butions
Other
benefits2, 7 	Total
Executive
A Gore 	– 	7 052 	7 112 	1 547 	1 094 	365 	17 170
HD Kallner 	– 	5 273 	9 539 	4 871 	272 	164 	20 119
NS Koopowitz3 	– 	18 340 	9 917 	5 726 	49 	528 	34 560
Dr A Ntsaluba 	– 	4 425 	4 371 	987 	343 	274 	10 400
A Pollard4 	– 	6 524 	4 373 	3 119 	221 	303 	14 540
B Swartzberg 	– 	4 993 	4 649 	2 808 	534 	182 	13 166
DM Viljoen 	– 	4 581 	4 843 	3 033 	722 	82 	13 261
Sub-total 	– 	51 188 	44 804 	22 091 	3 235 	1 898 	123 216
Non-executive
ME Tucker5 	5 975 	– 	– 	– 	– 	– 	5 975
HL Bosman6 	1 822 	– 	– 	– 	– 	– 	1 822
Dr BA Brink 	1 416 	– 	– 	– 	– 	– 	1 416
SE De Bruyn 	1 364 	– 	– 	– 	– 	– 	1 364
R Farber 7 	2 281 	– 	– 	– 	– 	3 295 	5 576
FN Khanyile8 	1 104 	– 	– 	– 	– 	– 	1 104
D Macready 	1 663 	– 	– 	– 	– 	– 	1 663
DR TV Maphai 	1 728 	– 	– 	– 	– 	– 	1 728
H Mayers 	315 	– 	– 	– 	– 	– 	315
M Schreuder 	679 	– 	– 	– 	– 	– 	679
SV Zilwa9 	1 832 	– 	– 	– 	– 	– 	1 832
Sub-total 	20 179 	– 	– 	– 	– 	3 295 	23 474
Total 	20 179 	51 188 	44 804 	22 091 	3 235 	5 193 	146 690
Less: paid by subsidiaries 	(20 179) 	(51 188) 	(44 804) 	(22 091) 	(3 235) 	(5 193) 	(146 690)
Paid by holding company 	– 	– 	– 	– 	– 	– 	–
1 Responding to the challenges of COVID-19 and in response to the call by the President of South Africa, all South African executive directors, and certain
non-executive directors and foreign-based executive directors, committed one third of their gross salaries and Board fees for three months to add to
Discovery’s contributions towards the Solidarity Fund and other COVID-19-related causes. Executive directors committed R0.9 million in the current year
(2020: Executive directors forfeited R1.7 million and non-executive directors forfeited R1.4 million).
2 “Other benefits” comprise medical aid contributions, travel and other allowances.
3 Salary and incentive are paid in GBP.
4 Salary and incentive are paid in USD.
5 Director's fees for services rendered are paid in GBP.
6 Director's fees for services rendered by HL Bosman were paid to Rand Merchant Insurance Holdings Limited.
7 Director’s fees for services and fees for other consulting services rendered by R Farber were paid in AUD. Director's fees for consulting services are included
as part of other benefits.
8 Director's fees for services rendered by F Khanyile were paid to WDB Investment Holdings Proprietary Limited.
9 Black non-executive directors participated in the Discovery Limited BEE transaction. SV Zilwa had a loan outstanding to the Company of R1 million as at
30 June 2021.
199	Discovery Annual Financial Statements 2022

-- 200 of 219 --

ANNEXURE C – DIRECTORATE continued
DIRECTORS’ PARTICIPATION IN LONG-TERM INCENTIVE SCHEMES
Discovery’s directors and prescribed officers participate in the various long-term incentive schemes offered by the Group and their
participation is disclosed below. Refer to Group note 31 for a detailed description of the various schemes offered.
Discovery Limited phantom share scheme
Directors and prescribed officers participation as at 30 June 2022:
Directors and prescribed officers
Outstanding
shares
Date
granted
Strike
price
R
Final
vesting
date
Value at
30 June 2022
R
A Gore 	8 106 	30/09/2016 	– 	30/09/2022 	1 038 379
27 894 	30/09/2017 	– 	30/09/2022 	3 573 221
36 021 	30/09/2018 	– 	30/09/2023 	4 614 290
HD Kallner 	18 980 	30/09/2016 	– 	30/09/2022 	2 431 274
18 708 	30/09/2017 	– 	30/09/2022 	2 396 495
146 628 	01/04/2018 	– 	31/03/2023 	18 782 983
24 159 	30/09/2018 	– 	30/09/2023 	3 094 768
A Ntsaluba 	9 557 	30/09/2016 	– 	30/09/2022 	1 224 284
19 733 	30/09/2017 	141.65 	30/09/2022 	–
9 866 	30/09/2017 	– 	30/09/2022 	1 263 835
21 234 	30/09/2018 	– 	30/09/2023 	2 720 075
A Pollard 	1 897 	30/09/2016 	– 	30/09/2022 	242 974
3 796 	30/09/2017 	– 	30/09/2022 	486 204
7 591 	30/09/2017 	141.65 	30/09/2022 	–
4 920 	30/09/2018 	– 	30/09/2023 	630 252
B Swartzberg 	10 873 	30/09/2016 	– 	30/09/2022 	1 392 863
3 929 	30/09/2017 	– 	30/09/2022 	503 305
7 858 	30/09/2017 	141.65 	30/09/2022 	–
8 456 	30/09/2018 	– 	30/09/2023 	1 083 214
DM Viljoen 	11 225 	30/09/2017 	– 	30/09/2022 	1 437 923
22 450 	30/09/2017 	141.65 	30/09/2022 	–
22 791 	30/09/2018 	– 	30/09/2023 	2 919 527
200	Discovery Annual Financial Statements 2022

-- 201 of 219 --

ANNEXURE C – DIRECTORATE continued
DIRECTORS’ PARTICIPATION IN LONG-TERM INCENTIVE SCHEMES continued
Discovery Limited long-term incentive plan
Directors and prescribed officers participation as at 30 June 2022:
Directors and prescribed officers
Outstanding
shares
Date
granted
Strike
price
R
Final
vesting
date
Value at
30 June 2022
R
A Gore 	76 399 	30/09/2019 	– 	30/09/2024 	9 786 712
30 434 	30/09/2020 	– 	30/09/2023 	3 898 595
69 707 	30/09/2020 	– 	30/09/2025 	8 929 467
68 786 	30/09/2021 	– 	30/09/2026 	8 811 487
HD Kallner 	51 240 	30/09/2019 	– 	30/09/2024 	6 563 844
98 985 	30/09/2020 	– 	30/09/2023 	12 679 979
46 752 	30/09/2020 	– 	30/09/2025 	5 988 931
46 135 	30/09/2021 	– 	30/09/2026 	5 909 894
A Ntsaluba 	45 253 	30/09/2019 	– 	30/09/2024 	5 796 909
17 846 	30/09/2020 	– 	30/09/2023 	2 286 073
41 289 	30/09/2020 	– 	30/09/2025 	5 289 121
40 744 	30/09/2021 	– 	30/09/2026 	5 219 306
A Pollard 	14 662 	30/09/2019 	– 	30/09/2024 	1 878 202
3 145 	30/09/2020 	– 	30/09/2023 	402 875
22 362 	30/09/2020 	– 	30/09/2025 	2 864 572
22 276 	30/09/2021 	– 	30/09/2026 	2 853 556
B Swartzberg 	15 372 	30/09/2019 	– 	30/09/2024 	1 969 153
11 501 	30/09/2020 	– 	30/09/2023 	1 473 278
23 376 	30/09/2020 	– 	30/09/2025 	2 994 466
23 068 	30/09/2021 	– 	30/09/2026 	2 955 011
DM Viljoen 	48 340 	30/09/2019 	– 	30/09/2024 	6 192 354
24 797 	30/09/2020 	– 	30/09/2023 	3 176 496
44 105 	30/09/2020 	– 	30/09/2025 	5 649 851
45 197 	30/09/2021 	– 	30/09/2026 	5 789 736
The Vitality Group Cash-settled plan
Directors and prescribed officers
Directors and prescribed officers
Outstanding
units
Date
granted
Exercise
price
US$
Final
vesting
date
Value at
30 June 2022
US$
A Pollard 	61 403 	30/09/2017 	– 	30/09/2022 	82 729
72 931 	30/09/2018 	– 	30/09/2023 	98 261
278 536 	30/09/2019 	– 	30/09/2024 	342 599
153 330 	30/09/2020 	– 	30/09/2025 	188 596
167 813 	30/09/2021 	– 	30/09/2026 	206 410
B Swartzberg 	63 561 	30/09/2017 	– 	30/09/2022 	85 637
125 328 	30/09/2018 	– 	30/09/2023 	168 857
287 542 	30/09/2019 	– 	30/09/2024 	353 677
160 279 	30/09/2020 	– 	30/09/2025 	197 145
173 772 	30/09/2021 	– 	30/09/2026 	213 740
The VitalityHealth and VitalityLife phantom share schemes
Directors and prescribed officers participation as at 30 June 2022:
Directors and prescribed officers
Outstanding
shares
Date
granted
Exercise
price
GBP
Final
vesting
date
Value at
30 June 2022
GBP
NS Koopowitz 	4 680 	05/11/2018 	– 	2022 	241 160
8 672 	01/03/2020 	– 	2023 	355 639
27 430 	05/01/2022 	– 	2024 	918 905
201	Discovery Annual Financial Statements 2022

-- 202 of 219 --

ANNEXURE C – DIRECTORATE continued
DIRECTORS’ PARTICIPATION IN LONG-TERM INCENTIVE SCHEMES continued
Directors’ interests in shares
According to the Register of Directors’ Interests, maintained by Discovery in accordance with the provisions of section 30(4)(d) of the
Companies Act, directors and prescribed officers of Discovery have disclosed the following interest in the ordinary shares of the Company
at 30 June 2022:
Directors and prescribed officers
Direct
beneficial
Indirect
beneficial
Total
2022
Direct
beneficial
Indirect
beneficial
Total
2021
A Gore 	– 	49 046 5591 	49 046 559 	– 	49 396 5591 	49 396 559
H Bosman 	– 	164 370 	164 370 	– 	77 027 	77 027
SE de Bruyn2 	– 	– 	– 	1 800 	– 	1 800
R Farber 	55 076 	– 	55 076 	55 076 	– 	55 076
HD Kallner 	100 398 	– 	100 398 	100 398 	– 	100 398
F Khanyile 	1 300 	– 	1 300 	1 300 	– 	1 300
NS Koopowitz 	– 	852 004 	852 004 	– 	962 004 	962 004
Dr TV Maphai 	1 919 	196 505 	198 424 	1 919 	196 505 	198 424
A Ntsaluba 	80 164 	– 	80 164 	90 164 	– 	90 164
A Pollard 	1 193 099 	– 	1 193 099 	1 193 099 	– 	1 193 099
B Swartzberg 	3 202 227 	22 635 1153 	25 837 342 	3 202 227 	22 635 1153 	25 837 342
DM Viljoen 	10 000 	– 	10 000 	10 000 	– 	10 000
SV Zilwa 	– 	680 	680 	– 	6 680 	6 680
4 644 183 	72 895 233 	77 539 416 	4 655 983 	73 273 890 	77 929 873
1 Includes 39 300 000 (2021: 42 400 000) ordinary shares which are subject to security.
2 On 24 November 2021, when SE de Bruyn retired. Her direct beneficial holding was 1 800 shares
3 Includes 11 500 000 (2021: 10 200 000) ordinary shares which are subject to security.
There has been no change in the directors’ interests in Discovery Limited’s shares between 30 June 2022 and the date of publication of
this annual report.
202	Discovery Annual Financial Statements 2022

-- 203 of 219 --

ANNEXURE D – ANALYSIS OF SHAREHOLDERS
at 30 June 2022
ORDINARY SHAREHOLDERS
Number of
shareholders
% of total
shareholders
Number of
shares
% of
issued
capital
Shareholder spread
1 – 1 000 shares 	41 061 	86.61 	6 752 122 	1.01
1 001 – 10 000 shares 	5 100 	10.76 	13 988 003 	2.09
10 001 – 100 000 shares 	935 	1.97 	28 733 889 	4.30
100 001 – 1 000 000 shares 	230 	0.49 	75 349 460 	11.26
1 000 001 shares and over 	83 	0.18 	544 139.997 	81.34
47 409 	100 	668 963 471 	100
Public/non-public shareholders
Non-public shareholders (more than 5%) 	21 	0.04 	172 036 768 	25.72
– Directors of the Company, including their associates 	12 	0.03 	77 539 416 	11.59
– Employee share trusts 	2 	0.00 	11 327 631 	1.70
– Own holdings 	1 	0.00 	680 268 	0.10
– Key management personnel and trustees of pension funds 	5 	0.01 	630 311 	0.09
– Strategic holdings (more than 10%) 	1 	0.00 	81 859 142 	12.24
Public shareholders 	47 388 	99.96 	496 926 703 	74.28
47 409 	100 	668 963 471 	100
Number of
shares 	%
Beneficial shareholders’ holding of 5% or more
Adrian Gore 	49 046 559 	7.33
Government Employees Pension Fund (including shares managed by Public Investment
Corporation) 	81 859 142 	12.24
Baillie Gifford & Co Ltd 	51 257 686 	7.66
Remgro Limited 	51 254 365 	7.66
Capital Group Companies Inc 	34 919 920 	5.22
B PREFERENCE SHAREHOLDERS
Number of
shareholders
% of total
shareholders
Number of
shares
% of
issued
capital
Shareholder spread
1 – 1 000 shares 	2 097 	71.04 	306 025 	3.83
1 001 – 10 000 shares 	735 	24.90 	2 255 176 	28.19
10 001 – 100 000 shares 	107 	3.62 	2 895 145 	36.19
100 001 – 1 000 000 shares 	13 	0.44 	2 543 654 	31.80
2 952 	100 	8 000 000 	100
Public/non-public shareholders
Public shareholders 	2 952 	100 	8 000 000 	100
Number of
shares 	%
Beneficial shareholders’ holding of 5% or more
Outsurance Insurance Company Ltd 	500 000 	6.25
203	Discovery Annual Financial Statements 2022

-- 204 of 219 --

ANNEXURE E – EMBEDDED VALUE
REPORT ON THE REVIEW OF THE EMBEDDED VALUE STATEMENT
OF DISCOVERY LIMITED AND ITS SUBSIDIARIES TO THE DIRECTORS OF DISCOVERY LIMITED
INTRODUCTION
We have reviewed the Embedded Value Statement of Discovery Limited and its subsidiaries (together the Discovery Limited Group) for the
year ended 30 June 2022, as set out on pages 205 to 215 of the Discovery Limited Annual Financial Statements for the year ended 30 June
2022 (the Report). The Report is prepared for the purpose of determining the value and performance of Discovery Limited Group. The
directors of Discovery Limited are responsible for the preparation and presentation of the Report in accordance with the embedded value
basis set out in the Basis of Preparation section of the Report, and for determining that the basis of preparation is acceptable in the
circumstances. Our responsibility is to express a conclusion on this Report based on our review.
SCOPE OF REVIEW
We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, “Review of Interim Financial
Information Performed by the Independent Auditor of the Entity.” A review of financial information consists of making inquiries, primarily
of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially
less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to
obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not
express an audit opinion.
CONCLUSION
Based on our review, nothing has come to our attention that causes us to believe that the Report is not prepared, in all material respects,
in accordance with the basis set out in the Basis of Preparation section of the Report.
BASIS OF ACCOUNTING AND RESTRICTION ON USE
Without modifying our conclusion, we draw attention to the Basis of Preparation section of the Report, which describes the basis of
accounting. The Report is prepared for the purpose of determining the value and performance of Discovery Limited Group. As a result,
the Report may not be suitable for another purpose. Our report is intended solely for the directors of Discovery Limited and should not
be used by any other parties. We agree to the publication of our report in the Discovery Limited Annual Financial Statements for the year
ended 30 June 2022, provided it is clearly understood by the recipients of the Discovery Limited Annual Financial Statements for the year
ended 30 June 2022 that they enjoy such receipt for information only and that we accept no duty of care to them in respect of our report.
PricewaterhouseCoopers Inc. 	KPMG Inc.
Director: Andrew Graham Taylor 	Director: Mark Danckwerts
Registered Auditor 	Registered Auditor
Johannesburg 	Johanneburg
7 September 2022 	7 September 2022
204	Discovery Annual Financial Statements 2022

-- 205 of 219 --

205	Discovery Annual Financial Statements 2022
ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
The embedded value of Discovery consists of the following components:
❚ 	the adjusted net worth attributed to the business at the valuation date;
❚ 	plus: the present value of expected future shareholder cash flows from the in-force covered business;
❚ 	less: the cost of required capital.
The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future after-
tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities,
whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new
business written by Discovery, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses and cost of
required capital. The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Limited Group. Covered
business includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”)
and Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping An Health,
Discovery Insure, Discovery Bank, VitalityInvest and Umbrella Funds, no published value has been placed on the current in-force business
as the businesses have not yet reached suitable scale with predictable experience.
In August 2011, Discovery raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference shares.
For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth.
The VitalityLife embedded value has been adjusted to allow for the agreement with Prudential in May 2022 to defer the transfer of the
VitalityLife business on the Prudential licence to the Vitality Life Limited licence ("the Part VII transfer").
The 30 June 2022 embedded value results and disclosures were subjected to an external review.

-- 206 of 219 --

ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 1: GROUP EMBEDDED VALUE
R million
30 June
2022
30 June
2021
%
change
Shareholders’ funds 	53 555 	46 419 	15
Adjustment to shareholders’ funds from published basis1 	(39 764) 	(34 184) 	16
Adjusted net worth2 	13 791 	12 235 	13
Value of in-force covered business before cost of required capital 	76 077 	67 175 	13
Cost of required capital 	(3 610) 	(4 765) 	24
Discovery Limited embedded value 	86 258 	74 645 	16
Number of shares (millions) 	657.0 	656.8
Embedded value per share 	R131.29 	R113.65 	16
Diluted number of shares (millions) 	668.3 	665.1
Diluted embedded value per share3 	R129.07 	R112.23 	15
1 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the
closing exchange rate of R20.00/GBP (June 2021: R19.74/GBP).
R million
30 June
2022
30 June
2021
Life net assets under insurance contracts 	(24 793) 	(20 675)
Vitality Life Limited net assets under insurance contracts 	(8 608) 	(7 703)
VitalityHealth financial reinsurance asset 	(3 021) 	(2 353)
VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax) 	(450) 	(407)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) 	(11) 	(12)
Goodwill relating to the acquisition of Standard Life Healthcare and the Prudential joint venture 	(2 475) 	(2 442)
Intangible assets (net of deferred tax) in covered businesses 	(864) 	(830)
Net preference share capital 	(779) 	(779)
Reversal of 1 Discovery Place IAS 17 financial lease accounting 	1 170 	975
Equity settled share based payment provision adjustment 	67 	42
(39 764) 	(34 184)
For the prior period, the “Vitality Life Limited net assets under insurance contracts” included an adjustment for the Discovery funded VitalityLife business
on the Prudential licence net assets under insurance contracts. From 30 June 2022, the Discovery funded VitalityLife business on the Prudential licence
net assets under insurance contracts are no longer eliminated in the embedded value because the Discovery funding was settled as part of the agreement
to delay the Part VII transfer in the period, aligning the financial operation of all VitalityLife business on the Prudential licence.
The “equity settled share based payment provision adjustment” reflects the difference between the provision in the IFRS equity and the mark-to-market
value of the equity settled share based payments.
206	Discovery Annual Financial Statements 2022

-- 207 of 219 --

207	Discovery Annual Financial Statements 2022
ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
2 	The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the
embedded value:
R million
30 June
2022
30 June
2021
Shareholders’ funds 	53 555 	46 419
Adjustment to shareholders' funds 	(39 764) 	(34 184)
Adjusted net worth 	13 791 	12 235
Excess of available capital over adjusted net worth 	35 342 	30 718
Available capital 	49 133 	42 953
Required capital 	39 318 	32 699
Excess available capital 	9 815 	10 254
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth and the available capital. This includes:
◼ The net preference share capital of R779 million which is included as available capital.
◼ The difference between Vitality Life Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth. For the prior period, this also adds back the
negative reserves eliminated on the Discovery funded VitalityLife business on the Prudential licence.
◼ The difference between Life’s Pillar 1 Own Funds and its adjusted net worth.
The following table sets out the required capital for each of the covered businesses:
R million
30 June
2022
30 June
2021
Health and Vitality 	1 000 	973
Life and Invest 	25 403 	22 059
VitalityHealth 	3 164 	2 847
VitalityLife 	9 751 	6 820
Total required capital 	39 318 	32 699
◼ For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost.
◼ For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
◼ For VitalityHealth, the required capital amount was set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement.
◼ For the VitalityLife business on the Prudential licence, the required capital was set equal to 1.5 times the UK Solvency I long-term insurance capital
requirement as per the agreement with Prudential following the long-term delay of the Part VII transfer. For the business sold on the Vitality Life
Limited licence, the required capital was set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement.
3 	The diluted embedded value per share adjusts for treasury shares held in the Discovery BEE Share Trust and as part of Discovery’s Long-term Incentive
Plan where the impact is dilutive.

-- 208 of 219 --

ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS
R million
Value before cost
of required capital
Cost of required
capital
Value after cost
of required capital
at 30 June 2022
Health and Vitality 	24 528 	(479) 	24 049
Life and Invest1 	32 073 	(1 509) 	30 564
VitalityHealth2 	10 658 	(583) 	10 075
VitalityLife2 	8 818 	(1 039) 	7 779
Total 	76 077 	(3 610) 	72 467
at 30 June 2021
Health and Vitality 	22 503 	(422) 	22 081
Life and Invest1 	27 777 	(1 183) 	26 594
VitalityHealth2 	8 230 	(462) 	7 768
VitalityLife 2 	8 665 	(2 698) 	5 967
Total 	67 175 	(4 765) 	62 410
1 Included in the Life and Invest value of in-force covered business is R1 734 million (June 2021: R1 675 million) in respect of investment management
services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R20.00/GBP (June 2021: R19.74/GBP).
TABLE 3: GROUP EMBEDDED VALUE EARNINGS
R million
30 June
2022
30 June
2021
Embedded value at end of period 	86 258 	74 645
Less: embedded value at beginning of period 	(74 645) 	(70 834)
Increase in embedded value 	11 613 	3 811
Net change in capital1 	(10) 	(7)
Dividends paid 	56 	63
Transfer to hedging reserve 	(309) 	(260)
Employee share option schemes 	(326) 	(330)
Embedded value earnings 	11 024 	3 277
Annualised return on opening embedded value 	14.8% 	4.6%
1 The net change in capital reflects share issues (net of costs and proceeds) and an increase (decrease) in treasury shares in the period.
208	Discovery Annual Financial Statements 2022

-- 209 of 219 --

ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS
Net
worth
Cost of
required
capital
Value of
in-force
covered
business
Year ended
30 June
2022
Year ended
30 June
2021
R million
Embedded
value
Embedded
value
Total profit from new business (at point of sale) 	(4 657) 	(309) 	7 027 	2 061 	1 891
Profit from existing business
◼ Expected return 	4 317 	148 	2 334 	6 799 	6 421
◼ Change in methodology and assumptions1 	3 093 	1 480 	(3 706) 	867 	(5 556)
◼ Experience variances 	202 	(102) 	3 024 	3 124 	4 917
Impairment, amortisation and fair value adjustment2 	(52) 	– 	– 	(52) 	(14)
Increase in goodwill and intangibles 	(418) 	– 	– 	(418) 	(336)
Other initiative costs 3 	(860) 	– 	24 	(836) 	(288)
Non-recurring expenses 	(130) 	– 	– 	(130) 	(85)
Acquisition costs4 	(41) 	– 	– 	(41) 	(40)
Finance costs 	(2 318) 	– 	– 	(2 318) 	(2 104)
Foreign exchange rate movements5 	1 034 	(62) 	199 	1 171 	(2 316)
Other 6 	(16) 	– 	– 	(16) 	(8)
Return on shareholders' funds7 	813 	– 	– 	813 	795
Embedded value earnings 	967 	1 155 	8 902 	11 024 	3 277
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the
operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous
embedded value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital expenditure
in VitalityInvest and Discovery Group Europe Limited. The prior period comparatives include the amortisation of the intangible asset raised under the
PrimeMed acquisition, which has since been dissolved.
3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health) and costs of start-up businesses
(including Discovery Bank, VitalityInvest, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest). Head office costs which
relate to non-covered business are also included in this item.
4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been
written over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value
of new business and therefore the costs are not deducted from the value of new business.
5 This item includes foreign exchange gains / (losses) emerging through the income statement, in addition to translation impacts on the cost of required
capital and value of in-force.
6 This item includes, among other items, the tax benefits or losses that will emerge as the VitalityHealth DAC and intangible software assets amortise or
increase.
7 The return on shareholders’ funds is shown net of tax and management charges.
209	Discovery Annual Financial Statements 2022

-- 210 of 219 --

ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 5: EXPERIENCE VARIANCES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Renewal expenses 	218 	– 	(3) 	2 	(239) 	– 	(22) 	– 	(44)
Lapses and surrenders 1 	18 	235 	(123) 	770 	– 	486 	(218) 	433 	1 601
Mortality and morbidity2 	– 	– 	(401) 	49 	563 	– 	(26) 	– 	185
Policy alterations1 	– 	64 	(437) 	426 	– 	– 	8 	(2) 	59
Backdated cancellations 	– 	– 	– 	– 	– 	– 	– 	– 	–
Premium and fee income 	152 	– 	115 	121 	398 	– 	(14) 	156 	928
Economic 3 	– 	– 	(19) 	(150) 	– 	– 	(6) 	– 	(175)
Commission 	– 	– 	– 	– 	(43) 	– 	– 	– 	(43)
Tax 4 	47 	– 	353 	(282) 	(16) 	– 	183 	– 	285
Reinsurance 	– 	– 	– 	– 	65 	– 	(195) 	74 	(56)
Maintain modelling term5 	– 	298 	– 	98 	– 	76 	– 	– 	472
Vitality benefits 	11 	– 	– 	– 	– 	– 	6 	– 	17
Other 6 	(21) 	(1) 	(4) 	(26) 	89 	– 	(237) 	95 	(105)
Total 	425 	596 	(519) 	1 008 	817 	562 	(521) 	756 	3 124
1 For Life and Invest, the combined lapse and surrender experience and policy alterations experience is relative to assumptions which include an allowance
for a short-term stress previously set in response to deteriorating experience from COVID-19 related impacts. For VitalityLife, large favourable variances
from lower lapses were partially offset by lower in-period commission clawbacks.
2 The mortality and morbidity experience for Life and Invest reflects a strain mainly due to increased morbidity experience. All confirmed COVID-19 claims
were offset against the provision previously set and have been in line with expectation. For VitalityHealth, while claim incidence was at normal levels,
claims severity was lower than assumed for the period under review due predominantly to clinical risk management interventions. There continue to be
material uncertainties about future claims severity, with potential increases resulting from delayed treatments or undiagnosed disease during the
pandemic.
3 The experience for Life and Invest arises largely due to a significant fall in asset values in the Invest business close to the end of the financial period,
partially offset by higher than expected inflation related increases on premium and benefit increases in Life.
4 The tax variance arises due to the timing difference between the expected tax payments and actual payments.
5 For Health and Vitality, Life and Invest and VitalityHealth, the projection term is rebased at each year-end. Therefore, an experience variance arises
because the total term of the in-force covered business is effectively increased by twelve months.
6 The key Other experience relates to cash flow timing variances in Life and Invest, profits and losses from companies within the VitalityHealth and
VitalityLife segments which are not part of covered business, including the net impact of the VitalityLife swaption program, excluding gains or losses from
the hedge which are included in the economic assumption changes item.
210	Discovery Annual Financial Statements 2022

-- 211 of 219 --

ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Modelling changes1 	– 	– 	(26) 	(320) 	– 	149 	589 	351 	743
Expenses2 	– 	(808) 	(49) 	(173) 	– 	– 	(189) 	(19) 	(1 238)
Lapses 3 	– 	57 	– 	(142) 	– 	1 642 	(254) 	270 	1 573
Mortality and morbidity4 	– 	– 	– 	(2 192) 	– 	(254) 	10 	(414) 	(2 850)
Benefit changes 	– 	83 	– 	– 	– 	– 	– 	– 	83
Vitality 	– 	– 	– 	– 	– 	– 	– 	– 	–
Tax 5 	– 	274 	(354) 	594 	– 	– 	– 	112 	626
Economic assumptions 6 	– 	527 	(31) 	(252) 	– 	(634) 	922 	(154) 	378
Premium and fee income 4,7 	– 	(314) 	– 	1 966 	– 	– 	– 	– 	1 652
Reinsurance and financing8 	– 	– 	2 452 	(2 423) 	– 	(30) 	22 	14 	35
Other 	– 	– 	1 	(136) 	– 	– 	– 	– 	(135)
Total 	– 	(181) 	1 993 	(3 078) 	– 	873 	1100 	160 	867
1 For Life and Invest, certain corrections were made to the modelled long-term projection of fee income and interest income. For VitalityHealth, the item
includes a correction to the in-force data. For VitalityLife, the item reflects the deferral of the Part VII transfer of policies from the Prudential, which
predominately includes a reduced cost of capital.
2 For Health and Vitality and Life and Invest, the renewal expenses assumption was updated to reflect an increase in budgeted expenses.
3 For Life, a provision was raised for the expected continued pressure on policy alterations experience over the short-term. For VitalityHealth, the lapse item
reflects the increase in the annuity factor assumption. For VitalityLife, the lapse item includes a reduction in the term policy book’s lapse assumptions.
4 For Life and Invest, the combined impact of the mortality and morbidity assumption change and the premium and fee income assumption change
reflects the impact of a basis strengthening for endemic COVID-19 impacts as well as other short- and long-term experience components, partially offset
by higher future expected premiums. For VitalityHealth, this item reflects an update to the valuation assumptions for the gross margin, as well as a release
of a COVID-19 related stress provision. For VitalityLife, this item includes an increase in the term policy book’s mortality assumptions.
5 This item largely reflects the reduction of the South African corporate tax rate from 28% to 27%. For Life and Invest, this item also reflects the impact of
allocation changes between tax funds, resulting in a change in current and deferred tax items.
6 For Life and Invest and Health and Vitality, the economic assumptions item relates to the impact of updating the assumptions relative to the Johannesburg
Stock Exchange (“JSE”) nominal and real yield risk-free curves at 30 June 2022. For Life and Invest this item also includes the impact of updating exchange
rate assumptions. For VitalityLife the item includes the impact of updating the assumptions relative to the Solvency II yield curves and the IFRS interest
rates, offset by the net change in the interest rate hedge.
7 For Health and Vitality, the premium and fee income item relates to discounts offered to in-house schemes.
8 For Life and Invest, the reinsurance and financing item primarily relates to the impact of financing arrangements, where the future expected cash flows
arising from part of the negative reserves are monetised to match other positive policy liabilities.
211	Discovery Annual Financial Statements 2022

-- 212 of 219 --

ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 7: EMBEDDED VALUE OF NEW BUSINESS
R million
30 June
2022
30 June
2021
%
Change
Health and Vitality
Present value of future profits from new business (at point of sale) 	958 	789
Cost of required capital 	(30) 	(24)
Present value of future profits from new business (at point of sale) after cost of
required capital 	928 	765 	12
New business annualised premium income1 	4 185 	3 704 	13
Life and Invest
Present value of future profits from new business (at point of sale)2 	795 	825
Cost of required capital 	(90) 	(82)
Present value of future profits from new business (at point of sale) after cost of
required capital 	705 	743 	(5)
New business annualised premium income3 	2 995 	2 947 	2
Annualised profit margin4 	3.0% 	3.0%
Annualised profit margin excluding Invest business 	5.3% 	5.7%
VitalityHealth 5
Present value of future profits from new business (at point of sale) 	398 	143
Cost of required capital 	(81) 	(61)
Present value of future profits from new business (at point of sale) after cost of
required capital 	317 	82 	287
New business annualised premium income6 	1 648 	1 263 	30
Annualised profit margin4 	2.6% 	0.9%
VitalityLife 7
Present value of future profits from new business (at point of sale) 	219 	396
Cost of required capital 	(108) 	(95)
Present value of future profits from new business (at point of sale) after cost of
required capital 	111 	301 	(63)
New business annualised premium income 	882 	871 	1
Annualised profit margin4 	1.4% 	4.1%
1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown
above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums
in respect of new business written during the period but only activated after 30 June 2022.
The total Health and Vitality new business annualised premium income written over the period was R7 548 million (June 2021: R6 103 million).
2 Included in the Life and Invest embedded value of new business is R55 million (June 2021: R53 million) in respect of investment management services
provided on off balance sheet investment business.
Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has
been recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium
is due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded
after receipt. Invest new business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the
reporting period, including policies whose first premium is due after the valuation date.
The new business annualised premium income of R2 995 million (June 2021: R2 947 million) (single premium APE: R1 421 million (June 2021:
R1 490 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total new business
annualised premium income written over the period, including automatic premium increases of R1 801 million (June 2021: R1 414 million) and servicing
increases of R668 million (June 2021: R640 million), was R5 464 million (June 2021: R5 001 million) (single premium APE: R1 492 million (June 2021:
R1 569 million)). Single premium business is included at 10% of the value of the single premium.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans, are shown in Table 5 as
experience variances and not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date
multiplied by the Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for
the Margin and Annuity Factor are shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised
premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month,
as well as premiums in respect of new business written during the period but only activated after 30 June 2022.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first
premium is due after the valuation date.
212	Discovery Annual Financial Statements 2022

-- 213 of 219 --

ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
BASIS OF PREPARATION
TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS
30 June
2022
30 June
2021
Beta coefficient 	0.75 	0.75
Equity risk premium (%) 	3.5 	3.5
Risk discount rate (%)
– Health and Vitality1 	14.375 	13.125
– Life and Invest1 	14.875 	13.625
– VitalityHealth 	5.016 	3.462
– VitalityLife 	4.997 	3.263
Rand / GBP exchange rate
Closing 	20.00 	19.74
Average 	20.25 	20.74
Margin over Expense inflation to derive Medical inflation (%)
South Africa 	3.00 	3.00
Expense inflation (%)2
South Africa 	– Health and Vitality 	7.85 	6.14
– Life and Invest 	7.74 	6.23
United Kingdom 	3.50 	2.50
Pre-tax investment return (%)
South Africa 	– Cash1 	10.75 	9.50
– Life and Invest bonds3 	12.25 	11.00
– Health and Vitality bonds3 	11.75 	10.50
– Equity1 	15.75 	14.50
United Kingdom 	– VitalityHealth risk-free rate 	2.39 	0.84
– VitalityLife risk–free rate 	2.37 	0.64
– VitalityLife IFRS interest rate 	2.92 	1.80
– VitalityLife investment return 	2.00 	1.44
Long-term corporation tax rate (%)
South Africa 	27 	28
United Kingdom 	25 	25
VitalityHealth Assumptions
– Margin (net of tax and cost of capital) (%)4 	12.00 	12.00
– Annuity Factor 	7.00 	6.18
Projection term
– Health and Vitality 	20 years 	20 years
– Discovery Life – VIF 	40 years 	40 years
– Group Life 	20 years 	20 years
– VitalityLife 	No cap 	No cap
– VitalityHealth5 	20 years 	20 years
1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted
average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The VitalityHealth margin (net of tax and cost of capital) remains unchanged at 12.00%. The assumption change noted in Table 6 to reduce the gross
margin assumption at 30 June 2022 has been largely offset by the release of the stress provision present in the gross margin assumption at 30 June 2021.
5 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.
213	Discovery Annual Financial Statements 2022

-- 214 of 219 --

ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
The Discovery Limited embedded value is calculated based on a risk discount rate using the CAPM approach with specific reference to the
Discovery beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount rate proxies the result of a
Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed beta calculated using
daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta will only change if the
capital structure of the Group and / or the observed beta calculated using daily returns over a long time period suggest the beta
assumption should depart significantly from the assumption at the financial year-end. As beta values reflect the historic performance of
share prices relative to the market they may not allow fully for non-market related and non-financial risk. Investors may want to form
their own view on an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available,
augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery
Limited group information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses
of an exceptional or non-recurring nature.
The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to the publicly available JSE risk-free
nominal yield curve.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the
net investment return assumption.
The risk-free rate assumption for VitalityHealth and VitalityLife was based on the single interest rate derived from the Prudential
Regulatory Authority yield curve. The inflation rate is consistent with the long-term market view of inflation.
From 30 June 2018, VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the
Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future
lapse rates and premium increases. The Margin assumption reflects profit margins after tax and Cost of Capital. The assumptions
underlying the Annuity Factor and Margin are set taking into account the current experience in the business at different durations.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible
assets. The Vitality Life Limited and the VitalityLife business on the Prudential licence required capital amount is assumed to earn the
investment return assumption, which is set based on the return on a portfolio of government and corporate bonds assumed to back the
required capital. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is limited to the cash flow
available after having met both the required capital amount and an internally defined liquidity target capital requirement of tangible
assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107:
Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into
account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2.
214	Discovery Annual Financial Statements 2022

-- 215 of 219 --

ANNEXURE E – EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
Sensitivity to the embedded value assumptions
The risk discount rate uses the CAPM approach with specific reference to the Discovery beta coefficient. As beta values reflect the historic performance
of share prices relative to the market they may not allow fully for non-market related and non-financial risk. Investors may want to form their own view
on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the embedded value and the embedded value of
new business at 30 June 2022 to changes in the risk discount rate is included in the tables below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action such as
risk premium increases where future experience is worse than the base assumptions.
TABLE 9: EMBEDDED VALUE SENSITIVITY
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Embedded
value
%
change	R million
Adjusted
net worth2
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Base 	13 791 	24 528 	(479) 	32 073 	(1 509) 	10 658 	(583) 	8 818 	(1 039) 	86 258
Impact of:
Risk discount rate +1% 	13 791 	23 170 	(518) 	28 971 	(1 590) 	10 075 	(552) 	8 216 	(902) 	80 661 	(6)
Risk discount rate – 1% 	13 791 	26 029 	(436) 	35 768 	(1 412) 	11 303 	(619) 	9 501 	(1 209) 	92 716 	7
Lapses – 10% 	13 519 	25 328 	(502) 	35 174 	(1 596) 	11 899 	(651) 	9 462 	(1 203) 	91 430 	6
Interest rates – 1%1 	12 588 	24 451 	(463) 	32 584 	(1 473) 	11 303 	(619) 	8 875 	(1 378) 	85 868 	–
Equity and property market value – 10% 	13 797 	24 528 	(479) 	31 466 	(1 529) 	10 658 	(583) 	8 818 	(1 039) 	85 637 	(1)
Equity and property return +1% 	13 791 	24 528 	(479) 	32 487 	(1 501) 	10 658 	(583) 	8 818 	(1 039) 	86 680 	–
Renewal expenses – 10% 	13 905 	27 047 	(443) 	32 722 	(1 469) 	11 435 	(583) 	9 024 	(1 038) 	90 600 	5
Mortality and morbidity – 5% 	14 039 	24 528 	(479) 	34 309 	(1 376) 	12 331 	(583) 	9 187 	(1 161) 	90 795 	5
Projection term +1 year 	13 791 	24 833 	(484) 	32 181 	(1 512) 	10 757 	(589) 	8 818 	(1 039) 	86 756 	1
1 All economic assumptions were reduced by 1%.
2 The sensitivity impact on the VitalityLife net of tax change in negative reserves is included in the adjusted net worth column.
The following table shows the effect of using different assumptions on the embedded value of new business.
TABLE 10: VALUE OF NEW BUSINESS SENSITIVITY
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Value of
new
business
%
change	R million
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Base 	958 	(30) 	795 	(90) 	398 	(81) 	219 	(108) 	2 061
Impact of:
Risk discount rate +1% 	881 	(33) 	601 	(95) 	293 	(76) 	119 	(91) 	1 599 	(22)
Risk discount rate – 1% 	1 042 	(28) 	1 023 	(84) 	514 	(88) 	333 	(131) 	2 581 	25
Lapses – 10% 	1 017 	(33) 	1 013 	(95) 	555 	(91) 	328 	(141) 	2 553 	24
Interest rates – 1%1 	966 	(30) 	801 	(88) 	514 	(88) 	241 	(174) 	2 142 	4
Equity and property return +1% 	958 	(30) 	824 	(89) 	398 	(81) 	219 	(108) 	2 091 	1
Renewal expense – 10% 	1 097 	(29) 	846 	(87) 	500 	(81) 	258 	(103) 	2 401 	16
Mortality and morbidity – 5% 	958 	(30) 	899 	(82) 	617 	(81) 	257 	(101) 	2 437 	18
Projection term +1 year 	975 	(31) 	802 	(90) 	415 	(81) 	219 	(108) 	2 101 	2
Acquisition costs – 10% 	986 	(30) 	949 	(90) 	435 	(81) 	360 	(108) 	2 421 	17
1 All economic assumptions were reduced by 1%.
215	Discovery Annual Financial Statements 2022

-- 216 of 219 --

ANNEXURE F – FIVE-YEAR REVIEW
for the year ended 30 June 2022
Group
2018
Group
2019
Group
2020
Group
2021
Group
2022
Compound
growth %
Income statement extracts (R million)
Profit from operations 	8 260 	7 536 	1 532 	5 304 	7 858 	(1)
Headline earnings 	5 803 	5 147 	296 	2 986 	5 204 	(3)
Abnormal expenses/(income) 	(402) 	(112) 	3 451 	420 	612
Normalised headline earnings 	5 401 	5 035 	3 747 	3 406 	5 816 	2
Diluted normalised headline earnings per
share (cents) 	836.9 	771.6 	566.7 	512.9 	877.3 	1
Statement of financial position extracts
(R million)
Total assets 	157 982 	180 233 	210 328 	246 694 	271 224 	14
Shareholders’ funds 	37 594 	43 083 	44 549 	46 415 	53 550 	9
Embedded value
Embedded value (R million) 	65 624 	71 217 	70 834 	74 645 	86 258 	7
Diluted embedded value per share (R) 	101.56 	108.30 	107.71 	112.23 	129.07 	6
Key ratios
Return on average equity (%) 	16 	16 	0.4 	7.1 	11.0
Return on average assets (%) 	4 	4 	0.1 	1.4 	2.1
Exchange rates
Rand/US$
– Closing 	13.81 	14.15 	17.41 	14.28 	16.47
– Average 	12.86 	14.17 	15.70 	15.42 	15.22
Rand/GBP
– Closing 	18.16 	17.98 	21.44 	19.74 	20.00
– Average 	17.33 	18.32 	19.75 	20.74 	20.25
Share statistics
Number of ordinary shares in issue
– Weighted average (000’s) 	645 014 	652 295 	656 648 	656 710 	656 901
– Diluted weighted average (000’s) 	645 408 	652 568 	661 242 	664 073 	663 082
– End of period (000’s) 	646 845 	658 291 	658 291 	665 769 	668 963
Price/diluted headline earnings (times) 	17.6 	19.3 	18.3 	24.7 	14.6
Share price (cents per share):
– High 	19 000 	17 830 	15 163 	15 738 	18 280
– Low 	12 719 	13 287 	5 815 	10 047 	11 760
– Closing 	14 750 	14 911 	10 455 	12 667 	12 810
Market capitalisation (R million) 	95 410 	98 158 	68 824 	84 333 	85 694
216	Discovery Annual Financial Statements 2022

-- 217 of 219 --

GLOSSARY OF TERMS
Abbreviation 	Meaning
CAE 	Chief Audit Executive
CCIC 	Capital, Currency and Investment Committee (CCIC)
CEO 	Chief Executive Officer
CFC 	Controlled Foreign Company
CFO 	Chief Financial Officer
CGU 	Cash generating unit
CIPC 	Companies and Intellectual Property Commission
Companies Act 	South African Companies Act, 71 of 2008
CRO 	Chief Risk Officer
CSM 	Contractual Service Margin (unearned profit)
Discovery 	Discovery Limited Group
DLAC 	Discovery Limited Audit Committee
DRG 	Discovery Risk Grades
ECL 	Expected credit losses
FCC 	Finance and Capital Committee
FinRe 	Financial Reinsurance - with risk transfer
FRC 	United Kingdom Financial Reporting Council
GIA 	Group Internal Audit
GMM 	General Measurement Model
HAF 	Head of Actuarial Function
IFA 	Insurance Fund Account
IFRS 	International Financial Reporting Standards
IRBA 	South African Independent Regulatory Board of Auditors
JSE 	Johannesburg Stock Exchange
LIC 	Liability for Incurred Claims
LRC 	Liability for Remaining Coverage
MAFR 	Mandatory audit firm rotation
Morbidity 	Morbidity claims are claims which arise as a result of an impairment of life due to an
illness or disability event insured by the policyholder
Mortality 	Mortality claims are claims which arise from the death of an insured life
NCD 	Negotiable certificates of deposits
OCI 	Other Comprehensive Income
OCR 	Oustanding Claims Reserve
PAA 	Premium Allocation Approach
PAH 	Ping An Health Insurance Company of China Ltd
SAICA 	South African Institute of Chartered Accountants
SAM 	Solvency Assessment and Management
TCFD 	Task Forced on Climate-Related Financial Disclosures
VFA 	Variable Fee Approach
WHT 	Withholding Tax
217	Discovery Annual Financial Statements 2022

-- 218 of 219 --

Discovery
+27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za
Subsidiaries of Discovery Limited are authorised financial services providers.

-- 219 of 219 --